"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtWith_AU_IN_FIRST","meanArtWith_AU_IN_LAST","meanArtWith_AU_IN_CORR","mean_articles_per_internal_author","mean_articles_per_internal_first_author","mean_articles_per_internal_last_author","mean_articles_per_internal_corresponding_author","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","meanCitationTrend","InternCoauthorship","AffCoauthorship","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"AOU_CAREGGI",2000,83,7.87951807228916,3.14457831325301,0.698795180722892,0.337349397590361,0.72289156626506,1.48295454545455,1.28888888888889,1.33333333333333,1.27659574468085,0.216867469879518,5,35,13,8,22,0.42,0.16,0.1,0.27,32.05,0.706982166570976,NA,0.132530120481928,0.518072289156627,0.445,0.355,0.339,0.342,"LEONARDO BOLOGNESE;GIOVANNI MARIA SANTORO;DAVID ANTONIUCCI;E. BERTONI;M. ZANAZZI;CESCO PIERONI;RENATO VALENTI;MAURIZIO TRAPANI;L. MOSCARELLI;ALBERTO ROSATI;VITTORIO BRIGANTI;MAURIZIO SALVADORI;GUIA MOSCHI;DOMENICO PRISCO;CARLO DANI;MARCO ZAPPA;GIUSEPPE BARLETTA;ROSSELLA MARCUCCI;DOMENICO PALLI;LUCA VAGGELLI","7;7;6;6;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3","LEONARDO BOLOGNESE;DOMENICO PALLI;LAURA PAPI;FRANCO CECCHI;PIETRO TONELLI;GIOVANNI MARIA SANTORO;CESCO PIERONI;EUǴENIO PACI;DAVID ANTONIUCCI;CARLO DANI;VITTORIO BRIGANTI;E. BERTONI;M. ZANAZZI;RENATO VALENTI;MAURIZIO TRAPANI;ENZO MERLER;GIUSEPPE BARLETTA;CHIARA LAZZERI;GORDON DR;GUIA MOSCHI","1.73;1.24;1.17;1;1;0.87;0.79;0.76;0.73;0.62;0.62;0.6;0.6;0.6;0.6;0.53;0.52;0.52;0.5;0.48","LEONARDO BOLOGNESE;GIOVANNI MARIA SANTORO;DAVID ANTONIUCCI;E. BERTONI;M. ZANAZZI;CESCO PIERONI;RENATO VALENTI;MAURIZIO TRAPANI;L. MOSCARELLI;ALBERTO ROSATI;VITTORIO BRIGANTI;MAURIZIO SALVADORI;GUIA MOSCHI;DOMENICO PRISCO;CARLO DANI;MARCO ZAPPA;GIUSEPPE BARLETTA;DOMENICO PALLI;LUCA VAGGELLI;EUǴENIO PACI","7;7;6;6;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3","LEONARDO BOLOGNESE;DOMENICO PALLI;LAURA PAPI;FRANCO CECCHI;PIETRO TONELLI;GIOVANNI MARIA SANTORO;CESCO PIERONI;EUǴENIO PACI;DAVID ANTONIUCCI;CARLO DANI;VITTORIO BRIGANTI;E. BERTONI;M. ZANAZZI;RENATO VALENTI;MAURIZIO TRAPANI;ENZO MERLER;GIUSEPPE BARLETTA;GUIA MOSCHI;MARCO ZAPPA;LUCA VAGGELLI","1.73;1.24;1.17;1;1;0.87;0.79;0.76;0.73;0.62;0.62;0.6;0.6;0.6;0.6;0.53;0.52;0.48;0.47;0.44","ALESSANDRA CALIGIURI;ANDREA BONACCHI;EVA EFSEN;FABIO MARRA;GIACOMO BATIGNANI;GIACOMO LAFFI;MASSIMO PINZANI;PAOLO GEÑTILINI;ROBERTO CAPORALE;ROBERTO GIULIO ROMANELLI;SABRINA PASTACALDI;DOMENICO PALLI;LEONARDO BOLOGNESE;GIOVANNI MARIA SANTORO;ANDREA GABBUTI;CANIO MARTINELLI;E. DI CINTIO;FABIO PARAZZINI;FEDERICA ALESSI;GIANCARLO GHISELLI","401;401;401;401;401;401;401;401;401;401;401;268;262;261;209;209;209;209;209;209","ROBERTO CAPORALE;GIOVANNI MARIA SANTORO;DAVID ANTONIUCCI;LEONARDO BOLOGNESE;MAURIZIO TRAPANI;GIACOMO TRALLORI;F. PACINI;G D'ALBASIO;OTTAVIANO TARANTINO;SIRO BAGNOLI;AGOSTINO OGNIBENE;CARLO DANI;DOMENICO PALLI;GIOVANNA BERTINI;GIUSEPPE BARLETTA;CANIO MARTINELLI;ROSARIA A.M.S. CASANO;ALESSANDRA FANELLI;GIANNI MESSERI;MARCO ZAPPA","401;261;180;174;165;153;139;139;139;139;136;129;129;124;124;112;112;105;105;104","GIOVANNI MARIA SANTORO;LEONARDO BOLOGNESE;DAVID ANTONIUCCI;CESCO PIERONI;E. BERTONI;MAURIZIO TRAPANI;RENATO VALENTI;VITTORIO BRIGANTI;MARCO ZAPPA;ANTONIO CASTAGNOLI;CARLO DANI;LUCA VAGGELLI;GIUSEPPE BARLETTA;GUIA MOSCHI;M. ZANAZZI;MAURIZIO SALVADORI;PIER FILIPPO FAZZINI;AGOSTINO OGNIBENE;ALBERTO BOSI;ALBERTO SANTINI","7;7;6;5;5;5;4;4;3;3;3;3;3;3;3;3;3;2;2;2","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;ENGINEERING;SOCIOLOGY;MATERIALS SCIENCE;POLITICAL SCIENCE;PSYCHOLOGY;ART;BUSINESS;ECONOMICS;ENVIRONMENTAL SCIENCE;GEOGRAPHY;MATHEMATICS","80;17;10;5;4;4;3;2;2;2;1;1;1;1;1;1","INTERNAL MEDICINE;CARDIOLOGY;PATHOLOGY;SURGERY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;IMMUNOLOGY;RADIOLOGY;ENDOCRINOLOGY;GENETICS;ANESTHESIA;OPTICS;PEDIATRICS;ONCOLOGY;PSYCHIATRY;BIOCHEMISTRY;VIROLOGY;CANCER RESEARCH;MECHANICAL ENGINEERING;PROGRAMMING LANGUAGE","67;21;21;17;13;13;12;12;10;10;8;8;7;6;6;5;5;4;4;4","CANCER;DISEASE;GENE;MYOCARDIAL INFARCTION;POPULATION;BLOOD PRESSURE;INCIDENCE (GEOMETRY);TRANSPLANTATION;ALTERNATIVE MEDICINE;ANGIOPLASTY;CONFIDENCE INTERVAL;HEART FAILURE;STENT;HUMAN IMMUNODEFICIENCY VIRUS (HIV);ASYMPTOMATIC;BIOPSY;CHEMOTHERAPY;HEMODYNAMICS;PROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;RECEPTOR","11;10;9;9;9;7;7;7;6;6;6;6;6;5;4;4;4;4;4;4;4","RESTENOSIS;VIRAL DISEASE;BREAST CANCER;COLORECTAL CANCER;EJECTION FRACTION;PLACEBO;VIRAL LOAD;INFLAMMATORY BOWEL DISEASE;THROMBOLYSIS;ALLELE;BONE MARROW TRANSPLANTATION;CARDIAC FUNCTION CURVE;CARDIAC OUTPUT;CARDIOMYOPATHY;CHEMOKINE;CROHN'S DISEASE;CYCLOPHOSPHAMIDE;DIASTOLE;GENOTYPE;HAZARD RATIO;HEART RATE;KIDNEY TRANSPLANTATION;MYCOBACTERIUM TUBERCULOSIS;PERCUTANEOUS CORONARY INTERVENTION;PHENOTYPE;PLASMINOGEN ACTIVATOR INHIBITOR-1;RENAL TRANSPLANT;RENIN–ANGIOTENSIN SYSTEM;REVASCULARIZATION;RNA;SEROCONVERSION;ULCERATIVE COLITIS;UNIVARIATE ANALYSIS","5;5;4;4;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","LENTIVIRUS;ANTIRETROVIRAL THERAPY;BONE MARROW TRANSPLANT;PRIMARY ANGIOPLASTY;REVERSE TRANSCRIPTASE;SENTINEL LYMPH NODE;SENTINEL NODE;SIDA;ALLELE FREQUENCY;ANTHRACYCLINE;ATROPHIC GASTRITIS;AUTONOMIC NERVOUS SYSTEM;AXILLA;AXILLARY LYMPH NODES;BRONCHOPULMONARY DYSPLASIA;CARDIAC INDEX;CENTRAL RETINAL VEIN OCCLUSION;CHEMILUMINESCENT IMMUNOASSAY;CHORIOAMNIONITIS;COLONOSCOPY;CORONARY RESTENOSIS;CORONARY STENTING;CXCR4;EPIRUBICIN;EXTRAPULMONARY TUBERCULOSIS;GERMLINE MOSAICISM;GERMLINE MUTATION;GLOMERULAR HYPERFILTRATION;GLUCAGON-LIKE PEPTIDE-1;HEART RATE VARIABILITY;HISTOCOMPATIBILITY;ILEITIS;INFLAMMATORY BOWEL DISEASES;INTRAVENTRICULAR HEMORRHAGE;ISOVOLUMETRIC CONTRACTION;LACUNAR STROKE;MAMMOGRAPHY;MEDULLARY THYROID CANCER;METASTATIC BREAST CANCER;MISSENSE MUTATION;NEONATAL MENINGITIS;NERVE BIOPSY;NUCLEAR GENE;OVARIAN CORTEX;P50;PENETRANCE;PLASMA RENIN ACTIVITY;POLYMORPHISM (COMPUTER SCIENCE);RENAL ARTERY STENOSIS;RETINOPATHY OF PREMATURITY;RUPTURE OF MEMBRANES;SOMATOSTATIN RECEPTOR 2;SPUTUM CULTURE;STREPTOCOCCUS AGALACTIAE;TROGLITAZONE;VINCRISTINE","3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;MYOCARDIAL INFARCTION;ITALY;;ANGIOPLASTY, BALLOON, CORONARY;COLORECTAL NEOPLASMS;HIV INFECTIONS;NEOPLASMS;RISK FACTORS;CORONARY DISEASE;TIME FACTORS;LYMPH NODES;PROSPECTIVE STUDIES;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS","66;45;43;33;25;22;22;19;15;11;11;11;11;11;10;10;9;9;8;8","CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;ACUTE MYELOID LEUKEMIA;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;DIAGNOSIS AND TREATMENT OF PATENT DUCTUS ARTERIOSUS;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;GLOBAL TRENDS IN COLORECTAL CANCER RESEARCH;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;PREVENTION AND TREATMENT OF HIV/AIDS INFECTION;;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;BREAST PATHOLOGY AND IMAGING TECHNIQUES;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT","4;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","CARDIAC IMAGING;TREATMENT;ANTIRETROVIRAL THERAPY;HIV;CARDIOVASCULAR RISK ASSESSMENT;CORONARY STENTS;ECHOCARDIOGRAPHY;HEART RATE VARIABILITY;MYCOBACTERIUM TUBERCULOSIS;MYOCARDIAL PERFUSION;REGIMEN;BONE MARROW TRANSPLANT;COLORECTAL CANCER;CONCORDANCE;CROHN'S DISEASE;CROSS-SECTIONAL STUDY;DISCONTINUATION;DUCTUS ARTERIOSUS;GAMMA PROBE;HIV INFECTION","6;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","ACUTE MYOCARDIAL;MYOCARDIAL INFARCTION;BONE MARROW;MARROW TRANSPLANT;PATIENTS TREATED;PRETERM INFANTS;ADVERSE REACTIONS;BREAST CANCER;CARDIOVASCULAR DISEASE;COHORT STUDY;COLORECTAL CANCER;CORONARY ANGIOPLASTY;CROHNS DISEASE;DUCTUS ARTERIOSUS;EXPOSURE CATEGORIES;GASTRIC CANCER;HIV INFECTION;HIV PATIENTS;LEFT VENTRICULAR;LOAD CONCENTRATIONS;LYMPH NODE;OCCULT BLOOD;OCTREOSCAN QUANTITATIVE;PATENT DUCTUS;PLASMA VIRAL;PRIMARY ANGIOPLASTY;PROTEASE INHIBITORS;QUANTITATIVE SPET;RANDOMIZED STUDY;RENAL TRANSPLANT","6;5;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HIV RNA;PLASMA HIV;RNA CONCENTRATIONS;VIRAL LOAD;ADVERSE REACTIONS;ANTIRETROVIRAL THERAPY;PI THERAPY;SAQUINAVIR HGC;CAD PATIENTS;ADVERSE EVENTS;AG MUTATION;CARDIOVASCULAR FUNCTION;CONFIDENCE INTERVAL;HIV INFECTION;MAIN OUTCOME;MONTHS CI;OUTCOME MEASURES;PATIENTS RECEIVING;RECEIVING NELFINAVIR;SESTAMIBI IMAGING;BID PERIOD;BID REGIMEN;CELL TRANSPLANTATION;HIGH-DOSE CYTARABINE;LV DYSFUNCTION;NORMAL SUBJECTS;PATIENTS TREATED;PHPT PATIENTS;QT INTERVAL;STEM CELL","8;8;8;8;6;6;6;6;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3",13,0.16,3,3,0,0,0,0,10,0,1,3,0,0,2,0,0,0,0,1,1,0,0,40,40,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,6.5,1740,1.26,0,0,41.5,0,0,1,0,0,0,0,1,0,2,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,"Italy","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1;1;1","CLINICAL RESEARCH;CANCER;CARDIOVASCULAR;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;HEMATOLOGY;ORPHAN DRUG;PREVENTION;RARE DISEASES;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;TRANSPLANTATION","2;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","1;1","2.4 SURVEILLANCE AND DISTRIBUTION;6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","1;1;1","BLOOD CANCER;LEUKEMIA / LEUKAEMIA","1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CAREGGI",2001,102,7.40196078431373,3.25490196078431,0.705882352941177,0.372549019607843,0.705882352941177,1.43913043478261,1.26315789473684,1.2258064516129,1.28571428571429,0.254901960784314,9,44,11,15,25,0.43,0.11,0.15,0.25,40.55,0.887434099602076,NA,0.205882352941176,0.588235294117647,0.436,0.386,0.357,0.389,"MAURIZIO SALVADORI;DAVID ANTONIUCCI;ALBERTO ROSATI;E. BERTONI;MASSIMO BONACCHI;ENRICO TORTOLI;LEONARDO BOLOGNESE;EDVIN PRIFTI;M. CELLERINI;GIUSEPPE BARLETTA;GUIDO SANI;ROSSELLA MARCUCCI;G. PÈPE;RENATO VALENTI;GIACOMO FRATI;GIAMPAOLO CERISANO;R. PIPERNO;SANDRA FEDI;ROSANNA ABBATE;M. ZANAZZI","9;7;6;6;6;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4","DAVID ANTONIUCCI;MAURIZIO SALVADORI;MASSIMO BONACCHI;SIRO BAGNOLI;SALVATORE SIA;M. CELLERINI;A MONTEREGGI;PIETRO TONELLI;D ANTONIUCCI;GIAMPAOLO CERISANO;GIUSEPPE BARLETTA;LAPO BENCINI;E. BERTONI;EDVIN PRIFTI;GIACOMO FRATI;ENRICO TORTOLI;ROSANNA ABBATE;ALBERTO ROSATI;MARCO ZAPPA;CARLO DANI","2.57;1.81;1.71;1;1;1;1;1;1;0.86;0.72;0.67;0.64;0.64;0.64;0.61;0.6;0.58;0.54;0.53","MAURIZIO SALVADORI;DAVID ANTONIUCCI;ALBERTO ROSATI;E. BERTONI;MASSIMO BONACCHI;ENRICO TORTOLI;LEONARDO BOLOGNESE;EDVIN PRIFTI;M. CELLERINI;GIUSEPPE BARLETTA;GUIDO SANI;ROSSELLA MARCUCCI;G. PÈPE;RENATO VALENTI;GIAMPAOLO CERISANO;R. PIPERNO;SANDRA FEDI;ROSANNA ABBATE;M. ZANAZZI;MARIA ROSA BIAGINI","9;7;6;6;6;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4","DAVID ANTONIUCCI;MAURIZIO SALVADORI;MASSIMO BONACCHI;SIRO BAGNOLI;SALVATORE SIA;M. CELLERINI;A MONTEREGGI;PIETRO TONELLI;D ANTONIUCCI;GIAMPAOLO CERISANO;GIUSEPPE BARLETTA;LAPO BENCINI;E. BERTONI;EDVIN PRIFTI;ENRICO TORTOLI;ROSANNA ABBATE;ALBERTO ROSATI;MARCO ZAPPA;CARLO DANI;CHIARA LAZZERI","2.57;1.81;1.71;1;1;1;1;1;1;0.86;0.72;0.67;0.64;0.64;0.61;0.6;0.58;0.54;0.53;0.53","ALBERTO BOSI;ANDREA BACIGALUPO;BARBARA BRUNO;M. BARBANTI;MARIA TERESA VAN LINT;NICOLETTA SACCHI;P ALESSANDRINO;PAOLO BRUZZI;PAOLO DI BARTOLOMEO;ROSA ONETO;STEFANO GUIDI;TERESA LAMPARELLI;DAVID ANTONIUCCI;ENRICO TORTOLI;AGOSTINO OGNIBENE;LEONARDO BOLOGNESE;GIANNI MESSERI;GIOVANNI MARIA SANTORO;RENATO VALENTI;A. MENCUCCI","538;511;511;511;511;511;511;511;511;511;511;511;341;325;316;310;301;301;301;285","ALBERTO BOSI;ANDREA BACIGALUPO;BARBARA BRUNO;M. BARBANTI;MARIA TERESA VAN LINT;NICOLETTA SACCHI;P ALESSANDRINO;PAOLO BRUZZI;PAOLO DI BARTOLOMEO;ROSA ONETO;STEFANO GUIDI;TERESA LAMPARELLI;DAVID ANTONIUCCI;GIOVANNI MARIA SANTORO;LEONARDO BOLOGNESE;RENATO VALENTI;ENRICO TORTOLI;AGOSTINO OGNIBENE;GIANNI MESSERI;ANGELA MIGLIORINI","538;511;511;511;511;511;511;511;511;511;511;511;341;301;301;301;297;285;285;245","MAURIZIO SALVADORI;DAVID ANTONIUCCI;E. BERTONI;ALBERTO ROSATI;MASSIMO BONACCHI;ANGELA MIGLIORINI;EDVIN PRIFTI;ENRICO TORTOLI;GIUSEPPE BARLETTA;MARIA ROSA BIAGINI;R. PIPERNO;GIAMPAOLO CERISANO;GIOVANNI MARIA SANTORO;LEONARDO BOLOGNESE;RENATO VALENTI;CARLO DANI;GUIA MOSCHI;GUIDO SANI;L. DI MARIA;L. MOSCARELLI","9;7;6;5;5;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;MATERIALS SCIENCE;PSYCHOLOGY;ENGINEERING;HISTORY;MATHEMATICS;SOCIOLOGY;COMPUTER SCIENCE;GEOLOGY","93;25;9;7;3;3;2;2;2;2;1;1","INTERNAL MEDICINE;CARDIOLOGY;SURGERY;PATHOLOGY;GENETICS;RADIOLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;ANESTHESIA;ENVIRONMENTAL HEALTH;VIROLOGY;PSYCHIATRY;OPTICS;UROLOGY;MICROBIOLOGY;MOLECULAR BIOLOGY;ANATOMY;DERMATOLOGY;GENERAL SURGERY","74;28;27;15;14;14;13;10;10;10;9;9;8;7;6;6;5;5;4;4;4","MYOCARDIAL INFARCTION;GENE;DISEASE;TRANSPLANTATION;BLOOD PRESSURE;CANCER;POPULATION;ARTERY;CORONARY ARTERY DISEASE;HEART FAILURE;KIDNEY;ODDS RATIO;ANGIOPLASTY;CONFIDENCE INTERVAL;INCIDENCE (GEOMETRY);RENAL FUNCTION;RISK FACTOR;ANTIBODY;BIOPSY;HEMODYNAMICS;HOMOCYSTEINE;STENT;THROMBOSIS","14;13;12;10;9;9;8;7;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4","KIDNEY TRANSPLANTATION;DIASTOLE;REVASCULARIZATION;EJECTION FRACTION;HYPERHOMOCYSTEINEMIA;PERCUTANEOUS CORONARY INTERVENTION;RENAL TRANSPLANT;BREAST CANCER;GENOTYPE;MYCOBACTERIUM;NEURORADIOLOGY;PRELOAD;RESTENOSIS;ADENOCARCINOMA;ALLELE;CARDIOGENIC SHOCK;CORONARY ANGIOGRAPHY;CUMULATIVE INCIDENCE;CYCLOSPORINS;DEEP VEIN;DEMENTIA;GENETIC LINKAGE;GENOME;HEART RATE;LIPOPROTEIN;MYCOBACTERIUM TUBERCULOSIS;NEUROPSYCHOLOGY;POLYMERASE CHAIN REACTION;PROSTATE CANCER;PULSE PRESSURE;RENAL BLOOD FLOW;SINUS RHYTHM;T LYMPHOCYTE;ULCERATIVE COLITIS;VENOUS THROMBOSIS","6;5;5;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","METHYLENETETRAHYDROFOLATE REDUCTASE;ACE INHIBITOR;ADJUVANT CHEMOTHERAPY;ADOPTIVE CELL TRANSFER;AL AMYLOIDOSIS;ANTIMYCOBACTERIAL;ANTIRETROVIRAL THERAPY;BASILIXIMAB;BIRBECK GRANULES;BROMOCRIPTINE;CENTRAL RETINAL VEIN OCCLUSION;COGNITIVE DECLINE;CORE BIOPSY;CORONARY STENTING;CYP3A4;DEEP BRAIN STIMULATION;DIASTOLIC FUNCTION;DNA MISMATCH REPAIR;DOPAMINE AGONIST;DOPPLER ECHOCARDIOGRAPHY;EPIRUBICIN;ETHAMBUTOL;FACTOR V LEIDEN;FLUORESCENCE IN SITU HYBRIDIZATION;GASTRINOMA;GENITAL WARTS;GLOBUS PALLIDUS;GLUCAGON-LIKE PEPTIDE-1;GLUCAGONOMA;HAPLOTYPE;HOLOPROSENCEPHALY;HUMAN MITOCHONDRIAL GENETICS;HUMAN PAPILLOMA VIRUS;HYPERDYNAMIC CIRCULATION;ILEITIS;IN SITU HYBRIDIZATION;LAMIVUDINE;LEFT ATRIAL ENLARGEMENT;LIPOPROTEIN(A);MAMMOGRAPHY;MITOCHONDRIAL DISEASE;MYCOLIC ACID;MYCOPLASMATACEAE;NEUROENDOCRINE DIFFERENTIATION;NO REFLOW PHENOMENON;NONTUBERCULOUS MYCOBACTERIA;NUCLEAR GENE;OLIGODENDROGLIOMA;OMEGA-N-METHYLARGININE;PLASMA RENIN ACTIVITY;PRIMARY ANGIOPLASTY;PROSTATE BIOPSY;PROSTATECTOMY;RECTAL EXAMINATION;RENAL SODIUM REABSORPTION;RESTRICTION DIGEST;RESTRICTION FRAGMENT LENGTH POLYMORPHISM;RESTRICTION MAP;RESTRICTION SITE;RIGHT CORONARY ARTERY;SF-36;SIDA;SINGLE-NUCLEOTIDE POLYMORPHISM;STEM CELL FACTOR;STROKE VOLUME;TARGET LESION;TERATOLOGY;THYMOGLOBULIN;TORQUE TENO VIRUS;TRANSRECTAL ULTRASONOGRAPHY;VASCULAR DEMENTIA;ZIDOVUDINE","4;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;AGED;MYOCARDIAL INFARCTION;KIDNEY TRANSPLANTATION;MYCOBACTERIUM;ITALY;FOLLOW-UP STUDIES;HYPERTENSION;;CORONARY DISEASE;IMMUNOSUPPRESSIVE AGENTS;RISK FACTORS;ADOLESCENT;AGED, 80 AND OVER;LYMPHOMA, NON-HODGKIN;TREATMENT OUTCOME","89;63;58;52;42;39;20;17;17;16;15;15;12;12;12;12;11;11;10;10","KIDNEY TRANSPLANTATION;CARDIAC SURGERY AND BYPASS GRAFTING OUTCOMES;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;BREAST PATHOLOGY AND IMAGING TECHNIQUES;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY;ROLE OF HOMOCYSTEINE IN HEALTH AND DISEASE;DIAGNOSIS AND MANAGEMENT OF CONGENITAL DIAPHRAGMATIC HERNIA;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;MANAGEMENT OF VALVULAR HEART DISEASE;PHEOCHROMOCYTOMA AND PARAGANGLIOMA;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;ANORECTAL SURGICAL PROCEDURES;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;CELLULAR SENESCENCE AND AGING-RELATED DISEASES;CHARGE SYNDROME AND RELATED GENETIC DISORDERS;CUTANEOUS ADNEXAL NEOPLASMS AND RELATED SYNDROMES","5;4;4;4;3;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1","CARDIAC IMAGING;TREATMENT;CARDIOVASCULAR EVALUATION;CARDIOVASCULAR RISK ASSESSMENT;HYPERHOMOCYSTEINEMIA;CARDIAC SURGERY RISK MODELS;HYPERTENSION;KIDNEY TRANSPLANTATION;LEFT VENTRICULAR FUNCTION;MYCOBACTERIUM ABSCESSUS;NEURORADIOLOGY;PRELOAD;ANTIRETROVIRAL THERAPY;BREAST CANCER;CADAVERIC SPASM;CARDIAC OUTCOMES;CAROTID ARTERY STENOSIS;CORONARY ARTERY BYPASS SURGERY;CORONARY STENTS;CUMULATIVE INCIDENCE","6;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","ACUTE MYOCARDIAL;MYOCARDIAL INFARCTION;RENAL TRANSPLANT;CORONARY ARTERY;LEFT VENTRICULAR;ACUTE REJECTION;ANGIOGRAPHIC OUTCOMES;ANTITHYMOCYTE GLOBULIN;ARTERY DISEASE;ARTERY STENTING;BEATING HEART;CADAVERIC RENAL;CARDIAC SURGERY;CARDIOVASCULAR DISEASE;END-STAGE CORONARY;EXTRACORPOREAL CIRCULATION;FOLLOW-UP STUDY;HEART MYOCARDIAL;ISOLATED SYSTOLIC;MITRAL VALVE;MONTH FOLLOW-UP;MYOCARDIAL REVASCULARIZATION;PRIMARY ANGIOPLASTY;PROGNOSTIC IMPLICATIONS;RENAL TRANSPLANTATION;SYSTOLIC HYPERTENSION;TRANSPLANT PATIENTS;TRANSPLANT RECIPIENTS;ULCERATIVE COLITIS;ACTIVE ULCERATIVE","5;5;5;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1","LANGERHANS CELLS;QUICK TIME;RENAL TRANSPLANT;THCY LEVELS;TRANSPLANT RECIPIENTS;CY LEVELS;FT CUTOFF;PSAD CUTOFF;VENOUS THROMBOSIS;GLUCOSE LOAD;IMA HARVESTING;LFHF RATIO;LIQUID CHROMATOGRAPHY;MITOCHONDRIAL DNA;ORAL GLUCOSE;POSTMETHIONINE NA;PSA CUTOFF;RISK FACTOR;BREAST CANCER;CARDIAC SYMPATHETIC;CARDIOVASCULAR EVENT;CARDIOVASCULAR EVENTS;CARDIOVASCULAR RISK;CELL COUNT;CONCOMITANTLY ADMINISTERED;CORONARY REVASCULARIZATION;COUNT CELLSMM;ENVIRONMENTAL ISOLATES;FACTOR VIII;FASTING NA","8;8;7;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3",15,0.15,4.92,3,0,0,0,0,4.25,1,1,3,0,0,3,0,1.75,0,0,3,0,0,0,44,44,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,10.33,1804.67,1.4,2,0.67,33.67,0,0,1,0,2,0,0,0,0,3,0,0,0,0,0,0,0,2,1,0,3,0,0,0,0,0,0,0,0,0,"Belgium","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY","3;2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;BREAST CANCER;COLO-RECTAL CANCER;DIGESTIVE DISEASES;HEMATOLOGY;ORPHAN DRUG;PATIENT SAFETY;RARE DISEASES;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;TRANSPLANTATION","3;3;2;1;1;1;1;1;1;1;1;1;1;1","CANCER","3","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","2;1;1;1","BREAST CANCER;COLON AND RECTAL CANCER;MYELOMA","1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","2;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CAREGGI",2002,106,7.9622641509434,2.84905660377359,0.481132075471698,0.320754716981132,0.481132075471698,1.5978835978836,1.34210526315789,1.30769230769231,1.34210526315789,0.311320754716981,8,56,18,14,12,0.53,0.17,0.13,0.11,47.15,0.854668216000681,NA,0.169811320754717,0.613207547169811,0.447,0.386,0.352,0.386,"CARLO DANI;DAVID ANTONIUCCI;MARCO PEZZATI;FRANCESCA TORRICELLI;ANGELA MIGLIORINI;M. CELLERINI;FIRMINO F. RUBALTELLI;GUIA MOSCHI;RENATO VALENTI;LEONARDO BOLOGNESE;M NISTRI;P MENNONNA;GIUSEPPE BARLETTA;PAOLO GEÑTILINI;ELENA MARTELLI;LUCA FILIPPI;M GORINI;GIOVANNA BERTINI;MAURIZIO TRAPANI;GIOVANNI MARIA SANTORO","8;8;7;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4","M GORINI;GIUSEPPE BARLETTA;M BINI;CARLO DANI;G. F. GENSINI;EDVIN PRIFTI;MARCO PEZZATI;C DANI;ALBERTO DOLARA;ALESSANDRO PULSONI;DAVID ANTONIUCCI;FRANCESCA TORRICELLI;FIRMINO F. RUBALTELLI;ELENA MARTELLI;GIOVANNA BERTINI;ANTONIO CORRADO;M. CELLERINI;ANGELA MIGLIORINI;GUIA MOSCHI;RENATO VALENTI","1.7;1.4;1.31;1.3;1.27;1.25;1.1;1;1;1;0.96;0.81;0.77;0.73;0.73;0.7;0.69;0.61;0.61;0.61","CARLO DANI;DAVID ANTONIUCCI;MARCO PEZZATI;FRANCESCA TORRICELLI;ANGELA MIGLIORINI;M. CELLERINI;FIRMINO F. RUBALTELLI;GUIA MOSCHI;RENATO VALENTI;LEONARDO BOLOGNESE;M NISTRI;P MENNONNA;GIUSEPPE BARLETTA;ELENA MARTELLI;LUCA FILIPPI;M GORINI;GIOVANNA BERTINI;MAURIZIO TRAPANI;GIOVANNI MARIA SANTORO;EMILIO VINCENZO DOVELLINI","8;8;7;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;3","M GORINI;GIUSEPPE BARLETTA;M BINI;CARLO DANI;G. F. GENSINI;EDVIN PRIFTI;MARCO PEZZATI;C DANI;ALBERTO DOLARA;ALESSANDRO PULSONI;DAVID ANTONIUCCI;FRANCESCA TORRICELLI;FIRMINO F. RUBALTELLI;ELENA MARTELLI;GIOVANNA BERTINI;ANTONIO CORRADO;M. CELLERINI;ANGELA MIGLIORINI;GUIA MOSCHI;RENATO VALENTI","1.7;1.4;1.31;1.3;1.27;1.25;1.1;1;1;1;0.96;0.81;0.77;0.73;0.73;0.7;0.69;0.61;0.61;0.61","CARLO DANI;FIRMINO F. RUBALTELLI;R BIADAIOLI;ELENA MARTELLI;GIOVANNA BERTINI;DAVID ANTONIUCCI;ANGELA MIGLIORINI;GUIA MOSCHI;RENATO VALENTI;IACOPO OLIVOTTO;GIOVANNI MARIA SANTORO;LEONARDO BOLOGNESE;MAURIZIO TRAPANI;ALOÏS GRATWOHL;BARRY J. MARON;BJÖRN P. FLYGENRING;FRANCO CECCHI;MARIA ROSA CONTE;PAOLO SPIRITO;PIETRO BELLONE","578;522;510;495;495;482;415;415;415;411;378;378;378;367;361;361;361;361;361;361","CARLO DANI;ELENA MARTELLI;GIOVANNA BERTINI;DAVID ANTONIUCCI;R BIADAIOLI;ANGELA MIGLIORINI;GUIA MOSCHI;RENATO VALENTI;GIOVANNI MARIA SANTORO;LEONARDO BOLOGNESE;MAURIZIO TRAPANI;FRANCO CECCHI;IACOPO OLIVOTTO;GIAMPAOLO CERISANO;PIERGIOVANNI BUONAMICI;A. MENICUCCI;RICCARDO SACCARDI;EMILIO VINCENZO DOVELLINI;BENEDETTA BARTOLOZZI;PA BERNABEI","495;495;495;482;439;415;415;415;378;378;378;361;361;306;306;299;263;236;190;190","DAVID ANTONIUCCI;ANGELA MIGLIORINI;CARLO DANI;GUIA MOSCHI;MARCO PEZZATI;RENATO VALENTI;ROSANNA ABBATE;ELENA MARTELLI;FRANCESCA TORRICELLI;GIOVANNA BERTINI;GIOVANNI MARIA SANTORO;GIUSEPPE BARLETTA;LEONARDO BOLOGNESE;MAURIZIO TRAPANI;P MENNONNA;M. CELLERINI;GIAMPAOLO CERISANO;M BINI;PIERGIOVANNI BUONAMICI;ANTONIO CORRADO","8;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;POLITICAL SCIENCE;PSYCHOLOGY;ECONOMICS;MATHEMATICS;MATERIALS SCIENCE;PHILOSOPHY;SOCIOLOGY","101;36;15;14;4;4;4;4;3;3;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;GENETICS;PATHOLOGY;ANESTHESIA;RADIOLOGY;ENDOCRINOLOGY;IMMUNOLOGY;BIOCHEMISTRY;PSYCHIATRY;OPTICS;GASTROENTEROLOGY;PEDIATRICS;FAMILY MEDICINE;CELL BIOLOGY;INTENSIVE CARE MEDICINE;ONCOLOGY;ORGANIC CHEMISTRY;PHARMACOLOGY","79;30;29;24;17;14;14;13;12;11;11;10;9;9;8;7;7;7;6;6","PREGNANCY;MYOCARDIAL INFARCTION;GENE;INCIDENCE (GEOMETRY);ALTERNATIVE MEDICINE;CANCER;DISEASE;HEMODYNAMICS;BLOOD PRESSURE;TRANSPLANTATION;CHEMOTHERAPY;ANGIOPLASTY;CEREBRAL BLOOD FLOW;CORONARY ARTERY DISEASE;POPULATION;RANDOMIZED CONTROLLED TRIAL;RECEPTOR;REGIMEN;STENT;THROMBOSIS","14;10;9;9;8;8;8;8;7;7;6;5;5;5;5;5;5;5;5;5","GESTATIONAL AGE;BREAST CANCER;CARDIOGENIC SHOCK;KIDNEY TRANSPLANTATION;OXYGEN SATURATION;PERCUTANEOUS CORONARY INTERVENTION;VASCULAR RESISTANCE;GESTATION;HEART RATE;PLACEBO;REVASCULARIZATION;UNSTABLE ANGINA;ANGIOTENSIN-CONVERTING ENZYME;AXILLARY NERVE;BIRTH WEIGHT;BRACHIAL PLEXUS BLOCK;CAESAREAN SECTION;CAROTID ENDARTERECTOMY;CYCLOPHOSPHAMIDE;DEOXYGENATED HEMOGLOBIN;DOSIMETER;EJECTION FRACTION;EMBRYO TRANSFER;EXON;FABRY DISEASE;FETUS;GENE EXPRESSION;HAEMATOPOIESIS;HUMAN LEUKOCYTE ANTIGEN;IN VITRO FERTILISATION;LEFT ATRIUM;LUTEINIZING HORMONE;MIDDLE CEREBRAL ARTERY;MUTATION;NEURORADIOLOGY;NITRIC OXIDE SYNTHASE;NUCLEOSIDE ANALOGUE;PHASES OF CLINICAL RESEARCH;PHENOTYPE;RNA;SEPTIC SHOCK;VAGINAL DELIVERY;VIRAL LOAD;WARFARIN","7;5;5;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ABCIXIMAB;ANTERIOR CEREBRAL ARTERY;ANTIRETROVIRAL THERAPY;CAROTID STENTING;PLACENTA;THERMOLUMINESCENT DOSIMETER;TIMI;ACE INHIBITOR;ACUTE PROMYELOCYTIC LEUKEMIA;ADJUVANT CHEMOTHERAPY;AROMATASE;AUTONOMIC NERVOUS SYSTEM;AXILLA;BARORECEPTOR;BAROREFLEX;BRADYCARDIA;CARDIAC INDEX;CD81;CEREBRAL AUTOREGULATION;CHEMOKINE RECEPTOR;COGNITIVE DECLINE;CONTROLLED OVARIAN HYPERSTIMULATION;CYTOGENETICS;DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;DEOXYCYTIDINE;DNA FRAGMENTATION;DNA METHYLATION;DOPPLER ECHOCARDIOGRAPHY;DUCTAL CARCINOMA;EMBRYO QUALITY;ENOS;EPIRUBICIN;ESTROGEN RECEPTOR;FILTRATION FRACTION;FOLLICLE-STIMULATING HORMONE;GESTATIONAL DIABETES;GIANT CELL ARTERITIS;GLOBOTRIAOSYLCERAMIDE;GLOMERULAR HYPERFILTRATION;GONADOTROPIN-RELEASING HORMONE;GRB2;HAMILTON DEPRESSION SCALE;HISTOCOMPATIBILITY;HLA-G;IN SITU HYBRIDIZATION;INTRACRANIAL ARTERIOVENOUS MALFORMATIONS;LAMIVUDINE;LOSS OF HETEROZYGOSITY;LYN;MAMMOGRAPHY;MESALAZINE;MICROSATELLITE;MUTATION TESTING;NURSING OUTCOMES CLASSIFICATION;OVARIAN HYPERSTIMULATION SYNDROME;OXALIPLATIN;PAROXETINE;PEROXYNITRITE;PLASMA RENIN ACTIVITY;POINT MUTATION;POLY ADP RIBOSE POLYMERASE;REVERSE TRANSCRIPTASE;REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;SALMONELLA ENTERICA;SELECTED REACTION MONITORING;SEVERE SEPSIS;SMALL FOR GESTATIONAL AGE;SOLID-PHASE MICROEXTRACTION;STROKE VOLUME;SULFASALAZINE;THERMAL DESORPTION;THROMBOPOIETIN;TISSUE FACTOR PATHWAY INHIBITOR;TOTAL BODY IRRADIATION;YOHIMBINE;ZIDOVUDINE","2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;AGED;MYOCARDIAL INFARCTION;;TREATMENT OUTCOME;ITALY;PROSPECTIVE STUDIES;POSTOPERATIVE COMPLICATIONS;TIME FACTORS;ADOLESCENT;LIVER CIRRHOSIS;RETROSPECTIVE STUDIES;AORTIC VALVE INSUFFICIENCY;HEMODYNAMICS;INFANT, NEWBORN;SCLERODERMA, SYSTEMIC","82;63;61;45;34;32;23;20;19;17;12;11;10;9;9;9;8;8;8;8","MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;NEONATAL BRAIN INJURY AND DEVELOPMENTAL CONSEQUENCES;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;GENETIC BASIS OF NEUTROPENIA DISORDERS;MANAGEMENT AND EPIDEMIOLOGY OF INFECTIVE ENDOCARDITIS;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;MOLECULAR RESEARCH ON BREAST CANCER;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ATRIAL FIBRILLATION;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM","6;5;5;4;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1","CARDIOVASCULAR RISK ASSESSMENT;CARDIAC IMAGING;REGIMEN;BRAIN OXYGENATION MONITORING;CEREBRAL BLOOD FLOW;CEREBRAL BLOOD FLOW MEASUREMENT;FABRY DISEASE;PRETERM INFANTS;TREATMENT;HYPERTENSION;IMMUNOSUPPRESSION;MYOCARDIAL PERFUSION;MYOCARDIAL REVASCULARIZATION;OXYGEN SATURATION;PULMONARY DISEASE;RESPIRATORY;STENTING;SUPINE POSITION;UNSTABLE ANGINA;ABCIXIMAB","6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2","ACUTE MYOCARDIAL;MYOCARDIAL INFARCTION;TERM INFANTS;BLOOD FLOW;CEREBRAL BLOOD;CORONARY ARTERY;FABRY DISEASE;PRETERM INFANTS;RENAL TRANSPLANTATION;SYSTEMIC SCLEROSIS;ABCIXIMAB THERAPY;ANTI-EMBOLISM SYSTEM;AORTA-TO-LEFT ATRIUM;ARTERY DISEASE;ARTERY STENT;ATRIUM FISTULA;BLOOD TRANSFUSIONS;BRACHIAL PLEXUS;CAESAREAN SECTION;CARE UNITS;CELL LINE;CELL TRANSPLANTATION;CEREBRAL HAEMODYNAMICS;CHEST PAIN;DIABETES MELLITUS;DOPPLER ASSESSMENT;ENDOCARDITIS AORTA-TO-LEFT;FLOW VELOCITY;FOUR-INJECTION BRACHIAL;HEALTHY PRETERM","5;5;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","NORMAL RANGE;CEREBRAL ARTERY;DE NOVO;MHC ANTIGENS;DIABETES MELLITUS;GESTATIONAL AGE;MIDDLE CEREBRAL;NON-CANCER SUBJECTS;AORTIC DISSECTION;CEREBRAL ARTERIES;DUCTAL CARCINOMA;MATERNAL MHC;NOVO APL;OBSERVATIONAL STUDIES;PATIENTS RECEIVED;RESPIRATORY FAILURE;TRANSIENT NDM;ANTERIOR CEREBRAL;BIRTH WEIGHT;CELL CLONES;CHRONIC RESPIRATORY;GROWTH RETARDATION;HEALTHY WOMEN;IMMUNOREACTIVE TRYPSINOGEN;IV ANTIBIOTICS;LUNG MACROPHAGES;NEONATAL DIABETES;NORMAL SUBJECTS;OT RESPONSIVENESS;PANCREATIC INSUFFICIENCY","9;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4",20,0.19,6,3,0,0,0,2,6.75,1,1.25,3,0,0,1,0,3.5,0,0,1,0,0,0,60.25,60.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,5.8,1318.17,3.41,2,0.33,77.5,0,0,3,0,3,0,0,0,0,6,0,0,0,0,0,0,0,6,0,0,6,0,0,0,0,0,0,0,0,0,"United States;Belgium;Italy","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","6;3;3;2;1","CLINICAL RESEARCH;RARE DISEASES;ORPHAN DRUG;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;PEDIATRIC;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;TRANSPLANTATION;AGING;AUTOIMMUNE DISEASE;CARDIOVASCULAR;HEART DISEASE;LYMPHOMA;NUTRITION;PATIENT SAFETY;PREVENTION;REGENERATIVE MEDICINE","5;4;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","CANCER;INFLAMMATORY AND IMMUNE SYSTEM;CARDIOVASCULAR","2;2;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","4;3","LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;BLOOD CANCER;HODGKIN'S DISEASE;MYELOMA;PANCREATIC CANCER","4;3;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","4;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CAREGGI",2003,122,7.20491803278689,2.86065573770492,0.581967213114754,0.352459016393443,0.60655737704918,1.59360730593607,1.24561403508772,1.38709677419355,1.27586206896552,0.278688524590164,5,49,26,13,24,0.4,0.21,0.11,0.2,49.91,0.942977795259916,NA,0.229508196721311,0.639344262295082,0.453,0.364,0.33,0.362,"DOMENICO PRISCO;ENRICO TORTOLI;ROSANNA ABBATE;CARLO DANI;DAVID ANTONIUCCI;MASSIMO SANTINI;GIAN FRANCO GENSINI;ANGELA MIGLIORINI;ALFREDO ZUPPIROLI;ANDREA MESSORI;IACOPO OLIVOTTO;MAURIZIO SALVADORI;SANDRA FEDI;LUIGI PADELETTI;LEONARDO BOLOGNESE;AGOSTINO OGNIBENE;RENATO MORETTI‐MARQUES;ALBERTO ROSATI;EDVIN PRIFTI;ANDREA GRAMMATICO","7;7;7;6;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4","ENRICO TORTOLI;CARLO DANI;ANDREA MESSORI;GIUSEPPE BARLETTA;ALFREDO ZUPPIROLI;S AITO;L PADELETTI;ROSANNA ABBATE;FABIO MORI;MAURIZIO SALVADORI;DAVID ANTONIUCCI;DOMENICO PRISCO;ALBERTO ROSATI;GIAN FRANCO GENSINI;RENATO MORETTI‐MARQUES;EDVIN PRIFTI;MASSIMO BONACCHI;LAPO BENCINI;SABRINA TRIPPOLI;LUIS SANCHEZ","2.04;1.7;1.33;1.17;1.16;1.09;1;0.93;0.87;0.87;0.83;0.77;0.77;0.76;0.75;0.75;0.75;0.75;0.75;0.75","DOMENICO PRISCO;ENRICO TORTOLI;ROSANNA ABBATE;CARLO DANI;DAVID ANTONIUCCI;GIAN FRANCO GENSINI;ANGELA MIGLIORINI;ALFREDO ZUPPIROLI;ANDREA MESSORI;IACOPO OLIVOTTO;MAURIZIO SALVADORI;SANDRA FEDI;LUIGI PADELETTI;LEONARDO BOLOGNESE;AGOSTINO OGNIBENE;RENATO MORETTI‐MARQUES;ALBERTO ROSATI;EDVIN PRIFTI;FIRMINO F. RUBALTELLI;MARCO PEZZATI","7;7;7;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4","ENRICO TORTOLI;CARLO DANI;ANDREA MESSORI;GIUSEPPE BARLETTA;ALFREDO ZUPPIROLI;S AITO;L PADELETTI;ROSANNA ABBATE;FABIO MORI;MAURIZIO SALVADORI;DAVID ANTONIUCCI;DOMENICO PRISCO;ALBERTO ROSATI;GIAN FRANCO GENSINI;RENATO MORETTI‐MARQUES;EDVIN PRIFTI;MASSIMO BONACCHI;LAPO BENCINI;SABRINA TRIPPOLI;LUIS SANCHEZ","2.04;1.7;1.33;1.17;1.16;1.09;1;0.93;0.87;0.87;0.83;0.77;0.77;0.76;0.75;0.75;0.75;0.75;0.75;0.75","IACOPO OLIVOTTO;FRANCO CECCHI;BARRY J. MARON;JOHN R. LESSER;MARIA ANGELA LOSI;MARTIN S. MARON;SANDRO BETOCCHI;SUSAN A. CASEY;ROBERTO GISTRI;GIAMPAOLO CHIRIATTI;PAOLO G. CAMICI;ROBERTO LORENZONI;ERIK BERNTORP;JAN ASTERMARK;MASSIMO MORFINI;SILVIA LINARI;DAVID ANTONIUCCI;GIOVANNI MARIA SANTORO;LEONARDO BOLOGNESE;RENATO VALENTI","2291;2276;1344;1344;1344;1344;1344;1344;887;731;731;731;523;523;523;374;346;346;346;346","FRANCO CECCHI;IACOPO OLIVOTTO;ROBERTO GISTRI;MASSIMO MORFINI;SILVIA LINARI;DAVID ANTONIUCCI;GIOVANNI MARIA SANTORO;RENATO VALENTI;ANGELA MIGLIORINI;GUIA MOSCHI;GUIDO PARODI;LEONARDO BOLOGNESE;F. BANCI BUONAMICI;G. DʼALBASIO;DANIELA VARGIU;AGOSTINO OGNIBENE;MAURIZIO SALVADORI;GIANNA MAZZARELLI;CARLO DANI;ELENA PEDEMONTE","2276;2276;887;523;374;346;346;346;317;317;317;317;209;202;201;193;187;163;159;156","DAVID ANTONIUCCI;ENRICO TORTOLI;ROSANNA ABBATE;ANDREA MESSORI;ANGELA MIGLIORINI;CARLO DANI;DOMENICO PRISCO;AGOSTINO OGNIBENE;ALBERTO ROSATI;EDVIN PRIFTI;FRANCO CECCHI;GIOVANNI MARIA SANTORO;IACOPO OLIVOTTO;LUIS SANCHEZ;MAURIZIO SALVADORI;RENATO VALENTI;GUIA MOSCHI;GUIDO PARODI;LEONARDO BOLOGNESE;ALFREDO ZUPPIROLI","6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;ECONOMICS;MATERIALS SCIENCE;SOCIOLOGY;PHILOSOPHY;POLITICAL SCIENCE;PSYCHOLOGY;ART;BUSINESS;HISTORY","113;33;16;14;9;7;5;3;3;3;2;2;2;1;1;1","INTERNAL MEDICINE;CARDIOLOGY;SURGERY;GENETICS;ENDOCRINOLOGY;PATHOLOGY;BIOCHEMISTRY;GASTROENTEROLOGY;RADIOLOGY;IMMUNOLOGY;OPTICS;INTENSIVE CARE MEDICINE;PEDIATRICS;PSYCHIATRY;ANESTHESIA;MECHANICAL ENGINEERING;GENERAL SURGERY;MICROBIOLOGY;MOLECULAR BIOLOGY;PHARMACOLOGY;QUANTUM MECHANICS","93;38;34;20;18;17;13;13;13;11;11;9;8;7;6;6;5;5;5;5;5","ATRIAL FIBRILLATION;GENE;MYOCARDIAL INFARCTION;HEART FAILURE;CHEMOTHERAPY;DISEASE;INCIDENCE (GEOMETRY);RISK FACTOR;STENOSIS;ALTERNATIVE MEDICINE;LESION;PREGNANCY;TRANSPLANTATION;BACTERIA;BLOOD PRESSURE;DIABETES MELLITUS;LAPAROSCOPY;BIOPSY;CLINICAL TRIAL;CONFIDENCE INTERVAL;ENZYME;HYPERTROPHIC CARDIOMYOPATHY;ISCHEMIA;ODDS RATIO;POPULATION;PROSPECTIVE COHORT STUDY;RESPIRATORY SYSTEM;STENT;STROKE (ENGINE)","13;12;12;10;7;7;7;7;7;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4","PERCUTANEOUS CORONARY INTERVENTION;EJECTION FRACTION;GENOTYPE;MYCOBACTERIUM;REVASCULARIZATION;ACUTE CORONARY SYNDROME;ALLELE;BIRTH WEIGHT;CARDIOMYOPATHY;HEART RATE;KIDNEY TRANSPLANTATION;PLACEBO;RESTENOSIS;ANGIOTENSIN-CONVERTING ENZYME;AORTIC VALVE REPLACEMENT;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CARDIOGENIC SHOCK;CONTRAINDICATION;CONVENTIONAL PCI;DOBUTAMINE;GESTATION;HEPATITIS C VIRUS;INSULIN RESISTANCE;ISCHEMIC STROKE;LAPAROSCOPIC SURGERY;LOW BIRTH WEIGHT;MESSENGER RNA;MITRAL VALVE REPAIR;MYCOBACTERIUM TUBERCULOSIS;MYOCARDIAL REVASCULARIZATION;NEURORADIOLOGY;POLYMERASE CHAIN REACTION;RENAL TRANSPLANT;SPINAL CORD DISEASES;SPUTUM;SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;THROMBIN;TISSUE FACTOR;TITER;TYPE 2 DIABETES;ULCERATIVE COLITIS;UNSTABLE ANGINA;VENOUS THROMBOSIS;VENTRICULAR OUTFLOW TRACT OBSTRUCTION;VIRAL LOAD;WARFARIN","6;5;5;5;5;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","NONTUBERCULOUS MYCOBACTERIA;ANTIRETROVIRAL THERAPY;CARDIAC RESYNCHRONIZATION THERAPY;FACTOR V LEIDEN;MYCOBACTERIUM FORTUITUM;TARGET LESION;THROMBIN GENERATION;ABCIXIMAB;ACID-FAST;ACUTE PROMYELOCYTIC LEUKEMIA;ALPHA (FINANCE);ANAPLASTIC ASTROCYTOMA;ANGIOTENSIN RECEPTOR;ARTICULAR CARTILAGE;ATRIAL TACHYCARDIA;BECLOMETASONE DIPROPIONATE;BONE METASTASIS;CEFTAZIDIME;CLAVULANIC ACID;COLONOSCOPY;CREB;DABIGATRAN;DEEP BRAIN STIMULATION;DETECTIVE QUANTUM EFFICIENCY;DIPEPTIDYL PEPTIDASE-4;DISCOVERY AND DEVELOPMENT OF DIRECT THROMBIN INHIBITORS;DNA SEQUENCER;ENOS;FAS RECEPTOR;GENE MUTATION;GESTATIONAL DIABETES;GLUCAGON-LIKE PEPTIDE-1;GLUCOSE TOLERANCE TEST;GLYCATED HAEMOGLOBIN;HYPERINSULINEMIA;HYPERINSULINEMIC HYPOGLYCEMIA;HYPERINSULINISM;IMPAIRED GLUCOSE TOLERANCE;INHA;INTERNAL TRANSCRIBED SPACER;INTRACRANIAL ARTERIOVENOUS MALFORMATIONS;IONIZATION CHAMBER;MAMMOGRAPHY;METHYLENETETRAHYDROFOLATE REDUCTASE;MICROSATELLITE;MULTILOCUS SEQUENCE TYPING;MYCOBACTERIUM BOVIS;MYCOBACTERIUM KANSASII;MYCOLIC ACID;NESIDIOBLASTOSIS;NORTHERN BLOT;ORAL ANTICOAGULANT;OVARIAN HYPERSTIMULATION SYNDROME;PLATELET-POOR PLASMA;POLY ADP RIBOSE POLYMERASE;POLYMORPHISM (COMPUTER SCIENCE);PYONEPHROSIS;RESTRICTION FRAGMENT LENGTH POLYMORPHISM;RIGHT CORONARY ARTERY;SPUTUM CULTURE;SUBSTANCE P;SYMPORTER;TISSUE FACTOR PATHWAY INHIBITOR;URAPIDIL;VO2 MAX","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;AGED;ADULT;;MYOCARDIAL INFARCTION;AGED, 80 AND OVER;ITALY;TREATMENT OUTCOME;PROSPECTIVE STUDIES;VENTRICULAR DYSFUNCTION, LEFT;FOLLOW-UP STUDIES;CARDIOMYOPATHY, HYPERTROPHIC;RISK FACTORS;HEMOPHILIA A;RETROSPECTIVE STUDIES;POSTOPERATIVE COMPLICATIONS;TIME FACTORS","88;66;64;49;42;37;25;23;21;20;18;17;17;15;14;14;13;12;11;11","MANAGEMENT OF VALVULAR HEART DISEASE;ATRIAL FIBRILLATION;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;THROMBOSIS AND COAGULATION DISORDERS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;HEALTH ECONOMICS AND QUALITY OF LIFE ASSESSMENT;CARDIAC SURGERY AND BYPASS GRAFTING OUTCOMES;DIAGNOSIS AND MANAGEMENT OF SYNCOPE;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;HEPATITIS C INFECTION AND TREATMENT;HERNIA REPAIR TECHNIQUES AND MATERIALS;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;KIDNEY TRANSPLANTATION;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;METABOLIC SYNDROME AND CARDIOVASCULAR DISEASE;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;PHEOCHROMOCYTOMA AND PARAGANGLIOMA","6;5;5;5;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2","TREATMENT;ANTICOAGULANT THERAPY;MYCOBACTERIUM ABSCESSUS;STROKE (ENGINE);TRANSCATHETER AORTIC-VALVE REPLACEMENT;ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY;ATRIAL FIBRILLATION;CARDIAC IMAGING;CONTINUOUS GLUCOSE MONITORING;LEFT VENTRICULAR FUNCTION;MYOCARDIAL REVASCULARIZATION;NONTUBERCULOUS MYCOBACTERIA;PACEMAKER THERAPY;PROSTHETIC VALVES EVALUATION;ADRENAL VEIN SAMPLING;ANGIOTENSIN;ANTITHROMBOTIC THERAPY;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CARDIAC RESYNCHRONIZATION THERAPY;CARDIOGENIC SHOCK","5;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2","LEFT VENTRICULAR;ATRIAL FIBRILLATION;ACUTE MYOCARDIAL;HYPERTROPHIC CARDIOMYOPATHY;MYOCARDIAL INFARCTION;CLINICAL OUTCOME;P- ATRIAL;THROMBIN GENERATION;ACUTE CORONARY;ANGIOGRAPHIC RESULTS;ATRIAL ARRHYTHMIA;ATRIAL TACHYARRHYTHMIA;CARDIAC RESYNCHRONIZATION;CARDIOGENIC SHOCK;CIRCULATING LEVELS;CONTRACTILE RESERVE;CORONARY STENT;CORONARY SYNDROMES;CRT PATIENTS;DDDRP PACEMAKER;EUROPEAN MASCOT;GENERATION ASSAY;HEART FAILURE;HEPATOCELLULAR CARCINOMA;INFARCTION COMPLICATED;INFLAMMATORY RESPONSE;ISCHEMIC STROKE;LAPAROSCOPIC TREATMENT;MASCOT STUDY;MITRAL VALVE","6;5;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","THROMBIN GENERATION;TB PATIENTS;FVIII INHIBITOR;INHIBITOR PLASMA;SCIENCEGOOGLE SCHOLAR;AORTIC VALVE;PEAK THROMBIN;FACTOR VIII;FEIBA INJECTION;LAG PHASE;PLASMA SAMPLES;THROMBIN POTENTIAL;NORMAL PLASMA;PEAK TIME;FEIBA TREATMENT;FLUORESCENCE SIGNAL;FU MIN;BREAST FEEDING;BU ML;HYPERTROPHIC CARDIOMYOPATHY;PATIENTS UNDERGOING;PROTHROMBIN COMPLEX;BAXTER BIOSCIENCE;GENERATION ASSAY;PROSPECTIVE RANDOMIZED;SINGLE DOSE;THROMBIN CONCENTRATION;BIOSCIENCE VIENNA;BLOOD SAMPLE;FIGURE VIEWERPOWERPOINT","58;18;16;16;16;14;14;12;12;11;11;11;10;10;9;9;9;8;8;8;8;8;7;7;7;7;7;6;6;6",22,0.18,6,3,1,0,0,2,3,0,1,4,0,0,2.5,0,1,1,0,1.75,0,0,0,57.5,57.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,4,634.75,2.02,0,0,53.5,0,0,0,0,2,0,1,1,0,4,0,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,0,0,0,0,"Germany","1","32 BIOMEDICAL AND CLINICAL SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3208 MEDICAL PHYSIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","4;2;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BRAIN DISORDERS;BREAST CANCER;CANCER;CARDIOVASCULAR;COLO-RECTAL CANCER;DIGESTIVE DISEASES;HEART DISEASE;LUNG;NEUROSCIENCES;ORPHAN DRUG;PREVENTION;RARE DISEASES;STROKE","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;CANCER;STROKE","2;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","3;2","COLON AND RECTAL CANCER;LUNG CANCER;OVARIAN CANCER;STOMACH CANCER","1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CAREGGI",2004,132,9.1060606060606,2.97727272727273,0.484848484848485,0.401515151515151,0.5,1.55335968379447,1.33333333333333,1.26190476190476,1.3469387755102,0.371212121212121,7,66,23,13,23,0.5,0.17,0.1,0.17,47.1,1.00095363122956,NA,0.21969696969697,0.704545454545455,0.469,0.437,0.385,0.437,"CARLO DANI;ALBERTO ROSATI;FIRMINO F. RUBALTELLI;MARCO PEZZATI;E. BERTONI;MAURIZIO SALVADORI;GIOVANNA BERTINI;DAVID ANTONIUCCI;LUCA FILIPPI;FRANCESCO DI COSTANZO;ENRICO TORTOLI;NICCOLÒ MARCHIONNI;GUIDO PARODI;M. ZANAZZI;ANGELA MIGLIORINI;P MENNONNA;ALBERTO BOSI;GIULIO MASOTTI;ANTONELLA D’ARMINIO MONFORTE;FRANCO AMMANNATI","10;9;9;9;8;8;8;7;6;5;5;5;5;5;4;4;4;4;4;4","ENRICO TORTOLI;CARLO DANI;E. BERTONI;DAVID ANTONIUCCI;FRANCO CECCHI;GIOVANNA BERTINI;FIRMINO F. RUBALTELLI;MARCO PEZZATI;MAURIZIO SALVADORI;SILVIA GASPERONI;GUIDO PARODI;ALBERTO ROSATI;STEFANO BAMBI;CARMINE SANTOMAGGIO;M. SALVADORI;LAPO BENCINI;LUCA FILIPPI;M. ZANAZZI;ALESSANDRA CECCHI;FRANCESCO DI COSTANZO","2.32;1.57;1.43;1.38;1.33;1.28;1.23;1.23;1.22;1.12;1.11;1.02;1;1;1;0.9;0.86;0.76;0.67;0.66","CARLO DANI;ALBERTO ROSATI;FIRMINO F. RUBALTELLI;MARCO PEZZATI;E. BERTONI;MAURIZIO SALVADORI;GIOVANNA BERTINI;DAVID ANTONIUCCI;LUCA FILIPPI;FRANCESCO DI COSTANZO;ENRICO TORTOLI;NICCOLÒ MARCHIONNI;GUIDO PARODI;M. ZANAZZI;ANGELA MIGLIORINI;P MENNONNA;ALBERTO BOSI;GIULIO MASOTTI;FRANCO AMMANNATI;GIOVANNI MARIA SANTORO","10;9;9;9;8;8;8;7;6;5;5;5;5;5;4;4;4;4;4;4","ENRICO TORTOLI;CARLO DANI;E. BERTONI;DAVID ANTONIUCCI;FRANCO CECCHI;GIOVANNA BERTINI;FIRMINO F. RUBALTELLI;MARCO PEZZATI;MAURIZIO SALVADORI;SILVIA GASPERONI;GUIDO PARODI;ALBERTO ROSATI;STEFANO BAMBI;CARMINE SANTOMAGGIO;M. SALVADORI;LAPO BENCINI;LUCA FILIPPI;M. ZANAZZI;ALESSANDRA CECCHI;FRANCESCO DI COSTANZO","2.32;1.57;1.43;1.38;1.33;1.28;1.23;1.23;1.22;1.12;1.11;1.02;1;1;1;0.9;0.86;0.76;0.67;0.66","ALBERTO BOSI;FRANCESCO FRASSONI;GUILLERMO SANZ;JÜRGEN FINKE;MARCOS DE LIMA;MYRIAM LABOPIN;N JACOBSEN;RAINER SCHWERDTFEGER;TAPANI RUUTU;VANDERSON ROCHA;WILLIAM ARCESE;ÉLIANE GLUCKMAN;MAURIZIO SALVADORI;CARLO DANI;GIOVANNA BERTINI;GIUSEPPE SEGOLONI;ALBERTO GROSSI;DONATO DONATI;ELIANA GOTTI;GIULIA GHERARDI","1106;1095;1095;1095;1095;1095;1095;1095;1095;1095;1095;1095;748;438;396;382;368;361;361;361","ALBERTO BOSI;MAURIZIO SALVADORI;CARLO DANI;ALBERTO GROSSI;MASSIMO MORFINI;FIRMINO F. RUBALTELLI;GIANNA MAZZARELLI;ENRICO TORTOLI;GIOVANNA BERTINI;MARCO PEZZATI;ALESSANDRO MARIOTTINI;LAPO BENCINI;MARCO SCATIZZI;RODOLFO CAPANNA;MASSIMO CALISTRI;RENATO MORETTI‐MARQUES;GIULIO MASOTTI;NICCOLÒ MARCHIONNI;ALESSANDRA CECCHI;ROBERTO SCIAGRÀ","1104;661;388;368;343;342;328;327;300;300;289;261;236;224;210;210;192;192;191;171","FIRMINO F. RUBALTELLI;CARLO DANI;MAURIZIO SALVADORI;ALBERTO ROSATI;E. BERTONI;GIOVANNA BERTINI;MARCO PEZZATI;DAVID ANTONIUCCI;ENRICO TORTOLI;FRANCESCO DI COSTANZO;LUCA FILIPPI;FRANCO AMMANNATI;GUIDO PARODI;M. ZANAZZI;P MENNONNA;GIULIO MASOTTI;NICCOLÒ MARCHIONNI;ALBERTO GROSSI;ALBERTO BOSI;ANGELA MIGLIORINI","8;7;7;6;6;6;6;5;5;5;5;4;4;4;4;4;4;3;3;3","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;ENGINEERING;CHEMISTRY;ECONOMICS;MATHEMATICS;COMPUTER SCIENCE;POLITICAL SCIENCE;SOCIOLOGY;ART;BUSINESS;GEOGRAPHY;HISTORY","124;49;10;9;8;7;6;5;4;4;4;1;1;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;CARDIOLOGY;GASTROENTEROLOGY;PATHOLOGY;ANESTHESIA;IMMUNOLOGY;INTENSIVE CARE MEDICINE;PEDIATRICS;RADIOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;ONCOLOGY;MECHANICAL ENGINEERING;OPTICS;PALEONTOLOGY;UROLOGY;CANCER RESEARCH;MICROBIOLOGY;OBSTETRICS;PSYCHIATRY","92;45;32;26;26;18;17;17;13;12;12;11;10;10;8;7;7;7;6;6;6;6","CANCER;GENE;DISEASE;PREGNANCY;TRANSPLANTATION;POPULATION;MYOCARDIAL INFARCTION;RETROSPECTIVE COHORT STUDY;CHEMOTHERAPY;COMPLICATION;CONFIDENCE INTERVAL;HEART FAILURE;RANDOMIZED CONTROLLED TRIAL;STAGE (STRATIGRAPHY);STENT;ANGIOPLASTY;HUMAN IMMUNODEFICIENCY VIRUS (HIV);INCIDENCE (GEOMETRY);LESION;REGIMEN;STROKE (ENGINE)","20;16;15;14;14;10;9;9;8;6;6;6;6;6;6;5;5;5;5;5;5","KIDNEY TRANSPLANTATION;COLORECTAL CANCER;GESTATION;BREAST CANCER;GESTATIONAL AGE;MYCOBACTERIUM;PERCUTANEOUS CORONARY INTERVENTION;HAZARD RATIO;16S RIBOSOMAL RNA;GENE EXPRESSION;GENOTYPE;MYCOPHENOLATE;MYCOPHENOLIC ACID;POLYMERASE CHAIN REACTION;RENAL TRANSPLANT;VENOUS THROMBOSIS;ACUTE LEUKEMIA;ADJUVANT THERAPY;ALLELE;CEREBRAL PERFUSION PRESSURE;CHEMOKINE;CORONARY ARTERIES;CYCLOPHOSPHAMIDE;DIASTOLE;DIFFUSE LARGE B-CELL LYMPHOMA;EJECTION FRACTION;EXON;FLUOROURACIL;GENETIC PREDISPOSITION;LIVE BIRTH;METASTASIS;MUTATION;NEUTROPENIA;ORGAN DONATION;ORGAN TRANSPLANTATION;PAGET'S DISEASE OF BONE;PATENT FORAMEN OVALE;PHENOTYPE;PHYLOGENETIC TREE;RENAL ARTERY;REVASCULARIZATION;THROMBOLYSIS;UNIVARIATE ANALYSIS;VIRAL DISEASE","9;7;7;6;5;5;5;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CXCL10;INTERNATIONAL PROGNOSTIC INDEX;MAMMOGRAPHY;METASTATIC BREAST CANCER;MYCOLIC ACID;NONTUBERCULOUS MYCOBACTERIA;OLIGOHYDRAMNIOS;PARADOXICAL EMBOLISM;RENAL ARTERY STENOSIS;SEQUESTOSOME 1;SIDA;SINGLE-NUCLEOTIDE POLYMORPHISM;ABCA4;ACTH RECEPTOR;ALLELE FREQUENCY;AMPLICON;ANAL VERGE;ANTIRETROVIRAL THERAPY;ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA;BRONCHOPULMONARY DYSPLASIA;BRONCHUS;CANDIDA KRUSEI;CAPECITABINE;CAPITAL FORMATION;CERVICAL LYMPH NODES;COLONOSCOPY;COMPUTED RADIOGRAPHY;CONCURRENT VALIDITY;CONGENITAL SYPHILIS;DESMOSTEROL;DNA MICROARRAY;DNA MISMATCH REPAIR;DOPAMINE ANTAGONIST;DUCTAL CARCINOMA;DYNAMIC HYPERINFLATION;ENOS;EPLERENONE;ESOPHAGEAL VARICES;FACTOR VIIA;FACTOR X;FEBRILE NEUTROPENIA;FILGRASTIM;FLUDARABINE;FRAMINGHAM HEART STUDY;GASTROEPIPLOIC ARTERY;GATED SPECT;GENE POLYMORPHISM;GENOTYPING;HAEMOPHILIA B;HAPLOTYPE;HEARTBURN;HEME OXYGENASE;HORMONAL THERAPY;HORMONE RECEPTOR;HORMONE THERAPY;IDARUBICIN;IMATINIB MESYLATE;INTERNAL TRANSCRIBED SPACER;INTRAVENTRICULAR HEMORRHAGE;IRINOTECAN;KARYOTYPE;KIDNEY DONATION;KILLIP CLASS;LACTOCOCCUS LACTIS;LAMIVUDINE;LYMPHOVASCULAR INVASION;MASKED HYPERTENSION;MEDULLARY CARCINOMA;MINIMUM BACTERICIDAL CONCENTRATION;MMP9;MOUSE MODEL OF COLORECTAL AND INTESTINAL CANCER;MULTIPLEX POLYMERASE CHAIN REACTION;OLIGODENDROGLIOMA;PAPILLARY THYROID CANCER;PERCUTANEOUS ETHANOL INJECTION;PHILADELPHIA CHROMOSOME;PRETERM LABOUR;RELATIVE SURVIVAL;RETINOPATHY OF PREMATURITY;RIBAVIRIN;RIBOSOMAL DNA;RIGHT GASTROEPIPLOIC ARTERY;SENTINEL NODE;SERINE PROTEASE;SPECIES COMPLEX;SYNOVIAL FLUID;TAMOXIFEN;TARGET LESION;TAXANE;TBARS;TERATOLOGY;TETRAPLEGIA;THROMBASTHENIA;TIMI;TIMP1;TREPONEMA;UNDIFFERENTIATED PLEOMORPHIC SARCOMA;VANCOMYCIN;VINCRISTINE;WHITE COAT HYPERTENSION","2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;;MYOCARDIAL INFARCTION;ITALY;TREATMENT OUTCOME;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;KIDNEY TRANSPLANTATION;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;ADOLESCENT;FOLLOW-UP STUDIES;HEART FAILURE;INFANT, NEWBORN;PROGNOSIS","101;69;64;50;45;45;30;27;25;24;18;16;15;14;14;13;13;12;12;12","DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;KIDNEY TRANSPLANTATION;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND TREATMENT OF HEART FAILURE;ETHICAL AND MEDICAL ASPECTS OF ORGAN DONATION;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;SARCOMA RESEARCH AND TREATMENT;BIOMEDICAL OPTICAL IMAGING AND SPECTROSCOPY;BREAST CANCER SCREENING TECHNOLOGY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND TREATMENT OF RENAL ARTERY STENOSIS;EFFECTS OF MEDICATION ON PREGNANCY OUTCOMES;HEPATITIS C INFECTION AND TREATMENT;LYMPHOID NEOPLASMS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;MOLECULAR RESEARCH ON BREAST CANCER;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;PATENT FORAMEN OVALE AND CEREBROVASCULAR EVENTS;POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME (PRES)","6;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","TREATMENT;CARDIAC IMAGING;REGIMEN;STROKE (ENGINE);CORONARY STENTS;CADAVERIC SPASM;DIAGNOSIS;DISCONTINUATION;KIDNEY TRANSPLANTATION;MYCOPHENOLATE;NONINVASIVE VENTILATION;NONTUBERCULOUS MYCOBACTERIA;QUALITY OF LIFE;ADJUVANT THERAPY;BIRTH OUTCOMES;BOLUS (DIGESTION);BREAST CANCER;CANCER COMMUNICATION;CEREBRAL BLOOD FLOW MEASUREMENT;CORONARY ARTERIES","7;5;5;5;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2","PRETERM INFANTS;ACUTE MYOCARDIAL;MYOCARDIAL INFARCTION;RENAL TRANSPLANTATION;BREAST CANCER;CORONARY INTERVENTION;HEART FAILURE;LEFT VENTRICULAR;PERCUTANEOUS CORONARY;PRETERM INFANT;STENT IMPLANTATION;ACUTE LEUKEMIA;ALLOGRAFT FAILURE;ARTERY STENOSIS;BONE MARROW;BONE PDB;CANCER PATIENTS;CEREBRAL HAEMODYNAMICS;CLINICAL FEATURES;CONVENTIONAL PHOTOTHERAPY;DIGITAL MAMMOGRAPHY;ELDERLY PATIENTS;HEPATOCELLULAR CARCINOMA;INCREASED RISK;INFECTIONS CAUSED;ITALIAN PATIENTS;ITALIAN SERIES;ITALIAN SOCIETY;MYCOPHENOLATE MOFETIL;MYCOPHENOLATE SODIUM","5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MECHANICAL VENTILATION;INFARCT SIZE;LEFT VENTRICULAR;ANTIRETROVIRAL THERAPY;COLON CANCER;HEART FAILURE;BLOOD FLOW;EC MPS;NON-INVASIVE MECHANICAL;SUBCOSTAL VIEW;VENTRICULAR MASS;ACUTE RESPIRATORY;BONE MARROW;MEDIAN SURVIVAL;NEUROLOGICAL OUTCOME;PATIENTS UNDERGOING;RESPIRATORY FAILURE;SPINAL ANESTHESIA;UC PATIENTS;CONFIDENCE INTERVAL;CXCL LEVELS;DE LA;DECISIONMAKING PROCESS;FEMORAL NERVE;FLOW VELOCITY;GRAFT FAILURE;LV REMODELING;MULTIVARIATE ANALYSIS;MYOCARDIAL INFARCTION;NERVE BLOCK","11;9;9;8;8;7;6;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4",25,0.19,6,3,0,1,0,1,4.25,0,1.75,4,0,0,1,0,2.75,0,0,1,0,0,0,78,78,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,4,411.67,2.62,0,0,25.83,0,0,2,0,4,0,0,0,0,6,0,0,0,0,0,0,0,6,0,0,6,0,0,0,0,0,0,0,0,0,"United States","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","6;5;2;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;BIOMEDICAL IMAGING;CARDIOVASCULAR;COLO-RECTAL CANCER;DIGESTIVE DISEASES;LUNG;ORPHAN DRUG;PATIENT SAFETY;PEDIATRIC;PEDIATRIC CANCER;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;TRANSPLANTATION","4;4;3;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;BLOOD;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM","2;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","6;1","LEUKEMIA / LEUKAEMIA;COLON AND RECTAL CANCER","2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","3",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CAREGGI",2005,179,9.21787709497207,3.30167597765363,0.53072625698324,0.396648044692737,0.53072625698324,1.58333333333333,1.31944444444444,1.57777777777778,1.31944444444444,0.346368715083799,6,106,14,24,22,0.59,0.08,0.13,0.12,37.62,0.710567855751078,NA,0.212290502793296,0.70391061452514,0.494,0.433,0.469,0.446,"ROSSELLA MARCUCCI;MAURIZIO SALVADORI;DOMENICO PRISCO;GIAN FRANCO GENSINI;E. BERTONI;DAVID ANTONIUCCI;LUIGI PADELETTI;ALBERTO ROSATI;MARCO PEZZATI;ROSANNA ABBATE;CHIARA POGGI;ENRICO TORTOLI;LUCA FILIPPI;ROSANNA ABBATE;ANGELA MIGLIORINI;ALBERTO BOSI;RICCARDO SACCARDI;DANIELA POLI;CANIO MARTINELLI;EMILIA ANTONUCCI","13;13;10;10;9;8;8;7;7;7;6;6;6;6;5;5;5;5;5;5","MAURIZIO SALVADORI;ROSSELLA MARCUCCI;MARCO PEZZATI;CHIARA POGGI;LUCA FILIPPI;GUIDO PARODI;GIAN FRANCO GENSINI;DAVID ANTONIUCCI;MASSIMO BONACCHI;E. BERTONI;DOMENICO PRISCO;STEFANO BAMBI;ANGELA MIGLIORINI;DANIELA POLI;LUIGI PADELETTI;MARCO INNOCENTI;ENRICO TORTOLI;ALBERTO PUPI;ALBERTO BOSI;LUCA DELCROIX","3.47;2.15;1.69;1.54;1.54;1.49;1.43;1.41;1.3;1.3;1.27;1;0.99;0.93;0.93;0.88;0.85;0.77;0.74;0.73","ROSSELLA MARCUCCI;MAURIZIO SALVADORI;DOMENICO PRISCO;GIAN FRANCO GENSINI;E. BERTONI;DAVID ANTONIUCCI;LUIGI PADELETTI;ALBERTO ROSATI;MARCO PEZZATI;ROSANNA ABBATE;CHIARA POGGI;ENRICO TORTOLI;LUCA FILIPPI;ROSANNA ABBATE;ANGELA MIGLIORINI;ALBERTO BOSI;RICCARDO SACCARDI;DANIELA POLI;CANIO MARTINELLI;EMILIA ANTONUCCI","13;13;10;10;9;8;8;7;7;7;6;6;6;6;5;5;5;5;5;5","MAURIZIO SALVADORI;ROSSELLA MARCUCCI;MARCO PEZZATI;CHIARA POGGI;LUCA FILIPPI;GUIDO PARODI;GIAN FRANCO GENSINI;DAVID ANTONIUCCI;MASSIMO BONACCHI;E. BERTONI;DOMENICO PRISCO;STEFANO BAMBI;ANGELA MIGLIORINI;DANIELA POLI;LUIGI PADELETTI;MARCO INNOCENTI;ENRICO TORTOLI;ALBERTO PUPI;ALBERTO BOSI;LUCA DELCROIX","3.47;2.15;1.69;1.54;1.54;1.49;1.43;1.41;1.3;1.3;1.27;1;0.99;0.93;0.93;0.88;0.85;0.77;0.74;0.73","IACOPO OLIVOTTO;FRANCO CECCHI;BARRY J. MARON;MARTIN S. MARON;A. JAMIL TAJIK;BERNARD J. GERSH;GORDON K. DANIELSON;HARTZELL V. SCHAFF;JOSEPH A. DEARANI;MICHAEL J. ACKERMAN;RICK A. NISHIMURA;ROBERT B. MCCULLY;SANDRO BETOCCHI;STEVE R. OMMEN;RICCARDO SACCARDI;ROSSELLA MARCUCCI;ALESSANDRO M. VANNUCCHI;DANIELA VARGIU;JAMES E. UDELSON;MARK S. LINK","1184;1136;1125;1125;731;731;731;731;731;731;731;731;731;731;454;437;396;394;394;394","IACOPO OLIVOTTO;FRANCO CECCHI;RICCARDO SACCARDI;DANIELA VARGIU;LUCA DELCROIX;MARCO INNOCENTI;GIOVANPAOLO PINI PRATO;AGOSTINO OGNIBENE;IOLANDA SPOSATO;ENRICO TORTOLI;FRANCESCA TORRICELLI;MARCO PEZZATI;ANDREA MINERVINI;GIULIO DEL POPOLO;ROSSELLA MARCUCCI;DAVID ANTONIUCCI;MAURIZIO SALVADORI;ANTONELLO GRIPPO;SERENA URBANI;MASSIMO CERUSO","1184;1136;454;394;220;220;215;206;206;194;193;186;185;172;165;159;158;157;157;155","MAURIZIO SALVADORI;E. BERTONI;DAVID ANTONIUCCI;MARCO PEZZATI;LUIGI PADELETTI;ALBERTO ROSATI;CHIARA POGGI;LUCA FILIPPI;ROSANNA ABBATE;DOMENICO PRISCO;ROSSELLA MARCUCCI;DANIELA POLI;CANIO MARTINELLI;GIAN FRANCO GENSINI;GUIDO PARODI;RICCARDO SACCARDI;ANGELA MIGLIORINI;CARLO DANI;EMILIA ANTONUCCI;ENRICO TORTOLI","11;8;8;7;7;6;6;6;6;6;6;5;5;5;5;5;5;4;4;4","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;MATERIALS SCIENCE;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE;GEOLOGY;BUSINESS;PSYCHOLOGY;ECONOMICS;GEOGRAPHY;SOCIOLOGY","167;51;17;13;11;8;8;8;6;6;5;3;3;2;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;IMMUNOLOGY;GENETICS;RADIOLOGY;PATHOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;ONCOLOGY;PSYCHIATRY;OPTICS;ANESTHESIA;CANCER RESEARCH;MECHANICAL ENGINEERING;NUCLEAR MEDICINE;PHYSICAL THERAPY","132;57;47;27;26;26;25;22;15;15;11;10;10;10;9;8;7;7;7;7","GENE;CANCER;MYOCARDIAL INFARCTION;TRANSPLANTATION;DISEASE;HEART FAILURE;CONFIDENCE INTERVAL;HOMOCYSTEINE;INCIDENCE (GEOMETRY);POPULATION;ANEURYSM;ATRIAL FIBRILLATION;RECEPTOR;MAGNETIC RESONANCE IMAGING;RISK FACTOR;STEM CELL;BLOOD PRESSURE;CORONARY ARTERY DISEASE;LYMPHOMA;THROMBOSIS;TUBERCULOSIS","21;18;18;17;16;15;9;9;9;9;8;8;8;7;7;7;6;6;6;6;6","PERCUTANEOUS CORONARY INTERVENTION;GENOTYPE;REVASCULARIZATION;EJECTION FRACTION;HAZARD RATIO;KIDNEY TRANSPLANTATION;BREAST CANCER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MUTATION;PERFORATION;ALLELE;FIBULA;HAEMATOPOIESIS;HYPERHOMOCYSTEINEMIA;LIPOPROTEIN;MYCOBACTERIUM;MYELOFIBROSIS;RENAL TRANSPLANT;RITUXIMAB;UNSTABLE ANGINA;VENTRICULAR PACING","8;7;7;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4","ABCIXIMAB;CARDIAC RESYNCHRONIZATION THERAPY;LIPOPROTEIN(A);ANTIRETROVIRAL THERAPY;AXILLA;BRADYCARDIA;BREAST CARCINOMA;CHRONIC ALLOGRAFT NEPHROPATHY;ENDOVASCULAR COILING;ENOS;EPWORTH SLEEPINESS SCALE;HERPESVIRIDAE;HISTOCOMPATIBILITY;MASTECTOMY;METHYLENETETRAHYDROFOLATE REDUCTASE;MYCOBACTERIUM INFECTIONS;OSTEONECROSIS OF THE JAW;TIMI;5-HT RECEPTOR;ACUTE LYMPHOCYTIC LEUKEMIA;ALCOHOL SEPTAL ABLATION;ALLELIC HETEROGENEITY;ANTIMYCOBACTERIAL;ATRIAL TACHYCARDIA;AXILLARY LYMPH NODES;BASE EXCISION REPAIR;BAYESIAN STATISTICS;BENCE JONES PROTEIN;BK VIRUS;BUSULFAN;CADASIL;CANDIDA DUBLINIENSIS;CAPECITABINE;CD38;CHRONOTROPIC;CLADE;COMPOUND HETEROZYGOSITY;CONVERGENT VALIDITY;CROSSOVER STUDY;CXCL10;CXCR4;DABIGATRAN;DIPEPTIDYL PEPTIDASE-4;DISCOVERY AND DEVELOPMENT OF DIRECT THROMBIN INHIBITORS;DISCRIMINANT VALIDITY;DNA MISMATCH REPAIR;DOPPLER ECHOCARDIOGRAPHY;DRUG-ELUTING STENT;EXCESSIVE DAYTIME SLEEPINESS;EXTERNAL BEAM RADIOTHERAPY;EXTRAMEDULLARY HEMATOPOIESIS;FACTOR V LEIDEN;FAMILIAL ADENOMATOUS POLYPOSIS;FOLINIC ACID;FONDAPARINUX;FRACTIONAL FLOW RESERVE;FRAMESHIFT MUTATION;FREQUENTIST INFERENCE;GENETIC HETEROGENEITY;GENOTYPE-PHENOTYPE DISTINCTION;GERD;GERMINAL CENTER;GERMLINE MUTATION;GIANT CELL ARTERITIS;GP41;HAPLOTYPE;HEARTBURN;HEMATOPOIETIC CELL;HER2/NEU;IDARUBICIN;IMATINIB MESYLATE;IMMUNOGLOBULIN CLASS SWITCHING;INTERMEDIATE UVEITIS;INTERNAL TRANSCRIBED SPACER;INTRAVENTRICULAR HEMORRHAGE;ISOTYPE;ISOVOLUMETRIC CONTRACTION;KIDNEY TRANSPLANT;LEUKOARAIOSIS;MACE;MEROPENEM;METASTATIC BREAST CANCER;MISSENSE MUTATION;MODIFIED RANKIN SCALE;MOLECULAR EPIDEMIOLOGY;MULTIPLEX POLYMERASE CHAIN REACTION;MUTATION FREQUENCY;NESIRITIDE;NKG2D;NODULAR SCLEROSIS;NONTUBERCULOUS MYCOBACTERIA;OPPORTUNISTIC PATHOGEN;ORAL ANTICOAGULANT;PDGFRA;PERTUSSIS TOXIN;PITUITARY NEOPLASM;PLATELET-DERIVED GROWTH FACTOR RECEPTOR;POINT MUTATION;PROSTATITIS;PYELOPLASTY;RANKL;RECOMBINATION-ACTIVATING GENE;RENAL ARTERY STENOSIS;RESTRICTION FRAGMENT LENGTH POLYMORPHISM;RETINITIS;RIGHT CORONARY ARTERY;SENTINEL LYMPH NODE;SENTINEL NODE;SEPTAL MYECTOMY;SIDA;SILENT PERIOD;SINGLE-STRAND CONFORMATION POLYMORPHISM;SOMATIC HYPERMUTATION;TBARS;THIOBARBITURIC ACID;THORACIC AORTIC ANEURYSM;TICLOPIDINE;TIROFIBAN;TOTAL BODY IRRADIATION;TRASTUZUMAB;UPGMA","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;AGED;ADULT;;TREATMENT OUTCOME;ITALY;MYOCARDIAL INFARCTION;AGED, 80 AND OVER;KIDNEY TRANSPLANTATION;MYCOBACTERIUM;POSTOPERATIVE COMPLICATIONS;RISK FACTORS;FOLLOW-UP STUDIES;HOMOCYSTEINE;CORONARY DISEASE;RETROSPECTIVE STUDIES;PROSPECTIVE STUDIES","132;90;86;73;67;59;45;28;27;23;21;19;18;18;18;17;17;16;14;13","CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;ROLE OF HOMOCYSTEINE IN HEALTH AND DISEASE;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ATRIAL FIBRILLATION;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;DIAGNOSIS AND TREATMENT OF RENAL ARTERY STENOSIS;ESOPHAGEAL INTERVENTION TECHNIQUES;KIDNEY TRANSPLANTATION;LYMPHOID NEOPLASMS;THROMBOSIS AND COAGULATION DISORDERS;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;HEALTH ECONOMICS AND QUALITY OF LIFE ASSESSMENT","6;5;5;4;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2","TREATMENT;CARDIOVASCULAR RISK ASSESSMENT;CARDIAC IMAGING;PRETERM INFANTS;ATRIAL FIBRILLATION;PERFORATION;STROKE (ENGINE);HYPERHOMOCYSTEINEMIA;IMMUNOSUPPRESSION;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;LEAD (GEOLOGY);LEFT VENTRICULAR FUNCTION;POSTINFARCTION VENTRICULAR SEPTAL DEFECT;RENAL TRANSPLANTATION;TRANSPLANTATION;UNSTABLE ANGINA;VENTRICULAR PACING;ABCIXIMAB;ANTICOAGULANT THERAPY;ANTITHROMBOTIC THERAPY","9;7;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;3;3;3","LEFT VENTRICULAR;MYOCARDIAL INFARCTION;ATRIAL FIBRILLATION;CELL TRANSPLANTATION;STEM CELL;ACUTE MYOCARDIAL;HEMATOPOIETIC STEM;RENAL TRANSPLANT;RISK FACTORS;VENOUS THROMBOEMBOLISM;ACUTE CORONARY;BREAST CANCER;CARDIAC RESYNCHRONIZATION;CARDIOVASCULAR RISK;CARE UNIT;CORONARY ARTERY;CORONARY INTERVENTION;DISTAL RADIAL;HYPERTROPHIC CARDIOMYOPATHY;ITALIAN POPULATION;MAGNETIC RESONANCE;MYCOPHENOLATE SODIUM;PANCREATIC CANCER;RENAL TRANSPLANTATION;RESYNCHRONIZATION THERAPY;TRANSPLANT RECIPIENTS;VENTRICULAR PACING;ABDOMINAL AORTIC;ALLOGENEIC HEMATOPOIETIC;ALLOGRAFT NEPHROPATHY","6;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;LEFT VENTRICULAR;ATRIAL FLUTTER;ATRIAL FIBRILLATION;ST-SEGMENT ELEVATION;INFARCT SIZE;MYOCARDIAL INFARCTION;RENAL TRANSPLANT;CORONARY ARTERY;DPP-IV ACTIVITY;PLASMA LEVELS;RISK FACTORS;MEDICINE UNIVERSITY;MOLECULAR MEDICINE;VENTRICULAR EF;ALENTERIC-COATED MYCOPHENOLATE;DIABETIC PATIENTS;MYCOPHENOLATE SODIUM;NK CELLS;TRANSPLANT -CROSSREF;AORTIC VALVE;BREAST CANCER;CATHETER ABLATION;COMUNALE MARGHERITA;FAVORABLE OUTCOME;FEEDING TUBE;FOGGIA ITALYSEARCH;KDA HSP;LOADING DOSE","24;20;19;14;13;12;10;10;10;9;9;9;9;8;8;8;7;7;7;7;7;6;6;6;6;6;6;6;6;6",28,0.16,3.94,2,0,0,0,1,2,0,1.5,2.25,0,1,1,1,2,0,0,1,0,0,0,57.75,57.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,5.75,837.88,2.31,3,0.38,51.38,0,0,1,0,4,0,2,1,0,7,1,0,0,0,0,0,0,7,1,0,8,0,0,0,0,0,0,0,0,0,"United States;Italy","4;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;3204 IMMUNOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;51 PHYSICAL SCIENCES;5105 MEDICAL AND BIOLOGICAL PHYSICS","7;4;3;2;2;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;PATIENT SAFETY;ATHEROSCLEROSIS;BIOENGINEERING;BIOTECHNOLOGY;BREAST CANCER;CARDIOVASCULAR;DIGESTIVE DISEASES;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;LUNG;LUNG CANCER;ORPHAN DRUG;PANCREATIC CANCER;RARE DISEASES","6;4;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","4;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","3;2;1","BREAST CANCER;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;PANCREATIC CANCER;STOMACH CANCER","1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","3;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CAREGGI",2006,204,9.00980392156863,3.60294117647059,0.519607843137255,0.441176470588235,0.524509803921569,1.75598086124402,1.24705882352941,1.60714285714286,1.27380952380952,0.284313725490196,7,114,51,9,19,0.56,0.25,0.04,0.09,51.77,1.01353611845204,NA,0.274509803921569,0.745098039215686,0.45,0.416,0.435,0.412,"GIAN FRANCO GENSINI;DAVID ANTONIUCCI;MAURIZIO SALVADORI;IACOPO OLIVOTTO;ALBERTO BOSI;NAZARIO CARRABBA;ENRICO TORTOLI;GUIDO PARODI;LUIGI PADELETTI;E. BERTONI;MASSIMO MARGHERI;ROSSELLA MARCUCCI;NICCOLÒ MARCHIONNI;LAURA STEFANI;M. C. R. VONO;ANDRÉA MORETTI;LOIRA TONCELLI;GIULIO MASOTTI;MARCO GIANASSI;ROSANNA ABBATE","22;11;10;9;9;9;8;8;8;7;7;7;7;6;6;6;6;6;6;6","GIAN FRANCO GENSINI;DAVID ANTONIUCCI;ENRICO TORTOLI;MASSIMO MORFINI;ROBERTO GUSINU;MAURIZIO SALVADORI;SALVATORE SIA;ALBERTO BOSI;CARLO NOZZOLI;NAZARIO CARRABBA;CINZIA FATINI;E. BERTONI;IACOPO OLIVOTTO;DANIELE CAMMELLI;STEFANO COLAGRANDE;PIETRO AMEDEO MODESTI;BEATRICE DILAGHI;GUIDO PARODI;CARLO DANI;ADRIANO PERIS","3.53;3.09;1.82;1.55;1.33;1.29;1.2;1.13;1.12;1.1;1.1;1.03;1.01;1;1;1;1;1;0.8;0.77","GIAN FRANCO GENSINI;DAVID ANTONIUCCI;MAURIZIO SALVADORI;IACOPO OLIVOTTO;ALBERTO BOSI;NAZARIO CARRABBA;ENRICO TORTOLI;GUIDO PARODI;LUIGI PADELETTI;E. BERTONI;MASSIMO MARGHERI;ROSSELLA MARCUCCI;NICCOLÒ MARCHIONNI;LAURA STEFANI;M. C. R. VONO;ANDRÉA MORETTI;LOIRA TONCELLI;GIULIO MASOTTI;MARCO GIANASSI;ROSANNA ABBATE","22;11;10;9;9;9;8;8;8;7;7;7;7;6;6;6;6;6;6;6","GIAN FRANCO GENSINI;DAVID ANTONIUCCI;ENRICO TORTOLI;MASSIMO MORFINI;ROBERTO GUSINU;MAURIZIO SALVADORI;SALVATORE SIA;ALBERTO BOSI;CARLO NOZZOLI;NAZARIO CARRABBA;CINZIA FATINI;E. BERTONI;IACOPO OLIVOTTO;DANIELE CAMMELLI;STEFANO COLAGRANDE;BEATRICE DILAGHI;GUIDO PARODI;CARLO DANI;ADRIANO PERIS;MASSIMO MARGHERI","3.53;3.09;1.82;1.55;1.33;1.29;1.2;1.13;1.12;1.1;1.1;1.03;1.01;1;1;1;1;0.8;0.77;0.77","IACOPO OLIVOTTO;FRANCO CECCHI;STEFANO NISTRI;ENRICO TORTOLI;BARRY J. MARON;CARLO GARZELLI;ANDREA GORI;ANGEL CATALDI;ANNA SAJDUDA;BARRY N. KREISWIRTH;BENJAMIN LIENS;C ELLERMEIER;CARLOS MARTÍN;CAROLINE ALLIX;CHRISTIAN MARTIN;CHRISTOPHE SOLA;DARÍO GARCÍA DE VIEDMA;DICK VAN SOOLINGEN;ELIZABETH M. STREICHER;FRANÇOISE PORTAELS","1819;1485;1257;1256;1186;1074;1017;1017;1017;1017;1017;1017;1017;1017;1017;1017;1017;1017;1017;1017","IACOPO OLIVOTTO;ENRICO TORTOLI;FRANCO CECCHI;ANDREY G. ZENOVICH;BARRY J. MARON;JAMES E. UDELSON;JEFFERY T. KUVIN;MARK S. LINK;MARTIN S. MARON;NATESA G. PANDIAN;STEFANO NISTRI;MASSIMO MARGHERI;GIAN FRANCO GENSINI;ANDREA UNGAR;MAURIZIO SALVADORI;ALBERTO BOSI;DAVID ANTONIUCCI;S AITO;GUIDO PARODI;NAZARIO CARRABBA","1504;1256;1186;953;953;953;953;953;953;953;953;753;593;556;547;508;489;425;409;402","GIAN FRANCO GENSINI;DAVID ANTONIUCCI;MAURIZIO SALVADORI;NAZARIO CARRABBA;ALBERTO BOSI;ENRICO TORTOLI;GUIDO PARODI;LUIGI PADELETTI;GIULIO MASOTTI;MASSIMO MARGHERI;ROSANNA ABBATE;ANDRÉA MORETTI;LAURA STEFANI;LOIRA TONCELLI;M. C. R. VONO;MARCO GIANASSI;IACOPO OLIVOTTO;CRISTINA GIGLIOLI;CARLO NOZZOLI;E. BERTONI","14;11;10;9;8;8;8;8;6;6;6;6;6;6;6;6;6;5;5;5","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;POLITICAL SCIENCE;MATHEMATICS;ECONOMICS;PHILOSOPHY;PSYCHOLOGY;BUSINESS;ENVIRONMENTAL SCIENCE;GEOLOGY;HISTORY;MATERIALS SCIENCE;SOCIOLOGY","193;59;22;17;10;10;9;8;6;3;3;2;1;1;1;1;1","INTERNAL MEDICINE;CARDIOLOGY;SURGERY;GENETICS;PATHOLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;INTENSIVE CARE MEDICINE;ENDOCRINOLOGY;BIOCHEMISTRY;GASTROENTEROLOGY;ANESTHESIA;PEDIATRICS;RADIOLOGY;MICROBIOLOGY;OPTICS;EMERGENCY MEDICINE;PHYSICAL THERAPY;UROLOGY;VIROLOGY","143;58;51;32;27;24;24;24;23;22;20;17;17;15;13;13;11;11;11;11","MYOCARDIAL INFARCTION;POPULATION;GENE;HEART FAILURE;CANCER;TRANSPLANTATION;DISEASE;INCIDENCE (GEOMETRY);BLOOD PRESSURE;CHEMOTHERAPY;PREGNANCY;RANDOMIZED CONTROLLED TRIAL;BACTERIA;MULTIVARIATE ANALYSIS;DIABETES MELLITUS;IN VITRO;MEDLINE;ALTERNATIVE MEDICINE;CARCINOMA;CONFIDENCE INTERVAL;CORONARY ARTERY DISEASE;TUBERCULOSIS","24;24;21;17;13;13;12;12;11;11;10;10;9;9;8;8;8;7;7;7;7;7","PERCUTANEOUS CORONARY INTERVENTION;CONVENTIONAL PCI;EJECTION FRACTION;REVASCULARIZATION;GENOTYPE;UNIVARIATE ANALYSIS;KIDNEY TRANSPLANTATION;CARDIOMYOPATHY;CYCLOPHOSPHAMIDE;HAZARD RATIO;MYCOBACTERIUM;MYCOBACTERIUM TUBERCULOSIS;BREAST CANCER;HEART RATE;MUTATION;MYCOPHENOLIC ACID;RESTENOSIS;ACUTE CORONARY SYNDROME;ADENOCARCINOMA;CARDIOGENIC SHOCK;CLINICAL ENDPOINT;DIASTOLE;HAEMATOPOIESIS;MYCOPHENOLATE;NITRIC OXIDE SYNTHASE;OCCULT;PERIPHERAL BLOOD MONONUCLEAR CELL;TITER","16;12;11;10;8;7;6;5;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","CARDIAC RESYNCHRONIZATION THERAPY;TIMI;MISSENSE MUTATION;VINCRISTINE;ANTIRETROVIRAL THERAPY;BRONCHOPULMONARY DYSPLASIA;COLONOSCOPY;DIASTOLIC FUNCTION;DRUG-ELUTING STENT;ECULIZUMAB;ENOS;GENE MUTATION;GESTATIONAL DIABETES;GLUCOSE TOLERANCE TEST;ISCHEMIC CARDIOMYOPATHY;KILLIP CLASS;MACE;MYCOBACTERIUM BOVIS;MYCOBACTERIUM TUBERCULOSIS COMPLEX;RIBAVIRIN;SENTINEL NODE","4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;;MYOCARDIAL INFARCTION;TREATMENT OUTCOME;AGED, 80 AND OVER;PROSPECTIVE STUDIES;FOLLOW-UP STUDIES;ITALY;CORONARY DISEASE;TIME FACTORS;ANGIOPLASTY, BALLOON, CORONARY;CARDIAC OUTPUT, LOW;LUNG NEOPLASMS;ADOLESCENT;BREAST NEOPLASMS","146;103;98;77;72;64;54;44;33;30;28;25;24;19;18;17;15;15;14;14","CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;KIDNEY TRANSPLANTATION;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;DIAGNOSIS AND MANAGEMENT OF ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY;MANAGEMENT AND TREATMENT OF HEMOPHILIA;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;TUBERCULOSIS;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;DIAGNOSIS AND TREATMENT OF HEART FAILURE;DIAGNOSIS AND TREATMENT OF LUNG CANCER;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;MOLECULAR RESEARCH ON BREAST CANCER;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;CARDIAC SURGERY AND BYPASS GRAFTING OUTCOMES;CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS;DIAGNOSIS AND MANAGEMENT OF SYNCOPE","7;7;6;6;6;5;5;4;4;3;3;3;3;3;3;2;2;2;2;2","CARDIAC IMAGING;LEFT VENTRICULAR FUNCTION;TREATMENT;UNIVARIATE ANALYSIS;CORONARY STENTS;CARDIAC RESYNCHRONIZATION THERAPY;DRUG-ELUTING STENTS;MYCOBACTERIUM TUBERCULOSIS;ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY;CARDIOVASCULAR RISK ASSESSMENT;DIABETES;FACTOR VIII;HYPERTENSION;LEFT VENTRICULAR NON-COMPACTION;MYOCARDIAL INFARCTION;MYOCARDIAL REVASCULARIZATION;REGIMEN;TIMI;ACUTE MYELOID LEUKEMIA;CLINICAL ENDPOINT","9;9;7;7;6;5;5;5;4;4;4;4;4;4;4;4;4;4;3;3","ACUTE MYOCARDIAL;MYOCARDIAL INFARCTION;LEFT VENTRICULAR;CORONARY INTERVENTION;HYPERTROPHIC CARDIOMYOPATHY;PERCUTANEOUS CORONARY;CELL LUNG;CUTTING EDGE;EDGE RESEARCH;LUNG CANCER;PROGNOSTIC SIGNIFICANCE;RESEARCH UPDATE;ATRIAL FIBRILLATION;BREAST CANCER;CANCER PATIENTS;CARE UNIT;CELL TRANSPLANTATION;INTENSIVE CARE;MINIMALLY INVASIVE;MYCOBACTERIUM TUBERCULOSIS;NITRIC OXIDE;PERIPHERAL BLOOD;PRETERM INFANTS;RENAL TRANSPLANT;RHEOLYTIC THROMBECTOMY;STEM CELL;THYROID CARCINOMA;ACUTE MYELOID;ACUTE PULMONARY;ADVANCED STAGE","12;12;7;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;HCV RNA;CHRONIC HEPATITIS;HEPATIC STELLATE;MM HG;ASPIRIN RESISTANCE;SD RANGE;STELLATE CELLS;VIROLOGIC RESPONSE;CA IX;LEFT VENTRICULAR;PEROXISOME PROLIFERATOR-ACTIVATED;UL SD;GENE EXPRESSION;HEART FAILURE;PROLIFERATOR-ACTIVATED RECEPTOR;COLLAGEN SYNTHESIS;DOSE REDUCTION;LYMPH NODE;PEGYLATED IFN-Α-B;PROTEIN KINASE;PUBMED GOOGLE;TRANSCRIPTIONAL ACTIVITY;IX MRNA;MYOCARDIAL INFARCTION;PH MMOLL;PPARΓ TRANSCRIPTIONAL;RECEPTOR Γ;VIRAL LOAD","41;34;24;15;14;13;12;12;12;12;11;11;11;10;9;9;9;8;8;8;8;8;8;8;7;7;7;7;7;7",26,0.13,5.3,3,0,1,0,4,2.75,0,1,3.75,0,1,5,0,2.5,1,2.5,11.5,3.25,0,0,90,90.75,1,1,1,0,0,0,0,0,0,0,0,0,2,0,0,0,4,1.09,3,0,1,2,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ANNUNZIATO FRANCESCO;MAGGI ENRICO;ROMAGNANI PAOLA;ROMAGNANI SERGIO","2;2;2;2","ANNUNZIATO, FRANCESCO;AZIENDA OSPEDALIERO UNIVERSITARIA CAREGGI;AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI;MAGGI, ENRICO;ROMAGNANI, PAOLA;ROMAGNANI, SERGIO","1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY","4;2","STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN","1;1",NA,NA,"A61K35/00;A61K35/28;C12N5/00;G01N33/569","2;2;2;2","A61K35/28;A61P1/16;A61P1/18;A61P11/00;A61P11/02;A61P13/00;A61P13/12;A61P25/00;A61P27/02;A61P27/16","2;2;2;2;2;2;2;2;2;2",11,5.8,524.45,2.82,2,0.18,55.18,0,0,3,1,4,0,0,3,0,9,2,0,0,0,0,0,0,10,1,0,11,0,0,0,0,0,0,0,0,0,"United States;Italy;Germany","3;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3207 MEDICAL MICROBIOLOGY","11;6;5;3;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;CANCER;RARE DISEASES;LYMPHOMA;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;INFECTIOUS DISEASES;PREVENTION;TRANSPLANTATION;LUNG;PATIENT SAFETY;PEDIATRIC;SEPSIS;VACCINE RELATED;ANTIMICROBIAL RESISTANCE;ASTHMA;BIODEFENSE","10;8;7;6;6;4;4;4;4;3;3;3;2;2;2;2;2;1;1;1","CANCER;INFECTION;RENAL AND UROGENITAL;RESPIRATORY","6;2;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;2.4 SURVEILLANCE AND DISTRIBUTION;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY","8;4;1;1;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;MYELOMA;OVARIAN CANCER","5;3;2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY","6;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CAREGGI",2007,203,8.38423645320197,3.45812807881773,0.502463054187192,0.413793103448276,0.576354679802956,1.64018691588785,1.29113924050633,1.47368421052632,1.23157894736842,0.305418719211823,6,108,47,14,22,0.53,0.23,0.07,0.11,50.14,0.95010735468492,NA,0.201970443349754,0.729064039408867,0.431,0.407,0.465,0.395,"GIAN FRANCO GENSINI;ROSSELLA MARCUCCI;ROSANNA ABBATE;DAVID ANTONIUCCI;ANNA MARIA GORI;SERAFINA VALENTE;SIMONE VANNI;STEFANO GRIFONI;ALBERTO BOSI;ROSANNA ABBATE;LUIGI PADELETTI;RITA PANICCIA;DOMENICO PRISCO;FRANCESCA TORRICELLI;EDOARDO MANNUCCI;GUIDO PARODI;PIERLUIGI STEFÀNO;ANDREA SODI;FRANCESCO SOFI;GIANFRANCO GENSINI","20;14;13;12;12;8;7;7;7;7;7;6;6;6;6;6;6;6;6;6","GUIDO PARODI;DAVID ANTONIUCCI;GIAN FRANCO GENSINI;MASSIMO CERUSO;SIMONE VANNI;ROSSELLA MARCUCCI;ROSANNA ABBATE;ANNA MARIA GORI;NICCOLÒ MARCHIONNI;MARIO FREGONARA MEDICI;FRANCESCA TORRICELLI;MATTEO MONAMI;SERAFINA VALENTE;RODOLFO CAPANNA;EDOARDO MANNUCCI;ALBERTO BOSI;ANDREA SODI;STEFANO GRIFONI;SANDRO GELSOMINO;PIERLUIGI STEFÀNO","2.55;2.3;2.15;1.98;1.72;1.49;1.45;1.12;1.03;1;0.96;0.95;0.91;0.89;0.88;0.82;0.8;0.79;0.74;0.73","GIAN FRANCO GENSINI;ROSSELLA MARCUCCI;ROSANNA ABBATE;DAVID ANTONIUCCI;ANNA MARIA GORI;SERAFINA VALENTE;SIMONE VANNI;STEFANO GRIFONI;ALBERTO BOSI;ROSANNA ABBATE;LUIGI PADELETTI;RITA PANICCIA;DOMENICO PRISCO;FRANCESCA TORRICELLI;EDOARDO MANNUCCI;GUIDO PARODI;PIERLUIGI STEFÀNO;ANDREA SODI;FRANCESCO SOFI;GIANFRANCO GENSINI","20;14;13;12;12;8;7;7;7;7;7;6;6;6;6;6;6;6;6;6","GUIDO PARODI;DAVID ANTONIUCCI;GIAN FRANCO GENSINI;MASSIMO CERUSO;SIMONE VANNI;ROSSELLA MARCUCCI;ROSANNA ABBATE;ANNA MARIA GORI;NICCOLÒ MARCHIONNI;MARIO FREGONARA MEDICI;FRANCESCA TORRICELLI;MATTEO MONAMI;SERAFINA VALENTE;RODOLFO CAPANNA;EDOARDO MANNUCCI;ALBERTO BOSI;ANDREA SODI;STEFANO GRIFONI;SANDRO GELSOMINO;PIERLUIGI STEFÀNO","2.55;2.3;2.15;1.98;1.72;1.49;1.45;1.12;1.03;1;0.96;0.95;0.91;0.89;0.88;0.82;0.8;0.79;0.74;0.73","ROSANNA ABBATE;GIAN FRANCO GENSINI;ROSSELLA MARCUCCI;FABIO MARRA;FRANCESCO VIZZUTTI;GIACOMO LAFFI;MASSIMO PINZANI;UMBERTO ARENA;ANNA MARIA GORI;STEFANIA MOSCARELLA;A. PETRARCA;RITA PANICCIA;DAVID ANTONIUCCI;VIERI BODDI;ANGELA MIGLIORINI;GIACOMO BELLI;ANNA LINDA ZIGNEGO;LUIGI REGA;ROBERTO GIULIO ROMANELLI;PIERGIOVANNI BUONAMICI","1948;1860;1606;1466;1466;1466;1466;1464;1445;1424;1392;1249;1190;933;812;772;759;758;758;727","GIAN FRANCO GENSINI;DAVID ANTONIUCCI;ROSANNA ABBATE;ROSSELLA MARCUCCI;ANGELA MIGLIORINI;ANNA MARIA GORI;GIACOMO BELLI;PIERGIOVANNI BUONAMICI;RITA PANICCIA;FABIO MARRA;MASSIMO PINZANI;ALBERTO SANTINI;GUIA MOSCHI;S AITO;CRISTINA GIGLIOLI;MASSIMO MORFINI;EDOARDO MANNUCCI;RICCARDO SACCARDI;ALBERTO BOSI;MARCO INNOCENTI","1208;1190;1161;911;812;783;772;727;723;708;708;676;676;458;449;419;399;371;368;325","GIAN FRANCO GENSINI;DAVID ANTONIUCCI;ROSANNA ABBATE;LUIGI PADELETTI;ALBERTO BOSI;CRISTINA GIGLIOLI;SERAFINA VALENTE;SIMONE VANNI;STEFANO GRIFONI;ROSSELLA MARCUCCI;GUIDO PARODI;FRANCESCA TORRICELLI;PIERLUIGI STEFÀNO;ANGELA MIGLIORINI;ANNA MARIA GORI;EDOARDO MANNUCCI;MASSIMO CERUSO;SANDRO GELSOMINO;CARLO DANI;FIRMINO F. RUBALTELLI","13;12;11;8;7;7;7;7;7;7;6;6;6;5;5;5;5;5;4;4","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;SOCIOLOGY;MATHEMATICS;ENGINEERING;POLITICAL SCIENCE;ECONOMICS;PHILOSOPHY;BUSINESS;GEOGRAPHY;PSYCHOLOGY;ENVIRONMENTAL SCIENCE;GEOLOGY;MATERIALS SCIENCE","192;60;27;13;12;10;9;7;6;5;5;3;3;2;1;1;1","INTERNAL MEDICINE;CARDIOLOGY;SURGERY;GENETICS;PATHOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;ENDOCRINOLOGY;IMMUNOLOGY;BIOCHEMISTRY;RADIOLOGY;OPTICS;PSYCHIATRY;ANESTHESIA;ONCOLOGY;PHARMACOLOGY;CELL BIOLOGY;EMERGENCY MEDICINE;DEMOGRAPHY;PEDIATRICS","144;59;54;38;28;27;25;20;19;16;16;13;13;12;11;11;10;10;9;9","GENE;POPULATION;MYOCARDIAL INFARCTION;CANCER;HEART FAILURE;DISEASE;ALTERNATIVE MEDICINE;BLOOD PRESSURE;CHEMOTHERAPY;ANTIBODY;COHORT;CONFIDENCE INTERVAL;INCIDENCE (GEOMETRY);PREGNANCY;CLINICAL TRIAL;DIABETES MELLITUS;PLATELET;RECEPTOR;STEM CELL;TRANSPLANTATION","25;24;23;17;17;14;9;9;9;8;8;8;8;8;7;7;7;7;7;7","PERCUTANEOUS CORONARY INTERVENTION;EJECTION FRACTION;MUTATION;BREAST CANCER;CLINICAL ENDPOINT;CONVENTIONAL PCI;VENTRICULAR REMODELING;CARDIOMYOPATHY;CLOPIDOGREL;COLORECTAL CANCER;GENOTYPE;METABOLIC SYNDROME;PHENOTYPE;PORTAL HYPERTENSION;PROGENITOR CELL;TYPE 2 DIABETES;ACUTE CORONARY SYNDROME;AUTOFLUORESCENCE;CATHETER ABLATION;CYCLOPHOSPHAMIDE;DEEP VEIN;DIASTOLE;EXON;FETUS;HAEMOPHILIA A;INFARCTION;METASTASIS;PHASES OF CLINICAL RESEARCH;PULMONARY VEIN;REPERFUSION THERAPY;RESTENOSIS;RITUXIMAB;VENOUS THROMBOSIS","14;8;8;7;7;7;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","CARDIAC RESYNCHRONIZATION THERAPY;DRUG-ELUTING STENT;MACE;PORTAL VENOUS PRESSURE;ESOPHAGEAL VARICES;GENE MUTATION;MAMMOGRAPHY;P2Y12;AL AMYLOIDOSIS;CXCR4;GERMLINE MUTATION;MISSENSE MUTATION;OXALIPLATIN;P-GLYCOPROTEIN;TIMI;AA AMYLOIDOSIS;ABDOMINAL OBESITY;ACINETOBACTER BAUMANNII;ACUTE LYMPHOCYTIC LEUKEMIA;AMNIOTIC FLUID;AMPLIFIED FRAGMENT LENGTH POLYMORPHISM;ANEUPLOIDY;ANGIOTENSIN RECEPTOR;ANISOMETROPIA;ANTHRACYCLINE;ANTIPLATELET DRUG;ANTIRETROVIRAL THERAPY;ARTHROPATHY;ASYMMETRIC DIMETHYLARGININE;ATP-BINDING CASSETTE TRANSPORTER;BALLOONING;BILLROTH I;BILLROTH II;BONE MORPHOGENETIC PROTEIN 7;C2C12;CAPECITABINE;CENTRAL RETINAL VEIN OCCLUSION;CHLORAMBUCIL;CMIN;COLONIC CANCER;CORONARY ARTERY ECTASIA;CROSSOVER STUDY;CYP2C19;CYP2D6;CYP3A4;DETECTIVE QUANTUM EFFICIENCY;DUCTAL CARCINOMA;DUMPING SYNDROME;DYSKINESIA;ELECTIVE CAESAREAN SECTION;ENDOTHELIAL PROGENITOR CELL;EPIRUBICIN;FIRST TRIMESTER;GASTRIC BYPASS;GATED SPECT;GEFITINIB;GERMINAL CENTER;HEAD CIRCUMFERENCE;INTERNAL TRANSCRIBED SPACER;ISOLEUCINE;KILLIP CLASS;KLEBSIELLA PNEUMONIAE;LEVODOPA;LOCAL BINARY PATTERNS;LYMPHANGIOGENESIS;LYMPHATIC VESSEL;MACULOPATHY;MERLIN (PROTEIN);MICROSATELLITE;MITRAL VALVE ANNULOPLASTY;MODIFIED RANKIN SCALE;MOLECULAR EPIDEMIOLOGY;MOLECULAR MEDICINE;MONOCHORIONIC TWINS;MYCOBACTERIUM BOVIS;NATIONAL CHOLESTEROL EDUCATION PROGRAM;NOD2;OCCUPATIONAL ACCIDENT;OSTEOCALCIN;OXYBUTYNIN;P2 RECEPTOR;P2Y RECEPTOR;PENETRANCE;PHARMACOGENETICS;POLYMORPHISM (COMPUTER SCIENCE);PPADS;PRENATAL DIAGNOSIS;PRIMARY ANGIOPLASTY;PROSTATECTOMY;PULMONARY VEIN STENOSIS;RADIONUCLIDE VENTRICULOGRAPHY;RESPECT FOR PERSONS;RESTRICTION FRAGMENT LENGTH POLYMORPHISM;RHODAMINE 123;RIBOTYPING;RIGHT CORONARY ARTERY;RUNX2;SALMONELLA ENTERITIDIS;SCEDOSPORIUM APIOSPERMUM;SECRETORY PATHWAY;SECRETORY VESICLE;SINGLE-NUCLEOTIDE POLYMORPHISM;STENOTROPHOMONAS MALTOPHILIA;STROKE VOLUME;SYMPATHETIC ACTIVITY;TRANSIENT ELASTOGRAPHY;TWIN TWIN TRANSFUSION SYNDROME;UTERINE MYOMECTOMY;VANCOMYCIN;VARDENAFIL;VASCULAR DEMENTIA;VASCULOGENESIS;VON WILLEBRAND DISEASE","6;4;4;4;3;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;AGED;ADULT;ITALY;MYOCARDIAL INFARCTION;;TREATMENT OUTCOME;AGED, 80 AND OVER;FOLLOW-UP STUDIES;BLOOD PLATELETS;PLATELET AGGREGATION INHIBITORS;RETROSPECTIVE STUDIES;BREAST NEOPLASMS;HEART FAILURE;VENTRICULAR DYSFUNCTION, LEFT;ANGIOPLASTY, BALLOON, CORONARY;RISK FACTORS","147;105;102;84;77;68;54;49;46;35;29;25;20;20;20;19;19;19;18;18","MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;MANAGEMENT OF VALVULAR HEART DISEASE;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;TREATMENT AND OUTCOMES OF HAND INJURIES;MANAGEMENT AND TREATMENT OF HEMOPHILIA;METABOLIC SYNDROME AND CARDIOVASCULAR DISEASE;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;ATRIAL FIBRILLATION;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;MOLECULAR MECHANISMS OF AMYLOIDOSIS;MOLECULAR MECHANISMS OF RETINAL DEGENERATION AND REGENERATION;MOLECULAR RESEARCH ON BREAST CANCER;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;CYCLOOXYGENASE-2 INHIBITORS IN INFLAMMATION AND CANCER;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;DIAGNOSIS AND MANAGEMENT OF HYPONATREMIA","9;7;6;5;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2","CARDIAC IMAGING;CARDIAC RESYNCHRONIZATION THERAPY;CLINICAL ENDPOINT;DRUG-ELUTING STENTS;PLATELET REACTIVITY;CORONARY STENTS;DIABETES;ECHOCARDIOGRAPHY;VENTRICULAR REMODELING;ATRIAL FIBRILLATION;DEEP VEIN THROMBOSIS;DIAGNOSIS;LEFT VENTRICULAR FUNCTION;MACE;MYOCARDIAL PERFUSION;MYOCARDIAL REVASCULARIZATION;PORTAL HYPERTENSION;REFRACTORY (PLANETARY SCIENCE);REPERFUSION THERAPY;ST-SEGMENT ELEVATION","10;7;7;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4","MYOCARDIAL INFARCTION;ACUTE MYOCARDIAL;LEFT VENTRICULAR;ICD ITALIAN;RISK FACTORS;CARDIAC RESYNCHRONIZATION;CORONARY ARTERY;ITALIAN REGISTRY;RESYNCHRONIZATION THERAPY;ATRIAL FIBRILLATION;BREAST CANCER;INSYNCINSYNC ICD;CARE UNITS;DUAL ANTIPLATELET;EMERGENCY DEPARTMENT;HEART DISEASE;HEART FAILURE;HYPERTROPHIC CARDIOMYOPATHY;LIVER STIFFNESS;MESENCHYMAL STEM;METABOLIC SYNDROME;PHASE II;PHYSICAL ACTIVITY;PLATELET REACTIVITY;PORTAL HYPERTENSION;SEVERE PORTAL;SPINAL CORD;STEM CELLS;TYPE DIABETIC;VENTRICULAR ARRHYTHMIAS","11;10;8;6;6;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","PUBMED SCOPUS;LYMPH NODE;CROSSREF PUBMED;LYMPH NODES;METASTATIC LYMPH;SENTINEL LYMPH;RISK FACTORS;BREAST CANCER;HYPERTROPHIC CARDIOMYOPATHY;LEFT VENTRICULAR;NF GENE;ANGIOTENSIN II;SURG -CROSSREF;CONFIDENCE INTERVAL;GASTRIC CANCER;AF IMAGES;AF-BASED TECHNIQUES;AUTOFLUORESCENCE MICROSCOPY;CARDIOMYOPATHY CENTER;EXTENDED LYMPHADENECTOMY;IMAGING AUTOFLUORESCENCE;LIVER STIFFNESS;SENTINEL NODE;ADJUVANT THERAPY;AF SPECTRA;BOSTON MASS;CANCER -ABSTRACT;CANCER PATIENTS;CARDIOLOGY TUFTS-NEW;CARDIOVASCULAR DISEASE","44;36;32;32;15;13;11;10;10;10;10;8;8;7;7;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5",38,0.19,6,3,4,1,0,1,4,1,1,3,0,1,5.75,0,2,1,0,6,1,0,0,70.75,70.75,3,2,1,1,0,0,0,0,0,0,0,0,4,0,0,0,3.5,1.99,1.75,0,1,4,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"MAGGI ENRICO;ROMAGNANI PAOLA;ROMAGNANI SERGIO;ANNUNZIATO FRANCESCO","4;4;4;2","AZIENDA OSPEDALIERO UNIVERSITARIA CAREGGI;AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI;MAGGI, ENRICO;ROMAGNANI, PAOLA;ROMAGNANI, SERGIO","3;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;31 BIOLOGICAL SCIENCES","8;4;2","BIOTECHNOLOGY;KIDNEY DISEASE;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN","2;2;2;2;2;2","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING","2","A61K35/12;A61K35/23;A61P13/12;C12N5/071;C12N5/074;G01N33/569;A61K35/00;A61K35/28;C12N5/00","2;2;2;2;2;2;1;1;1","A61P13/12;A61P25/00;A61P43/00;A61K35/12;A61K35/28;A61P19/08;C12N2500/25;C12N2501/11;C12N2501/12;C12N2501/39","3;3;3;2;2;2;2;2;2;2",19,5.06,1006.76,4.91,5,0.26,78.05,0,0,4,1,9,0,1,4,0,15,2,0,0,0,0,0,0,17,1,1,17,2,0,0,0,0,0,0,0,0,"Italy;United States;Japan","4;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;31 BIOLOGICAL SCIENCES;3204 IMMUNOLOGY;44 HUMAN SOCIETY;4403 DEMOGRAPHY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3107 MICROBIOLOGY;3213 PAEDIATRICS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","17;8;7;3;2;2;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;RARE DISEASES;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;PATIENT SAFETY;AUTOIMMUNE DISEASE;CARDIOVASCULAR;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;LYMPHOMA;ORPHAN DRUG;PEDIATRIC;PREVENTION;ARTHRITIS;ATHEROSCLEROSIS;BIOENGINEERING;BRAIN DISORDERS","16;11;8;5;5;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1","CANCER;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;ORAL AND GASTROINTESTINAL;REPRODUCTIVE HEALTH AND CHILDBIRTH","7;2;1;1;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY","12;1;1;1;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;BLOOD CANCER;BREAST CANCER;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;LUNG CANCER;MYELOMA;NOT SITE-SPECIFIC CANCER;PANCREATIC CANCER","3;2;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","6;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CAREGGI",2008,227,9.72246696035242,3.09691629955947,0.466960352422908,0.431718061674009,0.502202643171806,1.82124352331606,1.30864197530864,1.66101694915254,1.35714285714286,0.303964757709251,6,115,55,18,14,0.51,0.24,0.08,0.06,45.52,0.829485452774856,NA,0.286343612334802,0.770925110132159,0.497,0.38,0.436,0.378,"GIAN FRANCO GENSINI;ALBERTO BOSI;SANDRO GELSOMINO;DAVID ANTONIUCCI;GIUSEPPE DE CICCO;ROBERTO LORUSSO;FRANCESCA TORRICELLI;MASSIMO MARGHERI;NICCOLÒ MARCHIONNI;LUIGI RIGACCI;IACOPO OLIVOTTO;RODOLFO CAPANNA;RENATO VALENTI;CHIARA LAZZERI;CARLO ROSTAGNO;VALERIA SANTINI;FRANCO CECCHI;ROSANNA ABBATE;GIOVANNI BELTRAMI;RICCARDO SACCARDI","23;11;11;10;9;9;9;9;8;8;7;7;7;7;7;7;7;7;6;6","GIAN FRANCO GENSINI;DAVID ANTONIUCCI;SANDRO GELSOMINO;ROSANNA ABBATE;MASSIMO MORFINI;GIUSEPPE DE CICCO;ROBERTO LORUSSO;RODOLFO CAPANNA;RENATO VALENTI;GIOVANNI BELTRAMI;CARLO NOZZOLI;CARLO ROSTAGNO;CHIARA LAZZERI;ALBERTO BOSI;MARCO INNOCENTI;NICCOLÒ MARCHIONNI;DONATELLA LIPPI;FRANCESCO PAOLO LICARI;DOMENICO ANDREA CAMPANACCI;GIOVANNA BERTINI","3.16;2.94;1.67;1.65;1.43;1.42;1.4;1.3;1.25;1.22;1.19;1.1;1.08;1.08;1.07;1.03;1;1;0.97;0.95","GIAN FRANCO GENSINI;ALBERTO BOSI;SANDRO GELSOMINO;DAVID ANTONIUCCI;GIUSEPPE DE CICCO;ROBERTO LORUSSO;FRANCESCA TORRICELLI;MASSIMO MARGHERI;NICCOLÒ MARCHIONNI;LUIGI RIGACCI;IACOPO OLIVOTTO;RODOLFO CAPANNA;RENATO VALENTI;CHIARA LAZZERI;CARLO ROSTAGNO;VALERIA SANTINI;FRANCO CECCHI;ROSANNA ABBATE;GIOVANNI BELTRAMI;RICCARDO SACCARDI","23;11;11;10;9;9;9;9;8;8;7;7;7;7;7;7;7;7;6;6","GIAN FRANCO GENSINI;DAVID ANTONIUCCI;SANDRO GELSOMINO;ROSANNA ABBATE;MASSIMO MORFINI;GIUSEPPE DE CICCO;ROBERTO LORUSSO;RODOLFO CAPANNA;RENATO VALENTI;GIOVANNI BELTRAMI;CARLO NOZZOLI;CARLO ROSTAGNO;CHIARA LAZZERI;ALBERTO BOSI;MARCO INNOCENTI;NICCOLÒ MARCHIONNI;DONATELLA LIPPI;FRANCESCO PAOLO LICARI;DOMENICO ANDREA CAMPANACCI;GIOVANNA BERTINI","3.16;2.94;1.67;1.65;1.43;1.42;1.4;1.3;1.25;1.22;1.19;1.1;1.08;1.08;1.07;1.03;1;1;0.97;0.95","FRANCO CECCHI;IACOPO OLIVOTTO;NICCOLÒ MARCHIONNI;GIAN FRANCO GENSINI;STEFANO NISTRI;ROSANNA ABBATE;FRANCESCA TORRICELLI;CORRADO POGGESI;FRANCESCA GIROLAMI;ALBERTO BOSI;EDOARDO MANNUCCI;CORINNA ARMENTANO;ELISABETTA ZACHARA;FEDERICA RE;J. MARTIJN BOS;JEANNE L. THEIS;MICHAEL J. ACKERMAN;RACHAEL A. VAUBEL;STEVE R. OMMEN;GIULIO MASOTTI","1099;1099;979;939;906;842;794;705;705;629;606;599;599;599;599;599;599;599;599;564","NICCOLÒ MARCHIONNI;GIAN FRANCO GENSINI;EDOARDO MANNUCCI;CORRADO POGGESI;ALBERTO BOSI;GIULIO MASOTTI;FRANCO CECCHI;IACOPO OLIVOTTO;MATTEO MONAMI;RENATO VALENTI;ANGELA MIGLIORINI;MAURO DI BARI;RUBEN VERGARA;MARCO CAVALLINI;RICCARDO PINI;FRANCESCO VIZZUTTI;MASSIMO PINZANI;UMBERTO ARENA;LUIGI REGA;FABIO MARRA","979;726;606;599;596;564;500;500;496;496;491;483;444;424;424;410;410;410;407;384","GIAN FRANCO GENSINI;ROSANNA ABBATE;SANDRO GELSOMINO;ALBERTO BOSI;DAVID ANTONIUCCI;NICCOLÒ MARCHIONNI;LUIGI RIGACCI;CHIARA LAZZERI;RODOLFO CAPANNA;SERAFINA VALENTE;VALERIA SANTINI;CARLO NOZZOLI;EDOARDO MANNUCCI;FRANCESCA TORRICELLI;RENATO VALENTI;CARLO ROSTAGNO;MASSIMO MARGHERI;RICCARDO SACCARDI;PIERLUIGI STEFÀNO;ANDREA MINERVINI","19;10;9;9;8;8;8;7;7;7;7;6;6;6;6;6;6;6;5;5","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;POLITICAL SCIENCE;COMPUTER SCIENCE;MATHEMATICS;BUSINESS;ENGINEERING;PSYCHOLOGY;SOCIOLOGY;ECONOMICS;HISTORY;MATERIALS SCIENCE;ART;PHILOSOPHY;GEOGRAPHY;GEOLOGY","216;60;23;20;8;7;5;4;4;4;4;3;3;3;2;2;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;PATHOLOGY;GENETICS;GASTROENTEROLOGY;IMMUNOLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;RADIOLOGY;ONCOLOGY;INTENSIVE CARE MEDICINE;ANESTHESIA;OPTICS;PSYCHIATRY;PALEONTOLOGY;PEDIATRICS;PHARMACOLOGY;LAW;NUCLEAR MEDICINE;UROLOGY","166;77;59;43;30;26;26;22;21;20;19;16;15;14;12;12;11;10;10;8;8;8","MYOCARDIAL INFARCTION;GENE;HEART FAILURE;DISEASE;POPULATION;CANCER;CHEMOTHERAPY;ADVERSE EFFECT;RANDOMIZED CONTROLLED TRIAL;ALTERNATIVE MEDICINE;INCIDENCE (GEOMETRY);ANTIBODY;BLOOD PRESSURE;DIABETES MELLITUS;MITRAL REGURGITATION;STENT;BONE MARROW;COHORT;CONFIDENCE INTERVAL;HYPERTROPHIC CARDIOMYOPATHY;PERCUTANEOUS","35;31;29;21;18;17;16;15;15;13;11;10;10;10;9;9;8;8;8;8;8","PERCUTANEOUS CORONARY INTERVENTION;EJECTION FRACTION;CARDIOMYOPATHY;CONVENTIONAL PCI;MUTATION;CLINICAL ENDPOINT;GENE EXPRESSION;NEUTROPENIA;TOLERABILITY;ALLELE;CYCLOPHOSPHAMIDE;PLACEBO;RESTENOSIS;ACUTE CORONARY SYNDROME;FIBULA;GENOTYPE;HAZARD RATIO;HEMATOPOIETIC STEM CELL TRANSPLANTATION;LIVER FIBROSIS;METABOLIC SYNDROME;MYELODYSPLASTIC SYNDROMES;PHENOTYPE;VENTRICULAR REMODELING;VIRAL LOAD","21;12;11;10;7;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4","DNA METHYLATION;FEBRILE NEUTROPENIA;TRANSIENT ELASTOGRAPHY;ANTIRETROVIRAL THERAPY;CARDIAC RESYNCHRONIZATION THERAPY;FLUDARABINE;GENE MUTATION;HAPLOTYPE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;TARGET LESION;ABCIXIMAB;BENDAMUSTINE;BIVALIRUDIN;BUSULFAN;CLINICAL PHENOTYPE;CROSSOVER STUDY;DRUG-ELUTING STENT;EPTIFIBATIDE;FUNCTIONAL MITRAL REGURGITATION;MISSENSE MUTATION;PORTAL VENOUS PRESSURE;PRIMARY ANGIOPLASTY;SYNOVIAL FLUID;TICLOPIDINE;TIMI","4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;MALE;FEMALE;MIDDLE AGED;AGED;ADULT;;ITALY;MYOCARDIAL INFARCTION;TREATMENT OUTCOME;AGED, 80 AND OVER;MITRAL VALVE INSUFFICIENCY;ANGIOPLASTY, BALLOON, CORONARY;CORONARY ARTERY DISEASE;TIME FACTORS;ADOLESCENT;CARDIOMYOPATHY, HYPERTROPHIC;FOLLOW-UP STUDIES;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;HEART FAILURE","163;128;125;93;89;70;56;42;42;39;34;32;27;21;21;20;20;20;19;19","CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;MANAGEMENT OF VALVULAR HEART DISEASE;ACUTE MYELOID LEUKEMIA;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;LYMPHOID NEOPLASMS;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MANAGEMENT OF SPINAL METASTATIC TUMORS;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;BLOOD RHEOLOGY AND COAGULATION MECHANISMS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GENETIC BASIS OF PRIMARY IMMUNODEFICIENCY DISORDERS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MICROSURGICAL RECONSTRUCTION TECHNIQUES;RENAL CELL CARCINOMA","8;8;7;7;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3","CARDIAC IMAGING;DRUG-ELUTING STENTS;MITRAL REGURGITATION;CLINICAL ENDPOINT;REGIMEN;TOLERABILITY;CARDIAC RESYNCHRONIZATION THERAPY;CORONARY STENTS;DIAGNOSIS;POSTINFARCTION VENTRICULAR SEPTAL DEFECT;VALVULAR REGURGITATION;VENTRICULAR RECONSTRUCTION;ANTIRETROVIRAL THERAPY;AZACITIDINE;BONE METASTASES;CARDIAC SURGERY RISK MODELS;CARDIOVASCULAR EVALUATION;DILATED CARDIOMYOPATHY;LEFT VENTRICULAR FUNCTION;LIMB RECONSTRUCTION","11;7;7;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4","MYOCARDIAL INFARCTION;ACUTE MYOCARDIAL;LEFT VENTRICULAR;CORONARY INTERVENTION;HYPERTROPHIC CARDIOMYOPATHY;PERCUTANEOUS CORONARY;CORONARY ARTERY;CELL TRANSPLANTATION;STEM CELL;ARTERY DISEASE;HEART FAILURE;MITRAL REGURGITATION;PATIENTS PTS;PHASE II;ACUTE CORONARY;ACUTE LEUKEMIA;AUTOIMMUNE DISEASES;AZACITIDINE AZA;CLINICAL OUTCOME;DA CARCINOMA;DRUG-ELUTING STENTS;II TRIAL;LUNG CANCER;MESENCHYMAL STEM;METASTASI OSSEE;MYELODYSPLASTIC SYNDROMES;OSSEE DA;PRIMARY PERCUTANEOUS;PROSPECTIVE STUDY;RANDOMIZED PHASE","11;8;8;7;7;7;6;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","VEIN GRAFT;LEFT VENTRICULAR;MITRAL VALVE;MITRAL REGURGITATION;CORONARY ARTERY;ANTERIOR LEAFLET;PUBMED SCOPUS;MITRAL LEAFLET;SAPHENOUS VEIN;CARDIAC ARREST;CELL TRANSPLANTATION;POSTERIOR LEAFLET;STEM CELLS;CLOT LYSIS;CROSSREF PUBMED;LYSIS TIME;STEM CELL;LYME ARTHRITIS;PLASMINOGEN ACTIVATOR;POSTERIOR MITRAL;BONE FRACTURES;CONGENITAL MALFORMATIONS;DES THROMBOSIS;EXTRACORPOREAL CIRCULATION;GRAFT PERFORATION;MYOCARDIAL INFARCTION;PERCUTANEOUS CORONARY;PERCUTANEOUS TRANSLUMINAL;PHILADELPHIA -GOOGLE;STRONTIUM RANELATE","20;19;18;15;12;11;11;10;10;9;9;9;9;8;8;8;8;7;7;7;6;6;6;6;6;6;6;6;6;6",34,0.15,3,2,0,0,0,2,2,0,1,2,0,1,3,0,1.25,1,1,2,1,0,0,89,89.75,1,1,0,0,1,0,0,0,0,0,0,0,2,0,0,3,4,1.14,1,0,0,2,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ANNUNZIATO FRANCESCO;ENRICO MAGGI;FRANCESCO ANNUNZIATO;MAGGI ENRICO;PAOLA ROMAGNANI;ROMAGNANI PAOLA;ROMAGNANI SERGIO;SERGIO ROMAGNANI","1;1;1;1;1;1;1;1","AZIENDA OSPEDALIERO UNIVERSITARIA CAREGGI","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY","4;2","STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;REGENERATIVE MEDICINE;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN","2;2;1;1",NA,NA,"A61K35/28;A01N1/02;A61K35/00;A61K35/12;A61P43/00;C12N5/00;C12N5/06;C12Q1/02;C12Q1/68;G01N33/53","2;1;1;1;1;1;1;1;1;1","A61K35/28;A61P1/16;A61P1/18;A61P11/00;A61P11/02;A61P13/00;A61P13/12;A61P25/00;A61P27/02;A61P27/16","2;2;2;2;2;2;2;2;2;2",24,5.38,836.1,6.72,4,0.17,29.83,1,0,2,3,5,0,4,8,1,15,6,0,0,0,0,0,0,23,0,1,19,3,1,1,0,0,0,0,0,0,"Italy;United States","7;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3213 PAEDIATRICS;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3215 REPRODUCTIVE MEDICINE;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4204 MIDWIFERY","23;11;7;4;4;3;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;RARE DISEASES;CARDIOVASCULAR;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEART DISEASE;PATIENT SAFETY;HEMATOLOGY;PREVENTION;HEART DISEASE - CORONARY HEART DISEASE;CANCER;PEDIATRIC;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;ASSISTIVE TECHNOLOGY;ATHEROSCLEROSIS;AUTOIMMUNE DISEASE;BEHAVIORAL AND SOCIAL SCIENCE;BIOENGINEERING;DIGESTIVE DISEASES;HEALTH SERVICES;INFANT MORTALITY","19;10;8;8;7;7;6;6;4;3;3;3;2;2;2;2;2;2;2;2","CARDIOVASCULAR;CANCER;RESPIRATORY;BLOOD;EYE;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH","9;4;2;1;1;1;1","6.1 PHARMACEUTICALS;7.3 MANAGEMENT AND DECISION MAKING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;6.7 PHYSICAL;3.3 NUTRITION AND CHEMOPREVENTION;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","12;3;2;2;2;2;1;1;1","LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;HODGKIN'S DISEASE;STOMACH CANCER","2;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","3",2,4038629.5,333900.97,4,12.5,7.5,1,11,142045.147435897,1.59808345513838,"AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI;FRAUNHOFER SOCIETY;CENTER FOR USABILITY RESEARCH AND ENGINEERING;CENTRE FOR RESEARCH AND TECHNOLOGY HELLAS;DEPARTMENT OF MEDICAL SCIENCES;EUROPEAN RESEARCH AND PROJECT OFFICE;GERMAN SPORT UNIVERSITY COLOGNE;INSTITUTE OF TROPICAL MEDICINE ANTWERP;ISTITUTO SUPERIORE DI SANITÀ;LINK CONSULTING;MELISSA FOOD;MINISTRY OF HEALTH;NATIONAL RESEARCH COUNCIL;NATIONAL SCIENTIFIC AND TECHNICAL RESEARCH COUNCIL;OSWALDO CRUZ FOUNDATION;POLITECNICO DI MILANO;SAARLAND UNIVERSITY;SETH RESEARCH FOUNDATION;STELLENBOSCH UNIVERSITY;UNIVERSITY OF ANTIOQUIA","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","CP - COLLABORATIVE PROJECT (GENERIC) (FUNDING SCHEME);CSA-SA - SUPPORT ACTIONS (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2007-B (CALL FOR PROPOSAL);FP7-ICT - SPECIFIC PROGRAMME ""COOPERATION"": INFORMATION AND COMMUNICATION TECHNOLOGIES (PROGRAMME);FP7-ICT-2007-1 (CALL FOR PROPOSAL)","1;1;1;1;1;1","42 HEALTH SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;4203 HEALTH SERVICES AND SYSTEMS;46 INFORMATION AND COMPUTING SCIENCES;4605 DATA MANAGEMENT AND DATA SCIENCE","2;1;1;1;1;1;1","CHRONIC OBSTRUCTIVE PULMONARY DISEASE;CLINICAL RESEARCH;HEALTH SERVICES;HIV/AIDS;INFECTIOUS DISEASES;KIDNEY DISEASE;LUNG;PATIENT SAFETY;RARE DISEASES;TUBERCULOSIS","1;1;1;1;1;1;1;1;1;1","GENERIC HEALTH RELEVANCE;INFECTION","1;1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;7.1 INDIVIDUAL CARE NEEDS","1;1","KAPOSI'S SARCOMA","1","2.4 RESOURCES AND INFRASTRUCTURE RELATED TO ETIOLOGY;3.6 RESOURCES AND INFRASTRUCTURE RELATED TO PREVENTION","1;1","A01 CLINICAL MEDICINE;B11 COMPUTER SCIENCE AND INFORMATICS","1;1","3 GOOD HEALTH AND WELL BEING","2",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CAREGGI",2009,239,9.06276150627615,3.17991631799163,0.476987447698745,0.410041841004184,0.577405857740586,1.79245283018868,1.28089887640449,1.68965517241379,1.36633663366337,0.476987447698745,7,134,61,18,17,0.56,0.26,0.08,0.07,53.94,1.16602847950113,NA,0.221757322175732,0.778242677824268,0.484,0.427,0.433,0.426,"GIAN FRANCO GENSINI;ADRIANO PERIS;MANUELA BONIZZOLI;ENRICO TORTOLI;ALBERTO BOSI;DI FILIPPO A;ROSANNA ABBATE;ROSSELLA MARCUCCI;CHIARA LAZZERI;MAURIZIO SALVADORI;LUIGI RIGACCI;ANDREA A. CONTI;ANNA MARIA GORI;ROSANNA ABBATE;E. BERTONI;RICCARDO SACCARDI;CARLO NOZZOLI;RITA PANICCIA;BETTI GIUSTI;DOMENICO PRISCO","22;14;10;10;10;10;10;9;9;8;8;8;8;8;7;7;7;6;6;6","GIAN FRANCO GENSINI;ADRIANO PERIS;ANDREA A. CONTI;DI FILIPPO A;CARLO NOZZOLI;E. BERTONI;ENRICO TORTOLI;MANUELA BONIZZOLI;FRANCESCO DI COSTANZO;GIULIO DEL POPOLO;CHIARA LAZZERI;BEATRICE DILAGHI;VALERIA SANTINI;MAURIZIO SALVADORI;PIETRO AMEDEO MODESTI;FRANCESCO CAPPELLI;ROSANNA ABBATE;ROSANNA ABBATE;SANDRO GELSOMINO;RODOLFO CAPANNA","3.01;2.03;1.82;1.63;1.56;1.54;1.48;1.43;1.36;1.35;1.34;1.33;1.28;1.25;1.25;1.22;1.13;1.1;1.07;1.07","GIAN FRANCO GENSINI;ADRIANO PERIS;MANUELA BONIZZOLI;ENRICO TORTOLI;ALBERTO BOSI;DI FILIPPO A;ROSANNA ABBATE;ROSSELLA MARCUCCI;CHIARA LAZZERI;MAURIZIO SALVADORI;LUIGI RIGACCI;ANNA MARIA GORI;ROSANNA ABBATE;E. BERTONI;RICCARDO SACCARDI;CARLO NOZZOLI;RITA PANICCIA;BETTI GIUSTI;DOMENICO PRISCO;GIULIO DEL POPOLO","22;14;10;10;10;10;10;9;9;8;8;8;8;7;7;7;6;6;6;6","GIAN FRANCO GENSINI;ADRIANO PERIS;DI FILIPPO A;CARLO NOZZOLI;E. BERTONI;ENRICO TORTOLI;MANUELA BONIZZOLI;FRANCESCO DI COSTANZO;GIULIO DEL POPOLO;CHIARA LAZZERI;BEATRICE DILAGHI;VALERIA SANTINI;MAURIZIO SALVADORI;FRANCESCO CAPPELLI;ROSANNA ABBATE;ROSANNA ABBATE;SANDRO GELSOMINO;RODOLFO CAPANNA;STEFANO BAMBI;SILVIA LINARI","3.01;2.03;1.63;1.56;1.54;1.48;1.43;1.36;1.35;1.34;1.33;1.28;1.25;1.22;1.13;1.1;1.07;1.07;1;1","VALERIA SANTINI;C.L. BEACH;EVA HELLSTRÖM‐LINDBERG;GHULAM J. MUFTI;JAY T. BACKSTROM;JOHN F. SEYMOUR;LEWIS R. SILVERMAN;PIERRE FENAUX;STEVEN D. GORE;ALAN F. LIST;ARISTOTELES GIAGOUNIDIS;CARLO FINELLI;DAVID R. MCKENZIE;GUILLERMO SANZ;JOHN C. BYRD;JOHN M. BENNETT;LINDA ZIMMERMAN;NORBERT GATTERMANN;ROBERT SCHOCH;ROSANNA ABBATE","2499;2488;2488;2488;2488;2488;2488;2488;2488;2475;2475;2475;2475;2475;2475;2475;2475;2475;2475;1592","VALERIA SANTINI;ROSANNA ABBATE;GIAN FRANCO GENSINI;ROSSELLA MARCUCCI;RITA PANICCIA;BETTI GIUSTI;ANNA MARIA GORI;GIULIO DEL POPOLO;DAVID ANTONIUCCI;LUIGI RIGACCI;IACOPO OLIVOTTO;PIERGIOVANNI BUONAMICI;SERAFINA VALENTE;CRISTINA GIGLIOLI;RICCARDO SACCARDI;ALBERTO BOSI;GIACOMO GIANFALDONI;ENRICO TORTOLI;STEFANO GRIFONI;FRANCO CECCHI","2499;1369;1141;963;914;904;901;832;802;768;764;744;678;544;493;450;424;398;335;310","GIAN FRANCO GENSINI;ADRIANO PERIS;ROSANNA ABBATE;ENRICO TORTOLI;MANUELA BONIZZOLI;LUIGI RIGACCI;ROSSELLA MARCUCCI;CARLO NOZZOLI;RICCARDO SACCARDI;E. BERTONI;DI FILIPPO A;RITA PANICCIA;BEATRICE DILAGHI;GIULIO DEL POPOLO;SANDRO GELSOMINO;STEFANO ROMAGNOLI;ALBERTO BOSI;ANNA MARIA GORI;MAURIZIO SALVADORI;SERAFINA VALENTE","15;13;13;9;9;8;8;7;7;7;7;6;6;6;6;6;6;6;6;6","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;PSYCHOLOGY;POLITICAL SCIENCE;ECONOMICS;MATHEMATICS;MATERIALS SCIENCE;GEOGRAPHY;PHILOSOPHY;SOCIOLOGY;BUSINESS;GEOLOGY;HISTORY","225;59;19;15;13;12;9;8;5;4;3;2;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;PATHOLOGY;GENETICS;RADIOLOGY;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;GASTROENTEROLOGY;IMMUNOLOGY;ANESTHESIA;ENVIRONMENTAL HEALTH;ENDOCRINOLOGY;ONCOLOGY;PSYCHIATRY;MICROBIOLOGY;EMERGENCY MEDICINE;MECHANICAL ENGINEERING;NUCLEAR MEDICINE;PEDIATRICS","171;72;55;43;37;29;27;25;25;22;20;19;17;17;17;14;11;10;10;10","GENE;CONFIDENCE INTERVAL;TRANSPLANTATION;MYOCARDIAL INFARCTION;DISEASE;HEART FAILURE;POPULATION;CANCER;BLOOD PRESSURE;CHEMOTHERAPY;RANDOMIZED CONTROLLED TRIAL;KIDNEY;BACTERIA;PROSPECTIVE COHORT STUDY;RETROSPECTIVE COHORT STUDY;ADVERSE EFFECT;ATRIAL FIBRILLATION;DIABETES MELLITUS;MAGNETIC RESONANCE IMAGING;BONE MARROW;STEM CELL;STENT;STROKE (ENGINE);THROMBOSIS","31;22;21;20;19;18;18;17;16;16;13;12;11;10;10;9;9;9;9;8;8;8;8;8","HAZARD RATIO;KIDNEY TRANSPLANTATION;PERCUTANEOUS CORONARY INTERVENTION;MYCOBACTERIUM;HEMATOPOIETIC STEM CELL TRANSPLANTATION;BREAST CANCER;CARDIOMYOPATHY;CLINICAL ENDPOINT;EJECTION FRACTION;GENOTYPE;ACUTE CORONARY SYNDROME;ALLELE;CYCLOPHOSPHAMIDE;DIASTOLE;GENE EXPRESSION;MYCOBACTERIUM TUBERCULOSIS;RITUXIMAB;16S RIBOSOMAL RNA;CONVENTIONAL PCI;MYELODYSPLASTIC SYNDROMES;POLYMERASE CHAIN REACTION;UNIVARIATE ANALYSIS","13;10;10;8;7;6;6;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4","DRUG-ELUTING STENT;DNA METHYLATION;FLUDARABINE;INTERNAL TRANSCRIBED SPACER;MOLECULAR EPIDEMIOLOGY;MYCOBACTERIUM TUBERCULOSIS COMPLEX;RPOB;ACUTE LYMPHOCYTIC LEUKEMIA;ANTIRETROVIRAL THERAPY;BENDAMUSTINE;COCHRANE COLLABORATION;CXCL10;DOPPLER IMAGING;ENOS;GATA1;INTERNATIONAL PROGNOSTIC INDEX;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;LYMPHEDEMA;MISSENSE MUTATION;MYCOLIC ACID;NEUROEPITHELIAL CELL;P2Y12;PULSED-FIELD GEL ELECTROPHORESIS;RIBOSOME","4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;MALE;FEMALE;MIDDLE AGED;AGED;ADULT;;AGED, 80 AND OVER;TREATMENT OUTCOME;ITALY;YOUNG ADULT;PROSPECTIVE STUDIES;ADOLESCENT;FOLLOW-UP STUDIES;RISK FACTORS;DNA, BACTERIAL;MYCOBACTERIUM;MYOCARDIAL INFARCTION;ACUTE CORONARY SYNDROME;KIDNEY TRANSPLANTATION","174;127;123;103;89;85;60;44;40;37;27;26;25;25;25;23;22;22;21;21","DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;ACUTE MYELOID LEUKEMIA;KIDNEY TRANSPLANTATION;LYMPHOID NEOPLASMS;MANAGEMENT OF VALVULAR HEART DISEASE;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;ABDOMINAL COMPARTMENT SYNDROME AND INTRA-ABDOMINAL HYPERTENSION;ATRIAL FIBRILLATION;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND TREATMENT OF BONE FRACTURES;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;OPTIMIZATION OF PERIOPERATIVE FLUID THERAPY;PATHOPHYSIOLOGY AND CLINICAL CHARACTERISTICS OF STRESS-INDUCED CARDIOMYOPATHY;RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHOLESTEROL-LOWERING TREATMENT","8;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;2;2","TREATMENT;CARDIAC IMAGING;STROKE (ENGINE);CLINICAL ENDPOINT;KIDNEY TRANSPLANTATION;LEFT VENTRICULAR FUNCTION;PLATELET REACTIVITY;ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY;DEEP VEIN THROMBOSIS;MYCOBACTERIUM TUBERCULOSIS;REFRACTORY (PLANETARY SCIENCE);ATRIAL FIBRILLATION;ECHOCARDIOGRAPHY;INFARCTION TREATMENT;MYCOBACTERIUM ABSCESSUS;REGIMEN;TREATMENT OUTCOMES;UNIVARIATE ANALYSIS;ANTIRETROVIRAL THERAPY;AZACITIDINE","11;10;8;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4;3;3","LEFT VENTRICULAR;HYPERTROPHIC CARDIOMYOPATHY;ACUTE CORONARY;ATRIAL FIBRILLATION;CARDIOVASCULAR MEDICINE;CONTROLLED TRIAL;CORONARY ARTERY;HEART FAILURE;KIDNEY TRANSPLANTATION;LEFT MAIN;MYOCARDIAL INFARCTION;PERCUTANEOUS CORONARY;SP NOV;ANTIPLATELET THERAPY;AUTOIMMUNE DISEASES;BREAST CANCER;CELL CARCINOMA;CLINICAL OUTCOME;CORD BLOOD;CORONARY INTERVENTION;CORONARY SYNDROME;DUAL ANTIPLATELET;FIBRILLATION PATIENTS;MAIN CORONARY;MULTIPLE MYELOMA;MYCOBACTERIUM TUBERCULOSIS;MYELODYSPLASTIC SYNDROMES;PULMONARY EMBOLISM;RENAL TRANSPLANTATION;RETROSPECTIVE STUDY","8;6;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","FIVE-POINT LIKERT;LEFT VENTRICULAR;HEART FAILURE;BLOOD PRESSURE;AHF PATIENTSTHE;CONFIDENCE INTERVAL;FATTY ACIDS;HAZARD RATIO;ACUTE HEART;SYSTOLIC BLOOD;CARDIAC MORTALITY;CONVENTIONAL CARE;FAILURE SYNDROME;GASTRIC CANCER;PATIENTSTHE PDA;PDA TEST;RISK FACTORS;STAGE NA;TRANS FATTY;ANDROGEN SUPPRESSION;ODDS RATIO;REGRESSION ANALYSIS;SIGNIFICANT DIFFERENCES;ACUTE REJECTION;ATHEROMA VOLUME;AVIUM COMPLEX;BREAST CANCER;CARDIOVASCULAR RISK;FLORENCE ITALY;HEMATOPOIETIC STEM","24;20;15;13;12;12;11;10;9;9;8;8;8;8;8;8;8;8;8;7;7;7;7;6;6;6;6;6;6;6",46,0.19,6,3,0,1,0,4,10,0,1,3,0,1,8.25,0,1,1,2,5,2.25,0,0,89.5,89.5,4,1,1,2,0,2,1,0,0,0,0,0,3,3,1,4,3.14285714285714,2.89,1.14285714285714,1,1,6,0,0,2,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"MAGGI ENRICO;ROMAGNANI PAOLA;ROMAGNANI SERGIO;ANNUNZIATO FRANCESCO;MIRABELLA CARLO","6;6;6;3;1","AZIENDA OSPEDALIERO UNIVERSITARIA CAREGGI;REGIONE TOSCANA","7;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;31 BIOLOGICAL SCIENCES;3103 ECOLOGY","11;5;3;1","KIDNEY DISEASE;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN;BIOTECHNOLOGY;CLINICAL RESEARCH;TRANSPLANTATION","3;3;3;3;3;2;1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING","2","A61K35/00;A61K35/28;C12N5/00;G01N33/569;A61K35/12;A61K35/23;C12N5/071;C12N5/074;A61P13/12;C12N5/02","3;3;3;3;2;2;2;2;1;1","A61P43/00;A61P13/12;A61P25/00;A61K35/12;A61K35/28;A61P1/16;A61P1/18;A61P11/00;A61P11/02;A61P13/00","6;5;5;3;3;3;3;3;3;3",24,5.55,485.33,6.03,6,0.25,43.25,0,0,5,2,8,0,2,7,0,16,5,0,0,0,0,0,0,23,0,1,21,3,0,0,0,0,0,0,0,0,"United States;Italy;Japan","7;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","21;12;10;3;3;3;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;CANCER;PATIENT SAFETY;CARDIOVASCULAR;DIGESTIVE DISEASES;LYMPHOMA;ASSISTIVE TECHNOLOGY;BIOENGINEERING;HEART DISEASE;ORPHAN DRUG;PREVENTION;GENETICS;HEART DISEASE - CORONARY HEART DISEASE;LUNG;NEUROSCIENCES;TRANSPLANTATION;AGING","18;11;11;10;7;5;4;4;4;3;3;3;3;3;2;2;2;2;2;1","CANCER;CARDIOVASCULAR;ORAL AND GASTROINTESTINAL;BLOOD;RESPIRATORY","5;5;3;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.3 MEDICAL DEVICES;6.4 SURGERY;8.2 HEALTH AND WELFARE ECONOMICS","12;4;3;1;1;1;1","NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER;BRAIN TUMOR;HODGKIN'S DISEASE;LEUKEMIA / LEUKAEMIA;LUNG CANCER;NOT SITE-SPECIFIC CANCER;PARATHYROID CANCER","4;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.1 LOCALIZED THERAPIES - DISCOVERY AND DEVELOPMENT;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","4;3;2;1;1;1",1,2695402,149744.56,4,18,8,1,12,179481.286324786,1.33161514993552,"ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI;CF CONSULTING FINANZIAMENTI UNIONE EUROPEA;EUROPEAN SOCIETY OF CARDIOLOGY;FONDAZIONE TOSCANA GABRIELE MONASTERIO;HOSPITAL DE SANT PAU;INSTITUT CATALÀ DE LA SALUT;LEIDEN UNIVERSITY MEDICAL CENTER;MADRID HEALTH SERVICE;NATIONAL RESEARCH COUNCIL;QUEEN MARY UNIVERSITY OF LONDON;RECHTS DER ISAR HOSPITAL;ROYAL BROMPTON & HAREFIELD NHS FOUNDATION TRUST;TECHNICAL UNIVERSITY OF MUNICH;UNIVERSITY OF GENOA;UNIVERSITY OF NAPLES FEDERICO II;UNIVERSITY OF TURKU;UNIVERSITY OF ZURICH","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CP-FP - SMALL OR MEDIUM-SCALE FOCUSED RESEARCH PROJECT (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2007-B (CALL FOR PROPOSAL)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","1;1;1;1","ATHEROSCLEROSIS;BIOMEDICAL IMAGING;CARDIOVASCULAR;CLINICAL RESEARCH;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE","1;1;1;1;1;1","CARDIOVASCULAR","1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,3,"PUBLIC LIBRARY OF SCIENCE","3","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;46 INFORMATION AND COMPUTING SCIENCES","4;2;1;1;1;1;1","BIOTECHNOLOGY;BRAIN CANCER;BRAIN DISORDERS;CANCER;GENETICS;HUMAN GENOME;PEDIATRIC;PEDIATRIC RESEARCH INITIATIVE;RARE DISEASES","1;1;1;1;1;1;1;1;1","CANCER","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","2","CLINICAL","1","CLINICAL MEDICINE AND SCIENCE","3","BRAIN TUMOR","1",NA,NA
"AOU_CAREGGI",2010,292,9.62671232876712,3.74315068493151,0.534246575342466,0.441780821917808,0.75,2.02222222222222,1.45794392523364,1.74324324324324,1.67175572519084,0.441780821917808,8,162,61,23,24,0.55,0.21,0.08,0.08,35.87,0.793670440690964,NA,0.226027397260274,0.736301369863014,0.526,0.516,0.506,0.516,"ADRIANO PERIS;GIAN FRANCO GENSINI;GIOVANNI ZAGLI;CHIARA LAZZERI;MANUELA BONIZZOLI;DAVID ANTONIUCCI;E. BERTONI;MARCO CHIOSTRI;GIOVANNI CIANCHI;SERAFINA VALENTE;ALBERTO BOSI;MAURIZIO SALVADORI;GUIDO PARODI;M. ZANAZZI;MARCO CIAPETTI;LUIGI RIGACCI;ROSANNA ABBATE;STEFANO BATACCHI;CLAUDIO PICARIELLO;R SPINA","26;26;25;19;17;16;15;14;14;14;13;13;13;13;11;11;11;10;10;10","GIAN FRANCO GENSINI;CHIARA LAZZERI;DAVID ANTONIUCCI;ADRIANO PERIS;GIOVANNI ZAGLI;MARCO CHIOSTRI;SERAFINA VALENTE;M. ZANAZZI;E. BERTONI;GUIDO PARODI;EDOARDO MANNUCCI;ENRICO TORTOLI;MAURIZIO SALVADORI;CLAUDIO PICARIELLO;MANUELA BONIZZOLI;GIOVANNI CIANCHI;PAOLO MACCHIARINI;ROBERTO TARQUINI;ROSANNA ABBATE;MARIO MILCO D’ELIOS","4.21;3.44;2.95;2.76;2.6;2.58;2.54;2.38;2.1;2.04;2.03;2.01;1.94;1.9;1.74;1.4;1.31;1.23;1.18;1.11","ADRIANO PERIS;GIAN FRANCO GENSINI;GIOVANNI ZAGLI;CHIARA LAZZERI;MANUELA BONIZZOLI;DAVID ANTONIUCCI;E. BERTONI;MARCO CHIOSTRI;GIOVANNI CIANCHI;SERAFINA VALENTE;ALBERTO BOSI;MAURIZIO SALVADORI;GUIDO PARODI;M. ZANAZZI;MARCO CIAPETTI;LUIGI RIGACCI;ROSANNA ABBATE;STEFANO BATACCHI;CLAUDIO PICARIELLO;R SPINA","26;26;25;19;17;16;15;14;14;14;13;13;13;13;11;11;11;10;10;10","GIAN FRANCO GENSINI;CHIARA LAZZERI;DAVID ANTONIUCCI;ADRIANO PERIS;GIOVANNI ZAGLI;MARCO CHIOSTRI;SERAFINA VALENTE;M. ZANAZZI;E. BERTONI;GUIDO PARODI;EDOARDO MANNUCCI;ENRICO TORTOLI;MAURIZIO SALVADORI;CLAUDIO PICARIELLO;MANUELA BONIZZOLI;GIOVANNI CIANCHI;PAOLO MACCHIARINI;ROBERTO TARQUINI;ROSANNA ABBATE;MARIO MILCO D’ELIOS","4.21;3.44;2.95;2.76;2.6;2.58;2.54;2.38;2.1;2.04;2.03;2.01;1.94;1.9;1.74;1.4;1.31;1.23;1.18;1.11","GIAN FRANCO GENSINI;IACOPO OLIVOTTO;DAVID ANTONIUCCI;ADRIANO PERIS;GIOVANNI ZAGLI;GUIDO PARODI;GIOVANNI CIANCHI;FRANCESCA GIROLAMI;FRANCO CECCHI;FILIPPO BARTALESI;MANUELA BONIZZOLI;AIK BOSSINK;BEATE KAMPMANN;BERNHARD HELLMICH;CHRISTOPH LANGE;CONNIE ERKENS;DELIA GOLETTI;ELISABETH H. SCHÖLVINCK;GIOVANNI BATTISTA MIGLIORI;GIOVANNI SOTGIU","750;686;610;584;549;537;526;517;515;502;498;484;484;484;484;484;484;484;484;484","IACOPO OLIVOTTO;DAVID ANTONIUCCI;GIAN FRANCO GENSINI;GUIDO PARODI;ADRIANO PERIS;FRANCESCA GIROLAMI;FRANCO CECCHI;FILIPPO BARTALESI;GIOVANNI ZAGLI;GIOVANNI CIANCHI;MANUELA BONIZZOLI;GENNARO SANTORO;FRANCESCA TORRICELLI;STEFANO BATACCHI;CHIARA NOZZOLI;MASSIMO BALDI;KATIA BALDINI;FRANCESCO DI COSTANZO;ANGELA MIGLIORINI;MASSIMO MORFINI","679;578;568;536;530;510;508;502;495;472;444;420;419;390;382;374;367;355;327;316","ADRIANO PERIS;GIOVANNI ZAGLI;GIAN FRANCO GENSINI;CHIARA LAZZERI;MANUELA BONIZZOLI;DAVID ANTONIUCCI;GIOVANNI CIANCHI;MAURIZIO SALVADORI;SERAFINA VALENTE;E. BERTONI;GUIDO PARODI;M. ZANAZZI;MARCO CHIOSTRI;LUIGI RIGACCI;MARCO CIAPETTI;CLAUDIO PICARIELLO;R SPINA;STEFANO BATACCHI;ROSANNA ABBATE;ALBERTO BOSI","25;24;19;16;16;15;13;13;13;13;12;12;12;11;11;10;10;10;9;8","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ENGINEERING;COMPUTER SCIENCE;MATHEMATICS;ECONOMICS;PSYCHOLOGY;SOCIOLOGY;MATERIALS SCIENCE;POLITICAL SCIENCE;PHILOSOPHY;BUSINESS;HISTORY;ENVIRONMENTAL SCIENCE;GEOGRAPHY;GEOLOGY","276;56;42;22;18;11;8;7;7;7;6;6;5;3;2;1;1;1","INTERNAL MEDICINE;CARDIOLOGY;SURGERY;INTENSIVE CARE MEDICINE;PATHOLOGY;GASTROENTEROLOGY;GENETICS;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;RADIOLOGY;ANESTHESIA;BIOCHEMISTRY;OPTICS;ONCOLOGY;EMERGENCY MEDICINE;PHYSICAL THERAPY;MECHANICAL ENGINEERING;PEDIATRICS;CELL BIOLOGY;PHARMACOLOGY;PSYCHIATRY;UROLOGY","212;96;83;42;39;36;30;28;26;26;26;24;24;23;19;17;15;12;12;11;11;11;11","MYOCARDIAL INFARCTION;DISEASE;GENE;HEART FAILURE;POPULATION;TRANSPLANTATION;CANCER;DIABETES MELLITUS;INCIDENCE (GEOMETRY);CORONARY ARTERY DISEASE;ATRIAL FIBRILLATION;CHEMOTHERAPY;CONFIDENCE INTERVAL;INTENSIVE CARE UNIT;RANDOMIZED CONTROLLED TRIAL;STEM CELL;ADVERSE EFFECT;BLOOD PRESSURE;RECEPTOR;IN VITRO;LYMPHOMA;ODDS RATIO","45;30;28;26;25;25;24;21;21;17;14;13;13;13;13;11;10;10;10;9;9;9","PERCUTANEOUS CORONARY INTERVENTION;EJECTION FRACTION;CONVENTIONAL PCI;REVASCULARIZATION;ACUTE CORONARY SYNDROME;HAZARD RATIO;CARDIOGENIC SHOCK;CARDIOMYOPATHY;CLINICAL ENDPOINT;GENE EXPRESSION;COLORECTAL CANCER;RITUXIMAB;CORONARY CARE UNIT;IMATINIB;MYELODYSPLASTIC SYNDROMES;TYPE 2 DIABETES;UNIVARIATE ANALYSIS;VIRAL LOAD;DIASTOLE;GESTATIONAL AGE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;INSULIN RESISTANCE;RENAL TRANSPLANT","21;17;13;11;10;9;8;8;8;8;7;7;6;6;6;6;6;6;5;5;5;5;5","ANTIRETROVIRAL THERAPY;DNA METHYLATION;IMATINIB MESYLATE;KILLIP CLASS;TIMI;ABCIXIMAB;GLUCAGON-LIKE PEPTIDE-1;MACE;P2Y12;ADENOSINE DIPHOSPHATE;ARTHROPATHY;BIVALIRUDIN;CYTOREDUCTIVE SURGERY;DASATINIB;DIPEPTIDYL PEPTIDASE-4;DRUG-ELUTING STENT;FIRST TRIMESTER;HAPLOTYPE;INSULIN GLARGINE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;INTRA-AORTIC BALLOON PUMPING;INTRAPERITONEAL CHEMOTHERAPY;INTRAVENTRICULAR HEMORRHAGE;LAMIVUDINE;MYCOBACTERIUM BOVIS;NEONATAL RESPIRATORY DISTRESS SYNDROME;NEUROTENSIN;NILOTINIB;OSTEOCALCIN;PERITONEAL CARCINOMATOSIS;REVERSE TRANSCRIPTASE;RUNX2;VINCRISTINE","5;5;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;MYOCARDIAL INFARCTION;MIDDLE AGED;AGED;;ADULT;ANGIOPLASTY, BALLOON, CORONARY;ITALY;TREATMENT OUTCOME;CORONARY ARTERY DISEASE;AGED, 80 AND OVER;RISK FACTORS;ATRIAL FIBRILLATION;PROSPECTIVE STUDIES;TIME FACTORS;CARDIOVASCULAR DISEASES;RISK ASSESSMENT;HEART FAILURE","189;140;131;103;101;100;98;62;53;51;46;40;33;32;28;27;27;26;26;21","CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;ATRIAL FIBRILLATION;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;IMPACT OF HYPERGLYCEMIA ON HEALTH OUTCOMES;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;EFFICACY AND RESISTANCE IN CML TREATMENT;LYMPHOID NEOPLASMS;ACUTE MYELOID LEUKEMIA;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;MANAGEMENT OF VALVULAR HEART DISEASE;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF SEPSIS AND SEPTIC SHOCK;KIDNEY TRANSPLANTATION;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE","9;8;7;7;7;7;6;6;6;5;5;5;5;4;4;4;4;4;4;4","CARDIAC IMAGING;TREATMENT;ATRIAL FIBRILLATION;CARDIOVASCULAR RISK ASSESSMENT;CLINICAL ENDPOINT;CORONARY STENTS;REGIMEN;DRUG-ELUTING STENTS;LEFT VENTRICULAR FUNCTION;CORONARY CARE UNIT;POSTINFARCTION VENTRICULAR SEPTAL DEFECT;ST-SEGMENT ELEVATION;STROKE (ENGINE);UNIVARIATE ANALYSIS;AZACITIDINE;ECHOCARDIOGRAPHY;GLYCEMIC CONTROL;HIV;IMATINIB MESYLATE;MANTLE CELL LYMPHOMA","13;13;10;9;8;8;8;7;7;6;6;6;6;6;5;5;5;5;5;5","MYOCARDIAL INFARCTION;ATRIAL FIBRILLATION;INTENSIVE CARE;RENAL TRANSPLANT;STEM CELL;ACUTE MYOCARDIAL;CARE UNIT;CENTRAL VENOUS;LEFT VENTRICULAR;TRANSPLANT RECIPIENTS;CORONARY INTERVENTION;HYPERTROPHIC CARDIOMYOPATHY;RISK FACTORS;ST-ELEVATION MYOCARDIAL;CARDIOVASCULAR RISK;CELL TRANSPLANTATION;CLINICAL PRACTICE;CORONARY ARTERY;INFLAMMATORY BOWEL;LEFT MAIN;PERCUTANEOUS CORONARY;VENOUS CATHETERS;CARDIAC SURGERY;ELEVATION MYOCARDIAL;HEART FAILURE;HEMATOPOIETIC STEM;LIVER DISEASE;MAIN CORONARY;MYELODYSPLASTIC SYNDROMES;PRETERM INFANTS","19;11;8;8;8;7;7;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4","MYOCARDIAL INFARCTION;CONTROL SUBJECTS;CORONARY ARTERY;LEFT VENTRICULAR;PATIENTS UNDERGOING;HYPERTROPHIC CARDIOMYOPATHY;LV OUTFLOW;RISK FACTORS;CONSECUTIVE PATIENTS;GATA LOW;LIVER DISEASE;MORTALITY RATE;STEM CELLS;ATRIAL FIBRILLATION;CARDIAC SURGERY;CHEST PAIN;CIAGLIA BLUE;GLUCOSE TOLERANCE;SCIM III;ACUTE MYOCARDIAL;CLINIC BP;FATTY LIVER;INCREASED RISK;INDEPENDENT PREDICTOR;INTENSIVE CARE;LV DYSFUNCTION;REGRESSION ANALYSIS;TRANSPLANT RECIPIENTS;VENTRICULAR LV;AF LASTING","15;14;14;14;14;12;12;12;10;10;10;10;10;9;9;9;9;9;9;8;8;8;8;8;8;8;8;8;8;7",54,0.18,6,4.75,1,1.5,1,2,5.25,1,1,5,0,1,3.75,1.5,1,1,4,5.5,1,0,0,105.75,100.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,4.72,430.03,6.33,9,0.29,53.35,0,0,7,1,15,0,4,4,0,26,4,0,0,0,0,0,0,28,1,2,30,1,0,0,0,0,0,0,0,0,"United States;Italy;Switzerland","11;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;3204 IMMUNOLOGY;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;3212 OPHTHALMOLOGY AND OPTOMETRY;3213 PAEDIATRICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;4202 EPIDEMIOLOGY;4206 PUBLIC HEALTH","30;11;11;9;4;3;3;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;RARE DISEASES;BIOENGINEERING;LYMPHOMA;PEDIATRIC;CARDIOVASCULAR;AGING;ASSISTIVE TECHNOLOGY;CHILDHOOD LEUKEMIA;DIGESTIVE DISEASES;PATIENT SAFETY;PEDIATRIC CANCER;STEM CELL RESEARCH;ATHEROSCLEROSIS;BRAIN DISORDERS;CHRONIC PAIN;HEART DISEASE","27;24;14;14;14;5;5;5;4;3;3;3;3;3;3;3;2;2;2;2","CANCER;CARDIOVASCULAR;BLOOD;INFLAMMATORY AND IMMUNE SYSTEM;MUSCULOSKELETAL;NEUROLOGICAL;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY","9;4;1;1;1;1;1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.3 MEDICAL DEVICES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.7 PHYSICAL","20;3;3;2;2;1;1","LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;STOMACH CANCER;BLOOD CANCER;BREAST CANCER;LUNG CANCER;NOT SITE-SPECIFIC CANCER","5;5;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.2 SURVEILLANCE","11;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_CAREGGI",2011,304,10.6381578947368,3.20723684210526,0.450657894736842,0.375,0.50328947368421,1.82056074766355,1.41237113402062,1.58333333333333,1.53,0.493421052631579,6,152,63,36,24,0.5,0.21,0.12,0.08,35.6,0.836940894969501,NA,0.282894736842105,0.782894736842105,0.466,0.442,0.484,0.427,"GIAN FRANCO GENSINI;MARCO CHIOSTRI;CHIARA LAZZERI;SERAFINA VALENTE;ALBERTO BOSI;LUIGI RIGACCI;SANDRO GELSOMINO;PAOLA ATTANÀ;MASSIMO MORFINI;CLAUDIO PICARIELLO;RICCARDO SACCARDI;JOS G. MAESSEN;ADRIANO PERIS;ROBERTO LORUSSO;GIUSEPPE SPINELLI;GIOVANNI ZAGLI;EDOARDO MANNUCCI;STEFANO GRIFONI;VITO ANNESE;MANUELA BONIZZOLI","30;16;16;16;13;12;11;10;10;10;10;9;9;8;7;7;7;6;6;6","GIAN FRANCO GENSINI;CHIARA LAZZERI;SERAFINA VALENTE;MARCO CHIOSTRI;MASSIMO MORFINI;EDOARDO MANNUCCI;CLAUDIO PICARIELLO;MAURIZIO SALVADORI;PAOLA ATTANÀ;SANDRO GELSOMINO;PAOLO MACCHIARINI;ANDREA MINERVINI;JOS G. MAESSEN;STEFANO ROMAGNOLI;ELISA GRIFONI;ALBERTO BOSI;ADRIANO PERIS;CARLO NOZZOLI;ROBERTO LORUSSO;DAVID ANTONIUCCI","4.35;2.64;2.64;2.54;2.38;2.27;1.73;1.61;1.6;1.34;1.21;1.09;1.08;1.07;0.98;0.94;0.94;0.9;0.89;0.89","GIAN FRANCO GENSINI;MARCO CHIOSTRI;CHIARA LAZZERI;SERAFINA VALENTE;ALBERTO BOSI;LUIGI RIGACCI;SANDRO GELSOMINO;PAOLA ATTANÀ;MASSIMO MORFINI;CLAUDIO PICARIELLO;RICCARDO SACCARDI;ADRIANO PERIS;GIUSEPPE SPINELLI;GIOVANNI ZAGLI;EDOARDO MANNUCCI;STEFANO GRIFONI;VITO ANNESE;MANUELA BONIZZOLI;CARLO DANI;DAVID ANTONIUCCI","30;16;16;16;13;12;11;10;10;10;10;9;7;7;7;6;6;6;6;6","GIAN FRANCO GENSINI;CHIARA LAZZERI;SERAFINA VALENTE;MARCO CHIOSTRI;MASSIMO MORFINI;EDOARDO MANNUCCI;CLAUDIO PICARIELLO;MAURIZIO SALVADORI;PAOLA ATTANÀ;SANDRO GELSOMINO;PAOLO MACCHIARINI;ANDREA MINERVINI;STEFANO ROMAGNOLI;ALBERTO BOSI;ADRIANO PERIS;CARLO NOZZOLI;DAVID ANTONIUCCI;GIUSEPPE SPINELLI;LUIGI RIGACCI;GIUSEPPE BARLETTA","4.35;2.64;2.64;2.54;2.38;2.27;1.73;1.61;1.6;1.34;1.21;1.09;1.07;0.94;0.94;0.9;0.89;0.89;0.87;0.87","GIAN FRANCO GENSINI;ADRIANO PERIS;RICCARDO SACCARDI;MAURIZIO SALVADORI;CLAUDIO PONTICELLI;ROSANNA COPPO;ALESSANDRO AMORE;ALI G. GHARAVI;ANTONIO AMOROSO;BATTISTA FABIO VIOLA;BRUCE A. JULIAN;CLARA J. MEN;CLAUDIA IZZI;E. PRATI;FRANCESCA BERTINETTO;FRANCESCA LUGANI;FRANCESCO SCOLARI;GIAN MARCO GHIGGERI;GIOVANNI M. FRASCÀ;GIULIANO BOSCUTTI","979;855;644;592;575;575;570;570;570;570;570;570;570;570;570;570;570;570;570;570","ADRIANO PERIS;RICCARDO SACCARDI;MAURIZIO SALVADORI;GIAN FRANCO GENSINI;DAVID ANTONIUCCI;GUIDO PARODI;ANGELA MIGLIORINI;RENATO VALENTI;FRANCO CECCHI;GIOVANNI CIANCHI;ROSANNA ABBATE;STEFANO GRIFONI;CHIARA LAZZERI;PIERGIOVANNI BUONAMICI;SERAFINA VALENTE;IACOPO OLIVOTTO;GIOVANNI ZAGLI;BETTI GIUSTI;ROSSELLA MARCUCCI;MASSIMO MORFINI","790;644;592;552;535;519;517;517;510;496;478;461;456;452;412;409;389;384;384;379","GIAN FRANCO GENSINI;SERAFINA VALENTE;MARCO CHIOSTRI;CHIARA LAZZERI;LUIGI RIGACCI;SANDRO GELSOMINO;MASSIMO MORFINI;CLAUDIO PICARIELLO;RICCARDO SACCARDI;ALBERTO BOSI;FABIANA LUCÀ;PAOLA ATTANÀ;ADRIANO PERIS;GIUSEPPE SPINELLI;EDOARDO MANNUCCI;CRISTINA GIGLIOLI;DAVID ANTONIUCCI;NICCOLÒ MARCHIONNI;CARLO DANI;GIOVANNI ZAGLI","25;17;16;16;12;11;10;10;10;10;10;9;8;7;7;6;6;6;6;6","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;CHEMISTRY;ECONOMICS;POLITICAL SCIENCE;MATHEMATICS;PHILOSOPHY;PSYCHOLOGY;SOCIOLOGY;BUSINESS;HISTORY;MATERIALS SCIENCE;GEOLOGY","291;73;32;20;20;18;13;11;10;9;7;7;6;6;5;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;PATHOLOGY;GENETICS;IMMUNOLOGY;INTENSIVE CARE MEDICINE;GASTROENTEROLOGY;ANESTHESIA;RADIOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;ONCOLOGY;PSYCHIATRY;OPTICS;PEDIATRICS;BIOCHEMISTRY;PHYSICAL THERAPY;EMERGENCY MEDICINE;NURSING","218;97;68;43;40;39;32;31;26;26;25;24;23;23;21;20;19;17;16;16","GENE;MYOCARDIAL INFARCTION;DISEASE;HEART FAILURE;POPULATION;TRANSPLANTATION;CANCER;CHEMOTHERAPY;INCIDENCE (GEOMETRY);CONFIDENCE INTERVAL;BLOOD PRESSURE;DIABETES MELLITUS;ALTERNATIVE MEDICINE;INTENSIVE CARE UNIT;LYMPHOMA;ANTIBODY;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;PREGNANCY;ADVERSE EFFECT","30;26;25;22;22;21;20;18;18;16;15;15;14;14;14;13;13;13;12;11","PERCUTANEOUS CORONARY INTERVENTION;EJECTION FRACTION;CYCLOPHOSPHAMIDE;GENOTYPE;UNIVARIATE ANALYSIS;PLACEBO;ACUTE CORONARY SYNDROME;CARDIOMYOPATHY;CONVENTIONAL PCI;DIASTOLE;HAZARD RATIO;HEMATOPOIETIC STEM CELL TRANSPLANTATION;ALLELE;CLINICAL ENDPOINT;INFLAMMATORY BOWEL DISEASE;INSULIN RESISTANCE;RITUXIMAB;ULCERATIVE COLITIS;WARFARIN;COLORECTAL CANCER;CORONARY CARE UNIT;CROHN'S DISEASE;DIFFUSE LARGE B-CELL LYMPHOMA;FETUS;FOLLICULAR LYMPHOMA;GESTATION;GESTATIONAL AGE;MUTATION;PHENOTYPE;REVASCULARIZATION;SPINAL CORD INJURY;TYPE 2 DIABETES;VIRAL LOAD","12;9;8;8;8;7;6;6;6;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4","ANTIRETROVIRAL THERAPY;SINGLE-NUCLEOTIDE POLYMORPHISM;FLUDARABINE;VINCRISTINE;VITAMIN K ANTAGONIST;AL AMYLOIDOSIS;ALLELE FREQUENCY;ARTHROPATHY;DOPPLER IMAGING;DOUBLE BLIND;DRUG-ELUTING STENT;FACTOR VIIA;FAMILY PLANNING;GENETIC HETEROGENEITY;HOMEOSTATIC MODEL ASSESSMENT;MICROSATELLITE;MITRAL VALVE ANNULOPLASTY;NASOPHARYNGEAL CANCER;RETINOPATHY OF PREMATURITY;REVERSE TRANSCRIPTASE;SIDA;TIMI","4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;;ITALY;MYOCARDIAL INFARCTION;TREATMENT OUTCOME;AGED, 80 AND OVER;YOUNG ADULT;RETROSPECTIVE STUDIES;PROSPECTIVE STUDIES;RISK FACTORS;ADOLESCENT;FOLLOW-UP STUDIES;TIME FACTORS;HEMOPHILIA A;PROGNOSIS","215;165;161;125;110;97;82;70;55;53;50;44;40;34;34;32;32;28;25;25","MANAGEMENT AND TREATMENT OF HEMOPHILIA;MANAGEMENT OF VALVULAR HEART DISEASE;ATRIAL FIBRILLATION;LYMPHOID NEOPLASMS;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;IMPACT OF HYPERGLYCEMIA ON HEALTH OUTCOMES;PATHOPHYSIOLOGY AND TREATMENT OF SPINAL CORD INJURY;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;DIAGNOSIS AND TREATMENT OF HEART FAILURE;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;HEMATOPOIETIC STEM CELL BIOLOGY;MANAGEMENT OF VASCULAR ACCESS IN HEALTHCARE","9;9;8;8;8;6;6;5;5;4;4;4;4;3;3;3;3;3;3;3","CARDIAC IMAGING;CARDIOVASCULAR RISK ASSESSMENT;REGIMEN;ANTICOAGULANT THERAPY;TREATMENT;UNIVARIATE ANALYSIS;ECHOCARDIOGRAPHY;MANTLE CELL LYMPHOMA;ATRIAL FIBRILLATION;CONCOMITANT;INTERQUARTILE RANGE;LEFT VENTRICULAR FUNCTION;RECOMBINANT FACTOR VIIA;VENOUS THROMBOEMBOLISM;CLINICAL ENDPOINT;MITRAL REGURGITATION;PROSTHETIC VALVES EVALUATION;TRANSCATHETER AORTIC-VALVE REPLACEMENT;AUTOIMMUNE DISEASE EPIDEMIOLOGY;CORONARY CARE UNIT","12;10;10;9;8;8;7;7;6;6;6;6;6;6;5;5;5;5;4;4","MYOCARDIAL INFARCTION;MULTIPLE SCLEROSIS;RETROSPECTIVE STUDY;ATRIAL FIBRILLATION;HEART FAILURE;SPINAL CORD;ST-ELEVATION MYOCARDIAL;PRETERM INFANTS;ACUTE CORONARY;AUTOIMMUNE DISEASES;CELL TRANSPLANTATION;ELDERLY PATIENTS;ITALIAN PATIENTS;PROGNOSTIC ROLE;PULMONARY EMBOLISM;RANDOMIZED CONTROLLED;STEM CELL;ACUTE PULMONARY;AUTOIMMUNE DISEASE;CANCER PATIENTS;CHRONIC LYMPHOCYTIC;CORD INJURY;CORONARY SYNDROMES;CRITICALLY ILL;EMERGENCY DEPARTMENT;EXTREMELY PRETERM;FACTOR VII;HYPERTROPHIC CARDIOMYOPATHY;ILL PATIENTS;INFLAMMATORY BOWEL","8;7;7;6;6;6;6;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","PUBMED SCOPUS;CORONARY ARTERY;LEFT VENTRICULAR;AORTIC VALVE;AML TETHERING;PULMONARY ARTERY;CROSSREF PUBMED;HEMODYNAMIC PROGRESSION;AORTIC STENOSIS;RISK FACTORS;EJECTION FRACTION;CARE UNIT;INDEPENDENT PREDICTORS;MULTIVARIATE ANALYSIS;MYOCARDIAL INFARCTION;CONFIDENCE INTERVAL;CONSECUTIVE PATIENTS;HEART FAILURE;HR CI;INTENSIVE CARE;PATIENTS TREATED;PULMONARY VALVE;STROKE RISK;TAKO-TSUBO CARDIOMYOPATHY;CARDIOL -ABSTRACT;MM HG;SYMPTOM ONSET;ADVERSE EVENTS;ATRIAL FIBRILLATION;CAROTID STENOSIS","45;28;28;26;23;22;21;20;19;19;18;15;15;15;15;14;14;14;14;14;14;14;14;14;13;13;13;12;12;12",70,0.23,7,4.75,1,1.5,0,1.5,4.75,2,1,5,0,1,3,1,2,1,1,3,1,0,0,96,96,4,0,2,3,0,1,0,1,0,0,0,0,3,2,2,0,3.14285714285714,2.26,1.85714285714286,2,3,6,1,0,2,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"MAGGI ENRICO;ROMAGNANI PAOLA;ROMAGNANI SERGIO;MIRABELLA CARLO;ENRICO;ENRICO MAGGI;FRANCESCO ANNUNZIATO;LUNGHI CARLOTTA;NATIVI CRISTINA;PAOLA ROMAGNANI","3;3;3;2;1;1;1;1;1;1","AZIENDA OSPEDALIERO UNIVERSITARIA CAREGGI;REGIONE TOSCANA;LUNGHI CARLOTTA;NATIVI CRISTINA;RICHICHI BARBARA;TOMA LUCIO","7;2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","10;6;4;2;1;1","BIOTECHNOLOGY;KIDNEY DISEASE;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN;CANCER;IMMUNIZATION;ORPHAN DRUG;RARE DISEASES","3;3;3;3;3;3;1;1;1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;5.1 PHARMACEUTICALS","2;2","A61K35/12;C12N5/071;C12N5/074;A61K35/23;A61P13/12;A61F2/02;A61F2/08;A61F2/10;A61F2/28;A61K35/00","4;3;3;2;2;1;1;1;1;1","A61P43/00;A61P13/12;A61P25/00;A61K35/12;A61P19/08;C12N2500/25;C12N2501/11;C12N2501/12;C12N2501/39;C12N2501/395","6;4;4;3;3;3;3;3;3;3",23,5.57,775.52,4.62,6,0.26,78,0,0,4,0,7,0,4,8,0,16,5,0,0,0,0,0,0,21,2,0,20,2,0,1,0,0,0,0,0,0,"Italy;United States;France","4;3;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;31 BIOLOGICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;4007 CONTROL ENGINEERING, MECHATRONICS AND ROBOTICS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","21;11;4;4;3;3;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;CANCER;RARE DISEASES;CARDIOVASCULAR;HEMATOLOGY;HEART DISEASE;AGING;GENETICS;BIOENGINEERING;BIOTECHNOLOGY;NEUROSCIENCES;ORPHAN DRUG;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;ARTHRITIS;ASSISTIVE TECHNOLOGY;ATHEROSCLEROSIS;AUTOIMMUNE DISEASE","19;9;8;6;6;5;5;4;3;3;2;2;2;2;2;2;1;1;1;1","CANCER;CARDIOVASCULAR;MUSCULOSKELETAL;BLOOD;EYE;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL","4;3;2;1;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","11;3;1;1","LEUKEMIA / LEUKAEMIA;BREAST CANCER;LIVER CANCER;MELANOMA;NON-HODGKIN'S LYMPHOMA","3;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;1.4 CANCER PROGRESSION AND METASTASIS","4;3;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,"PUBLIC LIBRARY OF SCIENCE","7","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3105 GENETICS;49 MATHEMATICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4202 EPIDEMIOLOGY;4905 STATISTICS","5;4;3;3;2;2;1;1",NA,NA,"ORAL AND GASTROINTESTINAL","6","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","3;1",NA,NA,"CLINICAL MEDICINE AND SCIENCE","5","COLON AND RECTAL CANCER","4",NA,NA
"AOU_CAREGGI",2012,420,10.5285714285714,3.26904761904762,0.457142857142857,0.402380952380952,0.526190476190476,2.02058823529412,1.44029850746269,1.78947368421053,1.48,0.461904761904762,8,224,88,39,43,0.53,0.21,0.09,0.1,30.87,0.739110828803965,5.25103734439833,0.276190476190476,0.761904761904762,0.478,0.457,0.498,0.445,"GIAN FRANCO GENSINI;DAVID ANTONIUCCI;ALBERTO BOSI;GUIDO PARODI;EDOARDO MANNUCCI;RENATO VALENTI;ANGELA MIGLIORINI;NAZARIO CARRABBA;ALFREDO VANNACCI;FRANCESCO DI COSTANZO;SANDRO GELSOMINO;DANIELA POLI;NICCOLÒ MARCHIONNI;WALTER AGENO;LUIGI RIGACCI;M. ZANAZZI;FABIO FIRENZUOLI;E. BERTONI;ROSANNA ABBATE;DOMENICO PRISCO","30;20;16;15;14;14;13;13;13;12;12;12;12;12;12;12;11;11;11;10","EDOARDO MANNUCCI;GIAN FRANCO GENSINI;CARLO DANI;DAVID ANTONIUCCI;L. MOSCARELLI;ALFREDO VANNACCI;GUIDO PARODI;RENATO VALENTI;ANGELA MIGLIORINI;NAZARIO CARRABBA;FABIO FIRENZUOLI;M. ZANAZZI;DANIELA POLI;E. BERTONI;SERAFINA VALENTE;ALBERTO BOSI;SANDRO GELSOMINO;LUIGI GORI;PAOLO CARTA;DOMENICO PRISCO","4.41;3.69;3.28;2.06;1.81;1.79;1.72;1.68;1.56;1.53;1.53;1.52;1.4;1.38;1.37;1.32;1.29;1.24;1.2;1.18","GIAN FRANCO GENSINI;DAVID ANTONIUCCI;ALBERTO BOSI;GUIDO PARODI;EDOARDO MANNUCCI;RENATO VALENTI;ANGELA MIGLIORINI;NAZARIO CARRABBA;ALFREDO VANNACCI;FRANCESCO DI COSTANZO;SANDRO GELSOMINO;DANIELA POLI;NICCOLÒ MARCHIONNI;LUIGI RIGACCI;M. ZANAZZI;FABIO FIRENZUOLI;E. BERTONI;ROSANNA ABBATE;DOMENICO PRISCO;SERAFINA VALENTE","30;20;16;15;14;14;13;13;13;12;12;12;12;12;12;11;11;11;10;10","EDOARDO MANNUCCI;GIAN FRANCO GENSINI;CARLO DANI;DAVID ANTONIUCCI;L. MOSCARELLI;ALFREDO VANNACCI;GUIDO PARODI;RENATO VALENTI;ANGELA MIGLIORINI;NAZARIO CARRABBA;FABIO FIRENZUOLI;M. ZANAZZI;DANIELA POLI;E. BERTONI;SERAFINA VALENTE;ALBERTO BOSI;SANDRO GELSOMINO;LUIGI GORI;PAOLO CARTA;DOMENICO PRISCO","4.41;3.69;3.28;2.06;1.81;1.79;1.72;1.68;1.56;1.53;1.53;1.52;1.4;1.38;1.37;1.32;1.29;1.24;1.2;1.18","VALERIO DE STEFANO;GIAN FRANCO GENSINI;DAVID ANTONIUCCI;ELENA MARIA ELLI;ELISA RUMI;GUIDO FINAZZI;MARCO RUGGERI;MARIA LUIGIA RANDI;ROSSELLA CACCIOLA;TIZIANO BARBUI;RICCARDO CAVAZZINA;GENNARO SANTORO;SERGIO SIRAGUSA;ANTONIO SPADEA;ALESSANDRA IURLO;ALESSANDRO MARIA VANNUCCHI;ALESSIA TIEGHI;ANNA RITA SCORTECHINI;ARIANNA MASCIULLI;CATERINA MUSOLINO","1006;879;856;827;827;827;827;827;827;827;815;742;733;732;707;707;707;707;707;707","DAVID ANTONIUCCI;GIAN FRANCO GENSINI;GENNARO SANTORO;ALESSANDRO MARIA VANNUCCHI;LUIGI RIGACCI;SANDRO GELSOMINO;DANIELA POLI;ALBERTO BOSI;FEDERICO PERFETTO;FRANCESCO CAPPELLI;EDOARDO MANNUCCI;BENEDETTA PUCCINI;FABIANA LUCÀ;GUIDO PARODI;MASSIMO MORFINI;RENATO VALENTI;ANGELA MIGLIORINI;NAZARIO CARRABBA;FRANCESCO DI COSTANZO;LUIGI PADELETTI","856;784;742;707;466;396;387;377;360;340;326;323;315;314;296;277;274;273;268;266","GIAN FRANCO GENSINI;DAVID ANTONIUCCI;GUIDO PARODI;RENATO VALENTI;ROSANNA ABBATE;ALBERTO BOSI;ANGELA MIGLIORINI;NAZARIO CARRABBA;LUIGI RIGACCI;FRANCESCO DI COSTANZO;FABIO FIRENZUOLI;E. BERTONI;M. ZANAZZI;EDOARDO MANNUCCI;DANIELA POLI;PAOLO CARTA;ADRIANO PERIS;CARLO DANI;SANDRO GELSOMINO;FABIANA LUCÀ","23;20;15;14;13;13;13;13;12;12;11;11;11;11;10;9;9;9;9;8","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;ENGINEERING;ECONOMICS;PSYCHOLOGY;POLITICAL SCIENCE;MATERIALS SCIENCE;MATHEMATICS;PHILOSOPHY;SOCIOLOGY;BUSINESS;ART;GEOGRAPHY;GEOLOGY;HISTORY","399;113;40;27;23;20;19;14;8;7;7;6;6;3;2;2;2;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;GENETICS;PATHOLOGY;IMMUNOLOGY;GASTROENTEROLOGY;RADIOLOGY;INTENSIVE CARE MEDICINE;ONCOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;PSYCHIATRY;ENDOCRINOLOGY;OPTICS;PHYSICAL THERAPY;ANESTHESIA;FAMILY MEDICINE;PEDIATRICS;NURSING;PALEONTOLOGY;PHARMACOLOGY;UROLOGY","313;129;96;64;59;49;46;43;37;36;30;28;27;25;25;24;20;20;20;17;17;17;17","GENE;MYOCARDIAL INFARCTION;DISEASE;CHEMOTHERAPY;RANDOMIZED CONTROLLED TRIAL;HEART FAILURE;CANCER;POPULATION;TRANSPLANTATION;CONFIDENCE INTERVAL;ADVERSE EFFECT;PROSPECTIVE COHORT STUDY;RETROSPECTIVE COHORT STUDY;ATRIAL FIBRILLATION;HUMAN IMMUNODEFICIENCY VIRUS (HIV);ALTERNATIVE MEDICINE;DIABETES MELLITUS;INCIDENCE (GEOMETRY);CLINICAL TRIAL;LYMPHOMA;STEM CELL","42;42;34;31;31;29;28;26;26;24;19;19;19;18;17;16;16;16;15;15;15","PERCUTANEOUS CORONARY INTERVENTION;EJECTION FRACTION;VIRAL LOAD;CONVENTIONAL PCI;HAZARD RATIO;HEMATOPOIETIC STEM CELL TRANSPLANTATION;CLINICAL ENDPOINT;RITUXIMAB;TYPE 2 DIABETES;CARDIOMYOPATHY;COLORECTAL CANCER;ACUTE CORONARY SYNDROME;CLOPIDOGREL;PHENOTYPE;FOLLICULAR LYMPHOMA;INSULIN RESISTANCE;MUTATION;AORTIC VALVE STENOSIS;CARDIOGENIC SHOCK;CYCLOPHOSPHAMIDE;GENE EXPRESSION;PROGENITOR CELL","18;16;16;15;13;13;12;11;11;10;10;8;8;8;7;7;7;6;6;6;6;6","ANTIRETROVIRAL THERAPY;DRUG-ELUTING STENT;VITAMIN K ANTAGONIST;DNA METHYLATION;FONDAPARINUX;GERMLINE MUTATION;INFLAMMATORY BOWEL DISEASES;INTERNATIONAL PROGNOSTIC INDEX;RESTRICTIVE CARDIOMYOPATHY;REVERSE TRANSCRIPTASE;SPECKLE TRACKING ECHOCARDIOGRAPHY;TIMI;ADIPOKINE;ADIPONECTIN;ARTHROPATHY;BK VIRUS;BRONCHOPULMONARY DYSPLASIA;CARBOPLATIN;CARDIAC RESYNCHRONIZATION THERAPY;COLONOSCOPY;CXCL10;CYP2C19;CYSTATIN;FLUDARABINE;FOLINIC ACID;GENOTYPING;HAPLOINSUFFICIENCY;HARM AVOIDANCE;IDH1;IRINOTECAN;MACE;MULTIPLEX POLYMERASE CHAIN REACTION;NALIDIXIC ACID;NOVELTY SEEKING;PEMETREXED;PERITONEAL CARCINOMATOSIS;PRASUGREL;PROMOTER;PROSTATECTOMY;RETINOPATHY OF PREMATURITY;SPLENIC VEIN;TEMPERAMENT AND CHARACTER INVENTORY;TICLOPIDINE","12;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;MALE;FEMALE;MIDDLE AGED;;AGED;ADULT;ITALY;TREATMENT OUTCOME;AGED, 80 AND OVER;MYOCARDIAL INFARCTION;RETROSPECTIVE STUDIES;YOUNG ADULT;FOLLOW-UP STUDIES;PROSPECTIVE STUDIES;ADOLESCENT;ATRIAL FIBRILLATION;RISK FACTORS;HIV INFECTIONS;HEART VALVE PROSTHESIS IMPLANTATION","270;203;199;163;145;141;121;90;64;62;58;52;41;40;39;37;37;34;32;30","ATRIAL FIBRILLATION;MANAGEMENT OF VALVULAR HEART DISEASE;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;LYMPHOID NEOPLASMS;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;MANAGEMENT AND TREATMENT OF HEMOPHILIA;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;RENAL CELL CARCINOMA;ACUPUNCTURE MECHANISMS AND CLINICAL APPLICATIONS;ACUTE MYELOID LEUKEMIA;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;GASTRIC CANCER RESEARCH AND TREATMENT;PATHOPHYSIOLOGY AND MANAGEMENT OF CEREBRAL ANEURYSMS;PATHOPHYSIOLOGY AND MANAGEMENT OF PREECLAMPSIA;POLYOMAVIRUS-ASSOCIATED CARCINOGENESIS AND CLINICAL MANIFESTATIONS","14;13;11;11;8;8;7;5;5;5;5;5;4;4;4;4;4;4;4;4","TREATMENT;CARDIAC IMAGING;REGIMEN;STROKE (ENGINE);CLINICAL ENDPOINT;ATRIAL FIBRILLATION;ANTIRETROVIRAL THERAPY;TRANSCATHETER AORTIC-VALVE REPLACEMENT;PROSTHETIC VALVES EVALUATION;VENOUS THROMBOEMBOLISM;ECHOCARDIOGRAPHY;FOLLICULAR LYMPHOMA;HEMATOPOIETIC CELL TRANSPLANTATION;LEFT VENTRICULAR FUNCTION;ST-SEGMENT ELEVATION;CARDIOVASCULAR RISK ASSESSMENT;ETIOLOGY;HIV;ANTICOAGULANT THERAPY;DEEP VEIN THROMBOSIS","17;14;13;13;12;11;10;10;9;8;7;7;7;7;7;6;6;6;5;5","ATRIAL FIBRILLATION;LEFT VENTRICULAR;MYOCARDIAL INFARCTION;STEM CELL;AORTIC VALVE;CELL TRANSPLANTATION;CORONARY ARTERY;VEIN THROMBOSIS;INTERNATIONAL REGISTRY;MITRAL REGURGITATION;MULTICENTER STUDY;PATIENTS UNDERGOING;PILOT STUDY;PROGENITOR CELLS;RENAL TRANSPLANT;TRANSCATHETER AORTIC;TRANSPLANT RECIPIENTS;TYPE DIABETES;VALVE IMPLANTATION;BONE MARROW;CELL CARCINOMA;CONTROLLED TRIAL;CORONARY INTERVENTION;FONDAZIONE ITALIANA;HEART FAILURE;HEMATOPOIETIC STEM;HYPERTROPHIC CARDIOMYOPATHY;MINIMALLY INVASIVE;MITRAL VALVE;OBSERVATIONAL STUDY","11;9;9;9;8;8;8;7;6;6;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5","PUBMED SCOPUS;CROSSREF PUBMED;ALPHA ACTININ;MITRAL REGURGITATION;CORONARY ARTERY;MITRAL VALVE;MM HG;RAT BRAIN;LEFT VENTRICULAR;MULTIPLE SCLEROSIS;MUS PATIENTS;RISK FACTORS;RENAL FUNCTION;VALVE REPAIR;CLINICAL PRACTICE;CONFIDENCE INTERVAL;HEART FAILURE;HR CI;THYROID NODULES;CSFGLC ABS;HRM ANALYSIS;LVOT GRADIENT;MONTHS RANGE;SIGNIFICANTLY LOWER;TRANSPLANT RECIPIENTS;VALVE REPLACEMENT;FINE-NEEDLE ASPIRATION;KIDNEY INJURY;LEFT ATRIAL;RENAL TRANSPLANT","68;52;28;27;26;26;20;19;16;15;15;15;14;14;13;13;13;13;13;12;12;12;12;12;12;12;11;11;11;11",109,0.26,4,3,1,2,2,3,3.5,1,1,4,0,1,3,0,3,2,2,3,2,0,0,71,71,3,0,1,1,0,1,0,0,1,0,0,0,3,1,0,0,4,1.16,2.5,0,1,4,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"LUNGHI CARLOTTA;MAGGI ENRICO;NATIVI CRISTINA;RICHICHI BARBARA;ROMAGNANI SERGIO;TOMA LUCIO;GUARNA ANTONIO;OCCHIATO ERNESTO GIOVANNI;PARRONCHI PAOLA;ROMAGNANI PAOLA","2;2;2;2;2;2;1;1;1;1","AZIENDA OSPEDALIERO UNIVERSITARIA CAREGGI;GUARNA ANTONIO;MAGGI ENRICO;OCCHIATO ERNESTO GIOVANNI;PARRONCHI PAOLA;ROMAGNANI SERGIO;UNIV FIRENZE","4;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;34 CHEMICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3402 INORGANIC CHEMISTRY","5;2;2;2;2;1;1","VACCINE RELATED;BIOTECHNOLOGY;CANCER;IMMUNIZATION;CLINICAL RESEARCH;KIDNEY DISEASE;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN","3;2;2;2;1;1;1;1;1;1","5.1 PHARMACEUTICALS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING","2;1","A61K47/48;A61P35/00;A61K35/12;A61K35/23;A61K39/385;A61K39/395;A61P13/12;A61P37/00;C07H15/18;C07K16/18","2;2;1;1;1;1;1;1;1;1","A61K47/646;A61K47/549;A61K47/643;A61P35/00;C07K16/44;A61K35/12;A61K47/545;A61P13/12;A61P19/08;A61P25/00","3;2;2;2;2;1;1;1;1;1",41,5.72,611.97,6.82,15,0.37,68.34,0,0,4,2,9,0,6,20,0,24,15,0,0,0,0,0,0,34,4,3,39,2,0,0,0,0,0,0,0,0,"United States;Italy;France;Germany;Japan","9;5;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE;42 HEALTH SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3210 NUTRITION AND DIETETICS;3213 PAEDIATRICS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4201 ALLIED HEALTH AND REHABILITATION SCIENCE","37;18;11;10;4;4;3;3;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;RARE DISEASES;CARDIOVASCULAR;HEART DISEASE;LYMPHOMA;PREVENTION;AGING;PEDIATRIC;BIOMEDICAL IMAGING;BREAST CANCER;NEUROSCIENCES;STEM CELL RESEARCH;BRAIN DISORDERS;CHRONIC PAIN;GENETICS;NUTRITION;PAIN RESEARCH","39;19;12;11;11;9;6;6;6;5;5;4;4;4;4;3;3;3;3;3","CANCER;CARDIOVASCULAR;NEUROLOGICAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;BLOOD;MENTAL HEALTH;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL;STROKE","9;5;4;2;1;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES;7.1 INDIVIDUAL CARE NEEDS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;3.3 NUTRITION AND CHEMOPREVENTION;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.4 POPULATION SCREENING;5.1 PHARMACEUTICALS;6.6 PSYCHOLOGICAL AND BEHAVIOURAL;7.3 MANAGEMENT AND DECISION MAKING","23;7;6;2;2;1;1;1;1;1;1;1","NON-HODGKIN'S LYMPHOMA;BREAST CANCER;LEUKEMIA / LEUKAEMIA;PROSTATE CANCER;HODGKIN'S DISEASE;MYELOMA;STOMACH CANCER","6;3;3;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","11;3;1",2,4999455.5,499949.22,5.5,10.5,6,1,39.5,347139.911111111,1.20988681092785,"AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI;CEDARS-SINAI MEDICAL CENTER;EDITH COWAN UNIVERSITY;GENOS (CROATIA);IMPERIAL COLLEGE LONDON;INSTITUT GUSTAVE ROUSSY;INTERCYTEX (UNITED KINGDOM);KAROLINSKA INSTITUTET;LEIDEN UNIVERSITY MEDICAL CENTER;LEIPZIG UNIVERSITY;MAASTRICHT UNIVERSITY;MAX PLANCK SOCIETY;NATIONAL INTERUNIVERSITY CONSORTIUM OF MATERIALS SCIENCE AND TECHNOLOGY;NATIONAL RESEARCH COUNCIL;PHARMIDEX (UNITED KINGDOM);ROBERT KOCH INSTITUTE;UNIVERSITY COLLEGE LONDON;UNIVERSITY OF EDINBURGH;UNIVERSITY OF MODENA AND REGGIO EMILIA;UNIVERSITY OF ZAGREB","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","CP-FP - SMALL OR MEDIUM-SCALE FOCUSED RESEARCH PROJECT (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2012-INNOVATION-1 (CALL FOR PROPOSAL);FP7-NMP - SPECIFIC PROGRAMME ""COOPERATION"": NANOSCIENCES, NANOTECHNOLOGIES, MATERIALS AND NEW PRODUCTION TECHNOLOGIES (PROGRAMME);FP7-NMP-2011-SMALL-5 (CALL FOR PROPOSAL)","2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","2;1;1;1;1","PREVENTION;AUTOIMMUNE DISEASE;BIOENGINEERING;BIOTECHNOLOGY;CANCER;CROHN'S DISEASE;DIGESTIVE DISEASES;GENETICS;HUMAN GENOME;INFLAMMATORY BOWEL DISEASE;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN","2;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;ORAL AND GASTROINTESTINAL;RESPIRATORY","1;1;1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.2 CELLULAR AND GENE THERAPIES","1;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","2",NA,NA,7,"PUBLIC LIBRARY OF SCIENCE","7","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3207 MEDICAL MICROBIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;47 LANGUAGE, COMMUNICATION AND CULTURE;3101 BIOCHEMISTRY AND CELL BIOLOGY;3202 CLINICAL SCIENCES;4704 LINGUISTICS","7;5;3;2;2;1;1;1","ANTIMICROBIAL RESISTANCE;GENETICS;INFECTIOUS DISEASES;NETWORKING AND INFORMATION TECHNOLOGY R&D (NITRD)","1;1;1;1","INFECTION","1",NA,NA,NA,NA,"BASIC SCIENCE","2",NA,NA,NA,NA
"AOU_CAREGGI",2013,429,10.7995337995338,3.16550116550117,0.396270396270396,0.400932400932401,0.466200466200466,2.01337295690936,1.3739837398374,1.83870967741935,1.42142857142857,0.48018648018648,6,224,100,44,31,0.52,0.23,0.1,0.07,43.78,1.25460034722475,5.06968433591423,0.314685314685315,0.825174825174825,0.463,0.44,0.486,0.452,"GIAN FRANCO GENSINI;DAVID ANTONIUCCI;GUIDO PARODI;ALBERTO BOSI;RENATO VALENTI;ANGELA MIGLIORINI;MARCO CHIOSTRI;EDOARDO MANNUCCI;MASSIMO MORFINI;MARCO MATUCCI‐CERINIC;CARLO NOZZOLI;SERAFINA VALENTE;EMANUELE CECCHI;ALESSANDRO RAMBALDI;NICCOLÒ MARCHIONNI;ROSANNA ABBATE;STEFANO COLAGRANDE;IACOPO OLIVOTTO;BENEDETTA TOMBERLI;RUBEN VERGARA","31;21;19;16;16;15;13;12;11;11;11;11;10;10;10;10;9;9;9;9","GIAN FRANCO GENSINI;DAVID ANTONIUCCI;GUIDO PARODI;STEFANO ROMAGNOLI;RENATO VALENTI;ANGELA MIGLIORINI;EDOARDO MANNUCCI;MARCO CHIOSTRI;MARCO MATUCCI‐CERINIC;SERAFINA VALENTE;FEDERICO LAVORINI;STEFANO COLAGRANDE;ALBERTO BOSI;EMANUELE CECCHI;CARLO NOZZOLI;BENEDETTA TOMBERLI;MASSIMO MORFINI;BEATRICE DETTI;MARIO MAGGI;NICCOLÒ MARCHIONNI","3.73;2.33;2.16;1.98;1.88;1.85;1.71;1.64;1.48;1.42;1.32;1.3;1.21;1.19;1.19;1.19;1.15;1.15;1.12;1.12","GIAN FRANCO GENSINI;DAVID ANTONIUCCI;GUIDO PARODI;ALBERTO BOSI;RENATO VALENTI;ANGELA MIGLIORINI;MARCO CHIOSTRI;EDOARDO MANNUCCI;MASSIMO MORFINI;MARCO MATUCCI‐CERINIC;CARLO NOZZOLI;SERAFINA VALENTE;EMANUELE CECCHI;NICCOLÒ MARCHIONNI;ROSANNA ABBATE;STEFANO COLAGRANDE;IACOPO OLIVOTTO;BENEDETTA TOMBERLI;RUBEN VERGARA;LUCA BONI","31;21;19;16;16;15;13;12;11;11;11;11;10;10;10;9;9;9;9;9","GIAN FRANCO GENSINI;DAVID ANTONIUCCI;GUIDO PARODI;STEFANO ROMAGNOLI;RENATO VALENTI;ANGELA MIGLIORINI;EDOARDO MANNUCCI;MARCO CHIOSTRI;MARCO MATUCCI‐CERINIC;SERAFINA VALENTE;FEDERICO LAVORINI;STEFANO COLAGRANDE;ALBERTO BOSI;EMANUELE CECCHI;CARLO NOZZOLI;BENEDETTA TOMBERLI;MASSIMO MORFINI;BEATRICE DETTI;NICCOLÒ MARCHIONNI;RUBEN VERGARA","3.73;2.33;2.16;1.98;1.88;1.85;1.71;1.64;1.48;1.42;1.32;1.3;1.21;1.19;1.19;1.19;1.15;1.15;1.12;1.11","LEONARDO PANTONI;ANAND VISWANATHAN;BLOSSOM C. M. STEPHAN;BO NORRVING;CAROL BRAYNE;CHARLES DECARLI;CHARLOTTE CORDONNIER;CHRISTOPHER CHEN;COLIN SMITH;DAVID J. WERRING;ERIC E. SMITH;FERGUS DOUBAL;FRANK‐ERIK DE LEEUW;FRANZ FAZEKAS;FREDERIK BARKHOF;GEERT JAN BIESSELS;HUGUES CHABRIAT;INGO KILIMANN;JOANNA M. WARDLAW;JOHN T. O’BRIEN","4574;4479;4479;4479;4479;4479;4479;4479;4479;4479;4479;4479;4479;4479;4479;4479;4479;4479;4479;4479","LEONARDO PANTONI;VITO ANNESE;DAVID ANTONIUCCI;ALBERTO BOSI;GIAN FRANCO GENSINI;GUIDO PARODI;SERGIO SERNI;BENEDETTA BELLANDI;RENATO VALENTI;PEIMAN NAZERIAN;ANGELA MIGLIORINI;ROSANNA ABBATE;NAZARIO CARRABBA;MÓNICA MILLA;ROSSELLA MARCUCCI;GIAN MARÍA ROSSOLINI;MICHELE LANCIOTTI;VINCENZO COMITO;ALBERTO SANTINI;LISA PIERI","4574;1230;1222;790;783;696;649;621;596;583;542;536;472;459;456;443;433;424;418;387","DAVID ANTONIUCCI;GIAN FRANCO GENSINI;GUIDO PARODI;RENATO VALENTI;ANGELA MIGLIORINI;ALBERTO BOSI;SERAFINA VALENTE;CARLO NOZZOLI;EDOARDO MANNUCCI;MARCO CHIOSTRI;MASSIMO MORFINI;CRISTINA GIGLIOLI;ROSANNA ABBATE;STEFANO COLAGRANDE;NICCOLÒ MARCHIONNI;RUBEN VERGARA;BENEDETTA TOMBERLI;EMANUELE CECCHI;IACOPO OLIVOTTO;MARCO MATUCCI‐CERINIC","21;21;19;16;15;14;12;11;10;10;10;10;9;9;9;9;9;9;9;8","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;COMPUTER SCIENCE;CHEMISTRY;ECONOMICS;PSYCHOLOGY;SOCIOLOGY;MATHEMATICS;POLITICAL SCIENCE;BUSINESS;GEOGRAPHY;MATERIALS SCIENCE;PHILOSOPHY;ART;GEOLOGY;HISTORY","403;109;37;27;23;18;18;16;13;12;11;4;3;3;3;2;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;PATHOLOGY;GENETICS;RADIOLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;ONCOLOGY;GASTROENTEROLOGY;ENDOCRINOLOGY;BIOCHEMISTRY;PSYCHIATRY;PEDIATRICS;ANESTHESIA;OPTICS;PHYSICAL THERAPY;EMERGENCY MEDICINE;MECHANICAL ENGINEERING","323;124;112;64;59;48;40;39;36;34;33;32;29;28;27;26;24;18;17;17","DISEASE;MYOCARDIAL INFARCTION;CANCER;GENE;POPULATION;HEART FAILURE;CONFIDENCE INTERVAL;CHEMOTHERAPY;RANDOMIZED CONTROLLED TRIAL;COHORT;DIABETES MELLITUS;ADVERSE EFFECT;MULTIVARIATE ANALYSIS;TRANSPLANTATION;BLOOD PRESSURE;RADIATION THERAPY;STROKE (ENGINE);ATRIAL FIBRILLATION;OBSERVATIONAL STUDY;INCIDENCE (GEOMETRY)","53;50;49;49;38;34;27;24;22;19;19;18;18;17;16;16;16;15;15;14","PERCUTANEOUS CORONARY INTERVENTION;MUTATION;EJECTION FRACTION;HAZARD RATIO;CONVENTIONAL PCI;CLINICAL ENDPOINT;ACUTE CORONARY SYNDROME;BREAST CANCER;CARDIOMYOPATHY;GENOTYPE;RITUXIMAB;COLORECTAL CANCER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;REVASCULARIZATION;UNIVARIATE ANALYSIS;INFLAMMATORY BOWEL DISEASE;METASTASIS;PROSTATE CANCER;TYPE 2 DIABETES;ISCHEMIC STROKE;PROSTATE;ULCERATIVE COLITIS","22;16;15;15;14;13;10;10;10;10;10;9;9;9;9;8;8;8;8;7;7;7","IRINOTECAN;SINGLE-NUCLEOTIDE POLYMORPHISM;EXOME SEQUENCING;OXALIPLATIN;PRASUGREL;TICAGRELOR;ANTIRETROVIRAL THERAPY;BONE METASTASIS;CORONAVIRUS DISEASE 2019 (COVID-19);DRUG-ELUTING STENT;GERMLINE MUTATION;MACE;POINT MUTATION;PRIMARY ANGIOPLASTY;PROSTATECTOMY;SENTINEL NODE;TIMI;ATP-BINDING CASSETTE TRANSPORTER;AXILLA;CARDIAC RESYNCHRONIZATION THERAPY;CETUXIMAB;COGNITIVE DECLINE;COMPLEMENTATION;DRY-POWDER INHALER;EXTRAMEDULLARY HEMATOPOIESIS;FLUDARABINE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;INTRACRANIAL ARTERIOVENOUS MALFORMATIONS;KLEBSIELLA PNEUMONIAE;KRAS;LOWER URINARY TRACT SYMPTOMS;METASTATIC BREAST CANCER;MISSENSE MUTATION;MODIFIED RANKIN SCALE;OSTEOCALCIN;OSTEOPENIA;P-GLYCOPROTEIN;P2Y12;PROSTATE BIOPSY;RESTRICTIVE CARDIOMYOPATHY;SEX HORMONE-BINDING GLOBULIN;SUBSTANCE P;SYNOVIAL FLUID;TAMOXIFEN;THIENOPYRIDINE;TILT TABLE TEST","6;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;MALE;FEMALE;MIDDLE AGED;AGED;;ADULT;ITALY;TREATMENT OUTCOME;AGED, 80 AND OVER;MYOCARDIAL INFARCTION;RISK FACTORS;ADOLESCENT;YOUNG ADULT;RETROSPECTIVE STUDIES;FOLLOW-UP STUDIES;PROSPECTIVE STUDIES;PROGNOSIS;CORONARY ARTERY DISEASE;HEART FAILURE","279;214;205;169;150;140;134;93;76;72;51;47;46;46;45;44;44;41;38;33","MANAGEMENT OF VALVULAR HEART DISEASE;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;LYMPHOID NEOPLASMS;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;RADIOTHERAPY PHYSICS AND TECHNOLOGY;ATRIAL FIBRILLATION;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;RENAL CELL CARCINOMA;DIAGNOSIS AND MANAGEMENT OF SYNCOPE;EPIDEMIOLOGY AND MANAGEMENT OF SEXUAL DYSFUNCTION;MOLECULAR MECHANISMS OF AMYLOIDOSIS;OPTIMIZATION OF PERIOPERATIVE FLUID THERAPY;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH","10;9;8;7;7;7;7;7;7;7;6;6;6;6;5;5;5;5;5;4","CARDIAC IMAGING;TREATMENT;STROKE (ENGINE);CLINICAL ENDPOINT;CARDIOVASCULAR RISK ASSESSMENT;ECHOCARDIOGRAPHY;UNIVARIATE ANALYSIS;ATRIAL FIBRILLATION;ST-SEGMENT ELEVATION;INFARCTION TREATMENT;REGIMEN;TRANSCATHETER AORTIC-VALVE REPLACEMENT;DIAGNOSIS;INTERQUARTILE RANGE;RADIOTHERAPY;ANTICOAGULANT THERAPY;CARDIAC AMYLOIDOSIS;CARDIAC ULTRASOUND;CONCOMITANT;CUMULATIVE INCIDENCE","18;17;16;13;9;9;9;8;8;7;7;7;6;6;6;5;5;5;5;5","MYOCARDIAL INFARCTION;ATRIAL FIBRILLATION;LEFT VENTRICULAR;PRELIMINARY RESULTS;STEM CELL;CELL TRANSPLANTATION;CORONARY ARTERY;INFARCT SIZE;ACUTE CORONARY;ARTERY DISEASE;BREAST CANCER;CLINICAL OUTCOME;ISCHEMIC STROKE;PERCUTANEOUS CORONARY;PRIMARY ANGIOPLASTY;PULMONARY EMBOLISM;AORTIC VALVE;CANCER PATIENTS;CARDIOVASCULAR RISK;COLORECTAL CANCER;COMPUTED TOMOGRAPHY;ENDOVASCULAR TREATMENT;HEART FAILURE;HYPERTROPHIC CARDIOMYOPATHY;INFLAMMATORY BOWEL;INSULIN RESISTANCE;INTERNAL MEDICINE;MITRAL REGURGITATION;ACUTE ISCHEMIC;ACUTE MYOCARDIAL","12;9;9;9;9;8;7;7;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;4;4","LEFT VENTRICULAR;PULMONARY ARTERY;AZIENDA OSPEDALIERO-UNIVERSITARIA;OSPEDALIERO-UNIVERSITARIA CAREGGI;PATIENTS UNDERGOING;VESSELS AZIENDA;HEART FAILURE;CAREGGI FLORENCE;MD DEPARTMENT;PUBMED SCOPUS;FLORENCE ITALYSEARCH;STEMI PATIENTS;EJECTION FRACTION;MYOCARDIAL INFARCTION;BONE METASTASIS;HR CI;PATIENTS TREATED;SIGNIFICANTLY LOWER;CARE UNIT;DEPRESSIVE SYMPTOMS;INDEPENDENT PREDICTOR;RISK FACTORS;TYPE DIABETES;CORONARY INTERVENTION;DIASTOLIC DYSFUNCTION;ENDOTHELIAL CELLS;HAZARD RATIO;HEALTH CARE;INFARCT SIZE;INTENSIVE CARE","27;25;18;18;18;18;17;16;16;15;14;14;13;12;11;11;11;11;10;10;10;10;9;8;8;8;8;8;8;8",124,0.29,4.68,5,2,3,1,3,3,2,1,6,0,1,4.5,2,3,2,2.25,4,2,0,0,107.5,107.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,35,6.18,946.67,5.67,14,0.4,63.8,0,4,5,0,11,0,2,13,0,25,9,0,0,0,0,0,0,33,1,1,34,1,0,0,0,0,0,0,0,0,"United States;Japan;Belgium;Germany;Hungary;Israel;Italy;Poland;United Kingdom","6;3;2;2;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;3204 IMMUNOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;3206 MEDICAL BIOTECHNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;40 ENGINEERING;4201 ALLIED HEALTH AND REHABILITATION SCIENCE","32;15;9;5;3;2;2;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;PATIENT SAFETY;CARDIOVASCULAR;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;PREVENTION;AGING;AUTOIMMUNE DISEASE;LYMPHOMA;ORPHAN DRUG;PEDIATRIC;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;INFECTIOUS DISEASES;TRANSPLANTATION;ARTHRITIS","32;18;12;12;11;8;7;7;6;5;4;4;4;4;4;4;4;3;3;2","CANCER;INFLAMMATORY AND IMMUNE SYSTEM;CARDIOVASCULAR;BLOOD;EYE;INJURIES AND ACCIDENTS;MUSCULOSKELETAL;REPRODUCTIVE HEALTH AND CHILDBIRTH","8;3;2;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS","23;4;2;2;1;1;1","LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;LUNG CANCER;BLOOD CANCER;COLON AND RECTAL CANCER;HODGKIN'S DISEASE","9;4;2;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","12;2;2",1,8e+06,571428.57,5,14,7,1,0,303156.236507936,1.41511190711978,"AEC3 (UNITED KINGDOM);ARUP GROUP (UNITED KINGDOM);ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;ATOMIC ENERGY AND ALTERNATIVE ENERGIES COMMISSION;AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI;BOUYGUES (FRANCE);DEMO CONSULTANTS;KARLSRUHE INSTITUTE OF TECHNOLOGY;MOSTOSTAL WARSZAWA (POLAND);NCC (SWEDEN);NETHERLANDS ORGANISATION FOR APPLIED SCIENTIFIC RESEARCH;RIJNSTATE HOSPITAL;SCIENTIFIC AND TECHNICAL CENTER FOR BUILDING;THE ROTHERHAM NHS FOUNDATION TRUST","1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CP-IP - LARGE-SCALE INTEGRATING PROJECT (FUNDING SCHEME);FP7-2013-NMP-ENV-EEB (CALL FOR PROPOSAL);FP7-NMP - SPECIFIC PROGRAMME ""COOPERATION"": NANOSCIENCES, NANOTECHNOLOGIES, MATERIALS AND NEW PRODUCTION TECHNOLOGIES (PROGRAMME)","1;1;1","33 BUILT ENVIRONMENT AND DESIGN;3301 ARCHITECTURE;3302 BUILDING","1;1;1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"C13 ARCHITECTURE, BUILT ENVIRONMENT AND PLANNING","1","11 SUSTAINABLE CITIES AND COMMUNITIES;7 AFFORDABLE AND CLEAN ENERGY","1;1",48,"PUBLIC LIBRARY OF SCIENCE","48","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3105 GENETICS;34 CHEMICAL SCIENCES;42 HEALTH SCIENCES;46 INFORMATION AND COMPUTING SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;4202 EPIDEMIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;44 HUMAN SOCIETY;3009 VETERINARY SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3207 MEDICAL MICROBIOLOGY;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;4613 THEORY OF COMPUTATION;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3101 BIOCHEMISTRY AND CELL BIOLOGY","43;23;14;6;5;5;5;4;4;3;3;2;2;2;2;2;2;2;2;1","GENETICS;CLINICAL RESEARCH;DIGESTIVE DISEASES;AUTOIMMUNE DISEASE;INFLAMMATORY BOWEL DISEASE;RARE DISEASES;CROHN'S DISEASE;HUMAN GENOME;PREVENTION;HEMATOLOGY;HEPATITIS;HEPATITIS - B;INFECTIOUS DISEASES;LIVER DISEASE;LUNG;PAIN RESEARCH;BIOMEDICAL IMAGING;BRAIN DISORDERS;CANCER;CARDIOVASCULAR","10;8;7;5;5;4;3;3;3;2;2;2;2;2;2;2;1;1;1;1","ORAL AND GASTROINTESTINAL;CARDIOVASCULAR;NEUROLOGICAL;CANCER;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;METABOLIC AND ENDOCRINE","3;2;2;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS;2.4 SURVEILLANCE AND DISTRIBUTION","7;4;3;3;2;1","CLINICAL;BIOMEDICAL","6;3","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","18;7;2","COLON AND RECTAL CANCER;NOT SITE-SPECIFIC CANCER;KIDNEY CANCER;LEUKEMIA / LEUKAEMIA;LIVER CANCER;NON-HODGKIN'S LYMPHOMA","2;2;1;1;1;1","3 GOOD HEALTH AND WELL BEING","6"
"AOU_CAREGGI",2014,466,12.5665236051502,3.09656652360515,0.332618025751073,0.349785407725322,0.427038626609442,1.81738035264484,1.29166666666667,1.81111111111111,1.33557046979866,0.463519313304721,10,236,108,48,23,0.51,0.23,0.1,0.05,34.26,0.906652718045726,5.4187242798354,0.354077253218884,0.847639484978541,0.485,0.418,0.459,0.438,"GIAN FRANCO GENSINI;ALBERTO BOSI;DAVID ANTONIUCCI;LORENZO LIVI;GUIDO PARODI;FRANCESCO DI COSTANZO;GIAN MARÍA ROSSOLINI;ALESSANDRO RAMBALDI;SERAFINA VALENTE;LEONARDO PANTONI;ANGELA MIGLIORINI;ALESSANDRO M. VANNUCCHI;EDOARDO MANNUCCI;DANIELA GRETO;LISA PIERI;RENATO VALENTI;ADRIANO PERIS;ROSANNA ABBATE;PAOLA GUGLIELMELLI;MARCO MATUCCI‐CERINIC","23;21;14;14;13;12;11;11;11;10;10;10;10;9;9;9;9;9;8;8","GIAN FRANCO GENSINI;DAVID ANTONIUCCI;JACOPO MARTELLUCCI;U. RICCI;ALESSANDRO M. VANNUCCHI;MAURIZIO SALVADORI;SERAFINA VALENTE;LORENZO LIVI;GIAN MARÍA ROSSOLINI;ADRIANO PERIS;EDOARDO MANNUCCI;GUIDO PARODI;LEONARDO PANTONI;RITA PANICCIA;ALBERTO BOSI;MASSIMO CERUSO;STEFANO RAPI;STEFANO ROMAGNOLI;MARCO CHIOSTRI;CHIARA LAZZERI","2.81;2.34;1.97;1.87;1.61;1.61;1.52;1.42;1.29;1.22;1.21;1.2;1.17;1.17;1.16;1.14;1.12;1.04;1.01;1.01","GIAN FRANCO GENSINI;ALBERTO BOSI;DAVID ANTONIUCCI;LORENZO LIVI;GUIDO PARODI;FRANCESCO DI COSTANZO;GIAN MARÍA ROSSOLINI;SERAFINA VALENTE;LEONARDO PANTONI;ANGELA MIGLIORINI;ALESSANDRO M. VANNUCCHI;EDOARDO MANNUCCI;DANIELA GRETO;LISA PIERI;RENATO VALENTI;ADRIANO PERIS;ROSANNA ABBATE;PAOLA GUGLIELMELLI;MARCO MATUCCI‐CERINIC;ELISA GIOMMONI","23;21;14;14;13;12;11;11;10;10;10;10;9;9;9;9;9;8;8;8","GIAN FRANCO GENSINI;DAVID ANTONIUCCI;JACOPO MARTELLUCCI;U. RICCI;ALESSANDRO M. VANNUCCHI;MAURIZIO SALVADORI;SERAFINA VALENTE;LORENZO LIVI;GIAN MARÍA ROSSOLINI;ADRIANO PERIS;EDOARDO MANNUCCI;GUIDO PARODI;LEONARDO PANTONI;RITA PANICCIA;ALBERTO BOSI;MASSIMO CERUSO;STEFANO RAPI;STEFANO ROMAGNOLI;MARCO CHIOSTRI;CHIARA LAZZERI","2.81;2.34;1.97;1.87;1.61;1.61;1.52;1.42;1.29;1.22;1.21;1.2;1.17;1.17;1.16;1.14;1.12;1.04;1.01;1.01","LORENZO ORZALESI;A. HELEN WESTENBERG;A. MARINELLI;CARLO MESSINA;CORNEEL COENS;CORNELIS J.�H. VAN DE VELDE;DOMINIC A.X. SCHINAGL;EMIEL J. RUTGERS;GEERTJAN VAN TIENHOVEN;GRARD A. P. NIEUWENHUIJZEN;H.C.J. VAN DER MIJLE;HERMAN RIJNA;J. W. S. MERKUS;JAN BOGAERTS;JEAN H. G. KLINKENBIJL;LEEN SLAETS;LUIGI CATALIOTTI;MARIEKE E. STRAVER;MARKO SNOJ;MILA DONKER","1661;1538;1538;1538;1538;1538;1538;1538;1538;1538;1538;1538;1538;1538;1538;1538;1538;1538;1538;1538","LORENZO ORZALESI;LUIGI CATALIOTTI;LUCA BONI;GIAN MARÍA ROSSOLINI;RICCARDO SACCARDI;LUIGI RIGACCI;VITO ANNESE;GUIDO PARODI;ALBERTO BOSI;IACOPO OLIVOTTO;MARCO CARINI;STEFANO GUIDI;ANDREA MINERVINI;MAURIZIO SALVADORI;GIAN FRANCO GENSINI;DOMENICO ANDREA CAMPANACCI;FRANCESCA GIROLAMI;FRANCO CECCHI;SERGIO SERNI;FRANCESCA TORRICELLI","1661;1538;1113;824;672;669;566;541;476;398;371;339;325;299;298;293;293;293;278;276","ALBERTO BOSI;GIAN FRANCO GENSINI;DAVID ANTONIUCCI;GUIDO PARODI;FRANCESCO DI COSTANZO;GIAN MARÍA ROSSOLINI;LEONARDO PANTONI;ANGELA MIGLIORINI;EDOARDO MANNUCCI;RENATO VALENTI;LORENZO LIVI;DANIELA GRETO;ELISA GIOMMONI;SERAFINA VALENTE;ADRIANO PERIS;LUIGI RIGACCI;CHIARA LAZZERI;FRANCESCA TORRICELLI;JACOPO MARTELLUCCI;LORENZO ANTONUZZO","19;16;14;13;12;11;10;10;10;9;9;8;8;8;8;8;7;7;7;7","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;CHEMISTRY;MATHEMATICS;PSYCHOLOGY;ECONOMICS;PHILOSOPHY;SOCIOLOGY;POLITICAL SCIENCE;HISTORY;BUSINESS;MATERIALS SCIENCE;ART;ENVIRONMENTAL SCIENCE;GEOGRAPHY;GEOLOGY","445;107;51;31;30;26;26;21;15;13;11;10;8;4;4;3;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;GASTROENTEROLOGY;PATHOLOGY;RADIOLOGY;GENETICS;ONCOLOGY;INTENSIVE CARE MEDICINE;IMMUNOLOGY;PSYCHIATRY;BIOCHEMISTRY;ANESTHESIA;OPTICS;ENVIRONMENTAL HEALTH;ENDOCRINOLOGY;PHYSICAL THERAPY;PEDIATRICS;NUCLEAR MEDICINE;NURSING","346;125;74;73;73;67;64;64;49;48;38;28;27;26;24;23;23;22;21;19","CANCER;DISEASE;GENE;CHEMOTHERAPY;MYOCARDIAL INFARCTION;COHORT;CONFIDENCE INTERVAL;TRANSPLANTATION;BONE MARROW;POPULATION;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;HEART FAILURE;INCIDENCE (GEOMETRY);ADVERSE EFFECT;REGIMEN;PROSPECTIVE COHORT STUDY;RETROSPECTIVE COHORT STUDY;CLINICAL TRIAL;DIABETES MELLITUS","60;53;52;37;34;30;29;24;21;21;21;21;20;19;18;17;16;16;15;15","HAZARD RATIO;COLORECTAL CANCER;GENOTYPE;CLINICAL ENDPOINT;EJECTION FRACTION;MYELOFIBROSIS;PERCUTANEOUS CORONARY INTERVENTION;VIRAL LOAD;CONVENTIONAL PCI;INFLAMMATORY BOWEL DISEASE;BREAST CANCER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MYELODYSPLASTIC SYNDROMES;ALLELE;CYCLOPHOSPHAMIDE;ESCHERICHIA COLI;ESSENTIAL THROMBOCYTHEMIA;MUTATION;CARDIOMYOPATHY;GENE EXPRESSION;PLACEBO;PROSTATE","16;15;15;14;12;12;12;12;11;10;9;9;9;8;8;8;8;8;7;7;7;7","ANTIRETROVIRAL THERAPY;KLEBSIELLA PNEUMONIAE;MYELOPROLIFERATIVE NEOPLASM;RUXOLITINIB;TIMI;BUSULFAN;CHRONIC MYELOMONOCYTIC LEUKEMIA;CYBERKNIFE;DNA METHYLATION;GENOTYPING;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;IRINOTECAN;MOLECULAR EPIDEMIOLOGY;OXALIPLATIN;PRASUGREL;SINGLE-NUCLEOTIDE POLYMORPHISM;BINGE-EATING DISORDER;FLUDARABINE;IMATINIB MESYLATE;NEOADJUVANT THERAPY","12;7;5;5;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3","HUMANS;FEMALE;MALE;;MIDDLE AGED;AGED;ADULT;ITALY;TREATMENT OUTCOME;AGED, 80 AND OVER;MYOCARDIAL INFARCTION;FOLLOW-UP STUDIES;PROSPECTIVE STUDIES;RETROSPECTIVE STUDIES;YOUNG ADULT;ADOLESCENT;RISK FACTORS;PROGNOSIS;HIV INFECTIONS;TIME FACTORS","274;197;197;189;149;143;111;79;65;62;46;43;42;42;40;36;34;31;29;29","GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ACUTE MYELOID LEUKEMIA;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;LYMPHOID NEOPLASMS;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;ATRIAL FIBRILLATION;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;MANAGEMENT OF VALVULAR HEART DISEASE;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;KIDNEY TRANSPLANTATION;MOLECULAR RESEARCH ON BREAST CANCER;PANCREATIC CANCER RESEARCH AND TREATMENT;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;RENAL CELL CARCINOMA","11;11;10;9;9;8;8;8;7;7;7;7;6;6;6;5;5;5;5;5","TREATMENT;REGIMEN;CARDIAC IMAGING;CLINICAL ENDPOINT;STROKE (ENGINE);ANTIRETROVIRAL THERAPY;ATRIAL FIBRILLATION;DIAGNOSIS;CARDIOVASCULAR RISK ASSESSMENT;TRANSCATHETER AORTIC-VALVE REPLACEMENT;CONCOMITANT;ECHOCARDIOGRAPHY;IMAGE-GUIDED RADIOTHERAPY;INTERIM;PROSTHETIC VALVES EVALUATION;RALTEGRAVIR;ATAZANAVIR;CORONARY STENTS;CROSS-SECTIONAL STUDY;DEEP VEIN THROMBOSIS","19;17;16;14;13;11;8;8;7;7;6;6;6;6;6;6;5;5;5;5","ATRIAL FIBRILLATION;ELDERLY PATIENTS;STEM CELL;CELL TRANSPLANTATION;INFLAMMATORY BOWEL;KLEBSIELLA PNEUMONIAE;RETROSPECTIVE ANALYSIS;BOWEL DISEASE;HYPERTROPHIC CARDIOMYOPATHY;MYOCARDIAL INFARCTION;PATIENTS UNDERGOING;PROSPECTIVE MULTICENTER;SYSTEMIC SCLEROSIS;VEIN THROMBOSIS;ADVANCED PANCREATIC;AORTIC DISSECTION;BREAST CANCER;GASTRIC CANCER;HEART FAILURE;LEFT ATRIAL;LUNG CANCER;MAGNETIC RESONANCE;MULTICENTER RETROSPECTIVE;PATIENTS TREATED;PHASE III;SPLANCHNIC VEIN;ACUTE CORONARY;ALLOGENEIC STEM;AORTIC VALVE;CELL LUNG","9;9;8;7;7;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4","HR CI;MULTIVARIATE ANALYSIS;RESEARCH FUNDING;RISK FACTORS;LEFT VENTRICULAR;CONSECUTIVE PATIENTS;PATIENTS TREATED;ESSENTIAL OILS;CONTROL SUBJECTS;CV EVENTS;HEART FAILURE;HONORARIA RESEARCH;PATIENTS UNDERGOING;SIGNIFICANT DIFFERENCE;TLS RISK;ADVERSE EVENTS;CLINICAL PRACTICE;ESSENTIAL OIL;INFARCT SIZE;STATISTICALLY SIGNIFICANT;STEM CELL;VIRAL LOAD;XD XD;ADVISORY COMMITTEES;CONFIDENCE INTERVAL;EJECTION FRACTION;ENTITYS BOARD;ES-HC PATIENTS;GASTRIC CANCER;ADD RISK","25;20;20;20;17;15;15;14;13;13;13;13;13;13;12;11;11;11;11;11;11;11;11;10;10;10;10;10;10;9",158,0.34,6.44,6,3.5,3,1,4,3.75,1,1,7,1,1,5.25,1.5,2,1,3,4.5,3,0,0,89,89,2,0,1,0,0,1,1,2,0,0,0,0,1,4,0,0,2.2,0.76,1.4,3,2,3,0,0,1,0,0,3,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"MIRABELLA CARLO;LUNGHI CARLOTTA;NATIVI CRISTINA;RICHICHI BARBARA;TOMA LUCIO","3;2;2;2;2","AZIENDA OSPEDALIERO UNIVERSITARIA CAREGGI;REGIONE TOSCANA","5;2","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3204 IMMUNOLOGY;34 CHEMICAL SCIENCES;40 ENGINEERING;3101 BIOCHEMISTRY AND CELL BIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;4003 BIOMEDICAL ENGINEERING","3;2;2;2;2;1;1;1;1","BIOTECHNOLOGY;CANCER;DIGESTIVE DISEASES;HEMATOLOGY;IMMUNIZATION;VACCINE RELATED","1;1;1;1;1;1","5.1 PHARMACEUTICALS","1","A61L27/20;A01N61/00;A61F2/00;A61K31/00;A61K38/00;A61K47/48;A61P35/00;C07K16/44","2;1;1;1;1;1;1;1","A61L27/20;A61L27/22;A61L27/3633;A61L27/38;A61L27/3804;A61L27/3834;A61L27/56;A61L27/60;A61P43/00;A61K47/549","3;3;3;3;3;3;3;3;3;2",50,5.63,555.58,6.73,24,0.48,73.58,0,2,8,0,14,0,5,21,0,33,16,0,0,0,0,0,0,49,1,0,48,1,0,1,0,0,0,0,0,0,"United States;Italy;Japan;United Kingdom","16;6;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3212 OPHTHALMOLOGY AND OPTOMETRY;3203 DENTISTRY;3204 IMMUNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4205 NURSING;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","49;26;14;10;8;5;2;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;PATIENT SAFETY;DIGESTIVE DISEASES;PREVENTION;BIOMEDICAL IMAGING;LUNG;ORPHAN DRUG;CARDIOVASCULAR;AUTOIMMUNE DISEASE;GENETICS;HEART DISEASE;INFLAMMATORY BOWEL DISEASE;LYMPHOMA;PAIN RESEARCH;PEDIATRIC;TRANSPLANTATION","49;30;22;22;14;13;10;10;6;6;6;5;4;4;4;4;4;4;4;4","CANCER;ORAL AND GASTROINTESTINAL;BLOOD;MUSCULOSKELETAL;CARDIOVASCULAR;EYE;RESPIRATORY;GENERIC HEALTH RELEVANCE;INFECTION;MENTAL HEALTH","15;5;4;3;2;2;2;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.4 SURGERY;2.4 SURVEILLANCE AND DISTRIBUTION;7.3 MANAGEMENT AND DECISION MAKING","28;8;7;5;3;2;2;1;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER;HEAD AND NECK CANCER;LIVER CANCER;MYELOMA;ORAL CAVITY AND LIP CANCER;PANCREATIC CANCER;PHARYNGEAL CANCER;BLOOD CANCER;BREAST CANCER;LARYNGEAL CANCER;SALIVARY GLAND CANCER;SARCOMA","8;4;3;2;2;2;2;2;2;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;3.3 CHEMOPREVENTION;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","17;4;3;2;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,"PUBLIC LIBRARY OF SCIENCE","21","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;3105 GENETICS;3107 MICROBIOLOGY;3204 IMMUNOLOGY;4203 HEALTH SERVICES AND SYSTEMS;50 PHILOSOPHY AND RELIGIOUS STUDIES;5003 PHILOSOPHY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","32;14;4;2;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;INFECTIOUS DISEASES;PREVENTION;PHYSICAL INJURY - ACCIDENTS AND ADVERSE EFFECTS;ANTIMICROBIAL RESISTANCE;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;NEUROSCIENCES;PATIENT SAFETY;ATHEROSCLEROSIS;BIOMEDICAL IMAGING;CARDIOVASCULAR;DENTAL/ORAL AND CRANIOFACIAL DISEASE;GENETICS;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;HUMAN GENOME;OSTEOPOROSIS","6;6;6;4;3;3;2;2;2;1;1;1;1;1;1;1;1;1","INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL","3;1;1","6.4 SURGERY;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;7.3 MANAGEMENT AND DECISION MAKING","2;1;1;1;1;1","CLINICAL;BIOMEDICAL","8;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","15;1;1",NA,NA,NA,NA
"AOU_CAREGGI",2015,533,11.656660412758,3.24015009380863,0.390243902439024,0.365853658536585,0.632270168855535,2.10744810744811,1.38666666666667,1.78899082568807,1.53181818181818,0.525328330206379,9,267,121,60,37,0.5,0.23,0.11,0.07,30.25,0.811620856187427,5.40653775322282,0.348968105065666,0.849906191369606,0.481,0.424,0.472,0.443,"GIAN FRANCO GENSINI;ALESSANDRO M. VANNUCCHI;EDOARDO MANNUCCI;LORENZO LIVI;NICCOLÒ MARCHIONNI;GIAN MARÍA ROSSOLINI;ALBERTO BOSI;SERAFINA VALENTE;PAOLA GUGLIELMELLI;FRANCESCO FATTIROLLI;STEFANO GRIFONI;VITO ANNESE;FRANCESCO DI COSTANZO;ANDREA UNGAR;PEIMAN NAZERIAN;MARCO CHIOSTRI;ALESSANDRO RAMBALDI;STEFANO ROMAGNOLI;ROSANNA ABBATE;TIZIANA FANELLI","27;18;17;16;15;13;13;13;12;12;11;11;11;11;10;10;10;10;10;9","EDOARDO MANNUCCI;GIAN FRANCO GENSINI;FRANCESCO FATTIROLLI;STEFANO ROMAGNOLI;JACOPO MARTELLUCCI;CARLO DANI;NICCOLÒ MARCHIONNI;MAURIZIO SALVADORI;GIAN MARÍA ROSSOLINI;ANDREA UNGAR;CHIARA LAZZERI;SERAFINA VALENTE;MARCO CHIOSTRI;NAZARIO CARRABBA;ALESSANDRO M. VANNUCCHI;GIANCARLO CASTAMAN;LORENZO LIVI;ADRIANO PERIS;ANTONELLA GOZZINI;MARTINA RAFANELLI","3.61;3.3;3.19;2.79;2.15;2;1.77;1.71;1.7;1.66;1.56;1.54;1.39;1.39;1.36;1.35;1.27;1.26;1.23;1.23","GIAN FRANCO GENSINI;ALESSANDRO M. VANNUCCHI;EDOARDO MANNUCCI;LORENZO LIVI;NICCOLÒ MARCHIONNI;GIAN MARÍA ROSSOLINI;ALBERTO BOSI;SERAFINA VALENTE;PAOLA GUGLIELMELLI;FRANCESCO FATTIROLLI;STEFANO GRIFONI;VITO ANNESE;FRANCESCO DI COSTANZO;ANDREA UNGAR;PEIMAN NAZERIAN;MARCO CHIOSTRI;STEFANO ROMAGNOLI;ROSANNA ABBATE;TIZIANA FANELLI;SIMONE VANNI","27;18;17;16;15;13;13;13;12;12;11;11;11;11;10;10;10;10;9;9","EDOARDO MANNUCCI;GIAN FRANCO GENSINI;FRANCESCO FATTIROLLI;STEFANO ROMAGNOLI;JACOPO MARTELLUCCI;CARLO DANI;NICCOLÒ MARCHIONNI;MAURIZIO SALVADORI;GIAN MARÍA ROSSOLINI;ANDREA UNGAR;CHIARA LAZZERI;SERAFINA VALENTE;MARCO CHIOSTRI;NAZARIO CARRABBA;ALESSANDRO M. VANNUCCHI;GIANCARLO CASTAMAN;LORENZO LIVI;ADRIANO PERIS;ANTONELLA GOZZINI;MARTINA RAFANELLI","3.61;3.3;3.19;2.79;2.15;2;1.77;1.71;1.7;1.66;1.56;1.54;1.39;1.39;1.36;1.35;1.27;1.26;1.23;1.23","VITO ANNESE;TOM H. KARLSEN;ANDRÉ FRANKE;DERMOT MCGOVERN;GABRIELLE BOUCHER;JEFFREY C. BARRETT;JOHN D. RIOUX;L. PHILIP SCHUMM;LUKE JOSTINS;MARK J. DALY;PHILIPPE GOYETTE;RICHARD H. DUERR;ALESSANDRO M. VANNUCCHI;CLAIRE HARRISON;FRANCESCO PASSAMONTI;MARTIN GRIEßHAMMER;JEAN‐JACQUES KILADJIAN;RUBEN A. MESA;DANY HABR;FABRIZIO PANE","2581;982;967;967;967;967;967;967;967;967;967;967;856;818;789;786;784;784;780;780","VITO ANNESE;ALESSANDRO M. VANNUCCHI;GIULIO DEL POPOLO;GIAN MARÍA ROSSOLINI;SIMONE VANNI;STEFANO GRIFONI;LORENZO LIVI;PEIMAN NAZERIAN;DANIELA POLI;ICRO MEATTINI;FRANCESCA ROGAI;EDOARDO MANNUCCI;ALBERTO BOSI;DONATO CASELLA;MARCO BERNINI;PIERLUIGI BONOMO;DANIELA GRETO;JACOPO MARTELLUCCI;GABRIELE SIMONTACCHI;GENNARO SANTORO","2581;853;679;553;509;454;441;429;404;404;376;348;346;342;342;339;302;299;294;291","GIAN FRANCO GENSINI;EDOARDO MANNUCCI;SERAFINA VALENTE;ALESSANDRO M. VANNUCCHI;LORENZO LIVI;NICCOLÒ MARCHIONNI;PAOLA GUGLIELMELLI;GIAN MARÍA ROSSOLINI;STEFANO GRIFONI;VITO ANNESE;FRANCESCO FATTIROLLI;ALBERTO BOSI;FRANCESCO DI COSTANZO;PEIMAN NAZERIAN;ANDREA UNGAR;MARCO CHIOSTRI;STEFANO ROMAGNOLI;CHIARA LAZZERI;SIMONE VANNI;TIZIANA FANELLI","22;16;15;14;14;12;12;11;11;11;11;11;11;10;10;10;10;9;9;9","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;ENGINEERING;PSYCHOLOGY;MATHEMATICS;PHILOSOPHY;ECONOMICS;POLITICAL SCIENCE;SOCIOLOGY;MATERIALS SCIENCE;BUSINESS;GEOGRAPHY;GEOLOGY;HISTORY;ART;ENVIRONMENTAL SCIENCE","494;133;55;39;34;30;28;19;16;13;12;10;7;5;4;3;3;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;PATHOLOGY;GENETICS;IMMUNOLOGY;INTENSIVE CARE MEDICINE;RADIOLOGY;GASTROENTEROLOGY;PSYCHIATRY;ONCOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;ANESTHESIA;CANCER RESEARCH;ENDOCRINOLOGY;PEDIATRICS;PHYSICAL THERAPY;NUCLEAR MEDICINE;NURSING","374;135;96;81;71;65;65;63;55;52;51;47;44;36;35;33;31;29;27;27","CANCER;GENE;DISEASE;POPULATION;MYOCARDIAL INFARCTION;CHEMOTHERAPY;CONFIDENCE INTERVAL;COHORT;BONE MARROW;HEART FAILURE;RANDOMIZED CONTROLLED TRIAL;ATRIAL FIBRILLATION;DIABETES MELLITUS;ADVERSE EFFECT;PROSPECTIVE COHORT STUDY;ALTERNATIVE MEDICINE;TRANSPLANTATION;ANTIBODY;RADIATION THERAPY;STROKE (ENGINE)","62;57;52;44;43;34;33;25;24;24;23;22;22;21;21;20;20;18;18;18","CLINICAL ENDPOINT;HAZARD RATIO;COLORECTAL CANCER;MYELOFIBROSIS;MUTATION;ACUTE CORONARY SYNDROME;PERCUTANEOUS CORONARY INTERVENTION;BREAST CANCER;TYPE 2 DIABETES;UNIVARIATE ANALYSIS;GENE EXPRESSION;CYCLOPHOSPHAMIDE;EJECTION FRACTION;ESCHERICHIA COLI;WHITE MATTER;AORTIC VALVE REPLACEMENT;GENOTYPE;HEART RATE;INFLAMMATORY BOWEL DISEASE;PHASES OF CLINICAL RESEARCH;PHENOTYPE;PROGENITOR CELL;RITUXIMAB;ULCERATIVE COLITIS","19;18;17;17;13;12;12;11;11;10;9;8;8;8;8;7;7;7;7;7;7;7;7;7","RUXOLITINIB;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KLEBSIELLA PNEUMONIAE;KRAS;MYELOPROLIFERATIVE NEOPLASM;TIMI;CYBERKNIFE;PEMETREXED;VINCRISTINE;ARTHROPATHY;BENDAMUSTINE;CAPECITABINE;DNA METHYLATION;ENTEROBACTERIACEAE;FLUDARABINE;FRACTIONAL ANISOTROPY;GENE EXPRESSION PROFILING;IRINOTECAN;LIRAGLUTIDE;PRASUGREL;PROBAND;VANCOMYCIN;VASCULAR ENDOTHELIAL GROWTH FACTOR A","9;5;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","HUMANS;FEMALE;MALE;;MIDDLE AGED;AGED;ADULT;ITALY;AGED, 80 AND OVER;TREATMENT OUTCOME;PROSPECTIVE STUDIES;RETROSPECTIVE STUDIES;FOLLOW-UP STUDIES;MYOCARDIAL INFARCTION;RISK FACTORS;YOUNG ADULT;BIOMARKERS;TIME FACTORS;ADOLESCENT;RISK ASSESSMENT","312;223;223;205;174;162;118;76;73;63;56;54;45;39;38;38;35;32;31;31","MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ATRIAL FIBRILLATION;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;LYMPHOID NEOPLASMS;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MANAGEMENT OF VALVULAR HEART DISEASE;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;DIAGNOSIS AND MANAGEMENT OF SYNCOPE;MANAGEMENT OF DIABETES MELLITUS AND CARDIOVASCULAR RISK;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;ADVANCEMENTS IN LUNG CANCER RESEARCH;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND TREATMENT OF HEART FAILURE;PANCREATIC CANCER RESEARCH AND TREATMENT;STANDARDISATION OF LOWER URINARY TRACT FUNCTION;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH","19;12;9;8;8;8;8;7;7;7;7;7;7;6;6;6;6;6;5;5","CLINICAL ENDPOINT;STROKE (ENGINE);REGIMEN;ATRIAL FIBRILLATION;UNIVARIATE ANALYSIS;CARDIAC IMAGING;DISCONTINUATION;MYELOFIBROSIS;PROSTHETIC VALVES EVALUATION;RUXOLITINIB;ST-SEGMENT ELEVATION;DIABETES;TRANSCATHETER AORTIC-VALVE REPLACEMENT;CARDIAC ULTRASOUND;CARDIOVASCULAR RISK ASSESSMENT;SURGICAL AORTIC-VALVE REPLACEMENT;TREATMENT;DEEP VEIN THROMBOSIS;DIFFUSION MRI;ECHOCARDIOGRAPHY","19;18;12;11;10;9;9;9;9;9;9;8;8;7;7;7;7;6;6;6","ATRIAL FIBRILLATION;MYOCARDIAL INFARCTION;ACUTE CORONARY;AORTIC VALVE;CLINICAL PRACTICE;CORONARY SYNDROME;HYPERTROPHIC CARDIOMYOPATHY;PATIENTS TREATED;PILOT STUDY;SYSTEMIC SCLEROSIS;EXTRACORPOREAL MEMBRANE;INFLAMMATORY BOWEL;MEMBRANE OXYGENATION;MULTIPLE SCLEROSIS;PRIMARY MYELOFIBROSIS;ST-ELEVATION MYOCARDIAL;CANCER PATIENTS;CARDIAC REHABILITATION;COLORECTAL CANCER;COMPUTED TOMOGRAPHY;ELDERLY PATIENTS;EMERGENCY DEPARTMENT;HEART FAILURE;ISCHEMIC STROKE;LUNG CANCER;MYELOID LEUKEMIA;PANCREATIC CANCER;PATIENTS PTS;TYPE DIABETES;ADULT PATIENTS","11;9;8;8;7;7;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;5;4","RISK FACTORS;FLORENCE ITALY;MEDIAN AGE;FLORENCE FLORENCE;HOSPITAL FLORENCE;FLORENCE ITALYSEARCH;ADVERSE EVENTS;CONSECUTIVE PATIENTS;CROSSREF MEDLINE;PATIENTS TREATED;CONFIDENCE INTERVAL;GASTRIC CANCER;CV RISK;CAREGGI HOSPITAL;CAS GOOGLE;INFLAMMATORY BOWEL;MEDLINE CAS;SPEAKERS BUREAU;BLOOD PRESSURE;BOWEL DISEASE;CROHNS DISEASE;ULCERATIVE COLITIS;ADVANCED GASTRIC;CLINICAL PRACTICE;FLORENCE CAREGGI;PATIENTS UNDERGOING;ATRIAL FIBRILLATION;INTERVAL CI;MEDIAN FOLLOW-UP;MULTIVARIATE ANALYSIS","56;31;24;23;22;20;19;19;19;19;18;18;17;16;16;16;16;16;15;15;15;15;14;14;14;14;13;13;13;13",209,0.39,7,6,2,1,1,2,5,0,1,6,1,1,5,1,2,1,3,4,3,0,0,79,79,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0.06,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"MIRABELLA CARLO","1","AZIENDA OSPEDALIERO UNIVERSITARIA CAREGGI","1","32 BIOMEDICAL AND CLINICAL SCIENCES;37 EARTH SCIENCES;3705 GEOLOGY","1;1;1",NA,NA,"4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1","A61B10/00;A61B5/145;A61B5/15;C12M3/08;G01N33/49;G01N33/50","1;1;1;1;1;1","A61B10/0045;A61B10/0096;A61B2562/08;A61B5/15;A61B5/15003;A61B5/150221;A61B5/150236;A61B5/150244;A61B5/150305;A61B5/150366","1;1;1;1;1;1;1;1;1;1",52,4.98,868.71,7.02,34,0.65,109.06,0,1,13,2,19,0,1,16,0,39,13,0,0,0,0,0,0,45,5,2,52,0,0,0,0,0,0,0,0,0,"United States;Italy;Japan;Germany;Netherlands;Switzerland;Australia","9;6;5;2;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3213 PAEDIATRICS;3212 OPHTHALMOLOGY AND OPTOMETRY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4205 NURSING;48 LAW AND LEGAL STUDIES;4806 PRIVATE LAW AND CIVIL OBLIGATIONS","48;26;18;4;4;4;3;2;2;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;DIGESTIVE DISEASES;PATIENT SAFETY;HEMATOLOGY;AUTOIMMUNE DISEASE;CARDIOVASCULAR;PEDIATRIC;BREAST CANCER;INFLAMMATORY BOWEL DISEASE;CROHN'S DISEASE;HEART DISEASE;LUNG;ORPHAN DRUG;AGING;BIOENGINEERING;INFANT MORTALITY;NEUROSCIENCES","48;36;19;16;12;11;8;7;7;6;5;5;4;4;4;4;3;3;3;3","CANCER;CARDIOVASCULAR;ORAL AND GASTROINTESTINAL;BLOOD;EYE;INFLAMMATORY AND IMMUNE SYSTEM;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY;STROKE","15;4;4;2;2;2;1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.3 MEDICAL DEVICES","40;5;3;3;1;1;1","BREAST CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;COLON AND RECTAL CANCER;NON-HODGKIN'S LYMPHOMA;PANCREATIC CANCER;BLADDER CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;GASTROINTESTINAL TRACT;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;PROSTATE CANCER;STOMACH CANCER","5;4;3;2;2;2;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.6 END-OF-LIFE CARE","16;4;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,35,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE;TAYLOR & FRANCIS GROUP","33;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3105 GENETICS;3213 PAEDIATRICS;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;42 HEALTH SCIENCES;49 MATHEMATICAL SCIENCES;39 EDUCATION;3904 SPECIALIST STUDIES IN EDUCATION;44 HUMAN SOCIETY;46 INFORMATION AND COMPUTING SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3212 OPHTHALMOLOGY AND OPTOMETRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;34 CHEMICAL SCIENCES;3407 THEORETICAL AND COMPUTATIONAL CHEMISTRY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3502 BANKING, FINANCE AND INVESTMENT","33;16;8;5;4;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;GENETICS;BIOTECHNOLOGY;BREAST CANCER;ESTROGEN;HUMAN GENOME","5;5;3;3;2;1;1;1","CANCER;CARDIOVASCULAR;ORAL AND GASTROINTESTINAL;STROKE","4;2;1;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","2;2;1;1;1;1","CLINICAL;BIOMEDICAL","9;2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","13;4;2","MELANOMA;BREAST CANCER;LUNG CANCER;NOT SITE-SPECIFIC CANCER","2;1;1;1",NA,NA
"AOU_CAREGGI",2016,575,12.8452173913043,2.99826086956522,0.333913043478261,0.325217391304348,0.493913043478261,1.99076212471132,1.36170212765957,1.68468468468468,1.3921568627451,0.509565217391304,8,306,129,63,32,0.53,0.22,0.11,0.06,25.28,0.77819945787267,5.35070306038048,0.32695652173913,0.869565217391304,0.501,0.417,0.447,0.43,"GIAN MARÍA ROSSOLINI;C. TALAMONTI;LORENZO ANTONUZZO;IACOPO OLIVOTTO;S. PALLOTTA;LORENZO LIVI;ALESSANDRO M. VANNUCCHI;VITO ANNESE;DAVID ANTONIUCCI;NICCOLÒ MARCHIONNI;RENATO VALENTI;GUIDO PARODI;ANGELA MIGLIORINI;FRANCESCO DI COSTANZO;L. MARRAZZO;RODOLFO CAPANNA;ADRIANO PERIS;GIAN FRANCO GENSINI;SILVIA SCOCCIANTI;EDOARDO MANNUCCI","21;19;18;18;17;16;16;15;14;12;12;12;11;11;11;11;11;11;10;10","VITO ANNESE;GIAN MARÍA ROSSOLINI;EDOARDO MANNUCCI;IACOPO OLIVOTTO;S. PALLOTTA;C. TALAMONTI;GIANCARLO CASTAMAN;STEFANO ROMAGNOLI;RODOLFO CAPANNA;DAVID ANTONIUCCI;LORENZO LIVI;CARLO ROSTAGNO;STANISLAO RIZZO;L. MARRAZZO;FRANCESCO SOFI;TOMMASO GABBANI;RENATO VALENTI;NICCOLÒ MARCHIONNI;ANGELA MIGLIORINI;ADRIANO PERIS","3.62;2.64;2.36;2.06;2;1.82;1.79;1.49;1.48;1.47;1.46;1.46;1.36;1.36;1.32;1.32;1.31;1.28;1.23;1.19","GIAN MARÍA ROSSOLINI;C. TALAMONTI;LORENZO ANTONUZZO;IACOPO OLIVOTTO;S. PALLOTTA;LORENZO LIVI;ALESSANDRO M. VANNUCCHI;VITO ANNESE;DAVID ANTONIUCCI;NICCOLÒ MARCHIONNI;RENATO VALENTI;GUIDO PARODI;ANGELA MIGLIORINI;FRANCESCO DI COSTANZO;L. MARRAZZO;RODOLFO CAPANNA;ADRIANO PERIS;GIAN FRANCO GENSINI;SILVIA SCOCCIANTI;EDOARDO MANNUCCI","21;19;18;18;17;16;16;15;14;12;12;12;11;11;11;11;11;11;10;10","VITO ANNESE;GIAN MARÍA ROSSOLINI;EDOARDO MANNUCCI;IACOPO OLIVOTTO;S. PALLOTTA;C. TALAMONTI;GIANCARLO CASTAMAN;STEFANO ROMAGNOLI;RODOLFO CAPANNA;DAVID ANTONIUCCI;LORENZO LIVI;CARLO ROSTAGNO;STANISLAO RIZZO;L. MARRAZZO;FRANCESCO SOFI;TOMMASO GABBANI;RENATO VALENTI;NICCOLÒ MARCHIONNI;ANGELA MIGLIORINI;ADRIANO PERIS","3.62;2.64;2.36;2.06;2;1.82;1.79;1.49;1.48;1.47;1.46;1.46;1.36;1.36;1.32;1.32;1.31;1.28;1.23;1.19","VITO ANNESE;GIONATA FIORINO;FERNANDO GOMOLLÓN;ALESSANDRO ARMUZZI;MARCO DAPERNO;FERNANDO RIZZELLO;AXEL DIGNAß;FLORIAN RIEDER;GARRET J. CULLEN;GERASSIMOS J. MANTZARIS;GERT VAN ASSCHE;HERBERT TILG;JAMES O. LINDSAY;JOST LANGHORST;LAURENT PEYRIN‐BIROULET;MARCUS HARBORD;MIQUEL SANS;PAOLO GIONCHETTI;PASCAL JUILLERAT;STEPHAN R. VAVRICKA","2187;1987;1948;1863;1824;1791;1738;1738;1738;1738;1738;1738;1738;1738;1738;1738;1738;1738;1738;1738","VITO ANNESE;IACOPO OLIVOTTO;GIAN MARÍA ROSSOLINI;STEFANO GUIDI;ALESSANDRO M. VANNUCCHI;SIMONE VANNI;TIZIANA FANELLI;LORENZO ANTONUZZO;ADRIANO PERIS;PAOLA GUGLIELMELLI;SERAFINA VALENTE;CARMELA MANNARELLI;ENRICO MINETTI;ALESSANDRO BARTOLONI;ANNALISA PACILLI;ALESSANDRO PANCRAZZI;GIADA ROTUNNO;NATALIA MANETTI;RODOLFO CAPANNA;CARLO DANI","2186;1045;487;478;476;406;390;373;372;371;371;328;309;284;280;278;278;274;268;262","LORENZO ANTONUZZO;IACOPO OLIVOTTO;GIAN MARÍA ROSSOLINI;ALESSANDRO M. VANNUCCHI;C. TALAMONTI;LORENZO LIVI;S. PALLOTTA;DAVID ANTONIUCCI;VITO ANNESE;L. MARRAZZO;FRANCESCO DI COSTANZO;RENATO VALENTI;RODOLFO CAPANNA;SILVIA SCOCCIANTI;ADRIANO PERIS;ANGELA MIGLIORINI;EDOARDO MANNUCCI;M. CASATI;SERAFINA VALENTE;GUIDO PARODI","18;17;17;16;15;15;15;14;14;12;11;11;11;10;10;10;10;10;10;10","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;ENGINEERING;PSYCHOLOGY;MATHEMATICS;PHILOSOPHY;MATERIALS SCIENCE;ECONOMICS;POLITICAL SCIENCE;SOCIOLOGY;BUSINESS;GEOGRAPHY;GEOLOGY;HISTORY;ART;ENVIRONMENTAL SCIENCE","546;121;72;49;46;39;28;21;19;14;13;10;10;4;3;3;2;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;PATHOLOGY;RADIOLOGY;GASTROENTEROLOGY;ONCOLOGY;GENETICS;IMMUNOLOGY;ENVIRONMENTAL HEALTH;NUCLEAR MEDICINE;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;ANESTHESIA;OPTICS;PSYCHIATRY;ENDOCRINOLOGY;PEDIATRICS;NURSING;MECHANICAL ENGINEERING;PHYSICAL THERAPY","384;175;102;80;74;70;65;61;53;48;47;41;37;34;33;33;32;32;27;26;26","CANCER;DISEASE;GENE;POPULATION;CHEMOTHERAPY;MYOCARDIAL INFARCTION;ADVERSE EFFECT;COHORT;RANDOMIZED CONTROLLED TRIAL;HEART FAILURE;CLINICAL TRIAL;ALTERNATIVE MEDICINE;RADIATION THERAPY;RETROSPECTIVE COHORT STUDY;CONFIDENCE INTERVAL;ANTIBIOTICS;INCIDENCE (GEOMETRY);PROSPECTIVE COHORT STUDY;BONE MARROW;STROKE (ENGINE)","81;57;47;45;36;35;31;30;30;29;28;26;26;26;25;20;20;20;19;18","COLORECTAL CANCER;CLINICAL ENDPOINT;PERCUTANEOUS CORONARY INTERVENTION;BREAST CANCER;MYELOFIBROSIS;CARDIOMYOPATHY;ESCHERICHIA COLI;HAZARD RATIO;PLACEBO;EJECTION FRACTION;GENOTYPE;INFLAMMATORY BOWEL DISEASE;METASTASIS;TOLERABILITY;ULCERATIVE COLITIS;ALLELE;BEVACIZUMAB;MUTATION;PHASES OF CLINICAL RESEARCH;ACUTE CORONARY SYNDROME;ADENOCARCINOMA;CARDIOGENIC SHOCK;CONVENTIONAL PCI;GESTATIONAL AGE;HAEMATOPOIESIS;PROGRESSION-FREE SURVIVAL;RESTENOSIS","30;21;16;15;13;12;10;10;10;9;9;9;9;9;9;8;8;8;8;7;7;7;7;7;7;7;7","BIORESORBABLE SCAFFOLD;KRAS;KLEBSIELLA PNEUMONIAE;MYELOPROLIFERATIVE NEOPLASM;OXALIPLATIN;ANTIRETROVIRAL THERAPY;CETUXIMAB;CROSSOVER STUDY;FEBRILE NEUTROPENIA;IMIPENEM;IRINOTECAN;MODIFIED RANKIN SCALE;RUXOLITINIB;WHOLE GENOME SEQUENCING;CARDIAC RESYNCHRONIZATION THERAPY;COLONOSCOPY;DNA METHYLATION;ECULIZUMAB;ENTEROBACTERIACEAE;METASTATIC BREAST CANCER;RIBAVIRIN;VASCULAR DEMENTIA","7;7;6;6;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3","HUMANS;MALE;FEMALE;;MIDDLE AGED;AGED;ADULT;ITALY;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;PROSPECTIVE STUDIES;YOUNG ADULT;ADOLESCENT;POSTOPERATIVE COMPLICATIONS;RISK FACTORS;FOLLOW-UP STUDIES;STROKE;CARDIOMYOPATHY, HYPERTROPHIC;CARDIOVASCULAR DISEASES","340;255;251;222;207;185;156;121;93;87;80;54;54;45;43;42;39;35;32;32","RADIOTHERAPY PHYSICS AND TECHNOLOGY;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;MANAGEMENT OF VALVULAR HEART DISEASE;ATRIAL FIBRILLATION;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;DIAGNOSIS AND MANAGEMENT OF SYNCOPE;GASTRIC CANCER RESEARCH AND TREATMENT;RENAL CELL CARCINOMA;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;LYMPHOID NEOPLASMS;PANCREATIC CANCER RESEARCH AND TREATMENT;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN LUNG CANCER RESEARCH","18;14;12;12;12;11;11;10;8;8;8;7;7;7;6;6;6;6;5;5","CLINICAL ENDPOINT;STROKE (ENGINE);TREATMENT;CARDIAC IMAGING;REGIMEN;EVEROLIMUS;REFRACTORY (PLANETARY SCIENCE);CONCOMITANT;ECHOCARDIOGRAPHY;PROSTHETIC VALVES EVALUATION;RADIOTHERAPY;METASTATIC COLORECTAL CANCER;MYELOFIBROSIS;TOLERABILITY;TRANSCATHETER AORTIC-VALVE REPLACEMENT;IMAGING;BIORESORBABLE SCAFFOLD;DISCONTINUATION;DRUG-ELUTING STENTS;INTENSITY-MODULATED RADIOTHERAPY","21;19;14;13;12;11;11;10;10;10;10;9;9;9;9;8;7;7;7;7","COLORECTAL CANCER;HYPERTROPHIC CARDIOMYOPATHY;METASTATIC COLORECTAL;GASTRIC CANCER;INFLAMMATORY BOWEL;PATIENTS PTS;AORTIC VALVE;BOWEL DISEASE;CANCER MCRC;LUNG CANCER;OBSERVATIONAL STUDY;VALVE IMPLANTATION;ATRIAL FIBRILLATION;BREAST CANCER;MITRAL VALVE;MYOCARDIAL INFARCTION;NEUROENDOCRINE TUMORS;PATIENTS UNDERGOING;REAL WORLD;STEM CELL;SUBGROUP ANALYSIS;TRANSCATHETER AORTIC;ACUTE CORONARY;ACUTE MYOCARDIAL;CANCER PATIENTS;CLINICAL PRACTICE;CORONARY ARTERY;CORONARY SYNDROME;EXTRACORPOREAL MEMBRANE;MEMBRANE OXYGENATION","16;11;9;8;8;8;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5","HR CI;SAN RAFFAELE;ISI GOOGLE;CROSSREF PUBMED;PUBMED ISI;LDH LEVELS;MEDIAN AGE;RISK FACTORS;RADICAL NEPHRECTOMY;PATIENTS TREATED;HR CI-;HEART FAILURE;FLORENCE FLORENCE;LEFT VENTRICULAR;MEDIAN PFS;CARATTERE SCIENTIFICO;CLINICAL MEDICINE;CONFIDENCE INTERVAL;DEGLI STUDI;DI RICOVERO;EXPERIMENTAL ONCOLOGY;INSTITUTE DIVISION;INSTITUTE MILAN;INTERNAL MEDICINE;ISTITUTO DI;KIDNEY DISEASE;MILAN ITALY;NITRIC OXIDE;ONCOLOGY ISTITUTO;PATIENTS UNDERGOING","37;32;30;26;26;25;25;24;23;21;20;19;18;18;17;16;16;16;16;16;16;16;16;16;16;16;16;16;16;16",236,0.41,7,7,2,1.75,1,8.75,2,1,1,8,1,1,6,1,2,2,3,5,3,0,0,69.25,69.25,3,0,1,1,0,0,0,1,0,0,0,0,2,1,0,6,3,0.52,1.33333333333333,1,1,3,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ARCANGELI ANNAROSA;CRESCIOLI SILVIA;CROCIANI OLIVIA;LUNGHI CARLOTTA;MIRABELLA CARLO;NATIVI CRISTINA;RICHICHI BARBARA;SETTE ANGELICA;TOMA LUCIO","1;1;1;1;1;1;1;1;1","AZIENDA OSPEDALIERO UNIVERSITARIA CAREGGI;UNIV FIRENZE","3;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;34 CHEMICAL SCIENCES;31 BIOLOGICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;37 EARTH SCIENCES;3705 GEOLOGY","3;2;2;1;1;1;1","BIOTECHNOLOGY","1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","1;1","A61B10/00;A61B5/145;A61B5/15;A61K38/00;A61K47/48;A61P35/00;C07K16/28;C07K16/44;C12M3/08;G01N33/49","1;1;1;1;1;1;1;1;1;1","A61P35/00;A61B10/0045;A61B10/0096;A61B2562/08;A61B5/15;A61B5/15003;A61B5/150221;A61B5/150236;A61B5/150244;A61B5/150305","2;1;1;1;1;1;1;1;1;1",52,4.14,598.18,6.57,31,0.6,77.81,1,0,11,1,19,0,2,18,0,40,11,0,0,0,0,0,0,47,3,2,51,1,0,0,0,0,0,0,0,0,"United States;Italy;Japan;Brazil;France;Germany;Qatar;Serbia;Switzerland;United Kingdom","14;8;4;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3215 REPRODUCTIVE MEDICINE;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3203 DENTISTRY;3204 IMMUNOLOGY;3210 NUTRITION AND DIETETICS;3212 OPHTHALMOLOGY AND OPTOMETRY;3213 PAEDIATRICS;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3507 STRATEGY, MANAGEMENT AND ORGANISATIONAL BEHAVIOUR;4206 PUBLIC HEALTH","47;23;13;8;7;5;4;2;2;2;2;2;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;RARE DISEASES;PATIENT SAFETY;NEUROSCIENCES;CARDIOVASCULAR;PREVENTION;BRAIN DISORDERS;HEART DISEASE;BIOENGINEERING;LYMPHOMA;ORPHAN DRUG;PEDIATRIC;AUTOIMMUNE DISEASE;DIGESTIVE DISEASES;NEURODEGENERATIVE;PAIN RESEARCH;STEM CELL RESEARCH","48;37;20;17;17;12;9;7;7;6;6;5;5;5;5;4;4;4;4;4","CANCER;CARDIOVASCULAR;NEUROLOGICAL;METABOLIC AND ENDOCRINE;BLOOD;INFLAMMATORY AND IMMUNE SYSTEM;MUSCULOSKELETAL;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY;SKIN;STROKE","14;5;4;2;1;1;1;1;1;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;3.3 NUTRITION AND CHEMOPREVENTION;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES;5.3 MEDICAL DEVICES;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.3 MANAGEMENT AND DECISION MAKING;8.1 ORGANISATION AND DELIVERY OF SERVICES","28;5;5;1;1;1;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;MYELOMA;BLOOD CANCER;BREAST CANCER;COLON AND RECTAL CANCER;BRAIN TUMOR;ENDOMETRIAL CANCER;HODGKIN'S DISEASE;KIDNEY CANCER;LUNG CANCER;SARCOMA;STOMACH CANCER","6;6;3;2;2;2;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","14;3;2;2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE;TAYLOR & FRANCIS GROUP","39;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;4206 PUBLIC HEALTH;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;34 CHEMICAL SCIENCES;46 INFORMATION AND COMPUTING SCIENCES;51 PHYSICAL SCIENCES;52 PSYCHOLOGY;3103 ECOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;3402 INORGANIC CHEMISTRY;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4203 HEALTH SERVICES AND SYSTEMS","35;10;8;7;4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;HEMATOLOGY;BEHAVIORAL AND SOCIAL SCIENCE;CANCER;CARDIOVASCULAR;GENETICS;HEART DISEASE;NUTRITION;PREVENTION;RARE DISEASES;STEM CELL RESEARCH;AGING;ALCOHOLISM, ALCOHOL USE AND HEALTH;ARTHRITIS;AUTOIMMUNE DISEASE;BASIC BEHAVIORAL AND SOCIAL SCIENCE;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COMPLEMENTARY AND INTEGRATIVE HEALTH;DIGESTIVE DISEASES;HIV/AIDS","4;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM","3;3;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS","2;1","CLINICAL;BIOMEDICAL;POPULATION & SOCIETY","4;3;2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","14;2;2","NOT SITE-SPECIFIC CANCER;BREAST CANCER;COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;PROSTATE CANCER","4;1;1;1;1","3 GOOD HEALTH AND WELL BEING","5"
"AOU_CAREGGI",2017,612,14.0522875816993,3.12254901960784,0.320261437908497,0.338235294117647,0.447712418300654,2.07042253521127,1.36111111111111,1.89908256880734,1.37,0.542483660130719,5,324,141,66,32,0.53,0.23,0.11,0.05,23.42,0.794402413981874,5.16507703595009,0.320261437908497,0.897058823529412,0.495,0.476,0.475,0.485,"LORENZO LIVI;ALESSANDRO M. VANNUCCHI;PAOLA GUGLIELMELLI;LUIGI RIGACCI;IACOPO OLIVOTTO;ISACCO DESIDERI;ALESSANDRO RAMBALDI;ROSSELLA MARCUCCI;ICRO MEATTINI;VIERI SCOTTI;GIAN MARÍA ROSSOLINI;NICCOLÒ MARCHIONNI;S. PALLOTTA;GIULIO FRANCOLINI;ALBERTO BOSI;STANISLAO RIZZO;ANTONELLA GOZZINI;DANIELA GRETO;GIANNI VIRGILI;DOMENICO GALETTA","38;27;18;17;16;16;16;16;16;15;15;15;14;14;13;13;12;11;11;11","LORENZO LIVI;STANISLAO RIZZO;MAURIZIO SALVADORI;ARIS TSALOUCHOS;ALESSANDRO M. VANNUCCHI;MARCO INNOCENTI;FRANCESCO SOFI;ROSSELLA MARCUCCI;LORENZO ZAMMARCHI;DANIELA POLI;GIAN MARÍA ROSSOLINI;NICCOLÒ MARCHIONNI;ALBERTO BOSI;VALERIA SANTINI;PAOLA GUGLIELMELLI;GIANNI VIRGILI;MONICA DINU;GIUDITTA PAGLIAI;PIERLUIGI STEFÀNO;S. PALLOTTA","2.5;2.41;2.07;2;1.95;1.6;1.57;1.54;1.53;1.52;1.49;1.43;1.39;1.38;1.38;1.34;1.34;1.34;1.3;1.29","LORENZO LIVI;ALESSANDRO M. VANNUCCHI;PAOLA GUGLIELMELLI;LUIGI RIGACCI;IACOPO OLIVOTTO;ISACCO DESIDERI;ALESSANDRO RAMBALDI;ROSSELLA MARCUCCI;ICRO MEATTINI;VIERI SCOTTI;GIAN MARÍA ROSSOLINI;NICCOLÒ MARCHIONNI;S. PALLOTTA;GIULIO FRANCOLINI;ALBERTO BOSI;STANISLAO RIZZO;ANTONELLA GOZZINI;DANIELA GRETO;GIANNI VIRGILI;ALESSANDRO BARTOLONI","38;27;18;17;16;16;16;16;16;15;15;15;14;14;13;13;12;11;11;11","LORENZO LIVI;STANISLAO RIZZO;MAURIZIO SALVADORI;ARIS TSALOUCHOS;ALESSANDRO M. VANNUCCHI;MARCO INNOCENTI;FRANCESCO SOFI;ROSSELLA MARCUCCI;LORENZO ZAMMARCHI;DANIELA POLI;GIAN MARÍA ROSSOLINI;NICCOLÒ MARCHIONNI;ALBERTO BOSI;VALERIA SANTINI;PAOLA GUGLIELMELLI;GIANNI VIRGILI;MONICA DINU;GIUDITTA PAGLIAI;PIERLUIGI STEFÀNO;S. PALLOTTA","2.5;2.41;2.07;2;1.95;1.6;1.57;1.54;1.53;1.52;1.49;1.43;1.39;1.38;1.38;1.34;1.34;1.34;1.3;1.29","ALESSANDRO M. VANNUCCHI;ALESSANDRO RAMBALDI;PAOLA GUGLIELMELLI;FRANCESCO PASSAMONTI;MARIO CAZZOLA;TIZIANO BARBUI;ELISA RUMI;GIADA ROTUNNO;MARCO MATUCCI‐CERINIC;CARMELA MANNARELLI;IACOPO OLIVOTTO;SIMONE VANNI;STEFANO GRIFONI;ANNALISA PACILLI;PEIMAN NAZERIAN;VITTORIO ROSTI;CARLOMAURIZIO MONTECUCCO;FLORENZO IANNONE;GIOVANNI BAROSI;AYALEW TEFFERI","1432;1152;1151;1130;939;933;891;882;849;707;671;647;647;643;626;624;602;602;601;591","ALESSANDRO M. VANNUCCHI;PAOLA GUGLIELMELLI;GIADA ROTUNNO;MARCO MATUCCI‐CERINIC;CARMELA MANNARELLI;ANNALISA PACILLI;STEFANO GRIFONI;PEIMAN NAZERIAN;FRANCESCO MANNELLI;RICCARDO SACCARDI;GIANNI VIRGILI;IACOPO OLIVOTTO;ALESSANDRO RAMBALDI;ANIMESH PARDANANI;AYALEW TEFFERI;CURTIS A. HANSON;ELISA RUMI;FRANCESCO PASSAMONTI;GIOVANNI BAROSI;MARIO CAZZOLA","1430;1145;880;797;704;641;567;546;497;491;468;448;446;446;446;446;446;446;446;446","LORENZO LIVI;ALESSANDRO M. VANNUCCHI;LUIGI RIGACCI;IACOPO OLIVOTTO;GIAN MARÍA ROSSOLINI;ANTONELLA GOZZINI;ALESSANDRO BARTOLONI;VIERI SCOTTI;S. PALLOTTA;ICRO MEATTINI;ALBERTO BOSI;ISACCO DESIDERI;GIULIO FRANCOLINI;ROSSELLA MARCUCCI;STANISLAO RIZZO;LORENZO ANTONUZZO;NICCOLÒ MARCHIONNI;L. MARRAZZO;FRANCESCO SOFI;VALERIA SANTINI","29;25;17;14;13;12;12;12;12;11;11;10;10;10;10;10;10;9;9;9","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;CHEMISTRY;MATHEMATICS;PSYCHOLOGY;ECONOMICS;PHILOSOPHY;POLITICAL SCIENCE;SOCIOLOGY;HISTORY;MATERIALS SCIENCE;ART;BUSINESS;GEOGRAPHY;GEOLOGY","587;146;63;38;35;29;29;21;19;17;15;14;7;5;4;4;4;3","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;CARDIOLOGY;GENETICS;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;IMMUNOLOGY;RADIOLOGY;INTENSIVE CARE MEDICINE;ENDOCRINOLOGY;OPTICS;PSYCHIATRY;BIOCHEMISTRY;ANESTHESIA;NUCLEAR MEDICINE;PALEONTOLOGY;PEDIATRICS;PHYSICAL THERAPY","458;177;112;105;95;80;66;66;62;53;46;41;35;32;31;28;28;28;26;26","CANCER;DISEASE;POPULATION;GENE;COHORT;ADVERSE EFFECT;CHEMOTHERAPY;BONE MARROW;RETROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;CLINICAL TRIAL;MYOCARDIAL INFARCTION;HEART FAILURE;LUNG CANCER;TRANSPLANTATION;CONFIDENCE INTERVAL;INCIDENCE (GEOMETRY);RADIATION THERAPY;PREGNANCY;LYMPHOMA","98;69;61;47;43;40;38;34;34;31;30;30;29;28;28;27;27;25;24;22","BREAST CANCER;CLINICAL ENDPOINT;MYELOFIBROSIS;HAZARD RATIO;COLORECTAL CANCER;MUTATION;CARDIOMYOPATHY;EJECTION FRACTION;IMMUNOTHERAPY;MYELODYSPLASTIC SYNDROMES;TOLERABILITY;ESSENTIAL THROMBOCYTHEMIA;IMATINIB;PERCUTANEOUS CORONARY INTERVENTION;GESTATION;GESTATIONAL AGE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;RITUXIMAB;COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS;CROHN'S DISEASE;INFLAMMATORY BOWEL DISEASE;UNIVARIATE ANALYSIS","26;24;22;16;15;14;13;13;13;13;12;11;11;11;10;10;10;10;9;9;9;9","RUXOLITINIB;NIVOLUMAB;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;ANTIRETROVIRAL THERAPY;IMATINIB MESYLATE;NILOTINIB;KRAS;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;BRONCHOPULMONARY DYSPLASIA;DASATINIB;METASTATIC BREAST CANCER;ANAPLASTIC LYMPHOMA KINASE;BRENTUXIMAB VEDOTIN;ELTROMBOPAG;ENTEROBACTERIACEAE;EPIRETINAL MEMBRANE;MACULAR HOLE;MASTECTOMY;MISSENSE MUTATION;PARS PLANA;REGORAFENIB;SANGER SEQUENCING;STROKE VOLUME;TAMOXIFEN;THROMBOPOIETIN;USHER SYNDROME;VINCRISTINE","12;10;9;8;7;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","HUMANS;;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;TREATMENT OUTCOME;YOUNG ADULT;PROSPECTIVE STUDIES;RISK FACTORS;ADOLESCENT;LUNG NEOPLASMS;FOLLOW-UP STUDIES;PROGNOSIS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;HIV INFECTIONS","326;280;248;235;184;159;139;114;78;77;68;53;42;40;39;38;35;34;32;29","MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;LYMPHOID NEOPLASMS;EFFICACY AND RESISTANCE IN CML TREATMENT;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;DIAGNOSIS AND TREATMENT OF LUNG CANCER;MANAGEMENT OF VALVULAR HEART DISEASE;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;ADVANCEMENTS IN LUNG CANCER RESEARCH;CANCER IMMUNOTHERAPY;GASTRIC CANCER RESEARCH AND TREATMENT;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;RADIOTHERAPY PHYSICS AND TECHNOLOGY;ACUTE MYELOID LEUKEMIA;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;BREAST RECONSTRUCTION TECHNIQUES AND OUTCOMES;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;VITREORETINAL SURGERY TECHNIQUES","28;14;13;11;11;9;9;9;8;8;8;8;8;7;7;6;6;6;6;6","CLINICAL ENDPOINT;TREATMENT;REGIMEN;STROKE (ENGINE);CARDIAC IMAGING;DISCONTINUATION;MYELOFIBROSIS;RUXOLITINIB;TOLERABILITY;ECHOCARDIOGRAPHY;BREAST CANCER;EXPANDED ACCESS;REFRACTORY (PLANETARY SCIENCE);TRANSCATHETER AORTIC-VALVE REPLACEMENT;UNIVARIATE ANALYSIS;INTERQUARTILE RANGE;METASTATIC GASTRIC CANCER;NON-SMALL CELL LUNG CANCER;PROGRESSION-FREE SURVIVAL;IMATINIB MESYLATE","24;18;17;14;13;12;12;12;12;11;9;9;9;9;9;8;8;8;8;7","LUNG CANCER;HYPERTROPHIC CARDIOMYOPATHY;BREAST CANCER;CANCER PATIENTS;CLINICAL PRACTICE;ELDERLY PATIENTS;EXPANDED ACCESS;MYELOID LEUKEMIA;PATIENTS PTS;CHRONIC MYELOID;OBSERVATIONAL STUDY;PATIENTS TREATED;POLYCYTHEMIA VERA;AORTIC VALVE;BOWEL DISEASE;CLINICAL OUTCOMES;GASTRIC CANCER;INFLAMMATORY BOWEL;MEDITERRANEAN DIET;PHASE II;PRIMARY MYELOFIBROSIS;STEM CELL;SYSTEMIC SCLEROSIS;ACCESS PROGRAM;CELL TRANSPLANTATION;FINAL RESULTS;ITALIAN PATIENTS;PATIENTS UNDERGOING;ATRIAL FIBRILLATION;CANCER SCREENING","19;13;12;12;12;10;10;10;10;8;8;8;8;7;7;7;7;7;7;7;7;7;7;6;6;6;6;6;5;5","ADVERSE EVENTS;HR CI;CLINICAL PRACTICE;SURVIVAL OS;LUNG CANCER;PARTIAL NEPHRECTOMY;PROGRESSION-FREE SURVIVAL;PATIENTS TREATED;LEFT VENTRICULAR;CROHNS DISEASE;RISK FACTORS;CLINICAL TRIALS;MEDIAN FOLLOW-UP;HYPERTROPHIC CARDIOMYOPATHY;MEDIAN AGE;MONTHS RANGE;MULTIVARIATE ANALYSIS;HEART FAILURE;RESPONSE RATE;SSC PATIENTS;PATIENTS RECEIVED;RENAL FUNCTION;CANCER PATIENTS;COX REGRESSION;MEDIAN OS;PATIENTS EXPERIENCED;PATIENTS UNDERGOING;REGRESSION ANALYSIS;STATISTICALLY SIGNIFICANT;UC PATIENTS","43;35;33;29;28;25;25;22;21;19;19;18;18;17;17;17;17;16;16;16;15;15;14;14;14;14;14;14;14;14",234,0.38,5.89,7,2,1.75,1.75,3,1.75,0,1,7,2,1,7,1,1.75,2,3,5,3,0,0,74.5,74.5,2,1,1,0,0,0,0,0,0,0,0,0,2,0,0,1,2.5,0.26,1.5,1,1,2,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ARCANGELI ANNAROSA;CRESCIOLI SILVIA;CROCIANI OLIVIA;MIRABELLA CARLO;SETTE ANGELICA","1;1;1;1;1","AZIENDA OSPEDALIERO UNIVERSITARIA CAREGGI;UNIVERSITA DEGLI STUDI DI FIRENZE","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3204 IMMUNOLOGY;37 EARTH SCIENCES;3705 GEOLOGY","2;1;1;1;1","BIOTECHNOLOGY;CLINICAL RESEARCH","1;1","5.1 PHARMACEUTICALS","1","A61B10/00;A61B5/15;A61M39/08;A61M39/22;A61P35/00;C07K16/28;G01N33/49","1;1;1;1;1;1;1","A61B10/0045;A61B10/0096;A61B2562/08;A61B5/15;A61B5/15003;A61B5/150221;A61B5/150236;A61B5/150244;A61B5/150305;A61B5/150366","1;1;1;1;1;1;1;1;1;1",72,4.71,547.04,8.45,38,0.53,76.78,0,4,16,0,31,0,2,19,0,57,13,0,0,0,0,0,0,64,4,4,69,2,0,1,0,0,0,0,0,0,"United States;Italy;Japan;Belgium;Germany;Switzerland;Austria","17;11;5;3;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3213 PAEDIATRICS;3212 OPHTHALMOLOGY AND OPTOMETRY;3215 REPRODUCTIVE MEDICINE;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3203 DENTISTRY;3204 IMMUNOLOGY;3206 MEDICAL BIOTECHNOLOGY;3210 NUTRITION AND DIETETICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS","67;39;19;7;5;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;CANCER;PATIENT SAFETY;HEMATOLOGY;PEDIATRIC;CARDIOVASCULAR;LUNG;BIOENGINEERING;DIGESTIVE DISEASES;NEUROSCIENCES;ORPHAN DRUG;PREVENTION;AGING;AUTOIMMUNE DISEASE;HEART DISEASE;NEURODEGENERATIVE;CHILDHOOD LEUKEMIA;COMPARATIVE EFFECTIVENESS RESEARCH","64;48;21;19;15;12;10;9;9;5;5;5;5;5;4;4;4;4;3;3","CANCER;CARDIOVASCULAR;ORAL AND GASTROINTESTINAL;BLOOD;EYE;INFECTION;RESPIRATORY;METABOLIC AND ENDOCRINE;NEUROLOGICAL","16;7;4;2;2;2;2;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.3 MANAGEMENT AND DECISION MAKING;3.3 NUTRITION AND CHEMOPREVENTION;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;7.1 INDIVIDUAL CARE NEEDS","53;3;2;2;2;2;2;1;1;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;COLON AND RECTAL CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;PROSTATE CANCER;SALIVARY GLAND CANCER;ENDOMETRIAL CANCER;MYELOMA;NOT SITE-SPECIFIC CANCER","7;5;3;2;2;2;2;2;2;2;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","17;3;2;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,39,"PUBLIC LIBRARY OF SCIENCE;SCIELO JOURNALS","38;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;38 ECONOMICS;3801 APPLIED ECONOMICS;40 ENGINEERING;42 HEALTH SCIENCES;3105 GENETICS;3207 MEDICAL MICROBIOLOGY;34 CHEMICAL SCIENCES;4015 MARITIME ENGINEERING;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3204 IMMUNOLOGY;3213 PAEDIATRICS;33 BUILT ENVIRONMENT AND DESIGN;3302 BUILDING;3403 MACROMOLECULAR AND MATERIALS CHEMISTRY;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;44 HUMAN SOCIETY","24;8;7;6;5;4;4;3;3;3;2;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;INFECTIOUS DISEASES;LUNG;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;HEALTH SERVICES;HIV/AIDS;PEDIATRIC;PREVENTION;AUTOIMMUNE DISEASE;BEHAVIORAL AND SOCIAL SCIENCE;BURDEN OF ILLNESS;CANCER;CHRONIC PAIN;COMPARATIVE EFFECTIVENESS RESEARCH;COST EFFECTIVENESS RESEARCH;CROHN'S DISEASE;GENETICS;HEPATITIS;HEPATITIS - C","5;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","ORAL AND GASTROINTESTINAL;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;RESPIRATORY","4;2;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;5.1 PHARMACEUTICALS;8.1 ORGANISATION AND DELIVERY OF SERVICES;8.2 HEALTH AND WELFARE ECONOMICS","4;3;3;2;1;1;1;1","BIOMEDICAL;CLINICAL;HEALTH SERVICES & SYSTEMS;POPULATION & SOCIETY","4;4;3;1","CLINICAL MEDICINE AND SCIENCE;HEALTH SERVICES RESEARCH;BASIC SCIENCE;PUBLIC HEALTH","12;3;2;2","COLON AND RECTAL CANCER;NOT SITE-SPECIFIC CANCER","3;1","3 GOOD HEALTH AND WELL BEING","1"
"AOU_CAREGGI",2018,712,14.1207865168539,3.22191011235955,0.337078651685393,0.36376404494382,0.433988764044944,2.44610458911419,1.43712574850299,1.93283582089552,1.53731343283582,0.556179775280899,2,387,144,67,58,0.54,0.2,0.09,0.08,26.79,0.878285056147322,5.02794411177643,0.332865168539326,0.879213483146067,0.502,0.44,0.435,0.452,"LORENZO LIVI;IACOPO OLIVOTTO;CARLO DI MARIO;GIAN MARÍA ROSSOLINI;ISACCO DESIDERI;DOMENICO ANDREA CAMPANACCI;ADRIANO PERIS;ALESSANDRO M. VANNUCCHI;PIERLUIGI BONOMO;FRANCO CECCHI;ICRO MEATTINI;FRANCESCO DI COSTANZO;DANIELA GRETO;VIERI SCOTTI;GIOVANNI BELTRAMI;S. PALLOTTA;STANISLAO RIZZO;ANDREA CORATTI;MARCO MATUCCI‐CERINIC;L. MARRAZZO","34;25;23;19;18;17;17;16;16;16;16;15;14;14;14;14;14;13;13;13","CARLO DI MARIO;LORENZO LIVI;IACOPO OLIVOTTO;GIAN MARÍA ROSSOLINI;ADRIANO PERIS;MAURIZIO SALVADORI;ANDREA UNGAR;STANISLAO RIZZO;LAPO BENCINI;MICHELA BEZZI;ANDREA CORATTI;MARCO INNOCENTI;ALESSANDRO INNOCENTI;DOMENICO ANDREA CAMPANACCI;S. PALLOTTA;ISACCO DESIDERI;DARIO MELITA;GIANCARLO CASTAMAN;L. MARRAZZO;ICRO MEATTINI","2.92;2.9;2.44;2.3;2.01;2;1.94;1.92;1.83;1.79;1.59;1.55;1.55;1.55;1.53;1.52;1.48;1.47;1.47;1.46","LORENZO LIVI;IACOPO OLIVOTTO;CARLO DI MARIO;GIAN MARÍA ROSSOLINI;ISACCO DESIDERI;DOMENICO ANDREA CAMPANACCI;ADRIANO PERIS;ALESSANDRO M. VANNUCCHI;PIERLUIGI BONOMO;FRANCO CECCHI;ICRO MEATTINI;FRANCESCO DI COSTANZO;DANIELA GRETO;VIERI SCOTTI;GIOVANNI BELTRAMI;S. PALLOTTA;STANISLAO RIZZO;ANDREA CORATTI;MARCO MATUCCI‐CERINIC;L. MARRAZZO","34;25;23;19;18;17;17;16;16;16;16;15;14;14;14;14;14;13;13;13","CARLO DI MARIO;LORENZO LIVI;IACOPO OLIVOTTO;GIAN MARÍA ROSSOLINI;ADRIANO PERIS;MAURIZIO SALVADORI;ANDREA UNGAR;STANISLAO RIZZO;LAPO BENCINI;MICHELA BEZZI;ANDREA CORATTI;MARCO INNOCENTI;ALESSANDRO INNOCENTI;DOMENICO ANDREA CAMPANACCI;S. PALLOTTA;ISACCO DESIDERI;DARIO MELITA;GIANCARLO CASTAMAN;L. MARRAZZO;ICRO MEATTINI","2.92;2.9;2.44;2.3;2.01;2;1.94;1.92;1.83;1.79;1.59;1.55;1.55;1.55;1.53;1.52;1.48;1.47;1.47;1.46","PAOLO G. CASALI;ALESSANDRO GRONCHI;HANS GELDERBLOM;PIOTR RUTKOWSKI;SILVIA STACCHIOTTI;ANGELO PAOLO DEI TOS;SILVIA GASPERONI;GIOVANNI GRIGNANI;MARIA A. PANTALEO;PETER HOHENBERGER;A. BASSIM HASSAN;AKMAL SAFWAT;ANDREA FERRARI;ANGELA BUONADONNA;ANNA MARIA FREZZA;ANTONIO LÓPEZ–POUSA;AXEL LE CESNE;BERND KASPER;DAGMAR ADÁMKOVÁ KRÁKOROVÁ;ENRIQUE DE ÁLAVA","2695;2618;2618;2618;2618;2607;2567;2559;2559;2530;2529;2529;2529;2529;2529;2529;2529;2529;2529;2529","SILVIA GASPERONI;CARLO DI MARIO;IACOPO OLIVOTTO;ALESSANDRO M. VANNUCCHI;MARIA ROSARIA RASPOLLINI;PAOLA GUGLIELMELLI;FRANCESCA GIROLAMI;LORENZO LIVI;FRANCO CECCHI;GIAN MARÍA ROSSOLINI;ANDREA CORATTI;ANDREA UNGAR;DOMENICO ANDREA CAMPANACCI;VALERIA SANTINI;SALVATORE MANGIAFICO;FRANCESCO MANNELLI;ISACCO DESIDERI;PIERLUIGI BONOMO;JACOPO NORI;NICCOLÒ BARTALUCCI","2567;1275;1260;1100;925;880;770;715;632;561;392;375;359;359;350;342;328;295;278;269","LORENZO LIVI;IACOPO OLIVOTTO;CARLO DI MARIO;ALESSANDRO M. VANNUCCHI;DOMENICO ANDREA CAMPANACCI;GIAN MARÍA ROSSOLINI;ISACCO DESIDERI;ICRO MEATTINI;ADRIANO PERIS;VIERI SCOTTI;FRANCESCO DI COSTANZO;GIOVANNI BELTRAMI;ANDREA CORATTI;L. MARRAZZO;PIERLUIGI BONOMO;S. PALLOTTA;ALESSANDRO BARTOLONI;ANDREA UNGAR;GUIDO SCOCCIANTI;LUCA VOLTOLINI","30;26;20;17;16;15;15;15;14;14;14;14;13;13;13;13;12;12;12;12","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;CHEMISTRY;PSYCHOLOGY;ECONOMICS;POLITICAL SCIENCE;SOCIOLOGY;PHILOSOPHY;MATERIALS SCIENCE;BUSINESS;GEOLOGY;ART;ENVIRONMENTAL SCIENCE;GEOGRAPHY;HISTORY","690;147;64;57;41;37;35;27;18;16;14;12;11;6;5;3;3;3;2","INTERNAL MEDICINE;SURGERY;PATHOLOGY;CARDIOLOGY;RADIOLOGY;ONCOLOGY;GENETICS;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;IMMUNOLOGY;ENVIRONMENTAL HEALTH;PEDIATRICS;PSYCHIATRY;NUCLEAR MEDICINE;BIOCHEMISTRY;PHYSICAL THERAPY;OPTICS;NURSING;ANESTHESIA;GENERAL SURGERY","513;234;132;124;103;96;79;72;67;66;64;46;45;41;36;36;35;32;30;30","CANCER;DISEASE;POPULATION;COHORT;GENE;RADIATION THERAPY;CHEMOTHERAPY;RETROSPECTIVE COHORT STUDY;MYOCARDIAL INFARCTION;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;PREGNANCY;PROSPECTIVE COHORT STUDY;TRANSPLANTATION;ALTERNATIVE MEDICINE;HEART FAILURE;CLINICAL TRIAL;INCIDENCE (GEOMETRY);ATRIAL FIBRILLATION;LUNG","106;68;55;45;45;41;40;40;38;38;34;34;32;31;29;29;26;23;22;22","COLORECTAL CANCER;CLINICAL ENDPOINT;BREAST CANCER;CARDIOMYOPATHY;PHENOTYPE;PERCUTANEOUS CORONARY INTERVENTION;DEMENTIA;MUTATION;TOLERABILITY;ESCHERICHIA COLI;GESTATIONAL AGE;HAZARD RATIO;IMMUNOTHERAPY;VIRAL LOAD;WARFARIN;FETUS;MYELOFIBROSIS;PLACEBO;THROMBOLYSIS;UNIVARIATE ANALYSIS","29;24;22;21;13;12;11;11;11;10;10;10;10;10;10;9;9;9;9;9","KRAS;ANTIRETROVIRAL THERAPY;CETUXIMAB;KLEBSIELLA PNEUMONIAE;NIVOLUMAB;OXALIPLATIN;VON WILLEBRAND DISEASE;IRINOTECAN;MAMMOGRAPHY;MASTECTOMY;AZOOSPERMIA;DUCTAL CARCINOMA;IMATINIB MESYLATE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;MODIFIED RANKIN SCALE;PARS PLANA;PROBAND;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RESTRICTIVE CARDIOMYOPATHY;RIVAROXABAN;UMBILICAL ARTERY;VITAMIN K ANTAGONIST","11;9;8;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4","HUMANS;FEMALE;MALE;;MIDDLE AGED;AGED;ADULT;ITALY;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;TREATMENT OUTCOME;YOUNG ADULT;PROSPECTIVE STUDIES;PROGNOSIS;BREAST NEOPLASMS;FOLLOW-UP STUDIES;ADOLESCENT;POSTOPERATIVE COMPLICATIONS;RISK FACTORS;COHORT STUDIES","416;308;297;287;230;201;190;155;109;102;97;69;65;48;46;46;45;40;39;34","DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;MANAGEMENT OF VALVULAR HEART DISEASE;SARCOMA RESEARCH AND TREATMENT;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ATRIAL FIBRILLATION;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;DIAGNOSIS AND TREATMENT OF LUNG CANCER;ACUTE MYELOID LEUKEMIA;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;RADIOTHERAPY PHYSICS AND TECHNOLOGY;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;PANCREATIC CANCER RESEARCH AND TREATMENT;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;GASTRIC CANCER RESEARCH AND TREATMENT;VITREORETINAL SURGERY TECHNIQUES;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DIAGNOSIS AND MANAGEMENT OF SYNCOPE;EFFICACY AND RESISTANCE IN CML TREATMENT","16;15;15;14;12;12;12;11;10;10;10;9;9;9;8;8;8;7;7;7","CARDIAC IMAGING;CLINICAL ENDPOINT;TREATMENT;REGIMEN;CONCOMITANT;STROKE (ENGINE);PROSTHETIC VALVES EVALUATION;RADIOTHERAPY;TRANSCATHETER AORTIC-VALVE REPLACEMENT;DISCONTINUATION;INTERQUARTILE RANGE;TOLERABILITY;ANTIRETROVIRAL THERAPY;DILATED CARDIOMYOPATHY;METASTATIC COLORECTAL CANCER;NON-SMALL CELL LUNG CANCER;UNIVARIATE ANALYSIS;CLINICAL PRACTICE;CONCORDANCE;INFARCTION TREATMENT","26;24;23;17;16;16;14;14;13;12;11;11;9;9;9;9;9;8;8;8","HYPERTROPHIC CARDIOMYOPATHY;SYSTEMIC SCLEROSIS;LUNG CANCER;PATIENTS TREATED;AORTIC VALVE;CLINICAL PRACTICE;COHORT STUDY;ATRIAL FIBRILLATION;VON WILLEBRAND;BREAST CANCER;CANCER PATIENTS;COLORECTAL CANCER;ELDERLY PATIENTS;MAGNETIC RESONANCE;METASTATIC COLORECTAL;MYELOID LEUKEMIA;PILOT STUDY;PRELIMINARY RESULTS;CLINICAL TRIAL;OBSERVATIONAL STUDY;PROSPECTIVE STUDY;RISK FACTORS;STEM CELL;CELL CARCINOMA;CELL TRANSPLANTATION;CHRONIC MYELOID;CLINICAL OUTCOMES;MULTICENTER OBSERVATIONAL;ONCOLOGYEUROPEAN SOCIETY;PATIENTS UNDERGOING","16;13;11;11;10;10;10;9;9;8;8;8;8;8;8;8;8;8;7;7;7;7;7;6;6;6;6;6;6;6","PUBMED SCOPUS;CROSSREF PUBMED;SPEAKERS BUREAU;ADVISORY COMMITTEES;ENTITYS BOARD;RESEARCH FUNDING;PATIENTS TREATED;HONORARIA MEMBERSHIP;RISK FACTORS;ADVERSE EVENTS;ONCOL -CROSSREF;GASTROINTESTINAL STROMAL;CLINICAL PRACTICE;ADVISORY BOARD;HR CI;CLIN ONCOL;MEDIAN AGE;SOFT TISSUE;CONFIDENCE INTERVAL;ONCOL -ABSTRACT;SURVIVAL OS;CERVICAL CANCER;MEDIAN FOLLOW-UP;PRIMARY ENDPOINT;STATISTICALLY SIGNIFICANT;MUTATION TEST;PATIENTS RECEIVED;PATIENTS UNDERWENT;COLORECTAL CANCER;PROGRESSION-FREE SURVIVAL","145;101;93;86;86;70;60;44;41;40;35;34;33;32;32;31;31;28;27;26;26;25;23;22;22;21;21;21;20;20",306,0.43,8.05,9,2,1,1,2,3.5,0,1,10,1,1,8.75,2,1.75,2,3.25,6,4,0,0,63,62.75,2,0,0,0,0,1,1,0,0,0,0,0,0,2,0,0,2.5,0.22,1.5,1,1,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ARCANGELI ANNAROSA;CRESCIOLI SILVIA;CROCIANI OLIVIA;MIRABELLA CARLO;SETTE ANGELICA","1;1;1;1;1","AZIENDA OSPEDALIERO UNIVERSITARIA CAREGGI;UNIVERSITA DEGLI STUDI DI FIRENZE","2;1",NA,NA,NA,NA,NA,NA,"A61B10/00;A61B5/145;A61B5/15;A61P35/00;C07K16/28;C12M3/08;G01N33/49;G01N33/50","1;1;1;1;1;1;1;1","A61B10/0045;A61B10/0096;A61B2562/08;A61B5/15;A61B5/15003;A61B5/150221;A61B5/150236;A61B5/150244;A61B5/150305;A61B5/150366","1;1;1;1;1;1;1;1;1;1",74,4.47,776,8.77,35,0.47,90.46,0,3,10,0,31,0,3,27,0,58,15,0,0,0,0,0,0,65,3,6,73,1,0,0,0,0,0,0,0,0,"United States;Italy;Japan;United Kingdom;Switzerland;Canada;Germany;Netherlands;Spain","23;9;3;3;2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3204 IMMUNOLOGY;40 ENGINEERING;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;3105 GENETICS;3107 MICROBIOLOGY;3207 MEDICAL MICROBIOLOGY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;4003 BIOMEDICAL ENGINEERING;4012 FLUID MECHANICS AND THERMAL ENGINEERING","72;43;25;8;6;5;4;4;3;3;3;3;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;PATIENT SAFETY;HEMATOLOGY;DIGESTIVE DISEASES;PREVENTION;AUTOIMMUNE DISEASE;CARDIOVASCULAR;AGING;HEART DISEASE;LUNG;PEDIATRIC;DIABETES;INFLAMMATORY BOWEL DISEASE;NEURODEGENERATIVE;BIOTECHNOLOGY;CHILDHOOD LEUKEMIA;GENETICS","67;52;25;18;16;10;9;9;8;8;7;7;7;7;5;5;5;4;4;4","CANCER;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL;EYE;INFECTION;BLOOD;MENTAL HEALTH;MUSCULOSKELETAL;NEUROLOGICAL;RENAL AND UROGENITAL;RESPIRATORY","20;7;5;5;3;3;2;1;1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;2.4 SURVEILLANCE AND DISTRIBUTION;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.4 SURGERY","48;7;6;2;2;1;1;1;1","COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;BREAST CANCER;HEAD AND NECK CANCER;PROSTATE CANCER;KIDNEY CANCER;NON-HODGKIN'S LYMPHOMA;PHARYNGEAL CANCER;BLADDER CANCER;ENDOMETRIAL CANCER;LARYNGEAL CANCER;MELANOMA;ORAL CAVITY AND LIP CANCER;PANCREATIC CANCER;SALIVARY GLAND CANCER;SARCOMA;SKIN CANCER;SMALL INTESTINE CANCER;STOMACH CANCER","6;6;4;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;1.4 CANCER PROGRESSION AND METASTASIS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY","21;4;4;4;3;2;1;1",1,76166,12694.33,3,6,3,1,0,4231.44444444444,168.264054827613,"AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI;CORNELL UNIVERSITY;DURHAM VA MEDICAL CENTER;HARVARD UNIVERSITY;IRCCS HUMANITAS RESEARCH HOSPITAL;UNIVERSITAIR ZIEKENHUIS LEUVEN","1;1;1;1;1;1","CROHN'S AND COLITIS FOUNDATION","1","HRA - HEALTH RESEARCH ALLIANCE","1","LITWIN IBD PIONEERS PROGRAM (PROGRAM)","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1","CLINICAL RESEARCH;DIGESTIVE DISEASES;PATIENT SAFETY;PREVENTION","1;1;1;1","ORAL AND GASTROINTESTINAL","1","6.4 SURGERY","1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,34,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;KARGER PUBLISHERS;AMERICAN CHEMICAL SOCIETY","26;5;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3103 ECOLOGY;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3004 CROP AND PASTURE PRODUCTION;3107 MICROBIOLOGY;3108 PLANT BIOLOGY;49 MATHEMATICAL SCIENCES;52 PSYCHOLOGY;46 INFORMATION AND COMPUTING SCIENCES;5202 BIOLOGICAL PSYCHOLOGY;3204 IMMUNOLOGY;40 ENGINEERING;42 HEALTH SCIENCES;4905 STATISTICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3203 DENTISTRY;3207 MEDICAL MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","35;11;8;5;4;4;4;4;4;4;3;3;2;2;2;2;1;1;1;1","CLINICAL RESEARCH;NEUROSCIENCES;CANCER;NEURODEGENERATIVE;AGING;BASIC BEHAVIORAL AND SOCIAL SCIENCE;BEHAVIORAL AND SOCIAL SCIENCE;BIOMEDICAL IMAGING;BIOTECHNOLOGY;BRAIN DISORDERS;DIGESTIVE DISEASES;EYE DISEASE AND DISORDERS OF VISION;HEMATOLOGY;INFANT MORTALITY;INFECTIOUS DISEASES;KIDNEY DISEASE;LUNG;NEONATAL RESPIRATORY DISTRESS;PEDIATRIC;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD","5;5;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","STROKE;CANCER;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY","3;1;1;1","5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","2;2;1;1","CLINICAL;BIOMEDICAL","4;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","18;1","KIDNEY CANCER;NOT SITE-SPECIFIC CANCER;STOMACH CANCER","1;1;1","2 ZERO HUNGER","4"
"AOU_CAREGGI",2019,709,15.3187588152327,3.26375176304655,0.317348377997179,0.325811001410437,0.421720733427362,2.38699690402477,1.38888888888889,1.94117647058824,1.44444444444444,0.555712270803949,7,372,136,66,51,0.52,0.19,0.09,0.07,22.11,0.90930324709246,5.11284619917502,0.358251057827927,0.904090267983075,0.493,0.487,0.469,0.497,"CARLO DI MARIO;LORENZO LIVI;IACOPO OLIVOTTO;GIAN MARÍA ROSSOLINI;VIERI SCOTTI;SERGIO SERNI;ANDREA MINERVINI;MARCO CARINI;PAOLA GUGLIELMELLI;ROSSELLA MARCUCCI;GIANCARLO CASTAMAN;GIANMARTIN CITO;MARCO MATUCCI‐CERINIC;ALESSANDRO M. VANNUCCHI;ISACCO DESIDERI;ANDREA COCCI;STANISLAO RIZZO;RICCARDO SACCARDI;NICCOLÒ MARCHIONNI;ALESSIO MATTESINI","39;24;20;19;18;18;18;18;17;17;16;16;16;16;16;16;16;15;15;14","CARLO DI MARIO;ARIS TSALOUCHOS;MAURIZIO SALVADORI;STANISLAO RIZZO;LORENZO LIVI;VITTORIO MIELE;TOMASO CAPOROSSI;GIANCARLO CASTAMAN;GIAN MARÍA ROSSOLINI;ANDREA UNGAR;CARLO DANI;MARCO MATUCCI‐CERINIC;ROSSELLA MARCUCCI;SERGIO SERNI;IACOPO OLIVOTTO;MARCO CARINI;ANDREA MINERVINI;NICCOLÒ MARCHIONNI;DOMENICO ANDREA CAMPANACCI;GIANNI VIRGILI","3.94;3.1;3;1.87;1.87;1.79;1.77;1.74;1.71;1.56;1.54;1.53;1.47;1.46;1.44;1.43;1.41;1.39;1.35;1.34","CARLO DI MARIO;LORENZO LIVI;IACOPO OLIVOTTO;GIAN MARÍA ROSSOLINI;VIERI SCOTTI;SERGIO SERNI;ANDREA MINERVINI;MARCO CARINI;PAOLA GUGLIELMELLI;ROSSELLA MARCUCCI;GIANCARLO CASTAMAN;GIANMARTIN CITO;MARCO MATUCCI‐CERINIC;ALESSANDRO M. VANNUCCHI;ISACCO DESIDERI;ANDREA COCCI;STANISLAO RIZZO;RICCARDO SACCARDI;NICCOLÒ MARCHIONNI;ALESSIO MATTESINI","39;24;20;19;18;18;18;18;17;17;16;16;16;16;16;16;16;15;15;14","CARLO DI MARIO;ARIS TSALOUCHOS;MAURIZIO SALVADORI;STANISLAO RIZZO;LORENZO LIVI;VITTORIO MIELE;TOMASO CAPOROSSI;GIANCARLO CASTAMAN;GIAN MARÍA ROSSOLINI;ANDREA UNGAR;CARLO DANI;MARCO MATUCCI‐CERINIC;ROSSELLA MARCUCCI;SERGIO SERNI;IACOPO OLIVOTTO;MARCO CARINI;ANDREA MINERVINI;NICCOLÒ MARCHIONNI;DOMENICO ANDREA CAMPANACCI;GIANNI VIRGILI","3.94;3.1;3;1.87;1.87;1.79;1.77;1.74;1.71;1.56;1.54;1.53;1.47;1.46;1.44;1.43;1.41;1.39;1.35;1.34","CARLO DI MARIO;GIAN MARÍA ROSSOLINI;IACOPO OLIVOTTO;ANNALISA PANTOSTI;RICCARDO SACCARDI;TOMMASO GIANI;ALKIVIADIS VATOPOULOS;CHRISTIAN G. GISKE;DOROTA ŻABICKA;HAJO GRUNDMANN;HELENA ŽEMLIČKOVÁ;AISTĖ MIERAUSKAITĖ;AMOS ADLER;ANA KAFTANDZIEVA;ANASTASIA PAVELKOVICH;ANDI KORAQI;ANETTE M. HAMMERUM;ANIKA TRUDIĆ;ARJANA TAMBIĆ ANDRAŠEVIĆ;ARSIM KURTI","1236;1055;706;663;657;623;600;600;600;600;600;571;571;571;571;571;571;571;571;571","CARLO DI MARIO;GIAN MARÍA ROSSOLINI;IACOPO OLIVOTTO;RICCARDO SACCARDI;FRANCESCO CAPPELLI;ALESSANDRO M. VANNUCCHI;GAETANA STERRANTINO;ANDREA UNGAR;GIANCARLO CASTAMAN;MARIA ROSARIA RASPOLLINI;GIULIA RIVASI;MARCO CARINI;ANDREA MINERVINI;LUCA BONI;PAOLA GUGLIELMELLI;ANDREA MARI;ANDREA CORATTI;GIULIO FRANCOLINI;PEIMAN NAZERIAN;STEFANO GRIFONI","1139;909;706;644;483;459;458;422;401;397;383;355;341;313;296;295;256;245;243;243","CARLO DI MARIO;IACOPO OLIVOTTO;LORENZO LIVI;MARCO CARINI;VIERI SCOTTI;PAOLA GUGLIELMELLI;GIAN MARÍA ROSSOLINI;SERGIO SERNI;ANDREA MINERVINI;GIANMARTIN CITO;ANDREA UNGAR;ISACCO DESIDERI;MARCO MATUCCI‐CERINIC;VITTORIO MIELE;GIANCARLO CASTAMAN;ANDREA COCCI;RICCARDO SACCARDI;ALESSANDRO M. VANNUCCHI;ALBERTO BOSI;NICCOLÒ MARCHIONNI","34;21;20;18;17;16;15;15;15;14;14;14;14;14;14;14;14;13;13;13","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;CHEMISTRY;PSYCHOLOGY;MATHEMATICS;ECONOMICS;PHILOSOPHY;POLITICAL SCIENCE;SOCIOLOGY;MATERIALS SCIENCE;BUSINESS;GEOGRAPHY;HISTORY;ENVIRONMENTAL SCIENCE;ART;GEOLOGY","685;159;57;56;46;42;26;23;14;13;13;13;10;5;5;5;2;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;PATHOLOGY;ONCOLOGY;RADIOLOGY;GENETICS;GASTROENTEROLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;PSYCHIATRY;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;OPTICS;ANESTHESIA;MECHANICAL ENGINEERING;PEDIATRICS;UROLOGY;NUCLEAR MEDICINE","529;223;124;113;104;84;81;77;75;60;45;43;39;36;34;33;32;30;28;27","CANCER;DISEASE;POPULATION;GENE;CLINICAL TRIAL;COHORT;MYOCARDIAL INFARCTION;RANDOMIZED CONTROLLED TRIAL;RADIATION THERAPY;ADVERSE EFFECT;HEART FAILURE;RETROSPECTIVE COHORT STUDY;CONFIDENCE INTERVAL;PROSPECTIVE COHORT STUDY;CHEMOTHERAPY;TRANSPLANTATION;ALTERNATIVE MEDICINE;ATRIAL FIBRILLATION;BLOOD PRESSURE;BONE MARROW;INCIDENCE (GEOMETRY);STROKE (ENGINE)","110;75;58;56;43;41;41;40;38;37;37;37;36;36;35;31;30;25;25;25;25;25","CLINICAL ENDPOINT;BREAST CANCER;COLORECTAL CANCER;PERCUTANEOUS CORONARY INTERVENTION;PLACEBO;EJECTION FRACTION;HAZARD RATIO;METASTASIS;MYELODYSPLASTIC SYNDROMES;MYELOFIBROSIS;REVASCULARIZATION;CARDIOMYOPATHY;GENOTYPE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;IMMUNOTHERAPY;MULTICENTER STUDY;PROSTATE CANCER;UNIVARIATE ANALYSIS;DEMENTIA;HEART RATE","32;27;20;20;15;14;14;13;12;12;11;10;10;10;10;10;10;10;9;9","NIVOLUMAB;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;MODIFIED RANKIN SCALE;MYELOPROLIFERATIVE NEOPLASM;PARS PLANA;BREAST RECONSTRUCTION;CRIZOTINIB;FRACTIONAL FLOW RESERVE;KARYOTYPE;KLEBSIELLA PNEUMONIAE;MACE;MASTECTOMY;OXALIPLATIN;PROSTATECTOMY;SINGLE-NUCLEOTIDE POLYMORPHISM;TARGET LESION;VINCRISTINE;ANAPLASTIC LYMPHOMA KINASE;ANTHRACYCLINE;ANTIRETROVIRAL THERAPY;AZOOSPERMIA;COLECTOMY;COLONOSCOPY;DRUG-ELUTING STENT;INTRACYTOPLASMIC SPERM INJECTION;MACULAR HOLE;MALE INFERTILITY;MAMMOGRAPHY;NINTEDANIB;PEMBROLIZUMAB;PENILE CURVATURE;VENETOCLAX;VITAMIN K ANTAGONIST","7;6;6;5;5;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","HUMANS;;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;RETROSPECTIVE STUDIES;ITALY;TREATMENT OUTCOME;AGED, 80 AND OVER;LUNG NEOPLASMS;PROSPECTIVE STUDIES;YOUNG ADULT;RISK FACTORS;CORONARY ARTERY DISEASE;PROGNOSIS;FOLLOW-UP STUDIES;BREAST NEOPLASMS;STROKE","405;297;292;288;226;212;150;109;107;92;83;66;64;53;52;50;50;47;45;44","MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;MOLECULAR MECHANISMS OF AMYLOIDOSIS;ACUTE MYELOID LEUKEMIA;ATRIAL FIBRILLATION;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;LYMPHOID NEOPLASMS;DIAGNOSIS AND TREATMENT OF LUNG CANCER;MANAGEMENT AND TREATMENT OF HEMOPHILIA;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;CANCER IMMUNOTHERAPY;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;ADVANCEMENTS IN LUNG CANCER RESEARCH;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;SARCOMA RESEARCH AND TREATMENT;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF SYNCOPE","21;20;13;13;12;12;11;11;10;10;10;9;8;8;8;7;7;7;6;6","CLINICAL ENDPOINT;CARDIAC IMAGING;STROKE (ENGINE);TREATMENT;INTERQUARTILE RANGE;CARDIOVASCULAR RISK ASSESSMENT;CORONARY STENTS;ECHOCARDIOGRAPHY;INFARCTION TREATMENT;ATRIAL FIBRILLATION;CONCOMITANT;INTENSITY-MODULATED RADIOTHERAPY;RADIOTHERAPY;REGIMEN;UNIVARIATE ANALYSIS;CARDIAC AMYLOIDOSIS;MYELOFIBROSIS;DISCONTINUATION;DRUG-ELUTING STENTS;HEMATOLOGY","33;28;26;18;16;12;11;11;11;10;10;10;10;10;10;9;9;8;8;8","LUNG CANCER;CANCER PATIENTS;PATIENTS TREATED;ATRIAL FIBRILLATION;HYPERTROPHIC CARDIOMYOPATHY;SYSTEMIC SCLEROSIS;CELL TRANSPLANTATION;ELDERLY PATIENTS;MULTICENTER STUDY;BREAST CANCER;CELL LUNG;COLORECTAL CANCER;MAGNETIC RESONANCE;PHASE II;PROSPECTIVE MULTICENTER;RETROSPECTIVE STUDY;CARDIAC AMYLOIDOSIS;LEFT MAIN;MYELOID LEUKEMIA;OBSERVATIONAL STUDY;STEM CELL;ACUTE MYELOID;CLINICAL OUTCOMES;MULTIPLE MYELOMA;NON-SMALL CELL;ADULT PATIENTS;DOUBLE-BLIND PLACEBO-CONTROLLED;HEART FAILURE;MYELOPROLIFERATIVE NEOPLASMS;PROSPECTIVE STUDY","15;14;14;13;13;13;10;10;10;9;9;9;9;9;9;9;8;8;8;8;8;7;7;7;7;6;6;6;6;6","ADVISORY COMMITTEES;ENTITYS BOARD;RESEARCH FUNDING;SPEAKERS BUREAU;CONSULTANCY HONORARIA;ADVISORY CONSULTANCY;COMMITTEES SPEAKERS;COMMITTEES RESEARCH;HONORARIA MEMBERSHIP;HONORARIA RESEARCH;HR CI;ADVERSE EVENTS;FUNDING SPEAKERS;PATIENTS TREATED;CAREGGI FLORENCE;CONFIDENCE INTERVAL;AZIENDA OSPEDALIERO-UNIVERSITARIA;OSPEDALIERO-UNIVERSITARIA CAREGGI;CLINICAL PRACTICE;RISK FACTORS;FLORENCE ITALYSEARCH;HEART FAILURE;SIGNIFICANT DIFFERENCES;EQUITY OWNERSHIP;MEDIAN AGE;DIAGNOSTIC SENOLOGY;INTERVAL CI;MULTIVARIATE ANALYSIS;SENOLOGY UNIT;UNIT AZIENDA","264;264;219;198;96;70;57;52;50;48;42;41;40;39;35;35;34;34;31;31;28;28;28;27;27;26;26;26;26;26",332,0.47,7.96,10,2,1,0,2,1.75,1,1,10,1,1,10,1,1,2,5,6,5,0,0,54.25,54.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,88,4.71,674.51,10.14,41,0.47,68.28,0,3,16,3,22,0,4,40,0,59,28,0,0,0,0,0,0,82,5,1,86,1,0,1,0,0,0,0,0,0,"United States;Italy;Belgium;Germany;Japan;United Kingdom;France;Serbia;Switzerland","20;8;3;3;3;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;42 HEALTH SCIENCES;3213 PAEDIATRICS;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3215 REPRODUCTIVE MEDICINE;3203 DENTISTRY;3204 IMMUNOLOGY;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS;3212 OPHTHALMOLOGY AND OPTOMETRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4201 ALLIED HEALTH AND REHABILITATION SCIENCE","86;46;29;10;8;8;6;4;2;2;2;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;PATIENT SAFETY;HEMATOLOGY;PREVENTION;DIGESTIVE DISEASES;LUNG;CARDIOVASCULAR;AUTOIMMUNE DISEASE;HEART DISEASE;NUTRITION;AGING;COMPLEMENTARY AND INTEGRATIVE HEALTH;LUNG CANCER;LYMPHOMA;NEUROSCIENCES;GENETICS;PEDIATRIC","83;59;34;26;22;20;15;12;12;11;9;8;8;7;7;7;7;7;6;6","CANCER;CARDIOVASCULAR;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;BLOOD;MENTAL HEALTH;MUSCULOSKELETAL;NEUROLOGICAL;EYE;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;METABOLIC AND ENDOCRINE;RESPIRATORY","26;12;7;4;3;2;2;2;2;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);3.3 NUTRITION AND CHEMOPREVENTION;5.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;6.3 MEDICAL DEVICES;6.4 SURGERY","56;8;5;5;2;2;2;1;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;LIVER CANCER;MYELOMA;PROSTATE CANCER;BREAST CANCER;COLON AND RECTAL CANCER;NOT SITE-SPECIFIC CANCER;BLADDER CANCER;ENDOMETRIAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;KIDNEY CANCER","7;7;6;3;3;3;2;2;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;2.3 INTERACTIONS OF GENES AND/OR GENETIC POLYMORPHISMS WITH EXOGENOUS AND/OR ENDOGENOUS FACTORS;3.2 NUTRITIONAL SCIENCE IN CANCER PREVENTION;3.3 CHEMOPREVENTION;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;6.2 SURVEILLANCE","24;4;2;2;1;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;TAYLOR & FRANCIS GROUP;KARGER PUBLISHERS;SCIELO JOURNALS;SPRINGER NATURE","36;9;3;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;49 MATHEMATICAL SCIENCES;3204 IMMUNOLOGY;3215 REPRODUCTIVE MEDICINE;42 HEALTH SCIENCES;3207 MEDICAL MICROBIOLOGY;4905 STATISTICS;52 PSYCHOLOGY;3107 MICROBIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;38 ECONOMICS;3801 APPLIED ECONOMICS;3101 BIOCHEMISTRY AND CELL BIOLOGY;3105 GENETICS;3211 ONCOLOGY AND CARCINOGENESIS;3213 PAEDIATRICS;40 ENGINEERING;46 INFORMATION AND COMPUTING SCIENCES","58;15;11;11;6;5;5;4;4;4;3;3;3;3;2;2;2;2;2;2","CLINICAL RESEARCH;NEUROSCIENCES;GENETICS;RARE DISEASES;AUTOIMMUNE DISEASE;BRAIN DISORDERS;NEURODEGENERATIVE;PREVENTION;ARTHRITIS;MULTIPLE SCLEROSIS;ANTIMICROBIAL RESISTANCE;CANCER;HEMATOLOGY;VACCINE RELATED;AGING;CONTRACEPTION/REPRODUCTION;HIV/AIDS;INFECTIOUS DISEASES;BASIC BEHAVIORAL AND SOCIAL SCIENCE;BEHAVIORAL AND SOCIAL SCIENCE","10;7;6;6;5;5;5;5;4;4;3;3;3;3;2;2;2;2;1;1","INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;CANCER;CARDIOVASCULAR;NEUROLOGICAL;REPRODUCTIVE HEALTH AND CHILDBIRTH","4;4;2;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.6 PSYCHOLOGICAL AND BEHAVIOURAL;7.1 INDIVIDUAL CARE NEEDS;7.3 MANAGEMENT AND DECISION MAKING","5;4;3;1;1;1;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS","11;6;2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","21;4;1","LEUKEMIA / LEUKAEMIA;LIVER CANCER;LUNG CANCER;NON-HODGKIN'S LYMPHOMA","1;1;1;1","3 GOOD HEALTH AND WELL BEING;4 QUALITY EDUCATION","5;1"
"AOU_CAREGGI",2020,928,15.176724137931,3.18211206896552,0.330818965517241,0.337284482758621,0.405172413793103,2.57903930131004,1.51980198019802,2.1006711409396,1.56666666666667,0.582974137931034,6,452,215,98,39,0.49,0.23,0.11,0.04,19.7,0.781893135636395,5.90500252652857,0.311422413793103,0.875,0.527,0.439,0.471,0.452,"IACOPO OLIVOTTO;LORENZO LIVI;CARLO DI MARIO;ANDREA MINERVINI;ISACCO DESIDERI;NICCOLÒ MARCHIONNI;ALESSANDRO BARTOLONI;LORENZO ANTONUZZO;MARCO MATUCCI‐CERINIC;PIERLUIGI STEFÀNO;GIAN MARÍA ROSSOLINI;PIERLUIGI BONOMO;ALESSANDRO M. VANNUCCHI;VITTORIO MIELE;ICRO MEATTINI;LORENZO TOFANI;ORESTE GALLO;COSIMO BRUNI;ANDREA MARI;LUCA GIOVANNI LOCATELLO","47;35;28;25;25;23;23;22;21;21;20;20;19;19;19;17;17;17;17;16","MAURIZIO SALVADORI;ARIS TSALOUCHOS;IACOPO OLIVOTTO;VALENTINA SCHEGGI;PIERLUIGI STEFÀNO;CARLO DI MARIO;LUCA GIOVANNI LOCATELLO;ORESTE GALLO;LORENZO LIVI;VITTORIO MIELE;NICCOLÒ MARCHIONNI;ISACCO DESIDERI;GIANCARLO CASTAMAN;STANISLAO RIZZO;GIAN MARÍA ROSSOLINI;ALESSANDRO BARTOLONI;FABIO CIANCHI;FABRIZIO GIANSANTI;MARCO MATUCCI‐CERINIC;ADRIANO PERIS","6.5;5.5;4.27;3.58;3.1;2.88;2.75;2.72;2.65;2.4;2.35;1.95;1.94;1.92;1.91;1.85;1.82;1.82;1.78;1.77","IACOPO OLIVOTTO;LORENZO LIVI;CARLO DI MARIO;ANDREA MINERVINI;ISACCO DESIDERI;NICCOLÒ MARCHIONNI;ALESSANDRO BARTOLONI;LORENZO ANTONUZZO;MARCO MATUCCI‐CERINIC;PIERLUIGI STEFÀNO;GIAN MARÍA ROSSOLINI;PIERLUIGI BONOMO;ALESSANDRO M. VANNUCCHI;VITTORIO MIELE;ICRO MEATTINI;LORENZO TOFANI;ORESTE GALLO;COSIMO BRUNI;ANDREA MARI;LUCA GIOVANNI LOCATELLO","47;35;28;25;25;23;23;22;21;21;20;20;19;19;19;17;17;17;17;16","MAURIZIO SALVADORI;IACOPO OLIVOTTO;VALENTINA SCHEGGI;PIERLUIGI STEFÀNO;CARLO DI MARIO;LUCA GIOVANNI LOCATELLO;ORESTE GALLO;LORENZO LIVI;VITTORIO MIELE;NICCOLÒ MARCHIONNI;ISACCO DESIDERI;GIANCARLO CASTAMAN;STANISLAO RIZZO;GIAN MARÍA ROSSOLINI;ALESSANDRO BARTOLONI;FABIO CIANCHI;FABRIZIO GIANSANTI;MARCO MATUCCI‐CERINIC;ADRIANO PERIS;LORENZO ANTONUZZO","6.5;4.27;3.58;3.1;2.88;2.75;2.72;2.65;2.4;2.35;1.95;1.94;1.92;1.91;1.85;1.82;1.82;1.78;1.77;1.76","IACOPO OLIVOTTO;MARIA ROSARIA RASPOLLINI;ALEXANDRA TAYLOR;ALINA STURDZA;ANNA FAGOTTI;ANNEKE M. WESTERMANN;ANTONIO GONZÁLEZ-MARTÍN;CARIEN L. CREUTZBERG;CHRISTIAN MARTH;CHRISTINA FOTOPOULOU;CYRUS CHARGARI;D. O’DONNELL;DAVID CIBULA;DENIS QUERLEU;DOMENICA LORUSSO;FRANÇOIS PLANCHAMP;IGNACE VERGOTE;JALID SEHOULI;JONATHAN A. LEDERMANN;MANSOOR RAZA MIRZA","1469;1311;1168;1168;1168;1168;1168;1168;1168;1168;1168;1168;1168;1168;1168;1168;1168;1168;1168;1168","MARIA ROSARIA RASPOLLINI;IACOPO OLIVOTTO;VIERI SCOTTI;VITTORIO MIELE;OMBRETTA PARA;LORENZO LIVI;ALESSANDRO M. VANNUCCHI;LUCA VOLTOLINI;ALESSANDRO BARTOLONI;ICRO MEATTINI;SARA TOMASSETTI;FILIPPO PIERALLI;LORENZO ANTONUZZO;ADRIANO PERIS;PIERLUIGI BONOMO;VALERIA SANTINI;ISACCO DESIDERI;DILETTA COZZI;L. MARRAZZO;GIAN MARÍA ROSSOLINI","1311;1222;1089;812;728;712;622;616;606;579;514;512;509;500;495;493;473;425;411;405","IACOPO OLIVOTTO;LORENZO LIVI;CARLO DI MARIO;LORENZO ANTONUZZO;PIERLUIGI STEFÀNO;VITTORIO MIELE;PIERLUIGI BONOMO;NICCOLÒ MARCHIONNI;ALESSANDRO BARTOLONI;ADRIANO PERIS;ALESSANDRO M. VANNUCCHI;ISACCO DESIDERI;ICRO MEATTINI;VALERIA SANTINI;LUCA GIOVANNI LOCATELLO;GIANCARLO CASTAMAN;GIAN MARÍA ROSSOLINI;ORESTE GALLO;ANDREA CORATTI;ANDREA MARI","42;31;25;22;20;20;19;19;18;17;17;17;16;16;15;15;15;15;15;15","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;CHEMISTRY;PSYCHOLOGY;MATHEMATICS;SOCIOLOGY;ECONOMICS;POLITICAL SCIENCE;PHILOSOPHY;BUSINESS;MATERIALS SCIENCE;GEOGRAPHY;HISTORY;ART;ENVIRONMENTAL SCIENCE;GEOLOGY","899;190;77;59;58;43;36;35;35;33;24;15;12;11;5;5;3;3;2","INTERNAL MEDICINE;SURGERY;PATHOLOGY;CARDIOLOGY;ONCOLOGY;RADIOLOGY;GENETICS;INTENSIVE CARE MEDICINE;IMMUNOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;PSYCHIATRY;PEDIATRICS;VIROLOGY;NURSING;OPTICS;NUCLEAR MEDICINE;ENDOCRINOLOGY;ANESTHESIA;BIOCHEMISTRY;EMERGENCY MEDICINE","695;286;174;156;127;125;93;92;91;90;90;72;54;54;49;44;43;42;41;40;40","DISEASE;CANCER;POPULATION;COHORT;HEART FAILURE;CONFIDENCE INTERVAL;CLINICAL TRIAL;RANDOMIZED CONTROLLED TRIAL;GENE;RETROSPECTIVE COHORT STUDY;OUTBREAK;ADVERSE EFFECT;RADIATION THERAPY;CHEMOTHERAPY;ALTERNATIVE MEDICINE;ATRIAL FIBRILLATION;MYOCARDIAL INFARCTION;BONE MARROW;INCIDENCE (GEOMETRY);PREGNANCY;TRANSPLANTATION","163;139;85;70;67;61;53;53;52;51;50;45;45;43;42;36;36;34;30;29;29","INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;2019-20 CORONAVIRUS OUTBREAK;HAZARD RATIO;CARDIOMYOPATHY;BREAST CANCER;COLORECTAL CANCER;EJECTION FRACTION;METASTASIS;PLACEBO;MYELODYSPLASTIC SYNDROMES;MUTATION;MYELOFIBROSIS;PERCUTANEOUS CORONARY INTERVENTION;PHASES OF CLINICAL RESEARCH;IMMUNOTHERAPY;UNIVARIATE ANALYSIS;PROSTATE CANCER;ESCHERICHIA COLI;HEAD AND NECK CANCER;NEPHRECTOMY;NEURORADIOLOGY","95;42;40;33;32;31;30;28;22;21;20;18;17;15;15;14;14;12;11;11;11;11","CORONAVIRUS DISEASE 2019 (COVID-19);INTERNATIONAL PROGNOSTIC SCORING SYSTEM;RUXOLITINIB;KLEBSIELLA PNEUMONIAE;OXALIPLATIN;ANTIRETROVIRAL THERAPY;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;IRINOTECAN;KRAS;PEMBROLIZUMAB;CEFTAZIDIME;COGNITIVE DECLINE;MASTECTOMY;PROSTATECTOMY;ANDROGEN DEPRIVATION THERAPY;DIFFUSING CAPACITY;FOCAL SEGMENTAL GLOMERULOSCLEROSIS;GERMLINE MUTATION;METASTATIC BREAST CANCER;MISSENSE MUTATION;NIVOLUMAB;STROKE VOLUME","95;10;10;9;9;7;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;RETROSPECTIVE STUDIES;ITALY;COVID-19;TREATMENT OUTCOME;AGED, 80 AND OVER;PNEUMONIA, VIRAL;PROSPECTIVE STUDIES;CORONAVIRUS INFECTIONS;YOUNG ADULT;BREAST NEOPLASMS;RISK FACTORS;ADOLESCENT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS","529;392;229;216;180;166;121;112;111;78;77;63;62;59;58;46;41;41;39;39","CORONAVIRUS DISEASE 2019;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;ACUTE MYELOID LEUKEMIA;ATRIAL FIBRILLATION;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;MANAGEMENT OF VALVULAR HEART DISEASE;RENAL CELL CARCINOMA;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MOLECULAR MECHANISMS OF AMYLOIDOSIS;PANCREATIC CANCER RESEARCH AND TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;DIAGNOSIS AND MANAGEMENT OF CARDIAC TUMORS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;RADIOTHERAPY PHYSICS AND TECHNOLOGY;SARCOMA RESEARCH AND TREATMENT","29;27;25;16;16;16;13;13;13;10;10;10;10;9;9;8;8;8;8;8","PANDEMIC;CLINICAL ENDPOINT;2019-20 CORONAVIRUS OUTBREAK;CARDIAC IMAGING;TREATMENT;STROKE (ENGINE);CONCOMITANT;RADIOTHERAPY;ECHOCARDIOGRAPHY;UNIVARIATE ANALYSIS;ATRIAL FIBRILLATION;DILATED CARDIOMYOPATHY;TRANSCATHETER AORTIC-VALVE REPLACEMENT;TRANSFUSION THERAPY;CLINICAL CHARACTERISTICS;INFARCTION TREATMENT;NEURORADIOLOGY;PROSTHETIC VALVES EVALUATION;REFRACTORY (PLANETARY SCIENCE);CORONAVIRUS","53;44;39;36;31;27;20;17;14;14;13;13;13;12;11;11;11;11;11;10","HYPERTROPHIC CARDIOMYOPATHY;BREAST CANCER;ATRIAL FIBRILLATION;COVID- PANDEMIC;LUNG CANCER;PATIENTS TREATED;CANCER PATIENTS;MULTIPLE SCLEROSIS;COLORECTAL CANCER;MULTICENTER STUDY;CELL CARCINOMA;CELL LUNG;COHORT STUDY;COVID- PATIENTS;ELDERLY PATIENTS;SYSTEMIC SCLEROSIS;CLINICAL ONCOLOGY;CORONAVIRUS DISEASE;LEFT ATRIAL;MYELODYSPLASTIC SYNDROMES;PATIENTS PTS;PHASE III;RADIATION THERAPY;ACUTE MYELOID;EUROPEAN SOCIETY;ITALIAN ASSOCIATION;LEFT MAIN;LEFT VENTRICULAR;METASTATIC COLORECTAL;MINIMALLY INVASIVE","21;17;16;16;13;13;12;12;11;11;10;10;10;10;10;9;8;8;8;8;8;8;8;7;7;7;7;7;7;7","RESEARCH FUNDING;SPEAKERS BUREAU;ADVISORY COMMITTEES;ENTITYS BOARD;CONSULTANCY HONORARIA;HONORARIA RESEARCH;PATIENTS TREATED;ADVERSE EVENTS;HR CI;LEFT VENTRICULAR;CONSULTANCY MEMBERSHIP;CONSULTANCY RESEARCH;CURRENT EMPLOYMENT;MEDIAN AGE;CONFIDENCE INTERVAL;COVID- PATIENTS;FLORENCE ITALYSEARCH;INTENSIVE CARE;CLINICAL PRACTICE;FLORENCE ITALY;FUNDING SPEAKERS;HONORARIA MEMBERSHIP;PUBMED SCOPUS;COMMITTEES RESEARCH;HEART FAILURE;ACUTE RESPIRATORY;COVID- PANDEMIC;COMMITTEES SPEAKERS;ODDS RATIO;PRIMARY ENDPOINT","264;145;131;131;122;77;57;53;53;51;48;42;39;38;36;36;36;33;32;32;32;32;32;30;30;29;29;28;28;28",439,0.47,7.57,9,1,1,0,2,4.25,1,1,10,1,1,9,2.25,1,2,3,7,4,0,0,49,48.5,2,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,4,0.27,2,1,2,2,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BELTRAMI GIOVANNI;BOGANI PATRIZIA;DEL DUCA SARA;FANI RENATO;FIRENZUOLI FABIO;GALLO EUGENIA ROSARIA;MAGGINI VALENTINA;MENGONI ALESSIO","1;1;1;1;1;1;1;1","ADLER ORTHO SPA;AZIENDA OSPEDALIERO UNIV CAREGGI;AZIENDA OSPEDALIERO UNIVERSITARIA CAREGGI;UNIVERSITÀ DEGLI STUDI DI FIRENZE","1;1;1;1","40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","2;1","STEM CELL RESEARCH;TRANSPLANTATION","1;1",NA,NA,"A61F2/28","1","A61F2/28;A61F2/34;A61F2002/2835;A61F2002/30578;A61F2002/3082;C12Q1/6895","1;1;1;1;1;1",97,3.96,1105.9,9.67,59,0.61,76.33,0,1,15,1,35,0,2,43,0,59,38,0,0,0,0,0,0,90,1,6,97,0,0,0,0,0,0,0,0,0,"Italy;United States;Germany;Japan;Switzerland;Belgium;Denmark;Canada","24;18;3;3;3;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3212 OPHTHALMOLOGY AND OPTOMETRY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;3204 IMMUNOLOGY;3206 MEDICAL BIOTECHNOLOGY;3213 PAEDIATRICS;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3207 MEDICAL MICROBIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4205 NURSING","94;58;30;7;4;4;4;4;2;2;2;2;2;2;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;CANCER;PATIENT SAFETY;HEMATOLOGY;LUNG;PREVENTION;NEUROSCIENCES;CARDIOVASCULAR;DIGESTIVE DISEASES;HEART DISEASE;AGING;INFECTIOUS DISEASES;LUNG CANCER;NEURODEGENERATIVE;UROLOGIC DISEASES;BIOMEDICAL IMAGING;BRAIN DISORDERS;EMERGING INFECTIOUS DISEASES","91;56;35;34;25;15;14;14;12;10;10;10;8;8;8;7;7;6;6;6","CANCER;CARDIOVASCULAR;INFECTION;EYE;NEUROLOGICAL;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL;BLOOD;INFLAMMATORY AND IMMUNE SYSTEM;INJURIES AND ACCIDENTS;MENTAL HEALTH;METABOLIC AND ENDOCRINE;REPRODUCTIVE HEALTH AND CHILDBIRTH;STROKE","26;8;5;4;4;3;2;1;1;1;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS;2.4 SURVEILLANCE AND DISTRIBUTION;5.2 CELLULAR AND GENE THERAPIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.3 MANAGEMENT AND DECISION MAKING;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;5.3 MEDICAL DEVICES;6.3 MEDICAL DEVICES;8.1 ORGANISATION AND DELIVERY OF SERVICES","51;7;7;4;3;3;3;3;2;2;2;2;1;1;1;1","LUNG CANCER;LEUKEMIA / LEUKAEMIA;BLADDER CANCER;NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER;PROSTATE CANCER;BRAIN TUMOR;KIDNEY CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;BREAST CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;LIVER CANCER;NOT SITE-SPECIFIC CANCER;PANCREATIC CANCER;SALIVARY GLAND CANCER;SARCOMA;STOMACH CANCER","9;5;4;4;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;1.4 CANCER PROGRESSION AND METASTASIS;3.3 CHEMOPREVENTION;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;6.2 SURVEILLANCE","23;5;3;2;2;2;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,35,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE;ZENODO;SPRINGER NATURE;AMERICAN ASSOCIATION FOR CANCER RESEARCH;KARGER PUBLISHERS","10;10;8;5;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE;3101 BIOCHEMISTRY AND CELL BIOLOGY;3105 GENETICS;3107 MICROBIOLOGY;42 HEALTH SCIENCES;52 PSYCHOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3213 PAEDIATRICS;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;38 ECONOMICS;3801 APPLIED ECONOMICS;4203 HEALTH SERVICES AND SYSTEMS;4204 MIDWIFERY","46;16;11;7;5;3;3;3;3;3;2;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;PATIENT SAFETY;CANCER;RARE DISEASES;GENETICS;VACCINE RELATED;CARDIOVASCULAR;HEART DISEASE;HUMAN GENOME;NEUROSCIENCES;PREVENTION;ANTIMICROBIAL RESISTANCE;BIODEFENSE;BRAIN DISORDERS;EMERGING INFECTIOUS DISEASES;HEMATOLOGY;INFECTIOUS DISEASES;BRAIN CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;LUNG","15;7;6;6;5;5;4;4;4;4;4;3;3;3;3;3;3;2;2;2","CANCER;CARDIOVASCULAR;REPRODUCTIVE HEALTH AND CHILDBIRTH;INFECTION;GENERIC HEALTH RELEVANCE;NEUROLOGICAL","6;4;3;2;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;6.1 PHARMACEUTICALS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.4 SURVEILLANCE AND DISTRIBUTION;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.2 CELLULAR AND GENE THERAPIES","7;4;4;2;1;1;1;1;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS","14;4;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;HEALTH SERVICES RESEARCH;PUBLIC HEALTH","16;6;2;1","BLADDER CANCER;BRAIN TUMOR;LEUKEMIA / LEUKAEMIA;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;RETINOBLASTOMA","2;2;1;1;1;1;1;1","3 GOOD HEALTH AND WELL BEING","2"
"AOU_CAREGGI",2021,996,17.1526104417671,3.09437751004016,0.320281124497992,0.300200803212851,0.38855421686747,2.76999101527403,1.62755102040816,2.15107913669065,1.5668016194332,0.70281124497992,5,449,227,94,57,0.45,0.23,0.09,0.06,15.55,1.00859243033487,6.32101717018043,0.349397590361446,0.922690763052209,0.514,0.439,0.472,0.479,"IACOPO OLIVOTTO;ALESSANDRO M. VANNUCCHI;CARLO DI MARIO;NICCOLÒ MARCHIONNI;VITTORIO MIELE;ALESSANDRO BARTOLONI;LORENZO ANTONUZZO;LORENZO LIVI;GIAN MARÍA ROSSOLINI;MARCO MATUCCI‐CERINIC;ANDREA MINERVINI;ANDREA UNGAR;PIERLUIGI STEFÀNO;FRANCESCO CAPPELLI;PAOLA GUGLIELMELLI;ISACCO DESIDERI;CARLO FUMAGALLI;GIANCARLO CASTAMAN;SARA TOMASSETTI;FRANCESCA MAZZONI","53;41;34;33;32;31;28;27;26;22;22;21;21;21;19;18;18;17;17;17","IACOPO OLIVOTTO;NICCOLÒ MARCHIONNI;PIERLUIGI STEFÀNO;CARLO DI MARIO;VALENTINA SCHEGGI;MARCO INNOCENTI;ALESSANDRO M. VANNUCCHI;VITTORIO MIELE;GIAN MARÍA ROSSOLINI;ALESSANDRO BARTOLONI;LORENZO ANTONUZZO;RENATO VALENTI;ANDREA UNGAR;ANDREA MINERVINI;LORENZO LIVI;FRANCESCO CAPPELLI;MARCO MATUCCI‐CERINIC;CARLO FUMAGALLI;MARCO ALLINOVI;ALESSANDRO INNOCENTI","4.29;4.13;3.46;3.25;2.85;2.81;2.58;2.42;2.42;2.25;1.96;1.88;1.86;1.85;1.77;1.75;1.73;1.67;1.62;1.58","IACOPO OLIVOTTO;ALESSANDRO M. VANNUCCHI;CARLO DI MARIO;NICCOLÒ MARCHIONNI;VITTORIO MIELE;ALESSANDRO BARTOLONI;LORENZO ANTONUZZO;LORENZO LIVI;GIAN MARÍA ROSSOLINI;MARCO MATUCCI‐CERINIC;ANDREA MINERVINI;ANDREA UNGAR;PIERLUIGI STEFÀNO;FRANCESCO CAPPELLI;PAOLA GUGLIELMELLI;ISACCO DESIDERI;CARLO FUMAGALLI;GIANCARLO CASTAMAN;SARA TOMASSETTI;FRANCESCA MAZZONI","53;41;34;33;32;31;28;27;26;22;22;21;21;21;19;18;18;17;17;17","IACOPO OLIVOTTO;NICCOLÒ MARCHIONNI;PIERLUIGI STEFÀNO;CARLO DI MARIO;VALENTINA SCHEGGI;MARCO INNOCENTI;ALESSANDRO M. VANNUCCHI;VITTORIO MIELE;GIAN MARÍA ROSSOLINI;ALESSANDRO BARTOLONI;LORENZO ANTONUZZO;RENATO VALENTI;ANDREA UNGAR;ANDREA MINERVINI;LORENZO LIVI;FRANCESCO CAPPELLI;MARCO MATUCCI‐CERINIC;CARLO FUMAGALLI;MARCO ALLINOVI;ALESSANDRO INNOCENTI","4.29;4.13;3.46;3.25;2.85;2.81;2.58;2.42;2.42;2.25;1.96;1.88;1.86;1.85;1.77;1.75;1.73;1.67;1.62;1.58","IACOPO OLIVOTTO;SILVIA GASPERONI;ANGELO PAOLO DEI TOS;GIOVANNI GRIGNANI;MARIA A. PANTALEO;CLAUDIA SANGALLI;ALESSANDRO GRONCHI;AXEL LE CESNE;HANS GELDERBLOM;HEIKKI JOENSUU;JAVIER MARTÍN‐BROTO;JEAN‐YVES BLAY;MARTA SBARAGLIA;NADIA HINDI;OLIVIER MIR;PAOLO G. CASALI;PETER HOHENBERGER;PETER REICHARDT;PIOTR RUTKOWSKI;ROBIN L. JONES","1220;1164;1146;1146;1146;1139;1133;1133;1133;1133;1133;1133;1133;1133;1133;1133;1133;1133;1133;1133","IACOPO OLIVOTTO;SILVIA GASPERONI;ALESSANDRO M. VANNUCCHI;VITTORIO MIELE;ALESSANDRO BARTOLONI;FRANCESCO MAZZAROTTO;PAOLA GUGLIELMELLI;ANNA MARIA REPICE;CARLO DI MARIO;FRANCESCA MAZZONI;LEONARDO RENIERI;RICCARDO SACCARDI;LORENZO LIVI;DILETTA COZZI;LORENZO ANTONUZZO;FRANCESCO ANNUNZIATO;PEIMAN NAZERIAN;GIAN MARÍA ROSSOLINI;ANDREA MINERVINI;SERENA PILLOZZI","1197;1164;745;666;635;462;457;455;426;408;354;354;339;325;315;278;270;254;230;229","IACOPO OLIVOTTO;ALESSANDRO M. VANNUCCHI;VITTORIO MIELE;CARLO DI MARIO;NICCOLÒ MARCHIONNI;ALESSANDRO BARTOLONI;LORENZO ANTONUZZO;ANDREA MINERVINI;PIERLUIGI STEFÀNO;LORENZO LIVI;FRANCESCO CAPPELLI;ANDREA UNGAR;FRANCESCA MAZZONI;VALENTINA SCHEGGI;PAOLA GUGLIELMELLI;CARLO FUMAGALLI;GIANCARLO CASTAMAN;DILETTA COZZI;SARA TOMASSETTI;ANDREA MARI","53;37;35;34;29;26;24;20;19;19;18;17;16;16;15;15;15;14;14;14","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;PSYCHOLOGY;CHEMISTRY;MATHEMATICS;ECONOMICS;SOCIOLOGY;POLITICAL SCIENCE;PHILOSOPHY;MATERIALS SCIENCE;BUSINESS;HISTORY;GEOGRAPHY;GEOLOGY;ART;ENVIRONMENTAL SCIENCE","975;214;88;84;54;48;43;40;38;32;31;16;11;9;6;4;4;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;CARDIOLOGY;RADIOLOGY;ONCOLOGY;GENETICS;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;IMMUNOLOGY;INTENSIVE CARE MEDICINE;PSYCHIATRY;PEDIATRICS;OPTICS;BIOCHEMISTRY;PALEONTOLOGY;PHYSICAL THERAPY;NUCLEAR MEDICINE;VIROLOGY;EMERGENCY MEDICINE;MECHANICAL ENGINEERING","770;303;160;158;143;140;106;105;102;97;89;88;87;61;55;55;50;47;46;44;44","DISEASE;CANCER;POPULATION;COHORT;RETROSPECTIVE COHORT STUDY;GENE;HEART FAILURE;ADVERSE EFFECT;CHEMOTHERAPY;OBSERVATIONAL STUDY;INCIDENCE (GEOMETRY);CLINICAL TRIAL;CONFIDENCE INTERVAL;MYOCARDIAL INFARCTION;OUTBREAK;RADIATION THERAPY;LUNG;PROSPECTIVE COHORT STUDY;STROKE (ENGINE);HYPERTROPHIC CARDIOMYOPATHY","208;149;102;78;76;74;69;57;55;51;50;49;47;47;46;46;45;41;38;36","INFECTIOUS DISEASE (MEDICAL SPECIALTY);2019-20 CORONAVIRUS OUTBREAK;BREAST CANCER;CARDIOMYOPATHY;CLINICAL ENDPOINT;IMMUNOTHERAPY;COLORECTAL CANCER;HAZARD RATIO;MYELOFIBROSIS;EJECTION FRACTION;UNIVARIATE ANALYSIS;PERCUTANEOUS CORONARY INTERVENTION;MUTATION;PROSTATE CANCER;RITUXIMAB;INFLAMMATORY BOWEL DISEASE;GENOTYPE;PHENOTYPE;HEART RATE;ALLELE;CHRONIC LYMPHOCYTIC LEUKEMIA;CONVENTIONAL PCI;CRONBACH'S ALPHA;DEMENTIA;ESSENTIAL THROMBOCYTHEMIA;GESTATIONAL AGE;PHASES OF CLINICAL RESEARCH;TOLERABILITY","115;39;32;31;31;28;25;25;22;18;18;17;16;16;15;14;13;13;12;11;11;11;11;11;11;11;11;11","CORONAVIRUS DISEASE 2019 (COVID-19);RUXOLITINIB;PEMBROLIZUMAB;NIVOLUMAB;IPILIMUMAB;MODIFIED RANKIN SCALE;MACE;METASTATIC BREAST CANCER;STROKE VOLUME;KLEBSIELLA PNEUMONIAE;MISSENSE MUTATION;OXALIPLATIN;PROSTATECTOMY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;VENETOCLAX;ANDROGEN DEPRIVATION THERAPY;ANTIRETROVIRAL THERAPY;BENDAMUSTINE;BREAST RECONSTRUCTION;COGNITIVE DECLINE;ECULIZUMAB;FEBRILE NEUTROPENIA;GROUND-GLASS OPACITY;INFLAMMATORY BOWEL DISEASES;IRINOTECAN;MICROARRAY;MYELOPROLIFERATIVE NEOPLASM;PRENATAL DIAGNOSIS;SINGLE-NUCLEOTIDE POLYMORPHISM;USUAL INTERSTITIAL PNEUMONIA;VEDOLIZUMAB","114;12;11;9;7;7;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4",";HUMANS;FEMALE;MALE;COVID-19;RETROSPECTIVE STUDIES;MIDDLE AGED;AGED;ADULT;ITALY;TREATMENT OUTCOME;SARS-COV-2;AGED, 80 AND OVER;PROSPECTIVE STUDIES;PROGNOSIS;CARDIOMYOPATHY, HYPERTROPHIC;LUNG NEOPLASMS;RISK FACTORS;STROKE;POSTOPERATIVE COMPLICATIONS","513;478;192;169;148;132;127;121;109;103;79;67;59;59;44;40;39;39;39;38","DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;MOLECULAR MECHANISMS OF AMYLOIDOSIS;CANCER IMMUNOTHERAPY;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MANAGEMENT OF VALVULAR HEART DISEASE;ACUTE MYELOID LEUKEMIA;CORONAVIRUS DISEASE 2019;ATRIAL FIBRILLATION;RENAL CELL CARCINOMA;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;LYMPHOID NEOPLASMS;PANCREATIC CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF LUNG CANCER;RADIOMICS IN MEDICAL IMAGING ANALYSIS;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT","26;24;22;18;16;15;14;14;14;13;13;12;12;12;11;11;10;10;9;9","PANDEMIC;2019-20 CORONAVIRUS OUTBREAK;STROKE (ENGINE);CLINICAL ENDPOINT;CARDIAC IMAGING;TREATMENT;INTERQUARTILE RANGE;REGIMEN;UNIVARIATE ANALYSIS;CONCOMITANT;DISCONTINUATION;TRANSCATHETER AORTIC-VALVE REPLACEMENT;ECHOCARDIOGRAPHY;CARDIAC AMYLOIDOSIS;MYELOFIBROSIS;RADIOTHERAPY;CARDIAC ULTRASOUND;PROSTHETIC VALVES EVALUATION;CONCORDANCE;MICROSURGICAL RECONSTRUCTION","43;41;37;32;30;29;22;18;18;17;17;16;15;14;14;14;13;13;12;12","HYPERTROPHIC CARDIOMYOPATHY;MULTICENTER STUDY;LUNG CANCER;COVID- PANDEMIC;BREAST CANCER;CANCER PATIENTS;OBSERVATIONAL STUDY;RETROSPECTIVE STUDY;INTERSTITIAL LUNG;MULTIPLE SCLEROSIS;PROSTATE CANCER;SYSTEMIC SCLEROSIS;COLORECTAL CANCER;CELL LUNG;CLINICAL PRACTICE;COVID- PNEUMONIA;EMERGENCY DEPARTMENT;PILOT STUDY;RADIATION THERAPY;RISK FACTORS;AORTIC VALVE;CARDIAC AMYLOIDOSIS;COMPUTED TOMOGRAPHY;INFLAMMATORY BOWEL;PATIENTS TREATED;ATRIAL FIBRILLATION;CELL CARCINOMA;COVID- PATIENTS;HEART FAILURE;LUNG ULTRASOUND","32;20;18;15;14;14;14;14;12;12;12;12;11;10;10;10;10;10;10;10;9;9;9;9;9;8;8;8;8;8","ADVISORY COMMITTEES;ENTITYS BOARD;RESEARCH FUNDING;SPEAKERS BUREAU;PUBMED SCOPUS;HR CI;PATIENTS TREATED;HONORARIA MEMBERSHIP;RISK FACTORS;CLINICAL PRACTICE;COMMITTEES SPEAKERS;MEDIAN AGE;COVID- PATIENTS;COMMITTEES RESEARCH;CONSULTANCY HONORARIA;ADVERSE EVENTS;COVID- PNEUMONIA;PERSONAL FEES;CONSULTANCY MEMBERSHIP;COVID- PANDEMIC;HEART FAILURE;LEFT VENTRICULAR;CONSULTANCY RESEARCH;MULTIVARIATE ANALYSIS;HYPERTROPHIC CARDIOMYOPATHY;MEDIAN FOLLOW-UP;PERONEAL TUBERCLE;STATISTICALLY SIGNIFICANT;LOGISTIC REGRESSION;PATIENTS ADMITTED","298;298;255;157;93;82;76;67;61;60;59;55;53;52;50;48;48;47;46;45;44;44;43;41;39;39;39;37;36;35",506,0.51,10.63,11.75,1,1,0,2,1,1,1,14,1,1,12,1.25,2,2,4,8,4,0,0,37,37,2,0,0,2,0,1,0,0,0,0,0,0,1,1,1,0,3.66666666666667,0.36,3.33333333333333,1,3,3,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BARIA ENRICO;CICCHI RICCARDO;GACCI MAURO;MORSELLI SIMONE;PAVONE FRANCESCO SAVERIO;BELTRAMI GIOVANNI","2;2;2;2;2;1","AOUC AZIENDA OSPEDALIERO UNIV CAREGGI;CONSIGLIO NAZIONALE RICERCHE;LENS;UNIV DEGLI STUDI DI FIRENZE;ADLER ORTHO SPA;AZIENDA OSPEDALIERO UNIVERSITARIA CAREGGI","2;2;2;2;1;1","34 CHEMICAL SCIENCES;3401 ANALYTICAL CHEMISTRY","2;1",NA,NA,"4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","1","A61B5/00;A61F2/28;G01J;G01J3/02;G01J3/10;G01J3/28;G01J3/44;G01N21/00","1;1;1;1;1;1;1;1","A61B2503/42;A61B5/0071;A61B5/0075;A61B5/7267;G01J2003/102;G01J2003/106;G01J2003/283;G01J2003/2836;G01J2003/284;G01J3/021","2;2;2;2;2;2;2;2;2;2",92,3.86,568.53,9.47,46,0.5,80.16,1,3,16,3,36,0,1,32,0,70,22,0,0,0,0,0,0,85,5,2,92,0,0,0,0,0,0,0,0,0,"United States;Italy;Germany;Japan;Switzerland;United Kingdom;Netherlands;Saudi Arabia;Sweden","32;13;3;3;2;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3204 IMMUNOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3213 PAEDIATRICS;3215 REPRODUCTIVE MEDICINE;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;3101 BIOCHEMISTRY AND CELL BIOLOGY;3203 DENTISTRY;3207 MEDICAL MICROBIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;40 ENGINEERING","88;49;28;8;6;6;6;3;3;3;3;3;2;2;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;PATIENT SAFETY;HEMATOLOGY;PREVENTION;CARDIOVASCULAR;LUNG;HEART DISEASE;AGING;BRAIN DISORDERS;BIOENGINEERING;LYMPHOMA;NEURODEGENERATIVE;NEUROSCIENCES;PEDIATRIC;UROLOGIC DISEASES;AUTOIMMUNE DISEASE;BIOMEDICAL IMAGING","88;64;34;27;23;19;14;12;10;9;8;8;7;7;7;7;7;7;6;6","CANCER;CARDIOVASCULAR;REPRODUCTIVE HEALTH AND CHILDBIRTH;INFLAMMATORY AND IMMUNE SYSTEM;EYE;INFECTION;NEUROLOGICAL;RESPIRATORY;SKIN;MENTAL HEALTH;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL;STROKE","27;7;5;4;3;3;2;2;2;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.3 MEDICAL DEVICES;7.3 MANAGEMENT AND DECISION MAKING","61;13;7;5;4;2;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;BLADDER CANCER;LUNG CANCER;MYELOMA;HEAD AND NECK CANCER;KIDNEY CANCER;LARYNGEAL CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;PROSTATE CANCER;SALIVARY GLAND CANCER;LIVER CANCER;NOT SITE-SPECIFIC CANCER;SARCOMA","9;9;5;3;3;3;2;2;2;2;2;2;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.1 LOCALIZED THERAPIES - DISCOVERY AND DEVELOPMENT","24;5;5;2;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE;ZENODO;KARGER PUBLISHERS;SAGE JOURNALS;TAYLOR & FRANCIS GROUP;UNIVERSITY OF LEICESTER","22;18;12;3;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS;34 CHEMICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;44 HUMAN SOCIETY;3215 REPRODUCTIVE MEDICINE;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;4403 DEMOGRAPHY;49 MATHEMATICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3213 PAEDIATRICS;3401 ANALYTICAL CHEMISTRY;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;4205 NURSING;4206 PUBLIC HEALTH","91;29;9;9;5;4;4;4;3;2;2;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;BRAIN DISORDERS;CANCER;CARDIOVASCULAR;BIOMEDICAL IMAGING;NEUROSCIENCES;STROKE;HEART DISEASE;DIGESTIVE DISEASES;RARE DISEASES;KIDNEY DISEASE;PATIENT SAFETY;AGING;HEMATOLOGY;PEDIATRIC;LUNG;ATHEROSCLEROSIS;BEHAVIORAL AND SOCIAL SCIENCE;BRAIN CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES","19;12;12;10;9;9;8;7;6;6;5;5;4;4;4;3;2;2;2;2","CANCER;CARDIOVASCULAR;STROKE;RENAL AND UROGENITAL;BLOOD;INFECTION;INJURIES AND ACCIDENTS;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY","8;8;8;4;1;1;1;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;2.4 SURVEILLANCE AND DISTRIBUTION;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;7.1 INDIVIDUAL CARE NEEDS;7.3 MANAGEMENT AND DECISION MAKING","5;5;4;2;1;1;1;1;1;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS","22;4;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;HEALTH SERVICES RESEARCH","37;2;1","COLON AND RECTAL CANCER;BRAIN TUMOR;CERVICAL CANCER;HEAD AND NECK CANCER;KIDNEY CANCER;LEUKEMIA / LEUKAEMIA;NOT SITE-SPECIFIC CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER;BLADDER CANCER;LIVER CANCER;PROSTATE CANCER;SARCOMA","3;2;2;2;2;2;2;2;2;1;1;1;1","3 GOOD HEALTH AND WELL BEING;7 AFFORDABLE AND CLEAN ENERGY","1;1"
"AOU_CAREGGI",2022,1004,17.4362549800797,3.17828685258964,0.294820717131474,0.301792828685259,0.328685258964143,2.387265917603,1.38317757009346,1.88198757763975,1.42857142857143,0.712151394422311,2,424,221,105,42,0.42,0.22,0.1,0.04,11.27,1.26248035482908,5.97750796178345,0.369521912350598,0.919322709163347,0.528,0.464,0.503,0.487,"IACOPO OLIVOTTO;ALESSANDRO M. VANNUCCHI;NICCOLÒ MARCHIONNI;LORENZO LIVI;LORENZO ANTONUZZO;CARLO DI MARIO;CARLO FUMAGALLI;VITTORIO MIELE;MARIO MAGGI;ICRO MEATTINI;MATTIA ZAMPIERI;IACOPO OLIVOTTO;FRANCESCO CAPPELLI;GIAN MARÍA ROSSOLINI;GIANCARLO CASTAMAN;CLAIRE HARRISON;GIULIO FRANCOLINI;ALESSANDRO BARTOLONI;ANDREA UNGAR;JEAN‐JACQUES KILADJIAN","39;37;37;33;32;29;28;26;24;24;23;23;23;22;21;21;20;20;19;18","NICCOLÒ MARCHIONNI;ALESSANDRO M. VANNUCCHI;IACOPO OLIVOTTO;IACOPO OLIVOTTO;CARLO DI MARIO;CARLO FUMAGALLI;LORENZO LIVI;VITTORIO MIELE;CARLO DANI;PIERLUIGI STEFÀNO;LINDA VIGNOZZI;LORENZO ANTONUZZO;MARIO MAGGI;GIANCARLO CASTAMAN;GIAN MARÍA ROSSOLINI;ICRO MEATTINI;MATTIA ZAMPIERI;ANDREA UNGAR;ALESSIA ARGIRÒ;GIULIA MONTIGIANI","3.44;2.89;2.76;2.7;2.68;2.59;2.43;2.32;2.21;2.14;2.09;2.08;2.07;1.88;1.82;1.77;1.76;1.66;1.64;1.62","IACOPO OLIVOTTO;ALESSANDRO M. VANNUCCHI;NICCOLÒ MARCHIONNI;LORENZO LIVI;LORENZO ANTONUZZO;CARLO DI MARIO;CARLO FUMAGALLI;VITTORIO MIELE;MARIO MAGGI;ICRO MEATTINI;MATTIA ZAMPIERI;IACOPO OLIVOTTO;FRANCESCO CAPPELLI;GIAN MARÍA ROSSOLINI;GIANCARLO CASTAMAN;GIULIO FRANCOLINI;ALESSANDRO BARTOLONI;ANDREA UNGAR;CARLO DANI;ISACCO DESIDERI","39;37;37;33;32;29;28;26;24;24;23;23;23;22;21;20;20;19;18;18","NICCOLÒ MARCHIONNI;ALESSANDRO M. VANNUCCHI;IACOPO OLIVOTTO;IACOPO OLIVOTTO;CARLO DI MARIO;CARLO FUMAGALLI;LORENZO LIVI;VITTORIO MIELE;CARLO DANI;PIERLUIGI STEFÀNO;LINDA VIGNOZZI;LORENZO ANTONUZZO;MARIO MAGGI;GIANCARLO CASTAMAN;GIAN MARÍA ROSSOLINI;ICRO MEATTINI;MATTIA ZAMPIERI;ANDREA UNGAR;ALESSIA ARGIRÒ;GIULIA MONTIGIANI","3.44;2.89;2.76;2.7;2.68;2.59;2.43;2.32;2.21;2.14;2.09;2.08;2.07;1.88;1.82;1.77;1.76;1.66;1.64;1.62","MICHAEL R. SAVONA;BENJAMIN L. EBERT;ELLI PAPAEMMANUIL;EVA HELLSTRÖM‐LINDBERG;LUCA MALCOVATI;MARIO CAZZOLA;ROBERT P. HASSERJIAN;SEISHI OGAWA;ALESSANDRO M. VANNUCCHI;JEAN‐JACQUES KILADJIAN;AYALEW TEFFERI;ANDREAS REITER;TIZIANO BARBUI;ADAM BAGG;AKIKO SHIMAMURA;ATTILIO ORAZI;CHARLES G. MULLIGHAN;COURTNEY D. DINARDO;DANIEL A. ARBER;ERIC J. DUNCAVAGE","1928;1906;1906;1906;1906;1906;1906;1906;1832;1554;1529;1507;1482;1470;1470;1470;1470;1470;1470;1470","ALESSANDRO M. VANNUCCHI;JISKA RISTORI;ALESSANDRA D. FISHER;VALERIA SANTINI;VITTORIO MIELE;LORENZO ANTONUZZO;IACOPO OLIVOTTO;GIANCARLO CASTAMAN;FRANCESCO ANNUNZIATO;ALESSANDRO BARTOLONI;LORENZO ORZALESI;FRANCESCO CAPPELLI;ICRO MEATTINI;LORENZO ZAMMARCHI;GIAN MARÍA ROSSOLINI;SARA TOMASSETTI;ANNA MARIA REPICE;GABRIELE DRAGONI;MAURO DI BARI;FRANCESCA MAZZONI","1827;1219;1210;580;511;408;381;264;260;255;214;205;195;194;183;182;181;170;168;159","IACOPO OLIVOTTO;ALESSANDRO M. VANNUCCHI;CARLO DI MARIO;VITTORIO MIELE;NICCOLÒ MARCHIONNI;LORENZO ANTONUZZO;CARLO FUMAGALLI;GIANCARLO CASTAMAN;GIULIO FRANCOLINI;LORENZO LIVI;FRANCESCO CAPPELLI;ALESSANDRO BARTOLONI;MATTIA ZAMPIERI;PIERLUIGI STEFÀNO;ALESSIA ARGIRÒ;ICRO MEATTINI;ANDREA UNGAR;ANDREA MARI;CARLO DANI;ANDREA MINERVINI","50;34;29;28;24;24;23;21;20;20;19;19;18;17;16;16;15;15;15;15","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;CHEMISTRY;PSYCHOLOGY;SOCIOLOGY;MATHEMATICS;ECONOMICS;POLITICAL SCIENCE;PHILOSOPHY;BUSINESS;MATERIALS SCIENCE;GEOGRAPHY;ART;ENVIRONMENTAL SCIENCE;GEOLOGY;HISTORY","977;224;90;64;63;52;51;49;40;30;27;14;12;9;3;2;2;2;2","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;PATHOLOGY;ONCOLOGY;RADIOLOGY;GENETICS;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;PEDIATRICS;IMMUNOLOGY;PSYCHIATRY;INTENSIVE CARE MEDICINE;OPTICS;BIOCHEMISTRY;ANESTHESIA;FAMILY MEDICINE;MECHANICAL ENGINEERING;PALEONTOLOGY;EMERGENCY MEDICINE","801;279;198;166;139;125;121;113;100;98;97;76;74;63;57;52;46;44;42;38","DISEASE;CANCER;POPULATION;COHORT;RETROSPECTIVE COHORT STUDY;HEART FAILURE;GENE;ADVERSE EFFECT;CONFIDENCE INTERVAL;CLINICAL TRIAL;CHEMOTHERAPY;INCIDENCE (GEOMETRY);MYOCARDIAL INFARCTION;RANDOMIZED CONTROLLED TRIAL;PREGNANCY;PROSPECTIVE COHORT STUDY;HYPERTROPHIC CARDIOMYOPATHY;BLOOD PRESSURE;ALTERNATIVE MEDICINE;STROKE (ENGINE)","158;145;105;104;93;86;76;68;67;62;55;55;48;48;43;43;41;40;39;39","INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;CARDIOMYOPATHY;BREAST CANCER;COLORECTAL CANCER;EJECTION FRACTION;MYELOFIBROSIS;HAZARD RATIO;2019-20 CORONAVIRUS OUTBREAK;IMMUNOTHERAPY;HEART RATE;TOLERABILITY;UNIVARIATE ANALYSIS;PHASES OF CLINICAL RESEARCH;PROSTATE CANCER;MUTATION;PLACEBO;CARDIAC AMYLOIDOSIS;DEMENTIA;PERCUTANEOUS CORONARY INTERVENTION","74;46;43;39;29;29;29;27;23;22;20;20;20;19;19;17;17;15;15;15","CORONAVIRUS DISEASE 2019 (COVID-19);RUXOLITINIB;NIVOLUMAB;ANDROGEN DEPRIVATION THERAPY;KLEBSIELLA PNEUMONIAE;KRAS;MODIFIED RANKIN SCALE;METASTATIC BREAST CANCER;BRADYCARDIA;CETUXIMAB;CHEMOIMMUNOTHERAPY;COGNITIVE DECLINE;IRINOTECAN;MACE;MYELOPROLIFERATIVE NEOPLASM;EXOME SEQUENCING;FEBRILE NEUTROPENIA;HYPOACTIVE SEXUAL DESIRE DISORDER;IBRUTINIB;MEPOLIZUMAB;OXALIPLATIN","74;20;14;11;9;8;8;7;6;6;6;6;6;6;6;5;5;5;5;5;5","HUMANS;;RETROSPECTIVE STUDIES;FEMALE;MALE;COVID-19;TREATMENT OUTCOME;AGED;ADULT;MIDDLE AGED;PROSPECTIVE STUDIES;STROKE;CARDIOMYOPATHY, HYPERTROPHIC;ITALY;SARS-COV-2;LUNG NEOPLASMS;BREAST NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;HEMORRHAGE;CARDIOMYOPATHIES","519;474;150;139;111;109;81;72;65;64;61;56;43;43;41;39;38;32;31;30","MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;MOLECULAR MECHANISMS OF AMYLOIDOSIS;RENAL CELL CARCINOMA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;MANAGEMENT AND TREATMENT OF HEMOPHILIA;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;NEUROLOGICAL MANIFESTATIONS OF COVID-19 INFECTION;CORONAVIRUS DISEASE 2019;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;ACUTE MYELOID LEUKEMIA;ATRIAL FIBRILLATION;CANCER IMMUNOTHERAPY;CORONAVIRUS DISEASE 2019 RESEARCH;IMPACT OF COVID-19 INFECTION ON PREGNANCY OUTCOMES;LYMPHOID NEOPLASMS;RADIOMICS IN MEDICAL IMAGING ANALYSIS;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH","31;29;19;17;14;14;14;13;13;12;12;11;11;11;11;11;11;11;11;10","CLINICAL ENDPOINT;CARDIAC IMAGING;STROKE (ENGINE);TREATMENT;PANDEMIC;INTERQUARTILE RANGE;2019-20 CORONAVIRUS OUTBREAK;CARDIAC AMYLOIDOSIS;REGIMEN;RUXOLITINIB;RUXOLITINIB THERAPY;TOLERABILITY;UNIVARIATE ANALYSIS;CARDIOVASCULAR RISK ASSESSMENT;RADIOTHERAPY;CONCOMITANT;DISCONTINUATION;MYELOFIBROSIS;CANCER IMAGING;LEFT VENTRICULAR FUNCTION","46;44;38;33;27;26;22;20;20;20;20;20;20;18;18;16;16;16;15;15","HYPERTROPHIC CARDIOMYOPATHY;OBSERVATIONAL STUDY;BREAST CANCER;COLORECTAL CANCER;COVID- PANDEMIC;HEART FAILURE;LEFT VENTRICULAR;LUNG CANCER;CELL CARCINOMA;CLINICAL OUTCOMES;PROSTATE CANCER;ATRIAL FIBRILLATION;CARDIAC AMYLOIDOSIS;METASTATIC COLORECTAL;PATIENTS TREATED;PERCUTANEOUS CORONARY;PHASE II;PROSPECTIVE STUDY;RETROSPECTIVE STUDY;CANCER PATIENTS;CORONARY INTERVENTION;RENAL CELL;AORTIC VALVE;CLINICAL PRACTICE;INFLAMMATORY BOWEL;MAGNETIC RESONANCE;MULTICENTER RETROSPECTIVE;MULTIPLE SCLEROSIS;TRIAL NCT;COHORT STUDY","29;19;16;15;15;15;15;15;14;13;13;12;11;11;11;11;11;11;11;10;10;10;9;9;9;9;9;9;9;8","PATIENTS TREATED;MEDIAN AGE;ADVERSE EVENTS;HR CI;RISK FACTORS;CLINICAL PRACTICE;MEDIAN FOLLOW-UP;PRIMARY ENDPOINT;CONFIDENCE INTERVAL;HEART FAILURE;LEFT VENTRICULAR;CONSECUTIVE PATIENTS;FUNDING SOURCES;EJECTION FRACTION;HAZARD RATIO;VIEW LARGEDOWNLOAD;COVID- PANDEMIC;RESPONSE RATE;INCREASED RISK;PROGRESSION-FREE SURVIVAL;SURVIVAL OS;MULTIVARIATE ANALYSIS;SARS-COV- INFECTION;STATISTICALLY SIGNIFICANT;COHORT STUDY;CLINICAL OUTCOMES;PATIENTS UNDERGOING;RETROSPECTIVE STUDY;BREAST CANCER;HYPERTROPHIC CARDIOMYOPATHY","83;81;79;73;63;62;61;52;49;44;43;41;41;40;39;38;37;37;36;36;36;35;35;35;34;33;33;32;31;31",494,0.49,8.32,9,1,1,0,2,13.5,1,1,11,1,1,9,5,12.25,2,4,7,4,0,0,19,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,75,3.97,1536.27,6.54,34,0.45,102.01,0,1,12,5,22,0,6,29,0,53,21,0,0,0,0,0,0,70,4,1,74,1,0,0,0,0,0,0,0,0,"United States;Germany;Italy;Sweden;Japan;United Kingdom;Australia;Belgium;Denmark;Finland;Hungary;India;Norway;Spain","26;6;6;3;2;2;1;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4203 HEALTH SERVICES AND SYSTEMS;4206 PUBLIC HEALTH;3204 IMMUNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3107 MICROBIOLOGY;3209 NEUROSCIENCES;3212 OPHTHALMOLOGY AND OPTOMETRY;3213 PAEDIATRICS;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES","72;41;23;12;6;6;4;4;4;4;4;3;3;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;RARE DISEASES;PREVENTION;DIGESTIVE DISEASES;NEUROSCIENCES;LUNG;CARDIOVASCULAR;HEMATOLOGY;AGING;AUTOIMMUNE DISEASE;CHRONIC PAIN;HEART DISEASE;PAIN RESEARCH;BIOMEDICAL IMAGING;BRAIN DISORDERS;BREAST CANCER;COLO-RECTAL CANCER","74;56;30;25;21;14;12;12;9;8;8;7;7;7;7;7;6;6;5;5","CANCER;CARDIOVASCULAR;NEUROLOGICAL;INFLAMMATORY AND IMMUNE SYSTEM;ORAL AND GASTROINTESTINAL;RESPIRATORY;STROKE;GENERIC HEALTH RELEVANCE;METABOLIC AND ENDOCRINE;MUSCULOSKELETAL;BLOOD;EYE;INFECTION;REPRODUCTIVE HEALTH AND CHILDBIRTH;SKIN","24;9;5;4;4;4;3;2;2;2;1;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;5.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.1 INDIVIDUAL CARE NEEDS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.4 SURVEILLANCE AND DISTRIBUTION;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.4 POPULATION SCREENING;5.3 MEDICAL DEVICES","50;5;4;4;4;3;3;3;1;1;1;1;1;1","LUNG CANCER;COLON AND RECTAL CANCER;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;SARCOMA;STOMACH CANCER;BLADDER CANCER;BRAIN TUMOR;KIDNEY CANCER;LEUKEMIA / LEUKAEMIA;BLOOD CANCER;ENDOMETRIAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;HEAD AND NECK CANCER;LIVER CANCER;NOT SITE-SPECIFIC CANCER;PHARYNGEAL CANCER;RESPIRATORY SYSTEM","7;5;5;4;3;3;2;2;2;2;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;1.4 CANCER PROGRESSION AND METASTASIS;2.3 INTERACTIONS OF GENES AND/OR GENETIC POLYMORPHISMS WITH EXOGENOUS AND/OR ENDOGENOUS FACTORS;3.2 NUTRITIONAL SCIENCE IN CANCER PREVENTION;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","21;5;2;2;2;1;1;1;1",1,3360825,480117.86,6,7,4,1,0,80019.6428571429,12.5469192832117,"AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI;CLAUDE BERNARD UNIVERSITY LYON 1;FRENCH NATIONAL CENTRE FOR SCIENTIFIC RESEARCH;HOSPICES CIVILS DE LYON;TECHNICAL UNIVERSITY OF MUNICH;UNIVERSITY COLLEGE LONDON;UNIVERSITY OF FLORENCE","1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","HORIZON-EIC - HORIZON EIC GRANTS (FUNDING SCHEME);HORIZON-EIC-2021-PATHFINDERCHALLENGES-01 (CALL FOR PROPOSAL);HORIZON.3.1 - THE EUROPEAN INNOVATION COUNCIL (EIC) (PROGRAMME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1","BIOENGINEERING;BIOMEDICAL IMAGING;BRAIN CANCER;BRAIN DISORDERS;CANCER;NEUROSCIENCES;RARE DISEASES","1;1;1;1;1;1;1","CANCER","1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1;1","BRAIN TUMOR","1","4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","1;1","B12 ENGINEERING","1",NA,NA,52,"FRONTIERS;ZENODO;PUBLIC LIBRARY OF SCIENCE;KARGER PUBLISHERS;TAYLOR & FRANCIS GROUP","34;10;6;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3107 MICROBIOLOGY;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3105 GENETICS;34 CHEMICAL SCIENCES;52 PSYCHOLOGY;3001 AGRICULTURAL BIOTECHNOLOGY;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS;3215 REPRODUCTIVE MEDICINE;3401 ANALYTICAL CHEMISTRY;42 HEALTH SCIENCES;5202 BIOLOGICAL PSYCHOLOGY","93;40;15;12;5;5;5;4;3;2;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;RARE DISEASES;LUNG;CANCER;AUTOIMMUNE DISEASE;HEMATOLOGY;CARDIOVASCULAR;GENETICS;PREVENTION;HEART DISEASE;INFECTIOUS DISEASES;PATIENT SAFETY;PEDIATRIC;PNEUMONIA;PNEUMONIA & INFLUENZA;SCLERODERMA;VACCINE RELATED;BIODEFENSE;EMERGING INFECTIOUS DISEASES;ANTIMICROBIAL RESISTANCE","32;26;15;14;13;11;9;9;8;7;7;7;6;6;6;6;6;5;5;4","CANCER;CARDIOVASCULAR;RESPIRATORY;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM","12;9;7;6;6","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;2.4 SURVEILLANCE AND DISTRIBUTION;3.4 VACCINES;5.1 PHARMACEUTICALS","11;6;5;4;2;2;1;1;1","CLINICAL;BIOMEDICAL","25;13","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","36;4;1","BRAIN TUMOR;KIDNEY CANCER;LEUKEMIA / LEUKAEMIA;HODGKIN'S DISEASE;COLON AND RECTAL CANCER;ENDOMETRIAL CANCER;PROSTATE CANCER","3;3;3;2;1;1;1","3 GOOD HEALTH AND WELL BEING","10"
"AOU_CAREGGI",2023,1010,18.6693069306931,3.35247524752475,0.301980198019802,0.304950495049505,0.353465346534653,2.30900409276944,1.43192488262911,1.75,1.40551181102362,0.734653465346535,4,472,171,81,43,0.47,0.17,0.08,0.04,4.11,0.936768610085537,6.05037919826656,0.396039603960396,0.918811881188119,0.524,0.512,0.508,0.51,"ALESSANDRO M. VANNUCCHI;CARLO DI MARIO;LORENZO ANTONUZZO;LORENZO LIVI;IACOPO OLIVOTTO;ICRO MEATTINI;PAOLA GUGLIELMELLI;VALERIA SANTINI;ISACCO DESIDERI;ENRICO FAINARDI;ANDREA UNGAR;FRANCESCO CAPPELLI;RAMI S. KOMROKJI;ALESSANDRO BARTOLONI;CARLOTTA BECHERINI;DANIELA GRETO;PIERRE FENAUX;PIERLUIGI STEFÀNO;UWE PLATZBECKER;GIANCARLO CASTAMAN","46;39;35;33;32;26;25;23;20;20;20;20;19;19;18;18;18;18;18;16","CARLO DI MARIO;ALESSANDRO M. VANNUCCHI;LINDA VIGNOZZI;IACOPO OLIVOTTO;PIERLUIGI STEFÀNO;PAOLA GUGLIELMELLI;ICRO MEATTINI;LORENZO LIVI;ENRICO FAINARDI;GIULIA NARDI;LORENZO ANTONUZZO;ANDREA UNGAR;CARLO DANI;ALFREDO GIUSEPPE CERILLO;FRANCESCO CAPPELLI;ELISA MASEROLI;STEFANIA MUSCO;ALESSANDRO BARTOLONI;RAFFAELLA SANTI;NICCOLÒ CIARDETTI","4.69;3.54;2.62;2.6;2.3;2.18;2.01;1.95;1.95;1.92;1.81;1.68;1.63;1.62;1.59;1.56;1.45;1.44;1.42;1.42","ALESSANDRO M. VANNUCCHI;CARLO DI MARIO;LORENZO ANTONUZZO;LORENZO LIVI;IACOPO OLIVOTTO;ICRO MEATTINI;PAOLA GUGLIELMELLI;VALERIA SANTINI;ISACCO DESIDERI;ENRICO FAINARDI;ANDREA UNGAR;FRANCESCO CAPPELLI;ALESSANDRO BARTOLONI;CARLOTTA BECHERINI;DANIELA GRETO;PIERLUIGI STEFÀNO;GIANCARLO CASTAMAN;VALENTINA BESSI;GIULIO FRANCOLINI;STEFANIA MUSCO","46;39;35;33;32;26;25;23;20;20;20;20;19;18;18;18;16;16;16;16","CARLO DI MARIO;ALESSANDRO M. VANNUCCHI;LINDA VIGNOZZI;IACOPO OLIVOTTO;PIERLUIGI STEFÀNO;PAOLA GUGLIELMELLI;ICRO MEATTINI;LORENZO LIVI;ENRICO FAINARDI;GIULIA NARDI;LORENZO ANTONUZZO;ANDREA UNGAR;CARLO DANI;ALFREDO GIUSEPPE CERILLO;FRANCESCO CAPPELLI;ELISA MASEROLI;STEFANIA MUSCO;ALESSANDRO BARTOLONI;RAFFAELLA SANTI;NICCOLÒ CIARDETTI","4.69;3.54;2.62;2.6;2.3;2.18;2.01;1.95;1.95;1.92;1.81;1.68;1.63;1.62;1.59;1.56;1.45;1.44;1.42;1.42","IACOPO OLIVOTTO;LORENZO ANTONUZZO;MARIA ROSARIA RASPOLLINI;ICRO MEATTINI;DENIS QUERLEU;ANA FÉLIX;ANA OAKNIN;ARTEM STEPANYAN;CARLOS CENTENO;CHRISTHARDT KÖHLER;CYRUS CHARGARI;D. FISCHEROVÁ;DANIELA JAHNN-KUCH;DAVID CIBULA;DOMENICA LORUSSO;FEDRO A. PECCATORI;FLORENCE JOLY;FRANÇOIS PLANCHAMP;IGNACIO ZAPARDIEL;JACOB CHRISTIAN LINDEGAARD","293;233;233;230;226;218;218;218;218;218;218;218;218;218;218;218;218;218;218;218","IACOPO OLIVOTTO;MARIA ROSARIA RASPOLLINI;LORENZO ANTONUZZO;FEDERICO PERFETTO;ALESSANDRO M. VANNUCCHI;CARLO DI MARIO;ICRO MEATTINI;FRANCESCO CAPPELLI;ALESSIA ARGIRÒ;MATTIA ZAMPIERI;VALERIA SANTINI;PAOLA GUGLIELMELLI;VITTORIO MIELE;GIANCARLO CASTAMAN;DANIELE LAVACCHI;ANDREA MINERVINI;ANDREA MATUCCI;FILIPPO PIERALLI;GIUSEPPE GAETANO LOSCOCCO;JACOPO MARTELLUCCI","269;228;216;207;190;186;183;127;124;111;111;87;82;81;74;72;71;68;61;61","ALESSANDRO M. VANNUCCHI;CARLO DI MARIO;LORENZO ANTONUZZO;IACOPO OLIVOTTO;VALERIA SANTINI;PAOLA GUGLIELMELLI;FRANCESCO CAPPELLI;ALESSANDRO BARTOLONI;VITTORIO MIELE;PIERLUIGI STEFÀNO;DANIELA GRETO;GIANCARLO CASTAMAN;ANDREA UNGAR;GIULIO DEL POPOLO;FRANCESCO ORSO;LORENZO LIVI;ALESSIA ARGIRÒ;FEDERICO PERFETTO;DANIELE LAVACCHI;STEFANIA MUSCO","43;35;28;27;21;20;19;18;17;17;16;16;16;15;15;15;14;14;14;14","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;PSYCHOLOGY;ENGINEERING;CHEMISTRY;ECONOMICS;MATHEMATICS;SOCIOLOGY;POLITICAL SCIENCE;PHILOSOPHY;BUSINESS;MATERIALS SCIENCE;GEOGRAPHY;HISTORY;GEOLOGY","987;222;85;71;66;55;52;38;33;28;26;9;7;7;5;4;3","INTERNAL MEDICINE;SURGERY;ONCOLOGY;CARDIOLOGY;PATHOLOGY;GASTROENTEROLOGY;RADIOLOGY;GENETICS;ENVIRONMENTAL HEALTH;IMMUNOLOGY;INTENSIVE CARE MEDICINE;PSYCHIATRY;BIOCHEMISTRY;PEDIATRICS;UROLOGY;NURSING;PHYSICAL THERAPY;FAMILY MEDICINE;PALEONTOLOGY;NUCLEAR MEDICINE","806;320;177;176;168;133;120;108;105;101;79;70;58;58;53;48;48;42;40;39","CANCER;DISEASE;COHORT;POPULATION;GENE;HEART FAILURE;ADVERSE EFFECT;CHEMOTHERAPY;CLINICAL TRIAL;BONE MARROW;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;ALTERNATIVE MEDICINE;CONFIDENCE INTERVAL;MYOCARDIAL INFARCTION;RADIATION THERAPY;PREGNANCY;PROSPECTIVE COHORT STUDY;LYMPHOMA;OBSERVATIONAL STUDY","175;132;100;95;78;76;74;66;62;61;59;59;58;50;50;50;44;41;36;36","CLINICAL ENDPOINT;INFECTIOUS DISEASE (MEDICAL SPECIALTY);CARDIOMYOPATHY;COLORECTAL CANCER;EJECTION FRACTION;BREAST CANCER;PLACEBO;MYELOFIBROSIS;HAZARD RATIO;MYELODYSPLASTIC SYNDROMES;IMMUNOTHERAPY;PROSTATE;PROSTATE CANCER;RITUXIMAB;TOLERABILITY;2019-20 CORONAVIRUS OUTBREAK;PERCUTANEOUS CORONARY INTERVENTION;DEMENTIA;PHASES OF CLINICAL RESEARCH;MUTATION","56;47;39;36;36;33;31;28;27;27;26;25;21;20;20;19;19;17;17;16","CORONAVIRUS DISEASE 2019 (COVID-19);INTERNATIONAL PROGNOSTIC SCORING SYSTEM;RUXOLITINIB;NIVOLUMAB;PROSTATECTOMY;KRAS;MODIFIED RANKIN SCALE;PEMBROLIZUMAB;MYELOPROLIFERATIVE NEOPLASM;VENETOCLAX;ANDROGEN DEPRIVATION THERAPY;LOWER URINARY TRACT SYMPTOMS;MACE;ANTIRETROVIRAL THERAPY;BENDAMUSTINE;CARBOPLATIN;COGNITIVE DECLINE;DNA FRAGMENTATION;DNA METHYLATION;FRONTOTEMPORAL DEMENTIA;MEPOLIZUMAB;OXALIPLATIN;VINCRISTINE","47;18;18;16;15;13;10;9;8;8;7;7;7;6;6;6;6;6;6;6;6;6;6",";HUMANS;FEMALE;RETROSPECTIVE STUDIES;MALE;TREATMENT OUTCOME;AGED;COVID-19;ADULT;MIDDLE AGED;STROKE;PROSPECTIVE STUDIES;ITALY;NEOPLASM RECURRENCE, LOCAL;RISK FACTORS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ATRIAL FIBRILLATION;BREAST NEOPLASMS;ANTI-BACTERIAL AGENTS;BRAIN ISCHEMIA","558;446;122;114;94;77;63;63;56;56;51;47;41;32;29;26;25;25;24;24","MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ACUTE MYELOID LEUKEMIA;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;LYMPHOID NEOPLASMS;MOLECULAR MECHANISMS OF AMYLOIDOSIS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;STANDARDISATION OF LOWER URINARY TRACT FUNCTION;ATRIAL FIBRILLATION;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MANAGEMENT OF VALVULAR HEART DISEASE;PANCREATIC CANCER RESEARCH AND TREATMENT;PELVIC FLOOR DISORDERS;DIAGNOSIS AND TREATMENT OF LUNG CANCER;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;CORONAVIRUS DISEASE 2019;EPIDEMIOLOGY AND MANAGEMENT OF SEXUAL DYSFUNCTION","33;32;21;20;19;19;18;16;15;15;15;14;14;12;12;12;10;9;8;8","CLINICAL ENDPOINT;CARDIAC IMAGING;STROKE (ENGINE);TREATMENT;REGIMEN;DISCONTINUATION;MYELOFIBROSIS;CONCOMITANT;TOLERABILITY;CARDIOVASCULAR RISK ASSESSMENT;RUXOLITINIB;2019-20 CORONAVIRUS OUTBREAK;INFARCTION TREATMENT;REFRACTORY (PLANETARY SCIENCE);PANDEMIC;RADIOTHERAPY;CARDIAC AMYLOIDOSIS;DEPRESSION (ECONOMICS);ECHOCARDIOGRAPHY;LEFT VENTRICULAR FUNCTION","58;41;32;30;26;25;23;21;20;18;18;17;17;16;15;15;14;14;13;13","HYPERTROPHIC CARDIOMYOPATHY;MYELODYSPLASTIC SYNDROMES;BREAST CANCER;COHORT STUDY;STEM CELL;ATRIAL FIBRILLATION;CELL TRANSPLANTATION;COLORECTAL CANCER;ELDERLY PATIENTS;HEART FAILURE;LOWER-RISK MYELODYSPLASTIC;OBSERVATIONAL STUDY;RETROSPECTIVE STUDY;CANCER PATIENTS;MAGNETIC RESONANCE;PATIENTS TREATED;LUNG CANCER;MULTICENTER STUDY;MYELOID LEUKEMIA;PATIENTS UNDERGOING;PROSTATE CANCER;CARDIAC AMYLOIDOSIS;FONDAZIONE ITALIANA;IMERGE PHASE;ITALIANA LINFOMI;MINIMALLY INVASIVE;MULTIPLE MYELOMA;PATIENTS AFFECTED;PILOT STUDY;CROHNS DISEASE","20;18;17;16;16;14;13;12;12;12;12;12;12;11;11;11;10;10;10;10;10;9;9;9;9;9;9;9;9;8","HR CI;PATIENTS TREATED;MEDIAN AGE;ADVERSE EVENTS;MEDIAN FOLLOW-UP;STATISTICALLY SIGNIFICANT;HEART FAILURE;RISK FACTORS;SURVIVAL OS;MULTIVARIATE ANALYSIS;OBSERVATIONAL STUDY;PATIENTS UNDERGOING;SIGNIFICANT DIFFERENCES;PATIENTS RECEIVED;PRIMARY ENDPOINT;LEFT VENTRICULAR;BREAST CANCER;SIGNIFICANT DIFFERENCE;CLINICAL TRIALS;PATIENTS UNDERWENT;SURVIVAL PFS;CLINICAL PRACTICE;FLORENCE ITALY;RESPONSE RATE;RISK FACTOR;BONE MARROW;INCLUDED PATIENTS;ATRIAL FIBRILLATION;PATIENTS PTS;PROGRESSION-FREE SURVIVAL","126;90;79;67;63;54;51;46;46;43;43;43;42;41;41;37;35;35;34;33;33;32;32;31;31;30;30;29;29;29",377,0.37,11.7,15,1,2,0,3,0,1,1,16,1,1,15,1,1,2,5,10,5,0,0,9,9,3,0,0,4,0,0,0,0,0,0,0,0,2,0,2,0,4.75,0.56,3,0,4,2,0,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BETTINI RUGGERO;BUTTINI FRANCESCA;FONTANA GIOVANNI;LAVORINI FEDERICO;ANCONA ANDREA;BALDASSINI SAMUELE;BAMBI STEFANO;BARDACCI YARI;BOCCHI LEONARDO;CASATI LORENZO","2;2;2;2;1;1;1;1;1;1","AZIENDA OSPEDALIERO UNIV CAREGGI;UNIV DEGLI STUDI DI FIRENZE;UNIVERSITA’ DEGLI STUDI DI FIRENZE;AZIENDA OSPEDALIERO UNIV MEYER;TORINO POLITECNICO;UNIV DEGLI STUDI DI PARMA;UNIVERSITA’ DEGLI STUDI DI PARMA","4;2;2;1;1;1;1","40 ENGINEERING;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;32 BIOMEDICAL AND CLINICAL SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4009 ELECTRONICS, SENSORS AND DIGITAL HARDWARE","3;2;1;1;1;1","ASSISTIVE TECHNOLOGY;BIOENGINEERING","1;1",NA,NA,"A61K;A61K31/167;A61K9/00;A61K9/16;A61M1/36;A61M16/00;A61M16/04;A61M16/08;A61M16/16;A61M16/20","1;1;1;1;1;1;1;1;1;1","A61K31/167;A61K31/245;A61K31/445;A61K9/00;A61K9/0075;A61K9/1652;A61P11/14;A61B2562/0219;A61B2562/0261;A61B2562/0271","2;2;2;2;2;2;2;1;1;1",47,2.94,822.34,3.63,8,0.17,64.96,3,0,13,0,9,0,0,22,0,35,12,0,0,0,0,0,0,41,1,5,46,0,0,1,0,0,0,0,0,0,"Italy;United States;Germany;Australia;Denmark;Austria;Belgium;Finland;Greece;Netherlands;Spain;Sweden;Switzerland","14;11;4;3;3;1;1;1;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;3204 IMMUNOLOGY;3210 NUTRITION AND DIETETICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4206 PUBLIC HEALTH;52 PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3213 PAEDIATRICS;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;51 PHYSICAL SCIENCES;5109 SPACE SCIENCES;5202 BIOLOGICAL PSYCHOLOGY","45;26;17;6;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;RARE DISEASES;PATIENT SAFETY;PREVENTION;NEUROSCIENCES;LUNG;AGING;BRAIN DISORDERS;GENETICS;LYMPHOMA;NUTRITION;AUTOIMMUNE DISEASE;CARDIOVASCULAR;HEART DISEASE;INFECTIOUS DISEASES;LUNG CANCER;PAIN RESEARCH","43;30;18;12;12;10;10;9;8;7;5;5;5;5;4;4;4;4;4;4","CANCER;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;INFLAMMATORY AND IMMUNE SYSTEM;BLOOD;INFECTION;ORAL AND GASTROINTESTINAL;STROKE;EYE;GENERIC HEALTH RELEVANCE;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY","18;6;5;3;2;2;2;2;1;1;1;1","6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.4 SURVEILLANCE AND DISTRIBUTION;3.4 VACCINES;5.3 MEDICAL DEVICES;6.3 MEDICAL DEVICES;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS","33;4;4;2;2;2;1;1;1;1;1;1","LUNG CANCER;NON-HODGKIN'S LYMPHOMA;PROSTATE CANCER;LEUKEMIA / LEUKAEMIA;COLON AND RECTAL CANCER;NOT SITE-SPECIFIC CANCER;BLOOD CANCER;BREAST CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;MYELOMA;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER","5;5;4;3;2;2;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;3.2 NUTRITIONAL SCIENCE IN CANCER PREVENTION;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","13;3;2;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,43,"FRONTIERS;FUTURE SCIENCE GROUP;ZENODO;KARGER PUBLISHERS;PUBLIC LIBRARY OF SCIENCE;AMERICAN CHEMICAL SOCIETY;TAYLOR & FRANCIS GROUP","27;4;4;3;3;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;3213 PAEDIATRICS;52 PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3107 MICROBIOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;34 CHEMICAL SCIENCES;49 MATHEMATICAL SCIENCES;3203 DENTISTRY;3210 NUTRITION AND DIETETICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3401 ANALYTICAL CHEMISTRY;4201 ALLIED HEALTH AND REHABILITATION SCIENCE","70;19;17;7;6;6;5;4;3;3;2;2;2;2;2;1;1;1;1;1","CLINICAL RESEARCH;CARDIOVASCULAR;HEART DISEASE;CANCER;LUNG;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PREVENTION;BEHAVIORAL AND SOCIAL SCIENCE;RARE DISEASES;BRAIN DISORDERS;HEMATOLOGY;MENTAL HEALTH;PEDIATRIC;BIOMEDICAL IMAGING;NEUROSCIENCES;ACQUIRED COGNITIVE IMPAIRMENT;DEMENTIA;INFANT MORTALITY;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;PRETERM, LOW BIRTH WEIGHT AND HEALTH OF THE NEWBORN","30;17;16;12;11;10;9;8;8;6;6;6;6;5;5;4;4;4;4;4","CARDIOVASCULAR;CANCER;ORAL AND GASTROINTESTINAL;INFECTION;RESPIRATORY;INFLAMMATORY AND IMMUNE SYSTEM;MENTAL HEALTH;METABOLIC AND ENDOCRINE;RENAL AND UROGENITAL;STROKE","13;6;3;2;2;1;1;1;1;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS","10;8;5;2;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS","24;3;2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;HEALTH SERVICES RESEARCH;PUBLIC HEALTH","30;1;1;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;COLON AND RECTAL CANCER;BLADDER CANCER;BREAST CANCER;NON-HODGKIN'S LYMPHOMA","5;3;2;1;1;1","3 GOOD HEALTH AND WELL BEING","9"
"AOU_CAREGGI",2024,817,18.3390452876377,3.03304773561812,0.290085679314565,0.275397796817625,0.320685434516524,2.17559262510975,1.3314606741573,1.6304347826087,1.36458333333333,0.598531211750306,3,395,156,52,38,0.48,0.19,0.06,0.05,0.87,0.90931142486615,5.053531598513,0.405140758873929,0.93390452876377,0.481,0.448,0.442,0.431,"LORENZO ANTONUZZO;FRANCESCO CAPPELLI;CARLO DI MARIO;LORENZO LIVI;ISACCO DESIDERI;IACOPO OLIVOTTO;CARLO DANI;GIANCARLO CASTAMAN;AMEDEO AMEDEI;ICRO MEATTINI;MATTIA ZAMPIERI;VITTORIO MIELE;ANDREA UNGAR;ALESSANDRO BARTOLONI;GIAN MARÍA ROSSOLINI;GIANFRANCO SINAGRA;ENRICO FAINARDI;LUCA VOLTOLINI;LUCA VISANI;RICCARDO CAMPI","29;25;21;20;19;18;18;16;16;16;15;14;13;13;12;12;12;11;11;11","CARLO DI MARIO;GIANCARLO CASTAMAN;AMEDEO AMEDEI;ALESSANDRO INNOCENTI;LORENZO ANTONUZZO;GIUSEPPINA ROSSO;MAURIZIO SALVADORI;IACOPO OLIVOTTO;FRANCESCO CAPPELLI;VITTORIO MIELE;CARLO DANI;ICRO MEATTINI;RICCARDO CAMPI;SERENA PILLOZZI;MARCO ALLINOVI;ANDREA UNGAR;ANDREA LASTRUCCI;ISACCO DESIDERI;GABRIELE DRAGONI;TOMMASO INNOCENTI","2.5;2.24;2.2;2.17;2.14;2;2;1.67;1.66;1.57;1.56;1.31;1.29;1.25;1.2;1.17;1.13;1.11;1.11;1.11","LORENZO ANTONUZZO;FRANCESCO CAPPELLI;CARLO DI MARIO;LORENZO LIVI;ISACCO DESIDERI;IACOPO OLIVOTTO;CARLO DANI;GIANCARLO CASTAMAN;AMEDEO AMEDEI;ICRO MEATTINI;MATTIA ZAMPIERI;VITTORIO MIELE;ANDREA UNGAR;ALESSANDRO BARTOLONI;GIAN MARÍA ROSSOLINI;ENRICO FAINARDI;LUCA VOLTOLINI;LUCA VISANI;RICCARDO CAMPI;PIERLUIGI BONOMO","29;25;21;20;19;18;18;16;16;16;15;14;13;13;12;12;11;11;11;11","CARLO DI MARIO;GIANCARLO CASTAMAN;AMEDEO AMEDEI;ALESSANDRO INNOCENTI;LORENZO ANTONUZZO;MAURIZIO SALVADORI;IACOPO OLIVOTTO;FRANCESCO CAPPELLI;VITTORIO MIELE;CARLO DANI;ICRO MEATTINI;RICCARDO CAMPI;SERENA PILLOZZI;MARCO ALLINOVI;ANDREA UNGAR;ANDREA LASTRUCCI;ISACCO DESIDERI;GABRIELE DRAGONI;TOMMASO INNOCENTI;LORENZO LIVI","2.5;2.24;2.2;2.17;2.14;2;1.67;1.66;1.57;1.56;1.31;1.29;1.25;1.2;1.17;1.13;1.11;1.11;1.11;1.09","FRANCESCO CAPPELLI;ALDOSTEFANO PORCARI;MATTIA ZAMPIERI;LORENZO ANTONUZZO;ADAM IOANNOU;ALBERTO CIPRIANI;AVIVA PETRIE;CAROL WHELAN;JULIAN D. GILLMORE;MARIANNA FONTANA;MUHAMMAD U. RAUF;PHILIP N. HAWKINS;SCOTT D. SOLOMON;SIMONE LONGHI;YOUSUF RAZVI;CHRISTIAN NITSCHE;MICHELE EMDIN;AHMAD MASRI;RISHI PATEL;ICRO MEATTINI","49;46;45;44;41;41;41;41;41;41;41;41;41;41;41;40;40;38;38;36","FRANCESCO CAPPELLI;MATTIA ZAMPIERI;LORENZO ANTONUZZO;CARLO DI MARIO;ICRO MEATTINI;LORENZO LIVI;ALESSANDRO M. VANNUCCHI;LUCA VISANI;PAOLA GUGLIELMELLI;RICCARDO SACCARDI;GIUSEPPE GAETANO LOSCOCCO;CARLOTTA BECHERINI;VIOLA SALVESTRINI;ALESSANDRO ATANASIO;CHIARA MACCARI;GIULIO CAPECCHI;PIERLUIGI BONOMO;VALERIA SANTINI;GIANCARLO CASTAMAN;ANNA MARIA REPICE","49;44;35;32;30;27;25;25;23;23;21;20;19;18;18;18;18;16;15;14","LORENZO ANTONUZZO;FRANCESCO CAPPELLI;CARLO DI MARIO;GIANCARLO CASTAMAN;CARLO DANI;IACOPO OLIVOTTO;VITTORIO MIELE;ANDREA MINERVINI;ANDREA UNGAR;ICRO MEATTINI;ISACCO DESIDERI;ALESSANDRO M. VANNUCCHI;LUCA VISANI;LUCA VOLTOLINI;ALESSANDRO BARTOLONI;PIERLUIGI BONOMO;LORENZO LIVI;STEFANO BONGIOLATTI;GIULIO FRANCOLINI;PATRIZIA NENCINI","26;25;21;16;14;14;13;13;12;12;12;11;11;11;11;11;11;10;10;10","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;ENGINEERING;PSYCHOLOGY;CHEMISTRY;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY;ECONOMICS;PHILOSOPHY;BUSINESS;MATERIALS SCIENCE;ART;GEOLOGY;HISTORY;ENVIRONMENTAL SCIENCE;GEOGRAPHY","801;161;90;68;51;45;38;38;34;30;27;27;9;9;6;6;5;4;3","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;ONCOLOGY;INTENSIVE CARE MEDICINE;PATHOLOGY;RADIOLOGY;GENETICS;IMMUNOLOGY;PEDIATRICS;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;PSYCHIATRY;PHYSICAL THERAPY;ANESTHESIA;NURSING;BIOCHEMISTRY;LAW;ENDOCRINOLOGY;MECHANICAL ENGINEERING","607;200;148;124;107;100;89;84;82;63;58;53;53;42;39;38;37;33;32;32","CANCER;DISEASE;COHORT;RANDOMIZED CONTROLLED TRIAL;HEART FAILURE;POPULATION;GENE;CHEMOTHERAPY;RETROSPECTIVE COHORT STUDY;RADIATION THERAPY;PREGNANCY;CLINICAL TRIAL;MYOCARDIAL INFARCTION;OBSERVATIONAL STUDY;PROSPECTIVE COHORT STUDY;ADVERSE EFFECT;STROKE (ENGINE);BLOOD PRESSURE;TRANSPLANTATION;DIABETES MELLITUS","135;104;52;50;48;45;44;39;38;37;34;31;28;26;26;25;24;22;22;21","BREAST CANCER;IMMUNOTHERAPY;CARDIOMYOPATHY;CLINICAL ENDPOINT;PROSTATE CANCER;INFECTIOUS DISEASE (MEDICAL SPECIALTY);CARDIAC AMYLOIDOSIS;GESTATIONAL AGE;PROSTATE;COLORECTAL CANCER;ISCHEMIC STROKE;MULTICENTER STUDY;BLADDER CANCER;DEMENTIA;2019-20 CORONAVIRUS OUTBREAK;EJECTION FRACTION;CORONARY ANGIOGRAPHY;HAZARD RATIO;TOLERABILITY;GENOTYPE;HEART RATE;MYELODYSPLASTIC SYNDROMES;NEURORADIOLOGY","39;29;28;20;19;18;15;15;14;13;13;12;11;11;10;10;9;9;9;8;8;8;8","CORONAVIRUS DISEASE 2019 (COVID-19);NIVOLUMAB;PEMBROLIZUMAB;UROTHELIAL CARCINOMA;ANTIRETROVIRAL THERAPY;CALCITONIN GENE-RELATED PEPTIDE;COGNITIVE DECLINE;TRASTUZUMAB;BRONCHOPULMONARY DYSPLASIA;FRONTOTEMPORAL DEMENTIA;IRINOTECAN;MAMMOGRAPHY;METASTATIC BREAST CANCER;MICROSATELLITE;AL AMYLOIDOSIS;BREAST RECONSTRUCTION;BUSULFAN;CETUXIMAB;COLECTOMY;ENDOVASCULAR ANEURYSM REPAIR;FRACTIONAL FLOW RESERVE;HYPOACTIVE SEXUAL DESIRE DISORDER;MASTECTOMY;MODIFIED RANKIN SCALE;NEOADJUVANT THERAPY;OXALIPLATIN;PROSTATECTOMY;RETINOPATHY OF PREMATURITY;SEED DORMANCY;SIDA;STROKE VOLUME;SYSTEMIC THERAPY;UROTHELIAL CANCER;VEDOLIZUMAB;VON WILLEBRAND DISEASE","18;10;9;6;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;ITALY;AGED, 80 AND OVER;PROSPECTIVE STUDIES;RISK FACTORS;YOUNG ADULT;QUALITY OF LIFE;ROBOTIC SURGICAL PROCEDURES;ADOLESCENT;EUROPE;FOLLOW-UP STUDIES;INFANT, NEWBORN","520;294;177;163;135;117;92;65;59;53;39;35;28;22;19;17;16;16;16;14","MOLECULAR MECHANISMS OF AMYLOIDOSIS;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MANAGEMENT OF VALVULAR HEART DISEASE;RENAL CELL CARCINOMA;ACUTE MYELOID LEUKEMIA;ATRIAL FIBRILLATION;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;DIAGNOSIS AND TREATMENT OF LUNG CANCER;MOLECULAR RESEARCH ON BREAST CANCER;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF HEART FAILURE","24;18;16;14;13;13;12;11;10;9;9;8;8;8;7;7;7;6;6;6","CARDIAC IMAGING;TREATMENT;STROKE (ENGINE);CARDIAC AMYLOIDOSIS;CLINICAL ENDPOINT;INTERQUARTILE RANGE;RADIOTHERAPY;INFARCTION TREATMENT;CARDIOVASCULAR RISK ASSESSMENT;TRANSTHYRETIN;2019-20 CORONAVIRUS OUTBREAK;DIAGNOSIS;DISCONTINUATION;TRANSCATHETER AORTIC-VALVE REPLACEMENT;BREAST CANCER;CARDIOVASCULAR EVALUATION;HYPERTENSION;METASTATIC PROSTATE CANCER;PRETERM INFANTS;PROSTATE CANCER","32;28;24;21;21;16;16;14;13;11;10;10;10;10;9;9;9;9;9;9","BREAST CANCER;HYPERTROPHIC CARDIOMYOPATHY;CARDIAC AMYLOIDOSIS;LUNG CANCER;PROSTATE CANCER;MULTICENTER STUDY;PATIENTS TREATED;CANCER PATIENTS;COHORT STUDY;ISCHEMIC STROKE;OBSERVATIONAL STUDY;ATRIAL FIBRILLATION;HEART FAILURE;RANDOMIZED CONTROLLED;CELL CARCINOMA;DIABETIC FOOT;PRETERM INFANTS;MAGNETIC RESONANCE;PROSPECTIVE STUDY;RADIATION THERAPY;RETROSPECTIVE STUDY;CLINICAL OUTCOMES;INTENSIVE CARE;LEFT VENTRICULAR;LONG-TERM OUTCOMES;MULTIPLE SCLEROSIS;PHASE III;ACUTE ISCHEMIC;CLINICAL PRACTICE;COMPUTED TOMOGRAPHY","22;19;15;14;14;13;13;11;11;11;11;10;10;10;9;9;9;8;8;8;8;7;7;7;7;7;7;6;6;6","CLINICAL PRACTICE;RISK FACTORS;PATIENTS TREATED;STATISTICALLY SIGNIFICANT;HR CI;PATIENTS UNDERGOING;BREAST CANCER;HEART FAILURE;MEDIAN AGE;SIGNIFICANT DIFFERENCES;ADVERSE EVENTS;LEFT VENTRICULAR;INCLUDED PATIENTS;RETROSPECTIVE STUDY;PRETERM INFANTS;KIDNEY BIOPSY;OBSERVATIONAL STUDY;EJECTION FRACTION;LUNG CANCER;MEDIAN FOLLOW-UP;CLINICAL OUTCOMES;MULTIVARIATE ANALYSIS;PRIMARY ENDPOINT;REGRESSION ANALYSIS;CLINICAL TRIALS;LATE-ONSET SEPSIS;LOGISTIC REGRESSION;PATIENTS AFFECTED;PATIENTS UNDERWENT;MAGNETIC RESONANCE","43;41;38;33;32;30;27;27;26;25;23;23;22;22;21;20;20;19;19;19;18;18;18;18;17;17;17;17;17;16",3,0,3.1,6.5,0,0,0,0,0,0,0,7,0,0,6.5,0,0,2,1,4,1,0,0,0.5,0.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,3.57,206,0.68,1,0.14,39.57,0,0,2,0,2,0,0,3,0,5,2,0,0,0,0,0,0,7,0,0,7,0,0,0,0,0,0,0,0,0,"Switzerland;Germany;United States","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","6;4;4;3;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;RARE DISEASES;LYMPHOMA;PATIENT SAFETY;AGING;BEHAVIORAL AND SOCIAL SCIENCE;CARDIOVASCULAR;DEPRESSION;DIABETES;GENETICS;KIDNEY DISEASE;MENTAL HEALTH;ORPHAN DRUG;PREVENTION;REHABILITATION;STEM CELL RESEARCH;TRANSPLANTATION","7;6;6;6;6;5;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;GENERIC HEALTH RELEVANCE;METABOLIC AND ENDOCRINE;RENAL AND UROGENITAL","3;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.1 INDIVIDUAL CARE NEEDS","5;1;1;1","NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER;MYELOMA","5;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","4;2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;TAYLOR & FRANCIS GROUP","3;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3207 MEDICAL MICROBIOLOGY","11;4;2;2;1;1","CLINICAL RESEARCH;CARDIOVASCULAR;RARE DISEASES;ANTIMICROBIAL RESISTANCE;CONTRACEPTION/REPRODUCTION;DENTAL/ORAL AND CRANIOFACIAL DISEASE;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;GENETICS;HEART DISEASE;HYPERTENSION;INFECTIOUS DISEASES;LUNG;NEUROSCIENCES;NUTRITION;OBESITY;PNEUMONIA;PNEUMONIA & INFLUENZA;PREVENTION","4;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;INFECTION;ORAL AND GASTROINTESTINAL","2;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","CLINICAL;BIOMEDICAL","2;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","4;1","NOT SITE-SPECIFIC CANCER","1",NA,NA
